

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 9/00	A2	(11) International Publication Number: WO 99/66028 (43) International Publication Date: 23 December 1999 (23.12.99)									
<p>(21) International Application Number: PCT/EP99/04171</p> <p>(22) International Filing Date: 16 June 1999 (16.06.99)</p> <p>(30) Priority Data:</p> <table border="0"><tr><td>09/099,504</td><td>18 June 1998 (18.06.98)</td><td>US</td></tr><tr><td>60/101,631</td><td>24 September 1998 (24.09.98)</td><td>US</td></tr><tr><td>60/118,906</td><td>5 February 1999 (05.02.99)</td><td>US</td></tr></table> <p>(71) Applicant (for all designated States except AT/US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).</p> <p>(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): SCHUPP, Thomas [CH/CH]; Fröschmattweg 5, CH-4313 Möhlin (CH). LIGON, James, Madison [US/US]; 3616 South Pointe Drive, Apex, NC 27502 (US). MOLNAR, Istvan [HU/US]; 4004 Branchwood Drive, Durham, NC 27705 (US). ZIRKLE, Ross [US/US]; 6532 Wynbrook Way, Raleigh, NC 27612 (US). GÖRLACH, Jörn [DE/US]; 3907 King Charles Road, Durham, NC 27707 (US). CYR, Devon</p>		09/099,504	18 June 1998 (18.06.98)	US	60/101,631	24 September 1998 (24.09.98)	US	60/118,906	5 February 1999 (05.02.99)	US	<p>[US/US]; 413 Vuncannon Drive, Fuquay-Varina, NC 27526 (US).</p> <p>(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
09/099,504	18 June 1998 (18.06.98)	US									
60/101,631	24 September 1998 (24.09.98)	US									
60/118,906	5 February 1999 (05.02.99)	US									
<p>(54) Title: GENES FOR THE BIOSYNTHESIS OF EPOTHILONES</p> <p>(57) Abstract</p> <p>Nucleic acid molecules are isolated from <i>Sorangium cellulosum</i> that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.</p>											

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

GENES FOR THE BIOSYNTHESIS OF EPOTHILONES

FIELD OF THE INVENTION

The present invention relates generally to polyketides and genes for their synthesis. In particular, the present invention relates to the isolation and characterization of novel polyketide synthase and nonribosomal peptide synthetase genes from *Sorangium cellulosum* that are necessary for the biosynthesis of epothilones A and B.

BACKGROUND OF THE INVENTION

Polyketides are compounds synthesized from two-carbon building blocks, the β -carbon of which always carries a keto group, thus the name polyketide. These compounds include many important antibiotics, immunosuppressants, cancer chemotherapeutic agents, and other compounds possessing a broad range of biological properties. The tremendous structural diversity derives from the different lengths of the polyketide chain, the different side-chains introduced (either as part of the two-carbon building blocks or after the polyketide backbone is formed), and the stereochemistry of such groups. The keto groups may also be reduced to hydroxyls, enoyls, or removed altogether. Each round of two-carbon addition is carried out by a complex of enzymes called the polyketide synthase (PKS) in a manner similar to fatty acid biosynthesis.


The biosynthetic genes for an increasing number of polyketides have been isolated and sequenced. For example, see U.S. Patent Nos. 5,639,949, 5,693,774, and 5,716,849, all of which are incorporated herein by reference, which describe genes for the biosynthesis of soraphen. See also, Schupp *et al.*, *FEMS Microbiology Letters* 159: 201-207 (1998) and WO 98/07868, which describe genes for the biosynthesis of rifamycin, and U.S. Patent No. 5,876,991, which describes genes for the biosynthesis of tylactone, all of which are incorporated herein by reference. The encoded proteins generally fall into two types: type I and type II. Type I proteins are polyfunctional, with several catalytic domains carrying out different enzymatic steps covalently linked together (e.g. PKS for erythromycin, soraphen, rifamycin, and avermectin (MacNeil *et al.*, in *Industrial Microorganisms: Basic and Applied Molecular Genetics*, (ed.: Baltz *et al.*), American Society for Microbiology, Washington D. C.

pp. 245-256 (1993)); whereas type II proteins are monofunctional (Hutchinson *et al.*, in *Industrial Microorganisms: Basic and Applied Molecular Genetics*, (ed.: Baltz *et al.*), American Society for Microbiology, Washington D. C. pp. 203-216 (1993)).

For the simpler polyketides such as actinorhodin (produced by *Streptomyces coelicolor*), the several rounds of two-carbon additions are carried out iteratively on PKS enzymes encoded by one set of PKS genes. In contrast, synthesis of the more complicated compounds such as erythromycin and soraphen involves PKS enzymes that are organized into modules, whereby each module carries out one round of two-carbon addition (for review, see Hopwood *et al.*, in *Industrial Microorganisms: Basic and Applied Molecular Genetics*, (ed.: Baltz *et al.*), American Society for Microbiology, Washington D. C., pp. 267-275 (1993)).

Complex polyketides and secondary metabolites in general may contain substructures that are derived from amino acids instead of simple carboxylic acids. Incorporations of these building blocks are accomplished by non-ribosomal polypeptide synthetases (NRPSs). NRPSs are multienzymes that are organized in modules. Each module is responsible for the addition (and the additional processing, if required) of one amino acid building block. NRPSs activate amino acids by forming aminoacyl-adenylates, and capture the activated amino acids on thiol groups of phosphopantetheinyl prosthetic groups on peptidyl carrier protein domains. Further, NRPSs modify the amino acids by epimerization, N-methylation, or cyclization if necessary, and catalyse the formation of peptide bonds between the enzyme-bound amino acids. NRPSs are responsible for the biosynthesis of peptide secondary metabolites like cyclosporin, could provide polyketide chain terminator units as in rapamycin, or form mixed systems with PKSs as in yersiniabactin biosynthesis.

Epothilones A and B are 16-membered macrocyclic polyketides with an acylcysteine-derived starter unit that are produced by the bacterium *Sorangium cellulosum* strain So ce90 (Gerth *et al.*, *J. Antibiotics* 49: 560-563 (1996), incorporated herein by reference). The structure of epothilone A and B wherein R signifies hydrogen (epothilone A) or methyl (epothilone B) is:



The epothilones have a narrow antifungal spectrum and especially show a high cytotoxicity in animal cell cultures (*see*, Höfle *et al.*, Patent DE 4138042 (1993), incorporated herein by reference). Of significant importance, epothilones mimic the biological effects of taxol, both *in vivo* and in cultured cells (Bollag *et al.*, *Cancer Research* 55: 2325-2333 (1995), incorporated herein by reference). Taxol and taxotere, which stabilize cellular microtubules, are cancer chemotherapeutic agents with significant activity against various human solid tumors (Rowinsky *et al.*, *J. Natl. Cancer Inst.* 83: 1778-1781 (1991)). Competition studies have revealed that epothilones act as competitive inhibitors of taxol binding to microtubules, consistent with the interpretation that they share the same microtubule-binding site and possess a similar microtubule affinity as taxol. However, epothilones enjoy a significant advantage over taxol in that epothilones exhibit a much lower drop in potency compared to taxol against a multiple drug-resistant cell line (Bollag *et al.* (1995)). Furthermore, epothilones are considerably less efficiently exported from the cells by P-glycoprotein than is taxol (Gerth *et al.* (1996)). In addition, several epothilone analogs have been synthesized that have a superior cytotoxic activity as compared to epothilone A or epothilone B as demonstrated by their enhanced ability to induce the polymerization and stabilization of microtubules (WO 98/25929, incorporated herein by reference).

Despite the promise shown by the epothilones as anticancer agents, problems pertaining to the production of these compounds presently limit their commercial potential. The compounds are too complex for industrial-scale chemical synthesis and so must be produced by fermentation. Techniques for the genetic manipulation of myxobacteria such as *Sorangium cellulosum* are described in U.S. Patent No. 5,686,295, incorporated herein by reference. However, *Sorangium cellulosum* is notoriously difficult to ferment and production levels of epothilones are therefore low. Recombinant production of epothilones in heterologous hosts that are more amenable to fermentation could solve current production problems. However, the genes that encode the polypeptides responsible for epothilone bio-

- 4 -

synthesis have heretofore not been isolated. Furthermore, the strain that produces epothilones, i.e. So ce90, also produces at least one additional polyketide, spirangien, which would be expected to greatly complicate the isolation of the genes particularly responsible for epothilone biosynthesis.

Therefore, in view of the foregoing, one object of the present invention is to isolate the genes that are involved in the synthesis of epothilones, particularly the genes that are involved in the synthesis of epothilones A and B in myxobacteria of the Sorangium/-Polyangium group, i.e., *Sorangium cellulosum* strain So ce90. A further object of the invention is to provide a method for the recombinant production of epothilones for application in anticancer formulations.

SUMMARY OF THE INVENTION

In furtherance of the aforementioned and other objects, the present invention unexpectedly overcomes the difficulties set forth above to provide for the first time a nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of epothilone. In a preferred embodiment, the nucleotide sequence is isolated from a species belonging to *Myxobacteria*, most preferably *Sorangium cellulosum*.

In another preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:2, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 7-432 of SEQ ID NO:4, amino acids 539-859 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684 of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID

- 5 -

NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

In a more preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:2, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 7-432 of SEQ ID NO:4, amino acids 539-859 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684

of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

In yet another preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1,

nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

In an especially preferred embodiment, the present invention provides a nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said nucleotide sequence is selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of

SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

In yet another preferred embodiment, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of an epothilone, wherein said nucleotide sequence comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID

NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

The present invention also provides a chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule of the invention. Further, the present invention provides a recombinant vector comprising such a chimeric gene, wherein the vector is capable of being stably transformed into a host cell. Still further, the present invention provides a recombinant host cell comprising such a chimeric gene, wherein the host cell is capable of expressing the nucleotide sequence that encodes at least one polypeptide necessary for the biosynthesis of an epothilone. In a preferred embodiment, the recombinant host cell is a bacterium belonging to the order *Actinomycetales*, and in a more preferred embodiment the recombinant host cell is a strain of *Streptomyces*. In other embodiments, the recombinant host cell is any other bacterium amenable to fermentation, such as a pseudomonad or *E. coli*. Even further, the present invention provides a Bac clone comprising a nucleic acid molecule of the invention, preferably Bac clone pEPO15.

In another aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes an epothilone synthase domain.

According to one embodiment, the epothilone synthase domain is a β -ketoacyl-synthase (KS) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7. According to this embodiment, said KS domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids

3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.

According to another embodiment, the epothilone synthase domain is an acyltransferase (AT) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7. According to this embodiment, said AT domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino

acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.

According to still another embodiment, the epothilone synthase domain is an enoyl reductase (ER) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7. According to this embodiment, said ER domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of

SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1.

According to another embodiment, the epothilone synthase domain is an acyl carrier protein (ACP) domain, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7. According to this embodiment, said ACP domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40,

45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.

According to another embodiment, the epothilone synthase domain is a dehydratase (DH) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7. According to this embodiment, said DH domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1,

- 15 -

nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.

According to yet another embodiment, the epothilone synthase domain is a β -keto-reductase (KR) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7. According to this embodiment, said KR domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.

According to an additional embodiment, the epothilone synthase domain is a methyltransferase (MT) domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6. According to this embodiment, said MT domain preferably comprises amino acids 2671-3045 of SEQ ID NO:6. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to nucleotides 51534-52657 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of nucleotides 51534-52657 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is nucleotides 51534-52657 of SEQ ID NO:1.

According to another embodiment, the epothilone synthase domain is a thioesterase (TE) domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7. According to this embodiment, said TE domain preferably comprises amino acids 2165-2439 of SEQ ID NO:7. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to nucleotides 61427-62254 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of nucleotides 61427-62254 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is nucleotides 61427-62254 of SEQ ID NO:1.

In still another aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a non-ribosomal peptide synthetase, wherein said non-ribosomal peptide synthetase comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3. According to this

- 17 -

embodiment, said non-ribosomal peptide synthetase preferably comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3. Also, according to this embodiment, said nucleotide sequence preferably is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1. According to this embodiment, said nucleotide sequence more preferably comprises a consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair nucleotide portion identical in sequence to a respective consecutive 20, 25, 30, 35, 40, 45, or 50 (preferably 20) base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1. In addition, according to this embodiment, said nucleotide sequence most preferably is selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-

12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.

The present invention further provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:2-23.

In accordance with another aspect, the present invention also provides methods for the recombinant production of polyketides such as epothilones in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer. A specific advantage of these production methods is the chirality of the molecules produced; production in transgenic organisms avoids the generation of populations of racemic mixtures, within which some enantiomers may have reduced activity. In particular, the present invention provides a method for heterologous expression of epothilone in a recombinant host, comprising: (a) introducing into a host a chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule of the invention that comprises a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of epothilone; and (b) growing the host in conditions that allow biosynthesis of epothilone in the host. The present invention also provides a method for producing epothilone, comprising: (a) expressing epothilone in a recombinant host by the aforementioned method; and (b) extracting epothilone from the recombinant host.

According to still another aspect, the present invention provides an isolated polypeptide comprising an amino acid sequence that consists of an epothilone synthase domain.

According to one embodiment, the epothilone synthase domain is a β -ketoacyl-synthase (KS) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7. According to this embodiment,

said KS domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.

According to another embodiment, the epothilone synthase domain is an acyltransferase (AT) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7. According to this embodiment, said AT domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

According to still another embodiment, the epothilone synthase domain is an enoyl reductase (ER) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7. According to this embodiment, said ER domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

According to another embodiment, the epothilone synthase domain is an acyl carrier protein (ACP) domain, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of

SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7. According to this embodiment, said ACP domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

According to another embodiment, the epothilone synthase domain is a dehydratase (DH) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7. According to this embodiment, said DH domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

According to yet another embodiment, the epothilone synthase domain is a β -keto-reductase (KR) domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7. According to this embodiment, said KR domain preferably comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

According to an additional embodiment, the epothilone synthase domain is a methyl-transferase (MT) domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6. According to this embodiment, said MT domain preferably comprises amino acids 2671-3045 of SEQ ID NO:6.

According to another embodiment, the epothilone synthase domain is a thioesterase (TE) domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7. According to this embodiment, said TE domain preferably comprises amino acids 2165-2439 of SEQ ID NO:7.

Other aspects and advantages of the present invention will become apparent to those skilled in the art from a study of the following description of the invention and non-limiting examples.

DEFINITIONS

In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

Associated With / Operatively Linked: Refers to two DNA sequences that are related physically or functionally. For example, a promoter or regulatory DNA sequence is said to be "associated with" a DNA sequence that codes for an RNA or a protein if the two sequences are operatively linked, or situated such that the regulator DNA sequence will affect the expression level of the coding or structural DNA sequence.

Chimeric Gene: A recombinant DNA sequence in which a promoter or regulatory DNA sequence is operatively linked to, or associated with, a DNA sequence that codes for an mRNA or which is expressed as a protein, such that the regulator DNA sequence is able to regulate transcription or expression of the associated DNA sequence. The regulator DNA sequence of the chimeric gene is not normally operatively linked to the associated DNA sequence as found in nature.

Coding DNA Sequence: A DNA sequence that is translated in an organism to produce a protein.

Domain: That part of a polyketide synthase necessary for a given distinct activity. Examples include acyl carrier protein (ACP), β -ketosynthase (KS), acyltransferase (AT), β -ketoreductase (KR), dehydratase (DH), enoylreductase (ER), and thioesterase (TE) domains.

Epothilones: 16-membered macrocyclic polyketides naturally produced by the bacterium *Sorangium cellulosum* strain So ce90, which mimic the biological effects of taxol. In this application, "epothilone" refers to the class of polyketides that includes epothilone A and epothilone B, as well as analogs thereof such as those described in WO 98/25929.

Epothilone Synthase: A polyketide synthase responsible for the biosynthesis of epothilone.

Gene: A defined region that is located within a genome and that, besides the aforementioned coding DNA sequence, comprises other, primarily regulatory, DNA sequences responsible for the control of the expression, that is to say the transcription and translation, of the coding portion.

Heterologous DNA Sequence: A DNA sequence not naturally associated with a host cell into which it is introduced, including non-naturally occurring multiple copies of a naturally occurring DNA sequence.

Homologous DNA Sequence: A DNA sequence naturally associated with a host cell into which it is introduced.

Homologous Recombination: Reciprocal exchange of DNA fragments between homologous DNA molecules.

Isolated: In the context of the present invention, an isolated nucleic acid molecule or an isolated enzyme is a nucleic acid molecule or enzyme that, by the hand of man, exists apart from its native environment and is therefore not a product of nature. An isolated nucleic acid molecule or enzyme may exist in a purified form or may exist in a non-native environment such as, for example, a recombinant host cell.

Module: A genetic element encoding all of the distinct activities required in a single round of polyketide biosynthesis, i.e., one condensation step and all the β -carbonyl processing steps associated therewith. Each module encodes an ACP, a KS, and an AT activity to accomplish the condensation portion of the biosynthesis, and selected post-condensation activities to effect the β -carbonyl processing.

NRPS: A non-ribosomal polypeptide synthetase, which is a complex of enzymatic activities responsible for the incorporation of amino acids into secondary metabolites including, for example, amino acid adenylation, epimerization, N-methylation, cyclization, peptidyl carrier protein, and condensation domains. A functional NRPS is one that catalyzes the incorporation of an amino acid into a secondary metabolite.

NRPS gene: One or more genes encoding NRPSs for producing functional secondary metabolites, e.g., epothilones A and B, when under the direction of one or more compatible control elements.

Nucleic Acid Molecule: A linear segment of single- or double-stranded DNA or RNA that can be isolated from any source. In the context of the present invention, the nucleic acid molecule is preferably a segment of DNA.

ORF: Open Reading Frame.

PKS: A polyketide synthase, which is a complex of enzymatic activities (domains) responsible for the biosynthesis of polyketides including, for example, ketoreductase, dehydratase, acyl carrier protein, enoylreductase, ketoacyl ACP synthase, and acyltransferase. A functional PKS is one that catalyzes the synthesis of a polyketide.

PKS Genes: One or more genes encoding various polypeptides required for producing functional polyketides, e.g., epothilones A and B, when under the direction of one or more compatible control elements.

Substantially Similar: With respect to nucleic acids, a nucleic acid molecule that has at least 60 percent sequence identity with a reference nucleic acid molecule. In a preferred embodiment, a substantially similar DNA sequence is at least 80% identical to a reference DNA sequence; in a more preferred embodiment, a substantially similar DNA sequence is at least 90% identical to a reference DNA sequence; and in a most preferred embodiment, a substantially similar DNA sequence is at least 95% identical to a reference DNA sequence. A substantially similar DNA sequence preferably encodes a protein or peptide having substantially the same activity as the protein or peptide encoded by the reference DNA sequence. A substantially similar nucleotide sequence typically hybridizes to a reference nucleic acid molecule, or fragments thereof, under the following conditions: hybridization at 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO₄ pH 7.0, 1 mM EDTA at 50°C; wash with 2X SSC, 1% SDS, at 50°C. With respect to proteins or peptides, a substantially similar amino acid sequence is an amino acid sequence that is at least 90% identical to the amino acid sequence of a reference protein or peptide and has substantially the same activity as the reference protein or peptide.

Transformation: A process for introducing heterologous nucleic acid into a host cell or organism.

Transformed / Transgenic / Recombinant: Refers to a host organism such as a bacterium into which a heterologous nucleic acid molecule has been introduced. The nucleic acid molecule can be stably integrated into the genome of the host or the nucleic acid molecule can also be present as an extrachromosomal molecule. Such an extrachromosomal molecule can be auto-replicating. Transformed cells, tissues, or plants are understood to

encompass not only the end product of a transformation process, but also transgenic progeny thereof. A "non-transformed", "non-transgenic", or "non-recombinant" host refers to a wild-type organism, i.e., a bacterium, which does not contain the heterologous nucleic acid molecule.

Nucleotides are indicated by their bases by the following standard abbreviations: adenine (A), cytosine (C), thymine (T), and guanine (G). Amino acids are likewise indicated by the following standard abbreviations: alanine (ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C), glutamine (Gln; Q), glutamic acid (Glu; E), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V). Furthermore, (Xaa; X) represents any amino acid.

DESCRIPTION OF THE SEQUENCES IN THE SEQUENCE LISTING

SEQ ID NO:1 is the nucleotide sequence of a 68750 bp contig containing 22 open reading frames (ORFs), which comprises the epothilone biosynthesis genes.

SEQ ID NO:2 is the protein sequence of a type I polyketide synthase (EPOS A) encoded by *epoA* (nucleotides 7610-11875 of SEQ ID NO:1).

SEQ ID NO:3 is the protein sequence of a non-ribosomal peptide synthetase (EPOS P) encoded by *epoP* (nucleotides 11872-16104 of SEQ ID NO:1).

SEQ ID NO:4 is the protein sequence of a type I polyketide synthase (EPOS B) encoded by *epoB* (nucleotides 16251-21749 of SEQ ID NO:1).

SEQ ID NO:5 is the protein sequence of a type I polyketide synthase (EPOS C) encoded by *epoC* (nucleotides 21746-43519 of SEQ ID NO:1).

SEQ ID NO:6 is the protein sequence of a type I polyketide synthase (EPOS D) encoded by *epoD* (nucleotides 43524-54920 of SEQ ID NO:1).

SEQ ID NO:7 is the protein sequence of a type I polyketide synthase (EPOS E) encoded by *epoE* (nucleotides 54935-62254 of SEQ ID NO:1).

SEQ ID NO:8 is the protein sequence of a cytochrome P450 oxygenase homologue (EPOS F) encoded by *epoF* (nucleotides 62369-63628 of SEQ ID NO:1).

SEQ ID NO:9 is a partial protein sequence (partial Orf 1) encoded by *orf1* (nucleotides 1-1826 of SEQ ID NO:1).

- 25 -

SEQ ID NO:10 is a protein sequence (Orf 2) encoded by *orf2* (nucleotides 3171-1900 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:11 is a protein sequence (Orf 3) encoded by *orf3* (nucleotides 3415-5556 of SEQ ID NO:1).

SEQ ID NO:12 is a protein sequence (Orf 4) encoded by *orf4* (nucleotides 5992-5612 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:13 is a protein sequence (Orf 5) encoded by *orf5* (nucleotides 6226-6675 of SEQ ID NO:1).

SEQ ID NO:14 is a protein sequence (Orf 6) encoded by *orf6* (nucleotides 63779-64333 of SEQ ID NO:1).

SEQ ID NO:15 is a protein sequence (Orf 7) encoded by *orf7* (nucleotides 64290-63853 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:16 is a protein sequence (Orf 8) encoded by *orf8* (nucleotides 64363-64920 of SEQ ID NO:1).

SEQ ID NO:17 is a protein sequence (Orf 9) encoded by *orf9* (nucleotides 64727-64287 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:18 is a protein sequence (Orf 10) encoded by *orf10* (nucleotides 65063-65767 of SEQ ID NO:1).

SEQ ID NO:19 is a protein sequence (Orf 11) encoded by *orf11* (nucleotides 65874-65008 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:20 is a protein sequence (Orf 12) encoded by *orf12* (nucleotides 66338-65871 on the reverse complement strand of SEQ ID NO:1).

SEQ ID NO:21 is a protein sequence (Orf 13) encoded by *orf13* (nucleotides 66667-67137 of SEQ ID NO:1).

SEQ ID NO:22 is a protein sequence (Orf 14) encoded by *orf14* (nucleotides 67334-68251 of SEQ ID NO:1).

SEQ ID NO:23 is a partial protein sequence (partial Orf 15) encoded by *orf15* (nucleotides 68346-68750 of SEQ ID NO:1).

SEQ ID NO:24 is the universal reverse PCR primer sequence.

SEQ ID NO:25 is the universal forward PCR primer sequence.

SEQ ID NO:26 is the NH24 end "B" PCR primer sequence.

SEQ ID NO:27 is the NH2 end "A" PCR primer sequence.

SEQ ID NO:28 is the NH2 end "B" PCR primer sequence.

- 26 -

SEQ ID NO:29 is the pEPO15-NH6 end "B" PCR primer sequence.

SEQ ID NO:30 is the pEPO15-H2.7 end "A" PCR primer sequence.

DEPOSIT INFORMATION

The following material has been deposited with the Agricultural Research Service, Patent Culture Collection (NRRL), 1815 North University Street, Peoria, Illinois 61604, under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. All restrictions on the availability of the deposited material will be irrevocably removed upon the granting of a patent.

<u>Deposited Material</u>	<u>Accession Number</u>	<u>Deposit Date</u>
pEPO15	NRRL B-30033	June 11, 1998
pEPO32	NRRL B-30119	April 16, 1999

DETAILED DESCRIPTION OF THE INVENTION

The genes involved in the biosynthesis of epothilones can be isolated using the techniques according to the present invention. The preferable procedure for the isolation of epothilone biosynthesis genes requires the isolation of genomic DNA from an organism identified as producing epothilones A and B, and the transfer of the isolated DNA on a suitable plasmid or vector to a host organism that does not normally produce the polyketide, followed by the identification of transformed host colonies to which the epothilone-producing ability has been conferred. Using a technique such as λ ::Tn5 transposon mutagenesis (de Bruijn & Lupski, *Gene* 27: 131-149 (1984)), the exact region of the transforming epothilone-conferring DNA can be more precisely defined. Alternatively or additionally, the transforming epothilone-conferring DNA can be cleaved into smaller fragments and the smallest that maintains the epothilone-conferring ability further characterized. Whereas the host organism lacking the ability to produce epothilone may be a different species from the organism from which the polyketide derives, a variation of this technique involves the transformation of host DNA into the same host that has had its epothilone-producing ability disrupted by mutagenesis. In this method, an epothilone-producing organism is mutated and non-epothilone-producing mutants are isolated. These are then complemented by genomic DNA isolated from the epothilone-producing parent strain.

A further example of a technique that can be used to isolate genes required for epothilone biosynthesis is the use of transposon mutagenesis to generate mutants of an epothilone-producing organism that, after mutagenesis, fails to produce the polyketide. Thus, the region of the host genome responsible for epothilone production is tagged by the transposon and can be recovered and used as a probe to isolate the native genes from the parent strain. PKS genes that are required for the synthesis of polyketides and that are similar to known PKS genes may be isolated by virtue of their sequence homology to the biosynthetic genes for which the sequence is known, such as those for the biosynthesis of rifamycin or soraphen. Techniques suitable for isolation by homology include standard library screening by DNA hybridization.

Preferred for use as a probe molecule is a DNA fragment that is obtainable from a gene or another DNA sequence that plays a part in the synthesis of a known polyketide. A preferred probe molecule comprises a 1.2 kb *Sma*I DNA fragment encoding the ketosynthase domain of the fourth module of the soraphen PKS (U.S. Patent No. 5,716,849), and a more preferred probe molecule comprises the β -ketoacyl synthase domains from the first and second modules of the rifamycin PKS (Schupp *et al.*, *FEMS Microbiology Letters* 159: 201-207 (1998)). These can be used to probe a gene library of an epothilone-producing microorganism to isolate the PKS genes responsible for epothilone biosynthesis.

Despite the well-known difficulties with PKS gene isolation in general and despite the difficulties expected to be encountered with the isolation of epothilone biosynthesis genes in particular, by using the methods described in the instant specification, biosynthetic genes for epothilones A and B can surprisingly be cloned from a microorganism that produces that polyketide. Using the methods of gene manipulation and recombinant production described in this specification, the cloned PKS genes can be modified and expressed in transgenic host organisms.

The isolated epothilone biosynthetic genes can be expressed in heterologous hosts to enable the production of the polyketide with greater efficiency than might be possible from native hosts. Techniques for these genetic manipulations are specific for the different available hosts and are known in the art. For example, heterologous genes can be expressed in *Streptomyces* and other actinomycetes using techniques such as those described in McDaniel *et al.*, *Science* 262: 1546-1550 (1993) and Kao *et al.*, *Science* 265: 509-512 (1994), both of which are incorporated herein by reference. See also, Rowe *et al.*, *Gene*

216: 215-223 (1998); Holmes *et al.*, *EMBO Journal* 12(8): 3183-3191 (1993) and Bibb *et al.*, *Gene* 38: 215-226 (1985), all of which are incorporated herein by reference.

Alternately, genes responsible for polyketide biosynthesis, i.e., epothilone biosynthetic genes, can also be expressed in other host organisms such as pseudomonads and *E. coli*. Techniques for these genetic manipulations are specific for the different available hosts and are known in the art. For example, PKS genes have been successfully expressed in *E. coli* using the pT7-7 vector, which uses the T7 promoter. See, Tabor *et al.*, *Proc. Natl. Acad. Sci. USA* 82: 1074-1078 (1985), incorporated herein by reference. In addition, the expression vectors pKK223-3 and pKK223-2 can be used to express heterologous genes in *E. coli*, either in transcriptional or translational fusion, behind the *tac* or *trc* promoter. For the expression of operons encoding multiple ORFs, the simplest procedure is to insert the operon into a vector such as pKK223-3 in transcriptional fusion, allowing the cognate ribosome binding site of the heterologous genes to be used. Techniques for overexpression in gram-positive species such as *Bacillus* are also known in the art and can be used in the context of this invention (Quax *et al.*, in: *Industrial Microorganisms: Basic and Applied Molecular Genetics*, Eds. Baltz *et al.*, American Society for Microbiology, Washington (1993)).

Other expression systems that may be used with the epothilone biosynthetic genes of the invention include yeast and baculovirus expression systems. See, for example, "The Expression of Recombinant Proteins in Yeasts," Sudbery, P. E., *Curr. Opin. Biotechnol.* 7(5): 517-524 (1996); "Methods for Expressing Recombinant Proteins in Yeast," Mackay, *et al.*, Editor(s): Carey, Paul R., *Protein Eng. Des.* 105-153, Publisher: Academic, San Diego, Calif (1996); "Expression of heterologous gene products in yeast," Pichuanes, *et al.*, Editor(s): Cleland, J. L., Craik, C. S., *Protein Eng.* 129-161, Publisher: Wiley-Liss, New York, N. Y (1996); WO 98/27203; Kealey *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 505-509 (1998); "Insect Cell Culture: Recent Advances, Bioengineering Challenges And Implications In Protein Production," Palomares, *et al.*, Editor(s): Galindo, Enrique; Ramirez, Octavio T., *Adv. Bioprocess Eng.* Vol. II, Invited Pap. Int. Symp., 2nd (1998) 25-52, Publisher: Kluwer, Dordrecht, Neth; "Baculovirus Expression Vectors," Jarvis, Donald L., Editor(s): Miller, Lois K., *Baculoviruses* 389-431, Publisher: Plenum, New York, N. Y. (1997); "Production Of Heterologous Proteins Using The Baculovirus/Insect Expression System," Grittiths, *et al.*, *Methods Mol. Biol.* (Totowa, N. J.) 75 (Basic Cell Culture Protocols (2nd Edition)) 427-440 (1997); and "Insect Cell Expression Technology," Luckow, Verne A., *Protein Eng.* 183-218,

Publisher: Wiley-Liss, New York, N. Y. (1996); all of which are incorporated herein by reference.

Another consideration for expression of PKS genes in heterologous hosts is the requirement of enzymes for posttranslational modification of PKS enzymes by phosphopantetheinylation before they can synthesize polyketides. However, the enzymes responsible for this modification of type I PKS enzymes, phosphopantetheinyl (P-pant) transferases are not normally present in many hosts such as *E. coli*. This problem can be solved by coexpression of a P-pant transferase with the PKS genes in the heterologous host, as described by Kealey *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 505-509 (1998), incorporated herein by reference.

Therefore, for the purposes of polyketide production, the significant criteria in the choice of host organism are its ease of manipulation, rapidity of growth (*i.e.* fermentation), possession of the proper molecular machinery for processes such as posttranslational modification, and its lack of susceptibility to the polyketide being overproduced. Most preferred host organisms are actinomycetes such as strains of *Streptomyces*. Other preferred host organisms are pseudomonads and *E. coli*. The above-described methods of polyketide production have significant advantages over the technology currently used in the preparation of the compounds. These advantages include the cheaper cost of production, the ability to produce greater quantities of the compounds, and the ability to produce compounds of a preferred biological enantiomer, as opposed to racemic mixtures inevitably generated by organic synthesis. Compounds produced by heterologous hosts can be used in medical (*e.g.* cancer treatment in the case of epothilones) as well as agricultural applications.

EXPERIMENTAL

The invention will be further described by reference to the following detailed examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are described by Ausubel (ed.), *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc. (1994); T. Maniatis, E. F. Fritsch and J. Sambrook, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor laboratory, Cold Spring Harbor, NY (1989); and by T.J. Silhavy, M.L. Berman, and L.W. Enquist, *Experiments with Gene Fusions*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984).

Example 1: Cultivation of an Epothilone-Producing Strain of *Sorangium cellulosum*

Sorangium cellulosum strain 90 (DSM 6773, Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig) is streaked out and grown (30°C) on an agar plate of SolE medium (0.35% glucose, 0.05% tryptone, 0.15% MgSO₄ x 7H₂O, 0.05% ammonium sulfate, 0.1% CaCl₂, 0.006% K₂HPO₄, 0.01% sodium dithionite, 0.0008% Fe-EDTA, 1.2% HEPES, 3.5% [vol/vol] supernatant of sterilized stationary *S. cellulosum* culture) pH ad. 7.4. Cells from about 1 square cm are picked and inoculated into 5 mls of G51t liquid medium (0.2% glucose, 0.5% starch, 0.2% tryptone, 0.1% probion S, 0.05% CaCl₂x2H₂O, 0.05% MgSO₄x7H₂O, 1.2% HEPES, pH ad. 7.4) and incubated at 30°C with shaking at 225 rpm. After 4 days, the culture is transferred into 50 mls of G51t and incubated as above for 5 days. This culture is used to inoculate 500 mls of G51t and incubated as above for 6 days. The culture is centrifuged for 10 minutes at 4000 rpm and the cell pellet is resuspended in 50 mls of G51t.

Example 2: Generation of a Bacterial Artificial Chromosome (Bac) Library

To generate a Bac library, *S. cellulosum* cells cultivated as described in Example 1 above are embedded into agarose blocks, lysed, and the liberated genomic DNA is partially digested by the restriction enzyme *HindIII*. The digested DNA is separated on an agarose gel by pulsed-field electrophoresis. Large (approximately 90-150 kb) DNA fragments are

isolated from the agarose gel and ligated into the vector pBelobacII. pBelobacII contains a gene encoding chloramphenicol resistance, a multiple cloning site in the *lacZ* gene providing for blue/white selection on appropriate medium, as well as the genes required for the replication and maintenance of the plasmid at one or two copies per cell. The ligation mixture is used to transform *Escherichia coli* DH10B electrocompetent cells using standard electroporation techniques. Chloramphenicol-resistant recombinant (white, *lacZ* mutant) colonies are transferred to a positively charged nylon membrane filter in 384 3X3 grid format. The clones are lysed and the DNA is cross-linked to the filters. The same clones are also preserved as liquid cultures at -80°C.

Example 3: Screening the Bac Library of *Sorangium cellulosum* 90 for the Presence of Type I Polyketide Synthase-Related Sequences

The Bac library filters are probed by standard Southern hybridization procedures. The DNA probes used encode β -ketoacyl synthase domains from the first and second modules of the rifamycin polyketide synthase (Schupp *et al.*, *FEMS Microbiology Letters* 159: 201-207. (1998)). The probe DNAs are generated by PCR with primers flanking each ketosynthase domain using the plasmid pNE95 as the template (pNE95 equals cosmid 2 described in Schupp *et al.* (1998)). 25 ng of PCR-amplified DNA is isolated from a 0.5% agarose gel and labeled with ^{32}P -dCTP using a random primer labeling kit (Gibco-BRL, Bethesda MD, USA) according to the manufacturer's instructions. Hybridization is at 65°C for 36 hours and membranes are washed at high stringency (3 times with 0.1x SSC and 0.5% SDS for 20 min at 65°C). The labeled blot is exposed on a phosphorescent screen and the signals are detected on a PhosphorImager 445SI (screen and 445SI from Molecular Dynamics). This results in strong hybridization of certain Bac clones to the probes. These clones are selected and cultured overnight in 5 mls of Luria broth (LB) at 37°C. Bac DNA from the Bac clones of interest is isolated by a typical miniprep procedure. The cells are resuspended in 200 μl lysozyme solution (50mM glucose, 10 mM EDTA, 25 mM Tris-HCl, 5mg/ml lysozyme), lysed in 400 μl lysis solution (0.2 N NaOH and 2% SDS), the proteins are precipitated (3.0 M potassium acetate, adjusted to pH5.2 with acetic acid), and the Bac DNA is precipitated with isopropanol. The DNA is resuspended in 20 μl of nuclease-free distilled water, restricted with *Bam*HI (New England Biolabs, Inc.) and separated on a 0.7% agarose gel. The gel is blotted by Southern hybridization as described above and probed

- 32 -

under conditions described above, with a 1.2 kb *Sma*I DNA fragment encoding the ketosynthase domain of the fourth module of the soraphen polyketide synthase as the probe (see, U.S. Patent No. 5,716,849). Five different hybridization patterns are observed. One clone representing each of the five patterns is selected and named pEPO15, pEPO20, pEPO30, pEPO31, and pEPO33, respectively.

Example 4: Subcloning of *Bam*HI Fragments from pEPO15, pEPO20, pEPO30, pEPO31, and pEPO33

The DNA of the five selected Bac clones is digested with *Bam*HI and random fragments are subcloned into pBluescript II SK+ (Stratagene) at the *Bam*HI site. Subclones carrying inserts between 2 and 10 kb in size are selected for sequencing of the flanking ends of the inserts and also probed with the 1.2 *Sma*I probe as described above. Subclones that show a high degree of sequence homology to known polyketide synthases and/or strong hybridization to the soraphen ketosynthase domain are used for gene disruption experiments.

Example 5: Preparation of Streptomycin-Resistant Spontaneous Mutants of *Sorangium cellulosum* strain So ce90

0.1 ml of a three day old culture of *Sorangium cellulosum* strain So ce90, which is raised in liquid medium G52-H (0.2% yeast extract, 0.2% soyameal defatted, 0.8% potato starch, 0.2% glucose, 0.1% MgSO₄ x7H₂O, 0.1% CaCl₂ x2H₂O, 0.008% Fe-EDTA, pH ad 7.4 with KOH), is plated out on agar plates with SolE medium supplemented with 100 µg/ml streptomycin. The plates are incubated at 30°C for 2 weeks. The colonies growing on this medium are streptomycin-resistant mutants, which are streaked out and cultivated once more on the same agar medium with streptomycin for purification. One of these streptomycin-resistant mutants is selected and is called BCE28/2.

Example 6: Gene Disruptions in *Sorangium cellulosum* BCE28/2 Using the Subcloned *Bam*HI Fragments

The *Bam*HI inserts of the subclones generated from the five selected Bac clones as described above are isolated and ligated into the unique *Bam*HI site of plasmid pCIB132 (see, U.S. Patent No. 5,716,849). The pCIB132 derivatives carrying the inserts are transformed into *Escherichia coli* ED8767 containing the helper plasmid pUZ8 (Hedges and Matthew, *Plasmid* 2: 269-278 (1979)). The transformants are used as donors in conjugation experiments with *Sorangium cellulosum* BCE28/2 as recipient. For the conjugation, $5 \cdot 10^9$ cells of *Sorangium cellulosum* BCE28/2 from an early stationary phase culture (reaching about $5 \cdot 10^8$ cells/ml) grown at 30°C in liquid medium G51b (G51b equals medium G51t with tryptone replaced by peptone) are mixed in a 1:1 cellular ratio with a late-log phase culture (in LB liquid medium) of *E. coli* ED8767 containing pCIB132 derivatives carrying the subcloned *Bam*HI fragments and the helper plasmid pUZ8. The mixed cells are then centrifuged at 4000 rpm for 10 minutes and resuspended in 0.5 ml G51b medium. This cell suspension is then plated as a drop in the center of a plate with So1E agar containing 50 mg/l kanamycin. The cells obtained after incubation for 24 hours at 30°C are harvested and resuspended in 0.8 ml of G51b medium, and 0.1 to 0.3 ml of this suspension is plated out on a selective So1E solid medium containing phleomycin (30 mg/l), streptomycin (300 mg/l), and kanamycin (50 mg/l). The counterselection of the donor *Escherichia coli* strain takes place with the aid of streptomycin. The colonies that grow on this selective medium after an incubation time of 8-12 days at a temperature of 30°C are isolated with a plastic loop and streaked out and cultivated on the same agar medium for a second round of selection and purification. The colony-derived cultures that grow on this selective agar medium after 7 days at a temperature of 30°C are transconjugants of *Sorangium cellulosum* BCE28/2 that have acquired phleomycin resistance by conjugative transfer of the pCIB132 derivatives carrying the subcloned *Bam*HI fragments.

Integration of the pCIB132-derived plasmids into the chromosome of *Sorangium cellulosum* BCE28/2 by homologous recombination is verified by Southern hybridization. For this experiment, complete DNA from 5-10 transconjugants per transferred *Bam*HI fragment is isolated (from 10 ml cultures grown in medium G52-H for three days) applying the method described by Pospiech and Neumann, *Trends Genet.* 11: 217 (1995). For the Southern blot, the DNA isolated as described above is cleaved either with the restriction

- 34 -

enzymes *Bgl*II, *Cla*I, or *Not*I, and the respective *Bam*HI inserts or pCIB132 are used as 32P labelled probes.

Example 7: Analysis of the Effect of the Integrated *Bam*HI Fragments on Epothilone Production by *Sorangium cellulosum* After Gene Disruption

Transconjugant cells grown on about 1 square cm surface of the selective So1E plates of the second round of selection (see Example 6) are transferred by a sterile plastic loop into 10 ml of medium G52-H in an 50 ml Erlenmeyer flask. After incubation at 30°C and 180 rpm for 3 days, the culture is transferred into 50 ml of medium G52-H in an 200 ml Erlenmeyer flask. After incubation at 30°C and 180 rpm for 4-5 days, 10 ml of this culture is transferred into 50 ml of medium 23B3 (0.2 % glucose, 2 % potato starch, 1.6 % soya meal defatted, 0.0008 % Fe-EDTA Sodium salt, 0.5 % HEPES (4-(2-hydroxyethyl)-piperazine-1-ethane-sulfonic-acid), 2 % vol/vol polystyrene resin XAD16 (Rohm & Haas), pH adjusted to 7.8 with NaOH) in an 200 ml Erlenmeyer flask.

Quantitative determination of the epothilone produced takes place after incubation of the cultures at 30°C and 180 rpm for 7 days. The complete culture broth is filtered by suction through a 150 µm nylon filter. The resin remaining on the filter is then resuspended in 10 ml isopropanol and extracted by shaking the suspension at 180 rpm for 1 hour. 1 ml is removed from this suspension and centrifuged at 12,000 rpm in an Eppendorff Microfuge. The amount of epothilones A and B therein is determined by means of an HPLC and detection at 250 nm with a UV_DAD detector (HPLC with Waters -Symetry C18 column and a gradient of 0.02 % phosphoric acid 60%-0% and acetonitril 40%-100%).

Transconjugants with three different integrated *Bam*HI fragments subcloned from pEPO15, namely transconjugants with the *Bam*HI fragment of plasmid pEPO15-21, transconjugants with the *Bam*HI fragment of plasmid pEPO15-4-5, and transconjugants with the *Bam*HI fragment of plasmid pEPO15-4-1, are tested in the manner described above. HPLC analysis reveals that all transconjugants no longer produce epothilone A or B. By contrast, epothilone A and B are detectable in a concentration of 2-4 mg/l in transconjugants with *Bam*HI fragments integrated that are derived from pEPO20, pEPO30, pEPO31, pEPO33, and in the parental strain BCE28/2.

- 35 -

Example 8: Nucleotide Sequence Determination of the Cloned Fragments and Construction of Contigs

A. *Bam*HI Insert of Plasmid pEPO15-21

Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-21], and the nucleotide sequence of the 2.3-kb *Bam*HI insert in pEPO15-21 is determined. Automated DNA sequencing is done on the double-stranded DNA template by the dideoxynucleotide chain termination method, using Applied Biosystems model 377 sequencers. The primers used are the universal reverse primer (5' GGA AAC AGC TAT GAC CAT G 3' (SEQ ID NO:24)) and the universal forward primer (5' GTA AAA CGA CGG CCA GT 3' (SEQ ID NO:25)). In subsequent rounds of sequencing reactions, custom-synthesized oligonucleotides, designed for the 3' ends of the previously determined sequences, are used to extend and join contigs. Both strands are entirely sequenced, and every nucleotide is sequenced at least two times. The nucleotide sequence is compiled using the program Sequencer vers. 3.0 (Gene Codes Corporation), and analyzed using the University of Wisconsin Genetics Computer Group programs. The nucleotide sequence of the 2213-bp insert corresponds to nucleotides 20779-22991 of SEQ ID NO:1.

B. *Bam*HI Insert of Plasmid pEPO15-4-1

Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-4-1], and the nucleotide sequence of the 3.9-kb *Bam*HI insert in pEPO15-4-1 is determined as described in (A) above. The nucleotide sequence of the 3909-bp insert corresponds to nucleotides 16876-20784 of SEQ ID NO:1.

C. *Bam*HI Insert of Plasmid pEPO15-4-5

Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-4-5], and the nucleotide sequence of the 2.3-kb *Bam*HI insert in pEPO15-4-5 is determined as described in (A) above. The nucleotide sequence of the 2233-bp insert corresponds to nucleotides 42528-44760 of SEQ ID NO:1.

**Example 9: Subcloning and Ordering of DNA Fragments from pEPO15 Containing
Epothilone Biosynthesis Genes**

pEPO15 is digested to completion with the restriction enzyme *HindIII* and the resulting fragments are subcloned into pBluescript II SK- or pNEB193 (New England Biolabs) that has been cut with *HindIII* and dephosphorylated with calf intestinal alkaline phosphatase. Six different clones are generated and named pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24 (all based on pNEB193), and pEPO15-H2.7 and pEPO15-H3.0 (both based on pBluescript II SK-).

The *Bam*HI insert of pEPO15-21 is isolated and DIG-labeled (Non-radioactive DNA labeling and detection system, Boehringer Mannheim), and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signal is detected for pEPO15-NH24, indicating that pEPO15-21 is contained within pEPO15-NH24.

The *Bam*HI insert of pEPO15-4-1 is isolated and DIG-labeled as above, and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signals are detected for pEPO15-NH24 and pEPO15-H2.7. Nucleotide sequence data generated from one end each of pEPO15-NH24 and pEPO15-H2.7 are also in complete agreement with the previously determined sequence of the *Bam*HI insert of pEPO15-4-1. These experiments demonstrate that pEPO15-4-1 (which contains one internal *HindIII* site) overlaps pEPO15-H2.7 and pEPO15-NH24, and that pEPO15-H2.7 and pEPO15-NH24, in this order, are contiguous.

The *Bam*HI insert of pEPO15-4-5 is isolated and DIG-labeled as above, and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signal is detected for pEPO15-NH2, indicating that pEPO15-21 is contained within pEPO15-NH2.

Nucleotide sequence data is generated from both ends of pEPO15-NH2 and from the end of pEPO15-NH24 that does not overlap with pEPO15-4-1. PCR primers NH24 end "B": GTGACTGGCGCCTGGAATCTGCATGAGC (SEQ ID NO:26), NH2 end "A": AGCGGGAGCTTGCTAGACATTCTGTTTC (SEQ ID NO:27), and NH2 end "B": GACGCGCCTCGGGCAGCGCCCAA (SEQ ID NO:28), pointing towards the *HindIII* sites,

- 37 -

are designed based on these sequences and used in amplification reactions with pEPO15 and, in separate experiments, with *Sorangium cellulosum* So ce90 genomic DNA as the templates. Specific amplification is found with primer pair NH24 end "B" and NH2 end "A" with both templates. The amplimers are cloned into pBluescript II SK- and completely sequenced. The sequences of the amplimers are identical, and also agree completely with the end sequences of pEPO15-NH24 and pEPO15-NH2, fused at the *HindIII* site, establishing that the *HindIII* fragments of pEPO15-NH2 and pEPO15-NH24 are, in this order, contiguous.

The *HindIII* insert of pEPO15-H2.7 is isolated and DIG-labeled as above, and used as a probe in a DNA hybridization experiment at high stringency against pEPO15 digested by *NotI*. A *NotI* fragment of about 9 kb in size shows a strong hybridization, and is further subcloned into pBluescript II SK- that has been digested with *NotI* and dephosphorylated with calf intestinal alkaline phosphatase, to yield pEPO15-N9-16. The *NotI* insert of pEPO15-N9-16 is isolated and DIG-labeled as above, and used as a probe in DNA hybridization experiments at high stringency against pEPO15-NH1, pEPO15-NH2, pEPO15-NH6, pEPO15-NH24, pEPO15-H2.7 and pEPO15-H3.0. Strong hybridization signals are detected for pEPO15-NH6, and also for the expected clones pEPO15-H2.7 and pEPO15-NH24. Nucleotide sequence data is generated from both ends of pEPO15-NH6 and from the end of pEPO15-H2.7 that does not overlap with pEPO15-4-1. PCR primers are designed pointing towards the *HindIII* sites and used in amplification reactions with pEPO15 and, in separate experiments, with *Sorangium cellulosum* So ce90 genomic DNA as the templates. Specific amplification is found with primer pair pEPO15-NH6 end "B": CACCGAAGCGTCGATCTGGTCCATC (SEQ ID NO:29) and pEPO15-H2.7 end "A": CGGTCAGATCGACGACGGGCTTTCC (SEQ ID NO:30) with both templates. The amplimers are cloned into pBluescript II SK- and completely sequenced. The sequences of the amplimers are identical, and also agree completely with the end sequences of pEPO15-NH6 and pEPO15-H2.7, fused at the *HindIII* site, establishing that the *HindIII* fragments of pEPO15-NH6 and pEPO15-H2.7 are, in this order, contiguous.

All of these experiments, taken together, establish a contig of *HindIII* fragments covering a region of about 55 kb and consisting of the *HindIII* inserts of pEPO15-NH6, pEPO15-H2.7, pEPO15-NH24, and pEPO15-NH2, in this order. The inserts of the remaining two *HindIII* subclones, namely pEPO15-NH1 and pEPO15-H3.0, are not found to be parts of this contig.

**Example 10: Further Extension of the Subclone Contig Covering the Epóthilone
Biosynthesis Genes**

An approximately 2.2 kb *Bam*HI – *Hind*III fragment derived from the downstream end of the insert of pEPO15-NH2 and thus representing the downstream end of the subclone contig described in Example 9 is isolated, DIG-labeled, and used in Southern hybridization experiments against pEPO15 and pEPO15-NH2 DNAs digested with several enzymes. The strongly hybridizing bands are always found to be the same in size between the two target DNAs indicating that the *Sorangium cellulosum* So ce90 genomic DNA fragment cloned into pEPO15 ends with the *Hind*III site at the downstream end of pEPO15-NH2.

A cosmid DNA library of *Sorangium cellulosum* So ce90 is generated, using established procedures, in pScosTriplex-II (Ji, *et al.*, *Genomics* 31: 185-192 (1996)). Briefly, high-molecular weight genomic DNA of *Sorangium cellulosum* So ce90 is partially digested with the restriction enzyme *Sau*3AI to provide fragments with average sizes of about 40 kb, and ligated to *Bam*HI and *Xba*I digested pScosTriplex-II. The ligation mix is packaged with Gigapack III XL (Stratagene) and used to transfect *E. coli* XL1 Blue MR cells.

The cosmid library is screened with the approximately 2.2 kb *Bam*HI – *Hind*III fragment, derived from the downstream end of the insert of pEPO15-NH2, used as a probe in colony hybridization. A strongly hybridizing clone, named pEPO4E7 is selected.

pEPO4E7 DNA is isolated, digested with several restriction endonucleases, and probed in Southern hybridization experiments with the 2.2 kb *Bam*HI – *Hind*III fragment. A strongly hybridizing *Not*I fragment of approximately 9 kb in size is selected and subcloned into pBluescript II SK- to yield pEPO4E7-N9-8. Further Southern hybridization experiments reveal that the approximately 9 kb *Not*I insert of pEPO4E7-N9-8 overlaps pEPO15-NH2 over 6 kb in a *Not*I – *Hind*III fragment, while the remaining approximately 3 kb *Hind*III – *Not*I fragment would extend the subclone contig described in Example 9. End sequencing reveals, however, that the downstream end of the insert of pEPO4E7-N9-8 contains the *Bam*HI – *Not*I polylinker of pScosTriplex-II, thereby indicating that the genomic DNA insert of pEPO4E7 ends at a *Sau*3AI site within the extending *Hind*III – *Not*I fragment and that the *Not*I site is derived from pScosTriplex-II.

An approximately 1.6 kb *Pst*I – *Sa*I fragment derived from the approximately 3 kb extending *Hind*III – *Not*I subfragment of pEPO4E7-N9-8, containing only *Sorangium*

cellulosum So ce90—derived sequences free of vector, is used as a probe against the bacterial artificial chromosome library described in Example 2. Besides the previously-isolated EPO15, a Bac clone, named EPO32, is found to strongly hybridize to the probe. pEPO32 is isolated, digested with several restriction endonucleases, and hybridized with the approximately 1.6 kb *Pst*I – *Sal*I probe. A *Hind*III – *Eco*RV fragment of about 13 kb in size is found to strongly hybridize to the probe, and is subcloned into pBluescript II SK—digested with *Hind*III and *Hinc*II to yield pEPO32-HEV15.

Oligonucleotide primers are designed based on the downstream end sequence of pEPO15-NH2 and on the upstream (*Hind*III) end sequence derived from pEPO32-HEV15, and used in sequencing reactions with pEPO4E7-N9-8 as the template. The sequences reveal the existence of a small *Hind*III fragment (EPO4E7-H0.02) of 24 bp, undetectable in standard restriction analysis, separating the *Hind*III site at the downstream end of pEPO15-NH2 from the *Hind*III site at the upstream end of pEPO32-HEV15.

Thus, the subclone contig described in Example 9 is extended to include the *Hind*III fragment EPO4E7-H0.02 and the insert of pEPO32-HEV15, and constitutes the inserts of: pEPO15-NH6, pEPO15-H2.7, pEPO15-NH24, pEPO15-NH2, EPO4E7-H0.02 and pEPO32-HEV15, in this order.

Example 11: Nucleotide Sequence Determination of the Subclone Contig Covering the Epothilone Biosynthesis Genes

The nucleotide sequence of the subclone contig described in Example 10 is determined as follows.

pEPO15-H2.7. Plasmid DNA is isolated from the strain *Escherichia coli* DH10B [pEPO15-H2.7], and the nucleotide sequence of the 2.7-kb *Bam*HI insert in pEPO15-H2.7 is determined. Automated DNA sequencing is done on the double-stranded DNA template by the dideoxynucleotide chain termination method, using Applied Biosystems model 377 sequencers. The primers used are the universal reverse primer (5' GGA AAC AGC TAT GAC CAT G 3' (SEQ ID NO:24)) and the universal forward primer (5' GTA AAA CGA CGG CCA GT 3' (SEQ ID NO:25)). In subsequent rounds of sequencing reactions, custom-synthesized oligonucleotides, designed for the 3' ends of the previously determined sequences, are used to extend and join contigs.

- 40 -

pEPO15-NH6, pEPO15-NH24 and pEPO15-NH2. The *HindIII* inserts of these plasmids are isolated, and subjected to random fragmentation using a Hydroshear apparatus (Genomic Instrumentation Services, Inc.) to yield an average fragment size of 1-2 kb. The fragments are end-repaired using T4 DNA Polymerase and Klenow DNA Polymerase enzymes in the presence of desoxynucleotide triphosphates, and phosphorylated with T4 DNA Kinase in the presence of ribo-ATP. Fragments in the size range of 1.5-2.2 kb are isolated from agarose gels, and ligated into pBluescript II SK- that has been cut with *EcoRV* and dephosphorylated. Random subclones are sequenced using the universal reverse and the universal forward primers.

pEPO32-HEV15. pEPO32-HEV15 is digested with *HindIII* and *SspI*, the approximately 13.3 kb fragment containing the ~13 kb *HindIII* – *EcoRV* insert from *So. cellulorum* So ce90 and a 0.3 kb *HincII* – *SspI* fragment from pBluescript II SK- is isolated, and partially digested with *HaeIII* to yield fragments with an average size of 1-2 kb. Fragments in the size range of 1.5-2.2 kb are isolated from agarose gels, and ligated into pBluescript II SK- that has been cut with *EcoRV* and dephosphorylated. Random subclones are sequenced using the universal reverse and the universal forward primers.

The chromatograms are analyzed and assembled into contigs with the Phred, Phrap and Consed programs (Ewing, *et al.*, *Genome Res.* 8(3): 175-185 (1998); Ewing, *et al.*, *Genome Res.* 8(3): 186-194 (1998); Gordon, *et al.*, *Genome Res.* 8(3): 195-202 (1998)). Contig gaps are filled, sequence discrepancies are resolved, and low-quality regions are resequenced using custom-designed oligonucleotide primers for sequencing on either the original subclones or selected clones from the random subclone libraries. Both strands are completely sequenced, and every basepair is covered with at least a minimum aggregated Phred score of 40 (confidence level of 99.99%).

The nucleotide sequence of the 68750 bp contig is shown as SEQ ID NO:1.

Example 12: Nucleotide Sequence Analysis of the Epothilone Biosynthesis Genes

SEQ ID NO:1 is found to contain 22 ORFs as detailed below in Table 1:

Table 1

ORF	Start codon	Stop codon	Homology of deduced protein	Proposed function of deduced protein
<i>orf1</i>	outside of sequenced range	1826		
<i>orf2</i> *	3171	1900	Hypothetical protein SP: Q11037; DD-peptidase SP:P15555	
<i>orf3</i>	3415	5556	<i>Na/H antiporter PID: D1017724</i>	<i>Transport</i>
<i>orf4</i> *	5992	5612		
<i>orf5</i>	6226	6675		
<i>epoA</i>	7610	11875	Type I polyketide synthase	Epothilone synthase: Thiazole ring formation
<i>epoP</i>	11872	16104	Non-ribosomal peptide synthetase	Epothilone synthase: Thiazole ring formation
<i>epoB</i>	16251	21749	Type I polyketide synthase	Epothilone synthase: Polyketide backbone formation
<i>epoC</i>	21746	43519	Type I polyketide synthase	Epothilone synthase: Polyketide backbone formation
<i>epoD</i>	43524	54920	Type I polyketide synthase	Epothilone synthase: Polyketide backbone formation
<i>epoE</i>	54935	62254	Type I polyketide synthase	Epothilone synthase: Polyketide backbone formation
<i>epoF</i>	62369	63628	Cytochrome P450	Epothilone macrolactone oxidase
<i>orf6</i>	63779	64333		
<i>orf7</i> *	64290	63853		
<i>orf8</i>	64363	64920		
<i>orf9</i> *	64727	64287		
<i>orf10</i>	65063	65767		
<i>orf11</i> *	65874	65008		
<i>orf12</i> *	66338	65871		
<i>orf13</i>	66667	67137		
<i>orf14</i>	67334	68251	Hypothetical protein GI:3293544; Cation efflux system protein GI:2623026	Transport
<i>orf15</i>	68346	outside of sequenced range		

* On the reverse complement strand. Numbering according to SEQ ID NO:1.

epoA (nucleotides 7610-11875 of SEQ ID NO:1) codes for EPOS A (SEQ ID NO:2), a type I polyketide synthase consisting of a single module, and harboring the following domains: β -ketoacyl-synthase (KS) (nucleotides 7643-8920 of SEQ ID NO:1, amino acids 11-

437 of SEQ ID NO:2); acyltransferase (AT) (nucleotides 9236-10201 of SEQ ID NO:1, amino acids 543-864 of SEQ ID NO:2); enoyl reductase (ER) (nucleotides 10529-11428 of SEQ ID NO:1, amino acids 974-1273 of SEQ ID NO:2); and acyl carrier protein homologous domain (ACP) (nucleotides 11549-11764 of SEQ ID NO:1, amino acids 1314-1385 of SEQ ID NO:2). Sequence comparisons and motif analysis (Haydock, et al. *FEBS Lett.* 374: 246-248 (1995); Tang, et al., *Gene* 216: 255-265 (1998)) reveal that the AT encoded by EPOS A is specific for malonyl-CoA. EPOS A should be involved in the initiation of epothilone biosynthesis by loading the acetate unit to the multienzyme complex that will eventually form part of the 2-methylthiazole ring (C26 and C20).

epoP (nucleotides 11872-16104 of SEQ ID NO:1) codes for EPOS P (SEQ ID NO:3), a non-ribosomal peptide synthetase containing one module. EPOS P harbors the following domains:

- peptide bond formation domain, as delineated by motif K (amino acids 72-81 [FPLTDIQESY] of SEQ ID NO:3, corresponding to nucleotide positions 12085-12114 of SEQ ID NO:1); motif L (amino acids 118-125 [VVARHDML] of SEQ ID NO:3, corresponding to nucleotide positions 12223-12246 of SEQ ID NO:1); motif M (amino acids 199-212 [SIDLINVDLGSLSI] of SEQ ID NO:3, corresponding to nucleotide positions 12466-12507 of SEQ ID NO:1); and motif O (amino acids 353-363 [GDFTSMVLLDI] of SEQ ID NO:3, corresponding to nucleotide positions 12928-12960 of SEQ ID NO:1);
- aminoacyl adenylate formation domain, as delineated by motif A (amino acids 549-565 [LTYEELSRRSRRLGARL] of SEQ ID NO:3, corresponding to nucleotide positions 13516-13566 of SEQ ID NO:1); motif B (amino acids 588-603 [VAVLAVLESGAAYVPI] of SEQ ID NO:3, corresponding to nucleotide positions 13633-13680 of SEQ ID NO:1); motif C (amino acids 669-684 [AYVIYTSGSTGLPKGVI] of SEQ ID NO:3, corresponding to nucleotide positions 13876-13923 of SEQ ID NO:1); motif D (amino acids 815-821 [SLGGATE] of SEQ ID NO:3, corresponding to nucleotide positions 14313-14334 of SEQ ID NO:1); motif E (amino acids 868-892 [GQLYIGGVGLALGYWRDEEKTRKSF] of SEQ ID NO:3, corresponding to nucleotide positions 14473-14547 of SEQ ID NO:1); motif F (amino acids 903-912 [YKTGDLGRYL] of SEQ ID NO:3, corresponding to nucleotide positions 14578-14607 of SEQ ID NO:1); motif G (amino acids 918-940 [EFMGREDNQIKLRGYRVELGEIE] of SEQ ID NO:3, corresponding to nucleotide positions 14623-14692 of SEQ ID NO:1); motif H (amino acids 1268-1274 [LPEYMVP] of SEQ ID NO:3, corresponding to nucleotide positions 15673-15693 of SEQ ID NO:1); and

motif I (amino acids 1285-1297 [LTSNGKVDRKALR] of SEQ ID NO:3, corresponding to nucleotide positions 15724-15762 of SEQ ID NO:1);

- an unknown domain, inserted between motifs G and H of the aminoacyl adenylate formation domain (amino acids 973-1256 of SEQ ID NO:3, corresponding to nucleotide positions 14788-15639 of SEQ ID NO:1); and
- a peptidyl carrier protein homologous domain (PCP), delineated by motif J (amino acids 1344-1351 [GATSIHIV] of SEQ ID NO:3, corresponding to nucleotide positions 15901-15924 of SEQ ID NO:1).

It is proposed that EPOS P is involved in the activation of a cysteine by adenylation, binding the activated cysteine as an aminoacyl-S-PCP, forming a peptide bond between the enzyme-bound cysteine and the acetyl-S-ACP supplied by EPOS A, and the formation of the initial thiazoline ring by intramolecular heterocyclization. The unknown domain of EPOS P displays very weak homologies to NAD(P)H oxidases and reductases from *Bacillus* species. Thus, this unknown domain and/or the ER domain of EPOS A may be involved in the oxidation of the initial 2-methylthiazoline ring to a 2-methylthiazole.

epoB (nucleotides 16251-21749 of SEQ ID NO:1) codes for EPOS B (SEQ ID NO:4), a type I polyketide synthase consisting of a single module, and harboring the following domains: KS (nucleotides 16269-17546 of SEQ ID NO:1, amino acids 7-432 of SEQ ID NO:4); AT (nucleotides 17865-18827 of SEQ ID NO:1, amino acids 539-859 of SEQ ID NO:4); dehydratase (DH) (nucleotides 18855-19361 of SEQ ID NO:1, amino acids 869-1037 of SEQ ID NO:4); β -ketoreductase (KR) (nucleotides 20565-21302 of SEQ ID NO:1, amino acids 1439-1684 of SEQ ID NO:4); and ACP (nucleotides 21414-21626 of SEQ ID NO:1, amino acids 1722-1792 of SEQ ID NO:4). Sequence comparisons and motif analysis reveal that the AT encoded by EPOS B is specific for methylmalonyl-CoA. EPOS A should be involved in the first polyketide chain extension by catalysing the Claisen-like condensation of the 2-methyl-4-thiazolecarboxyl-S-PCP starter group with the methylmalonyl-S-ACP, and the concomitant reduction of the β -keto group of C17 to an enoyl.

epoC (nucleotides 21746-43519 of SEQ ID NO:1) codes for EPOS C (SEQ ID NO:5), a type I polyketide synthase consisting of 4 modules. The first module harbors a KS (nucleotides 21860-23116 of SEQ ID NO:1, amino acids 39-457 of SEQ ID NO:5); a malonyl CoA-specific AT (nucleotides 23431-24397 of SEQ ID NO:1, amino acids 563-884 of SEQ ID NO:5); a KR (nucleotides 25184-25942 of SEQ ID NO:1, amino acids 1147-1399 of SEQ ID NO:5); and an ACP (nucleotides 26045-26263 of SEQ ID NO:1, amino acids 1434-1506 of

- 44 -

SEQ ID NO:5). This module incorporates an acetate extender unit (C14-C13) and reduces the β -keto group at C15 to the hydroxyl group that takes part in the final lactonization of the epothilone macrolactone ring. The second module of EPOS C harbors a KS (nucleotides 26318-27595 of SEQ ID NO:1, amino acids 1524-1950 of SEQ ID NO:5); a malonyl CoA-specific AT (nucleotides 27911-28876 of SEQ ID NO:1, amino acids 2056-2377 of SEQ ID NO:5); a KR (nucleotides 29678-30429 of SEQ ID NO:1, amino acids 2645-2895 of SEQ ID NO:5); and an ACP (nucleotides 30539-30759 of SEQ ID NO:1, amino acids 2932-3005 of SEQ ID NO:5). This module incorporates an acetate extender unit (C12-C11) and reduces the β -keto group at C13 to a hydroxyl group. Thus, the nascent polyketide chain of epothilone corresponds to epothilone A, and the incorporation of the methyl side chain at C12 in epothilone B would require a post-PKS C-methyltransferase activity. The formation of the epoxi ring at C13-C12 would also require a post-PKS oxidation step. The third module of EPOS C harbors a KS (nucleotides 30815-32092 of SEQ ID NO:1, amino acids 3024-3449 of SEQ ID NO:5); a malonyl CoA-specific AT (nucleotides 32408-33373 of SEQ ID NO:1, amino acids 3555-3876 of SEQ ID NO:5); a DH (nucleotides 33401-33889 of SEQ ID NO:1, amino acids 3886-4048 of SEQ ID NO:5); an ER (nucleotides 35042-35902 of SEQ ID NO:1, amino acids 4433-4719 of SEQ ID NO:5); a KR (nucleotides 35930-36667 of SEQ ID NO:1, amino acids 4729-4974 of SEQ ID NO:5); and an ACP (nucleotides 36773-36991 of SEQ ID NO:1, amino acids 5010-5082 of SEQ ID NO:5). This module incorporates an acetate extender unit (C10-C9) and fully reduces the β -keto group at C11. The fourth module of EPOS C harbors a KS (nucleotides 37052-38320 of SEQ ID NO:1, amino acids 5103-5525 of SEQ ID NO:5); a methylmalonyl CoA-specific AT (nucleotides 38636-39598 of SEQ ID NO:1, amino acids 5631-5951 of SEQ ID NO:5); a DH (nucleotides 39635-40141 of SEQ ID NO:1, amino acids 5964-6132 of SEQ ID NO:5); an ER (nucleotides 41369-42256 of SEQ ID NO:1, amino acids 6542-6837 of SEQ ID NO:5); a KR (nucleotides 42314-43048 of SEQ ID NO:1, amino acids 6857-7101 of SEQ ID NO:5); and an ACP (nucleotides 43163-43378 of SEQ ID NO:1, amino acids 7140-7211 of SEQ ID NO:5). This module incorporates a propionate extender unit (C24 and C8-C7) and fully reduces the β -keto group at C9.

epoD (nucleotides 43524-54920 of SEQ ID NO:1) codes for EPOS D (SEQ ID NO:6), a type I polyketide synthase consisting of 2 modules. The first module harbors a KS (nucleotides 43626-44885 of SEQ ID NO:1, amino acids 35-454 of SEQ ID NO:6); a methylmalonyl CoA-specific AT (nucleotides 45204-46166 of SEQ ID NO:1, amino acids 561-881 of SEQ ID NO:6); a KR (nucleotides 46950-47702 of SEQ ID NO:1, amino acids

1143-1393 of SEQ ID NO:6); and an ACP (nucleotides 47811-48032 of SEQ ID NO:1, amino acids 1430-1503 of SEQ ID NO:6). This module incorporates a propionate extender unit (C23 and C6-C5) and reduces the β -keto group at C7 to a hydroxyl group. The second module harbors a KS (nucleotides 48087-49361 of SEQ ID NO:1, amino acids 1522-1946 of SEQ ID NO: 6); a methylmalonyl CoA-specific AT (nucleotides 49680-50642 of SEQ ID NO:1, amino acids 2053-2373 of SEQ ID NO:6); a DH (nucleotides 50670-51176 of SEQ ID NO:1, amino acids 2383-2551 of SEQ ID NO:6); a methyltransferase (MT, nucleotides 51534-52657 of SEQ ID NO:1, amino acids 2671-3045 of SEQ ID NO:6); a KR (nucleotides 53697-54431 of SEQ ID NO:1, amino acids 3392-3636 of SEQ ID NO:6); and an ACP (nucleotides 54540-54758 of SEQ ID NO:1, amino acids 3673-3745 of SEQ ID NO:6). This module incorporates a propionate extender unit (C21 or C22 and C4-C3) and reduces the β -keto group at C5 to a hydroxyl group. This reduction is somewhat unexpected, since epothilones contain a keto group at C5. Discrepancies of this kind between the deduced reductive capabilities of PKS modules and the redox state of the corresponding positions in the final polyketide products have been, however, reported in the literature (see, for example, Schwecke, et al., *Proc. Natl. Acad. Sci. USA* 92: 7839-7843 (1995) and Schupp, et al., *FEMS Microbiology Letters* 159: 201-207 (1998)). An important feature of epothilones is the presence of gem-methyl side groups at C4 (C21 and C22). The second module of EPOS D is predicted to incorporate a propionate unit into the growing polyketide chain, providing one methyl side chain at C4. This module also contains a methyltransferase domain integrated into the PKS between the DH and the KR domains, in an arrangement similar to the one seen in the HMWP1 yersiniabactin synthase (Gehring, A.M., DeMoll, E., Fetherston, J.D., Mori, I., Mayhew, G.F., Blattner, F.R., Walsh, C.T., and Perry, R.D.: Iron acquisition in plague: modular logic in enzymatic biogenesis of yersiniabactin by *Yersinia pestis*. *Chem. Biol.* 5, 573-586, 1998). This MT domain in EPOS D is proposed to be responsible for the incorporation of the second methyl side group (C21 or C22) at C4.

epoE (nucleotides 54935-62254 of SEQ ID NO:1) codes for EPOS E (SEQ ID NO:7), a type I polyketide synthase consisting of one module, harboring a KS (nucleotides 55028-56284 of SEQ ID NO:1, amino acids 32-450 of SEQ ID NO:7); a malonyl CoA-specific AT (nucleotides 56600-57565 of SEQ ID NO:1, amino acids 556-877 of SEQ ID NO:7); a DH (nucleotides 57593-58087 of SEQ ID NO:1, amino acids 887-1051 of SEQ ID NO:7); a probably nonfunctional ER (nucleotides 59366-60304 of SEQ ID NO:1, amino acids 1478-1790 of SEQ ID NO:7); a KR (nucleotides 60362-61099 of SEQ ID NO:1, amino acids 1810-2055

of SEQ ID NO:7); an ACP (nucleotides 61211-61426 of SEQ ID NO:1, amino acids 2093-2164 of SEQ ID NO:7); and a thioesterase (TE) (nucleotides 61427-62254 of SEQ ID NO:1, amino acids 2165-2439 of SEQ ID NO:7). The ER domain in this module harbors an active site motif with some highly unusual amino acid substitutions that probably render this domain inactive. The module incorporates an acetate extender unit (C2-C1), and reduces the β -keto at C3 to an enoyl group. Epothilones contain a hydroxyl group at C3, so this reduction also appears to be excessive as discussed for the second module of EPOS D. The TE domain of EPOS E takes part in the release and cyclization of the grown polyketide chain via lactonization between the carboxyl group of C1 and the hydroxyl group of C15.

Five ORFs are detected upstream of *epoA* in the sequenced region. The partially sequenced *orf1* has no homologues in the sequence databanks. The deduced protein product (Orf 2, SEQ ID NO:10) of *orf2* (nucleotides 3171-1900 on the reverse complement strand of SEQ ID NO:1) shows strong similarities to hypothetical ORFs from *Mycobacterium* and *Streptomyces coelicolor*, and more distant similarities to carboxypeptidases and DD-peptidases of different bacteria. The deduced protein product of *orf3* (nucleotides 3415-5556 of SEQ ID NO:1), Orf 3 (SEQ ID NO:11), shows homologies to Na/H antiporters of different bacteria. Orf 3 might take part in the export of epothilones from the producer strain. *orf4* and *orf5* have no homologues in the sequence databanks.

Eleven ORFs are found downstream of *epoE* in the sequenced region. *epoF* (nucleotides 62369-63628 of SEQ ID NO:1) codes for EPOS F (SEQ ID NO:8), a deduced protein with strong sequence similarities to cytochrome P450 oxygenases. EPOS F may take part in the adjustment of the redox state of the carbons C12, C5, and/or C3. The deduced protein product of *orf14* (nucleotides 67334-68251 of SEQ ID NO:1), Orf 14 (SEQ ID NO:22) shows strong similarities to GI:3293544, a hypothetical protein with no proposed function from *Streptomyces coelicolor*, and also to GI:2654559, the human embryonic lung protein. It is also more distantly related to cation efflux system proteins like GI:2623026 from *Methanobacterium thermoautotrophicum*, so it might also take part in the export of epothilones from the producing cells. The remaining ORFs (*orf6-orf13* and *orf15*) show no homologies to entries in the sequence databanks.

Example 13: Recombinant Expression of Epothilone Biosynthesis Genes

Epothilone synthase genes according to the present invention are expressed in heterologous organisms for the purposes of epothilone production at greater quantities than can be accomplished by fermentation of *Sorangium cellulosum*. A preferable host for heterologous expression is *Streptomyces*, e.g. *Streptomyces coelicolor*, which natively produces the polyketide actinorhodin. Techniques for recombinant PKS gene expression in this host are described in McDaniel *et al.*, *Science* 262: 1546-1550 (1993) and Kao *et al.*, *Science* 265: 509-512 (1994). See also, Holmes *et al.*, *EMBO Journal* 12(8): 3183-3191 (1993) and Bibb *et al.*, *Gene* 38: 215-226 (1985), as well as U.S. Patent Nos. 5,521,077, 5,672,491, and 5,712,146, which are incorporated herein by reference.

According to one method, the heterologous host strain is engineered to contain a chromosomal deletion of the actinorhodin (*act*) gene cluster. Expression plasmids containing the epothilone synthase genes of the invention are constructed by transferring DNA from a temperature-sensitive donor plasmid to a recipient shuttle vector in *E. coli* (McDaniel *et al.* (1993) and Kao *et al.* (1994)), such that the synthase genes are built-up by homologous recombination within the vector. Alternatively, the epothilone synthase gene cluster is introduced into the vector by restriction fragment ligation. Following selection, e.g. as described in Kao *et al.* (1994), DNA from the vector is introduced into the *act*-minus *Streptomyces coelicolor* strain according to protocols set forth in Hopwood *et al.*, *Genetic Manipulation of Streptomyces. A Laboratory Manual* (John Innes Foundation, Norwich, United Kingdom, 1985), incorporated herein by reference. The recombinant *Streptomyces* strain is grown on R2YE medium (Hopwood *et al.* (1985)) and produces epothilones. Alternatively, the epothilone synthase genes according to the present invention are expressed in other host organisms such as pseudomonads, *Bacillus*, yeast, insect cells and/or *E. coli*. PKS and NRPS genes are preferably expressed in *E. coli* using the pT7-7 vector, which uses the T7 promoter. See, Tabor *et al.*, *Proc. Natl. Acad. Sci. USA* 82: 1074-1078 (1985). In another embodiment, the expression vectors pKK223-3 and pKK223-2 are used to express PKS and NRPS genes in *E. coli*, either in transcriptional or translational fusion, behind the *tac* or *trc* promoter. Expression of PKS and NRPS genes in heterologous hosts, which do not naturally have the phosphopantetheinyl (P-pant) transferases needed for post-translational modification of PKS enzymes, requires the coexpression in the host of a P-pant transferase, as described by Kealey *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 505-509 (1998).

Example 14: Isolation of Epothilones from Producing Strains

Examples of cultivation, fermentation, and extraction procedures for polyketide isolation, which are useful for extracting epothilones from both native and recombinant hosts according to the present invention, are given in WO 93/10121, incorporated herein by reference, in Example 57 of U.S. Patent No. 5,639,949, in Gerth *et al.*, *J. Antibiotics* 49: 560-563 (1996), and in Swiss patent application no. 396/98, filed February 19, 1998, and U.S. patent application no. 09/248,910 (that discloses also preferred mutant strains of *Sorangium cellulosum*), both of which are incorporated herein by reference. The following are procedures that are useful for isolating epothilones from cultured *Sorangium cellulosum* strains such as So ce90, and may also be used for the isolation of epothilone from recombinant hosts.

A: Cultivation of epothilone-producing strains:

Strain: *Sorangium cellulosum* Soce-90 or a recombinant host strain according to the present invention.

Preservation of the strain: In liquid N₂.

Media: Precultures and intermediate cultures: G52
Main culture: 1B12

G52 Medium:

yeast extract, low in salt (BioSpringer, Maisen Alfort, France)	2 g/l
MgSO ₄ (7 H ₂ O)	1 g/l
CaCl ₂ (2 H ₂ O)	1 g/l
soya meal defatted Soyamine 50T (Lucas Meyer, Hamburg, Germany)	2 g/l
potato starch Noredux A-150 (Blattmann, Waedenswil, Switzerland)	8 g/l
glucose anhydrous	2 g/l
EDTA-Fe(III)-Na salt (8 g/l)	1 ml/l

- 49 -

pH 7.4, corrected with KOH

Sterilisation: 20 mins. 120 °C

1B12 Medium:

potato starch Noredux A-150 (Blattmann, Waedenswil, Switzerland)	20 g/l
soya meal defatted Soyamine 50T (Lucas Meyer, Hamburg, Germany)	11 g/l
EDTA-Fe(III)-Na salt	8 mg/l

pH 7.8, corrected with KOH

Sterilisation: 20 mins. 120 °C

Addition of cyclodextrins and cyclodextrin derivatives:

Cyclodextrins (Fluka, Buchs, Switzerland, or Wacker Chemie, Munich, Germany) in different concentrations are sterilised separately and added to the 1B12 medium prior to seeding.

Cultivation: 1 ml of the suspension of *Sorangium cellulosum* Soce-90 from a liquid N₂ ampoule is transferred to 10 ml of G52 medium (in a 50 ml Erlenmeyer flask) and incubated for 3 days at 180 rpm in an agitator at 30°C, 25 mm displacement. 5 ml of this culture is added to 45 ml of G52 medium (in a 200 ml Erlenmeyer flask) and incubated for 3 days at 180 rpm in an agitator at 30°C, 25 mm displacement. 50 ml of this culture is then added to 450 ml of G52 medium (in a 2 litre Erlenmeyer flask) and incubated for 3 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

Maintenance culture: The culture is overseeded every 3-4 days, by adding 50 ml of culture to 450 ml of G52 medium (in a 2 litre Erlenmeyer flask). All experiments and fermentations are carried out by starting with this maintenance culture.

Tests in a flask:

(I) Preculture in an agitating flask:

- 50 -

Starting with the 500 ml of maintenance culture, 1 x 450 ml of G52 medium are seeded with 50 ml of the maintenance culture and incubated for 4 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

(ii) Main culture in the agitating flask:

40 ml of 1B12 medium plus 5 g/l 4-morpholine-propane-sulfonic acid (= MOPS) powder (in a 200 ml Erlenmeyer flask) are mixed with 5 ml of a 10x concentrated cyclodextrin solution, seeded with 10 ml of preculture and incubated for 5 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

Fermentation: Fermentations are carried out on a scale of 10 litres, 100 litres and 500 litres. 20 litre and 100 litre fermentations serve as an intermediate culture step. Whereas the pre-cultures and intermediate cultures are seeded as the maintenance culture 10% (v/v), the main cultures are seeded with 20% (v/v) of the intermediate culture. Important: In contrast to the agitating cultures, the ingredients of the media for the fermentation are calculated on the final culture volume including the inoculum. If, for example, 18 litres of medium + 2 litres of inoculum are combined, then substances for 20 litres are weighed in, but are only mixed with 18 litres.

Preculture in an agitating flask:

Starting with the 500 ml maintenance culture, 4 x 450 ml of G52 medium (in a 2 litre Erlenmeyer flask) are each seeded with 50 ml thereof, and incubated for 4 days at 180 rpm in an agitator at 30°C, 50 mm displacement.

Intermediate culture, 20 litres or 100 litres:

20 litres: 18 litres of G52 medium in a fermenter having a total volume of 30 litres are seeded with 2 litres of the preculture. Cultivation lasts for 3-4 days, and the conditions are: 30°C, 250 rpm, 0.5 litres of air per litre liquid per min, 0.5 bars excess pressure, no pH control.


100 litres: 90 litres of G52 medium in a fermenter having a total volume of 150 litres are seeded with 10 litres of the 20 litre intermediate culture. Cultivation lasts for 3-4 days, and the conditions are: 30°C, 150 rpm, 0.5 litres of air per litre liquid per min, 0.5 bars excess pressure, no pH control.

Main culture, 10 litres, 100 litres or 500 litres:

10 litres: The media substances for 10 litres of 1B12 medium are sterilised in 7 litres of water, then 1 litre of a sterile 10% 2-(hydroxypropyl) - β -cyclodextrin solution are added, and seeded with 2 litres of a 20 litre intermediate culture. The duration of the main culture is 6-7 days, and the conditions are: 30°C, 250 rpm, 0.5 litres of air per litre of liquid per min, 0.5 bars excess pressure, pH control with H_2SO_4/KOH to pH 7.6 +/- 0.5 (i.e. no control between pH 7.1 and 8.1).

100 litres: The media substances for 100 litres of 1B12 medium are sterilised in 70 litres of water, then 10 litres of a sterile 10% 2-(hydroxypropyl) - β -cyclodextrin solution are added, and seeded with 20 litres of a 20 litre intermediate culture. The duration of the main culture is 6-7 days, and the conditions are: 30°C, 200 rpm, 0.5 litres air per litre liquid per min., 0.5 bars excess pressure, pH control with H_2SO_4/KOH to pH 7.6 +/- 0.5. The chain of seeding for a 100 litre fermentation is shown schematically as follows:

maintenance culture (500ml)



500 litres: The media substances for 500 litres of 1B12 medium are sterilised in 350 litres of water, then 50 litres of a sterile 10% 2-(hydroxypropyl) - β -cyclodextrin solution are added, and seeded with 100 litres of a 100 litre intermediate culture. The duration of the main culture is 6-7 days, and the conditions are: 30°C, 120 rpm, 0.5 litres air per litre liquid per min., 0.5 bars excess pressure, pH control with H_2SO_4/KOH to pH 7.6 +/- 0.5.

Product analysis:Preparation of the sample:

- 52 -

50 ml samples are mixed with 2 ml of polystyrene resin Amberlite XAD16 (Rohm + Haas, Frankfurt, Germany) and shaken at 180 rpm for one hour at 30°C. The resin is subsequently filtered using a 150 µm nylon sieve, washed with a little water and then added together with the filter to a 15 ml Nunc tube.

Elution of the product from the resin:

10 ml of isopropanol (>99%) are added to the tube with the filter and the resin. Afterwards, the sealed tube is shaken for 30 minutes at room temperature on a Rota-Mixer (Labinco BV, Netherlands). Then, 2 ml of the liquid are centrifuged off and the supernatant is added using a pipette to HPLC tubes.

HPLC analysis:

Column:	Waters-Symetry C18, 100 x 4 mm, 3.5 µm WAT066220 + preliminary column 3.9 x 20 mm WAT054225
Solvents:	A: 0.02 % phosphoric acid B: Acetonitrile (HPLC-Quality)
Gradient:	41% B from 0 to 7 min. 100% B from 7.2 to 7.8 min. 41% B from 8 to 12 min.
Oven temp.:	30°C
Detection:	250 nm, UV-DAD detection
Injection vol.:	10 µl
Retention time:	Epo A: 4.30 min Epo B: 5.38 min

B: Effect of the addition of cyclodextrin and cyclodextrin derivatives to the epothilone concentrations attained.


Cyclodextrins are cyclic (α -1,4)-linked oligosaccharides of α -D-glucopyranose with a relatively hydrophobic central cavity and a hydrophilic external surface area.

The following are distinguished in particular (the figures in parenthesis give the number of glucose units per molecule): α -cyclodextrin (6), β -cyclodextrin (7), γ -cyclodextrin (8), δ -cyclodextrin (9), ϵ -cyclodextrin (10), ζ -cyclodextrin (11), η -cyclodextrin (12), and θ -cyclodextrin (13). Especially preferred are δ -cyclodextrin and in particular α -cyclodextrin, β -cyclodextrin or γ -cyclodextrin, or mixtures thereof.

Cyclodextrin derivatives are primarily derivatives of the above-mentioned cyclodextrins, especially of α -cyclodextrin, β -cyclodextrin or γ -cyclodextrin, primarily those in which one or more up to all of the hydroxy groups (3 per glucose radical) are etherified or esterified. Ethers are primarily alkyl ethers, especially lower alkyl, such as methyl or ethyl ether, also propyl or butyl ether; the aryl-hydroxyalkyl ethers, such as phenyl-hydroxy-lower-alkyl, especially phenyl-hydroxyethyl ether; the hydroxyalkyl ethers, in particular hydroxy-lower-alkyl ethers, especially 2-hydroxyethyl, hydroxypropyl such as 2-hydroxypropyl or hydroxybutyl such as 2-hydroxybutyl ether; the carboxyalkyl ethers, in particular carboxy-lower-alkyl ethers, especially carboxymethyl or carboxyethyl ether; derivatised carboxyalkyl ethers, in particular derivatised carboxy-lower-alkyl ether in which the derivatised carboxy is etherified or amidated carboxy (primarily aminocarbonyl, mono- or di-lower-alkyl-aminocarbonyl, morpholino-, piperidino-, pyrrolidino- or piperazino-carbonyl, or alkyloxycarbonyl), in particular lower alkyloxycarbonyl-lower-alkyl ether, for example methyloxycarbonylpropyl ether or ethyloxycarbonylpropyl ether; the sulfoalkyl ethers, in particular sulfo-lower-alkyl ethers, especially sulfobutyl ether; cyclodextrins in which one or more OH groups are etherified with a radical of formula



wherein alk is alkyl, especially lower alkyl, and n is a whole number from 2 to 12, especially 2 to 5, in particular 2 or 3; cyclodextrins in which one or more OH groups are etherified with a radical of formula



wherein R' is hydrogen, hydroxy, $-\text{O}-(\text{alk-O})_z\text{-H}$, $-\text{O}-(\text{alk}(-\text{R})-\text{O})_p\text{-H}$ or $-\text{O}-(\text{alk}(-\text{R})-\text{O})_q\text{-alk-CO-Y}$; alk in all cases is alkyl, especially lower alkyl; m, n, p, q and z are a whole number from 1 to 12, preferably 1 to 5, in particular 1 to 3; and Y is OR_1 or NR_2R_3 , wherein R_1 , R_2 and R_3 independently of one another, are hydrogen or lower alkyl, or R_2 and R_3 combined together with the linking nitrogen signify morpholino, piperidino, pyrrolidino or piperazino; or branched cyclodextrins, in which etherifications or acetals with other sugar molecules are present, especially glucosyl-, diglucosyl- (G_2 - β -cyclodextrin), maltosyl- or dimaltosyl-cyclodextrin, or N-acetylglucosaminyl-, glucosaminyl-, N-acetylgalactosaminyl- or galactosaminyl-cyclodextrin.

Esters are primarily alkanoyl esters, in particular lower alkanoyl esters, such as acetyl esters of cyclodextrins.

It is also possible to have cyclodextrins in which two or more different said ether and ester groups are present at the same time.

Mixtures of two or more of the said cyclodextrins and/or cyclodextrin derivatives may also exist.

Preference is given in particular to α -, β - or γ -cyclodextrins or the lower alkyl ethers thereof, such as methyl- β -cyclodextrin or in particular 2,6-di-O-methyl- β -cyclodextrin, or in particular the hydroxy lower alkyl ethers thereof, such as 2-hydroxypropyl- α -, 2-hydroxypropyl- β - or 2-hydroxypropyl- γ -cyclodextrin.

The cyclodextrins or cyclodextrin derivatives are added to the culture medium preferably in a concentration of 0.02 to 10, preferably 0.05 to 5, especially 0.1 to 4, for example 0.1 to 2 percent by weight (w/v).

Cyclodextrins or cyclodextrin derivatives are known or may be produced by known processes (see for example US 3,459,731; US 4,383,992; US 4,535,152; US 4,659,696; EP 0 094 157; EP 0 149 197; EP 0 197 571; EP 0 300 526; EP 0 320 032; EP 0 499 322; EP 0 503 710; EP 0 818 469; WO 90/12035; WO 91/11200; WO 93/19061; WO 95/08993; WO 96/14090; GB 2,189,245; DE 3,118,218; DE 3,317,064 and the references mentioned therein, which also refer to the synthesis of cyclodextrins or cyclodextrin derivatives, or also: T. Loftsson and M.E. Brewster (1996): Pharmaceutical Applications of Cyclodextrins: Drug Solubilization and Stabilisation: Journal of Pharmaceutical Science 85 (10):1017-1025; R.A. Rajewski and V.J. Stella(1996): Pharmaceutical Applications of Cyclodextrins: In Vivo Drug Delivery: Journal of Pharmaceutical Science 85 (11): 1142-1169).

All the cyclodextrin derivatives tested here are obtainable from the company Fluka, Buchs, CH. The tests are carried out in 200 ml agitating flasks with 50 ml culture volume. As controls, flasks with adsorber resin Amberlite XAD-16 (Rohm & Haas, Frankfurt, Germany) and without any adsorber addition are used. After incubation for 5 days, the following epothilone titres can be determined by HPLC:

Table 2:

Addition	order No.	Conc [%w/v] ¹	Ep A [mg/l]	Ep B [mg/l]
Amberlite XAD-16 (v/v)		2.0 (%v/v)	9.2	3.8

- 55 -

Addition	order No.	Conc [%w/v] ¹	Epo A [mg/l]	Epo B [mg/l]
2-hydroxypropyl- β -cyclodextrin	56332	0.1	2.7	1.7
2-hydroxypropyl- β -cyclodextrin	"	0.5	4.7	3.3
2-hydroxypropyl- β -cyclodextrin	"	1.0	4.7	3.4
2-hydroxypropyl- β -cyclodextrin	"	2.0	4.7	4.1
2-hydroxypropyl- β -cyclodextrin	"	5.0	1.7	0.5
2-hydroxypropyl- α -cyclodextrin	56330	0.5	1.2	1.2
2-hydroxypropyl- α -cyclodextrin	"	1.0	1.2	1.2
2-hydroxypropyl- α -cyclodextrin	"	5.0	2.5	2.3
β -cyclodextrin	28707	0.1	1.6	1.3
β -cyclodextrin	"	0.5	3.6	2.5
β -cyclodextrin	"	1.0	4.8	3.7
β -cyclodextrin	"	2.0	4.8	2.9
β -cyclodextrin	"	5.0	1.1	0.4
methyl- β -cyclodextrin	66292	0.5	0.8	<0.3
methyl- β -cyclodextrin	"	1.0	<0.3	<0.3
methyl- β -cyclodextrin	"	2.0	<0.3	<0.3
2,6 di-o-methyl- β -cyclodextrin	39915	1.0	<0.3	<0.3
2-hydroxypropyl- γ -cyclodextrin	56334	0.1	0.3	<0.3
2-hydroxypropyl- γ -cyclodextrin	"	0.5	0.9	0.8
2-hydroxypropyl- γ -cyclodextrin	"	1.0	1.1	0.7
2-hydroxypropyl- γ -cyclodextrin	"	2.0	2.6	0.7
2-hydroxypropyl- γ -cyclodextrin	"	5.0	5.0	1.1
no addition			0.5	0.5

¹) Apart from Amberlite (%v/v), all percentages are by weight (%w/v).

Few of the cyclodextrins tested (2,6-di-o-methyl- β -cyclodextrin, methyl- β -cyclodextrin) display no effect or a negative effect on epothilone production at the concentrations used.

1-2% 2-hydroxy-propyl- β -cyclodextrin and β -cyclodextrin increase epothilone production in the examples by 6 to 8 times compared with production using no cyclodextrins.

C: 10 litre fermentation with 1% 2-(hydroxypropyl)- β -cyclodextrin):

Fermentation is carried out in a 15 litre glass fermenter. The medium contains 10 g/l of 2-(hydroxypropyl)- β -cyclodextrin from Wacker Chemie, Munich, Germany. The progress of fermentation is illustrated in Table 3. Fermentation is ended after 6 days and working up takes place.

Table 3: Progress of a 10 litre fermentation

duration of culture [d]	Epothilone A [mg/l]	Epothilone B [mg/l]
0	0	0
1	0	0
2	0.5	0.3
3	1.8	2.5
4	3.0	5.1
5	3.7	5.9
6	3.6	5.7

D: 100 litre fermentation with 1% 2-(hydroxypropyl)- β -cyclodextrin):

Fermentation is carried out in a 150 litre fermenter. The medium contains 10 g/l of 2-(Hydroxypropyl)- β -cyclodextrin. The progress of fermentation is illustrated in Table 4. The fermentation is harvested after 7 days and worked up.

Table 4: Progress of a 100 litre fermentation

duration of culture [d]	Epothilone A [mg/l]	Epothilone B [mg/l]
0	0	0
1	0	0
2	0.3	0

- 57 -

3	0.9	1.1
4	1.5	2.3
5	1.6	3.3
6	1.8	3.7
7	1.8	3.5

E: 500 litre fermentation with 1% 2-(hydroxypropyl)- β -cyclodextrin):

Fermentation is carried out in a 750 litre fermenter. The medium contains 10 g/l of 2-(Hydroxypropyl)- β -cyclodextrin. The progress of fermentation is illustrated in Table 5. The fermentation is harvested after 7 days and worked up.

Table 5: Progress of a 500 litre fermentation

duration of culture [d]	Epothilone A [mg/l]	Epothilone B [mg/l]
0	0	0
1	0	0
2	0	0
3	0.6	0.6
4	1.7	2.2
5	3.1	4.5
6	3.1	5.1

F: Comparison example 10 litre fermentation without adding an adsorber:

Fermentation is carried out in a 15 litre glass fermenter. The medium does not contain any cyclodextrin or other adsorber. The progress of fermentation is illustrated in Table 6. The fermentation is not harvested and worked up.

Table 6: Progress of a 10 litre fermentation without adsorber.

duration of culture [d]	Epothilone A [mg/l]	Epothilone B [mg/l]
0	0	0
1	0	0
2	0	0
3	0	0
4	0.7	0.7
5	0.7	1.0
6	0.8	1.3

G: Working up of the epothilones: Isolation from a 500 litre main culture:

The volume of harvest from the 500 litre main culture of example 2D is 450 litres and is separated using a Westfalia clarifying separator Type SA-20-06 (rpm = 6500) into the liquid phase (centrifugate + rinsing water = 650 litres) and solid phase (cells = ca. 15 kg). The main part of the epothilones are found in the centrifugate. The centrifuged cell pulp contains < 15% of the determined epothilone portion and is not further processed. The 650 litre centrifugate is then placed in a 4000 litre stirring vessel, mixed with 10 litres of Amberlite XAD-16 (centrifugate:resin volume = 65:1) and stirred. After a period of contact of ca. 2 hours, the resin is centrifuged away in a Heine overflow centrifuge (basket content 40 litres; rpm = 2800). The resin is discharged from the centrifuge and washed with 10-15 litres of deionised water. Desorption is effected by stirring the resin twice, each time in portions with 30 litres of isopropanol in 30 litre glass stirring vessels for 30 minutes. Separation of the isopropanol phase from the resin takes place using a suction filter. The isopropanol is then removed from the combined isopropanol phases by adding 15-20 litres of water in a vacuum-operated circulating evaporator (Schmid-Verdampfer) and the resulting water phase of ca. 10 litres is extracted 3x each time with 10 litres of ethyl acetate. Extraction is effected in 30 litre glass stirring vessels. The ethyl acetate extract is concentrated to 3-5 litres in a vacuum-operated circulating evaporator (Schmid-Verdampfer) and afterwards concentrated to dryness in a rotary evaporator (Büchi type) under vacuum. The result is an ethyl acetate extract of 50.2 g. The ethyl acetate extract is dissolved in

- 59 -

500 ml of methanol, the insoluble portions filtered off using a folded filter, and the solution added to a 10 kg Sephadex LH 20 column (Pharmacia, Uppsala, Sweden) (column diameter 20 cm, filling level ca. 1.2 m). Elution is effected with methanol as eluant. Epothilone A and B is present predominantly in fractions 21-23 (at a fraction size of 1 litre). These fractions are concentrated to dryness in a vacuum on a rotary evaporator (total weight 9.0 g). These Sephadex peak fractions (9.0 g) are thereafter dissolved in 92 ml of acetonitrile:-water:-methylene chloride = 50:40:2, the solution filtered through a folded filter and added to a RP column (equipment Prepbar 200, Merck; 2.0 kg LiChrospher RP-18 Merck, grain size 12 μ m, column diameter 10 cm, filling level 42 cm; Merck, Darmstadt, Germany). Elution is effected with acetonitrile:water = 3:7 (flow rate = 500 ml/min.; retention time of epothilone A = ca. 51-59 mins.; retention time of epothilone B = ca. 60-69 mins.). Fractionation is monitored with a UV detector at 250 nm. The fractions are concentrated to dryness under vacuum on a Büchi-Rotavapor rotary evaporator. The weight of the epothilone A peak fraction is 700 mg, and according to HPLC (external standard) it has a content of 75.1%. That of the epothilone B peak fraction is 1980 mg, and the content according to HPLC (external standard) is 86.6%. Finally, the epothilone A fraction (700 mg) is crystallised from 5 ml of ethyl acetate:toluene = 2:3, and yields 170 mg of epothilone A pure crystallisate [content according to HPLC (% of area) = 94.3%]. Crystallisation of the epothilone B fraction (1980 mg) is effected from 18 ml of methanol and yields 1440 mg of epothilone B pure crystallisate [content according to HPLC (% of area) = 99.2%]. m.p. (Epothilone B): e.g. 124-125 °C; ¹H-NMR data for Epothilone B: 500 MHz-NMR, solvent: DMSO-d₆. Chemical displacement δ in ppm relative to TMS. s = singlet; d = doublet; m = multiplet

δ (Multiplicity)	Integral (number of H)
7.34 (s)	1
6.50 (s)	1
5.28 (d)	1
5.08 (d)	1
4.46 (d)	1
4.08 (m)	1

- 60 -

3.47 (m)	1
3.11 (m)	1
2.83 (dd)	1
2.64 (s)	3
2.36 (m)	2
2.09 (s)	3
2.04 (m)	1
1.83 (m)	1
1.61 (m)	1
1.47 - 1.24 (m)	4
1.18 (s)	6
1.13 (m)	2
1.06 (d)	3
0.89 (d + s, overlapping)	6
$\Sigma = 41$	

Example 15: Medical Uses of Recombinantly Produced Epothilones

Pharmaceutical preparations or compositions comprising epothilones are used for example in the treatment of cancerous diseases, such as various human solid tumors. Such anticancer formulations comprise, for example, an active amount of an epothilone together with one or more organic or inorganic, liquid or solid, pharmaceutically suitable carrier materials. Such formulations are delivered, for example, enterally, nasally, rectally, orally, or parenterally, particularly intramuscularly or intravenously. The dosage of the active ingredient is dependent upon the weight, age, and physical and pharmacokinetical condition of the patient and is further dependent upon the method of delivery. Because epothilones mimic the biological effects of taxol, epothilones may be substituted for taxol in compositions and methods utilizing taxol in the treatment of cancer. See, for example, U.S.

Patent Nos. 5,496,804, 5,565,478, and 5,641,803, all of which are incorporated herein by reference.

For example, for treatments, epothilone B is supplied in individual 2 ml glass vials formulated as 1 mg/1 ml of clear, colorless intravenous concentrate. The substance is formulated in polyethylene glycol 300 (PEG 300) and diluted with 50 or 100 ml 0.9% Sodium Chloride Injection, USP, to achieve the desired final concentration of the drug for infusion. It is administered as a single 30-minute intravenous infusion every 21 days (treatment three-weekly) for six cycles, or as a single 30-minute intravenous infusion every 7 days (weekly treatment).

Preferably, for weekly treatment, the dose is between about 0.1 and about 6, preferably about 0.1 and about 5 mg/m², more preferably about 0.1 and about 3 mg/m², even more preferably 0.1 and 1.7 mg/m², most preferably about 0.3 and about 1 mg/m²; for three-weekly treatment (treatment every three weeks or every third week) the dose is between about 0.3 and about 18 mg/m², preferably about 0.3 and about 15 mg/m², more preferably about 0.3 and about 12 mg/m², even more preferably about 0.3 and about 7.5 mg/m², still more preferably about 0.3 and about 5 mg/m², most preferably about 1.0 and about 3.0 mg/m². This dose is preferably administered to the human by intravenous (i.v.) administration during 2 to 180 min, preferably 2 to 120 min, more preferably during about 5 to about 30 min, most preferably during about 10 to about 30 min, e.g. during about 30 min.

While the present invention has been described with reference to specific embodiments thereof, it will be appreciated that numerous variations, modifications, and embodiments are possible, and accordingly, all such variations, modifications and embodiments are to be regarded as being within the spirit and scope of the present invention.


BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSE OF PATENT PROCEDURES

INTERNATIONAL FORM

TO
Novartis AG
Novartis Corporation
Patent and Trademark Dept.
3054 Cornwallis Rd.
Research Triangle Park, NC 27709

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
Issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

NAME AND ADDRESS
OF DEPOSITOR

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Escherichia coli</i> DH10B [pEP015]	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NRRL B-30033
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by: <input type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on June 11, 1998 (date of the original deposit) ¹	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I. above was received by this International Depositary Authority on _____ (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____ (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 7-21-98


¹ Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSE OF PATENT PROCEDURES

INTERNATIONAL FORM

TO
Novartis AG
c/o Novartis Agricultural Biotechnology
Research, Int.
Patent & Trademark Department
3054 Cornwallis Road
Research Triangle Park, NC 27709
NAME AND ADDRESS
OF DEPOSITOR

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: Escherichia coli DH10B [pBPO32]	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NRRL B-30119
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by:	
<input type="checkbox"/> a scientific description	
<input checked="" type="checkbox"/> a proposed taxonomic designation	
(Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on April 16, 1999 (date of the original deposit) ¹	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I. above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Agricultural Research Culture Collection (NRRL) International Depositary Authority Address: 1815 N. University Street Peoria, Illinois 61604 U.S.A.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 5-26-99

¹ Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

What is claimed is:

1. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one polypeptide involved in the biosynthesis of epothilone.
2. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence is isolated from a myxobacterium.
3. An isolated nucleic acid molecule according to claim 2, wherein said myxobacterium is *Sorangium cellulosum*.
4. A chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule according to claim 1.
5. A recombinant vector comprising a chimeric gene according to claim 4.
6. A recombinant host cell comprising a chimeric gene according to claim 4.
7. The recombinant host cell of claim 6, which is a bacteria.
8. The recombinant host cell of claim 7, which is an Actinomycete.
9. The recombinant host cell of claim 8, which is *Streptomyces*.
10. A Bac clone comprising a nucleic acid molecule according to claim 1.
11. The Bac clone of claim 10, which is pEPO15.
12. An isolated nucleic acid molecule according to claim 1, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:2, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids

118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 7-432 of SEQ ID NO:4, amino acids 539-859 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684 of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

13. An isolated nucleic acid molecule according to claim 12, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:2, amino acids 11-437 of SEQ ID NO:2, amino acids 543-864 of SEQ ID NO:2, amino acids 974-1273 of SEQ ID NO:2, amino acids 1314-1385 of SEQ ID NO:2, SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino

acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, amino acids 1344-1351 of SEQ ID NO:3, SEQ ID NO:4, amino acids 7-432 of SEQ ID NO:4, amino acids 539-859 of SEQ ID NO:4, amino acids 869-1037 of SEQ ID NO:4, amino acids 1439-1684 of SEQ ID NO:4, amino acids 1722-1792 of SEQ ID NO:4, SEQ ID NO:5, amino acids 39-457 of SEQ ID NO:5, amino acids 563-884 of SEQ ID NO:5, amino acids 1147-1399 of SEQ ID NO:5, amino acids 1434-1506 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 3886-4048 of SEQ ID NO:5, amino acids 4433-4719 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, SEQ ID NO:6, amino acids 35-454 of SEQ ID NO:6, amino acids 561-881 of SEQ ID NO:6, amino acids 1143-1393 of SEQ ID NO:6, amino acids 1430-1503 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, amino acids 2053-2373 of SEQ ID NO:6, amino acids 2383-2551 of SEQ ID NO:6, amino acids 2671-3045 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, SEQ ID NO:7, amino acids 32-450 of SEQ ID NO:7, amino acids 556-877 of SEQ ID NO:7, amino acids 887-1051 of SEQ ID NO:7, amino acids 1478-1790 of SEQ ID NO:7, amino acids 1810-2055 of SEQ ID NO:7, amino acids 2093-2164 of SEQ ID NO:7, amino acids 2165-2439 of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:22.

14. An isolated nucleic acid molecule according to claim 12, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ

ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

15. A nucleic acid molecule according to claim 12, wherein said nucleotide sequence is selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID

NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

16. A chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule according to claim 12.

17. A recombinant vector comprising a chimeric gene according to claim 16.

18. A recombinant host cell comprising a chimeric gene according to claim 16.

19. The recombinant host cell of claim 18, which is a bacteria.

20. The recombinant host cell of claim 19, which is an Actinomycete.

21. The recombinant host cell of claim 20, which is *Streptomyces*.

22. An isolated nucleic acid molecule according to claim 1, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: the complement of nucleotides 1900-3171 of SEQ ID NO:1, nucleotides 3415-5556 of SEQ ID NO:1, nucleotides 7610-11875 of SEQ ID NO:1, nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID

NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, nucleotides 15901-15924 of SEQ ID NO:1, nucleotides 16251-21749 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 21746-43519 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 43524-54920 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, nucleotides 51534-52657 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, nucleotides 54935-62254 of SEQ ID NO:1, nucleotides 55028-56284 of SEQ ID NO:1, nucleotides 56600-57565 of SEQ ID NO:1, nucleotides 57593-58087 of SEQ ID NO:1, nucleotides 59366-60304 of SEQ ID NO:1, nucleotides 60362-61099 of SEQ ID NO:1, nucleotides 61211-61426 of SEQ ID NO:1, nucleotides 61427-62254 of SEQ ID NO:1, nucleotides 62369-63628 of SEQ ID NO:1, nucleotides 67334-68251 of SEQ ID NO:1, and nucleotides 1-68750 SEQ ID NO:1.

23. A chimeric gene comprising a heterologous promoter sequence operatively linked to a nucleic acid molecule according to claim 22.

24. A recombinant vector comprising a chimeric gene according to claim 23.

25. A recombinant host cell comprising a chimeric gene according to claim 23.

26. The recombinant host cell of claim 25, which is a bacteria.
27. The recombinant host cell of claim 26, which is an Actinomycete.
28. The recombinant host cell of claim 27, which is *Streptomyces*.
29. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes at least one epothilone synthase domain.
30. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a β -ketoacyl-synthase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.
31. An isolated nucleic acid molecule according to claim 30, wherein said β -ketoacyl-synthase domain comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.
32. An isolated nucleic acid molecule according to claim 30, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.

33. An isolated nucleic acid molecule according to claim 30, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.

34. An isolated nucleic acid molecule according to claim 30, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 7643-8920 of SEQ ID NO:1, nucleotides 16269-17546 of SEQ ID NO:1, nucleotides 21860-23116 of SEQ ID NO:1, nucleotides 26318-27595 of SEQ ID NO:1, nucleotides 30815-32092 of SEQ ID NO:1, nucleotides 37052-38320 of SEQ ID NO:1, nucleotides 43626-44885 of SEQ ID NO:1, nucleotides 48087-49361 of SEQ ID NO:1, and nucleotides 55028-56284 of SEQ ID NO:1.

35. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is an acyltransferase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

36. An isolated nucleic acid molecule according to claim 35, wherein said acyltransferase domain comprises an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

37. An isolated nucleic acid molecule according to claim 35, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.

38. An isolated nucleic acid molecule according to claim 35, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.

39. An isolated nucleic acid molecule according to claim 35, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 9236-10201 of SEQ ID NO:1, nucleotides 17865-18827 of SEQ ID NO:1, nucleotides 23431-24397 of SEQ ID NO:1, nucleotides 27911-28876 of SEQ ID NO:1, nucleotides 32408-33373 of SEQ ID NO:1, nucleotides 38636-39598 of SEQ ID NO:1, nucleotides 45204-46166 of SEQ ID NO:1, nucleotides 49680-50642 of SEQ ID NO:1, and nucleotides 56600-57565 of SEQ ID NO:1.

40. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is an enoyl reductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

41. An isolated nucleic acid molecule according to claim 40, wherein said enoyl reductase domain comprises an amino acid sequence selected from the group consisting

of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

42. An isolated nucleic acid molecule according to claim 40, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1.

43. An isolated nucleic acid molecule according to claim 40, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1.

44. An isolated nucleic acid molecule according to claim 40, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 10529-11428 of SEQ ID NO:1, nucleotides 35042-35902 of SEQ ID NO:1, nucleotides 41369-42256 of SEQ ID NO:1, and nucleotides 59366-60304 of SEQ ID NO:1.

45. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is an acyl carrier protein domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

46. An isolated nucleic acid molecule according to claim 45, wherein said acyl carrier protein domain comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID

NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

47. An isolated nucleic acid molecule according to claim 45, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.

48. An isolated nucleic acid molecule according to claim 45, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.

49. An isolated nucleic acid molecule according to claim 45, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 11549-11764 of SEQ ID NO:1, nucleotides 21414-21626 of SEQ ID NO:1, nucleotides 26045-26263 of SEQ ID NO:1, nucleotides 30539-30759 of SEQ ID NO:1, nucleotides 36773-36991 of SEQ ID NO:1, nucleotides 43163-43378 of SEQ ID NO:1, nucleotides 47811-48032 of SEQ ID NO:1, nucleotides 54540-54758 of SEQ ID NO:1, and nucleotides 61211-61426 of SEQ ID NO:1.

50. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a dehydratase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of:

amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

51. An isolated nucleic acid molecule according to claim 50, wherein said dehydratase domain comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

52. An isolated nucleic acid molecule according to claim 50, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.

53. An isolated nucleic acid molecule according to claim 50, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.

54. An isolated nucleic acid molecule according to claim 50, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 18855-19361 of SEQ ID NO:1, nucleotides 33401-33889 of SEQ ID NO:1, nucleotides 39635-40141 of SEQ ID NO:1, nucleotides 50670-51176 of SEQ ID NO:1, and nucleotides 57593-58087 of SEQ ID NO:1.

55. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a β -ketoreductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino

acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

56. An isolated nucleic acid molecule according to claim 55, wherein said β -ketoreductase domain comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

57. An isolated nucleic acid molecule according to claim 55, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.

58. An isolated nucleic acid molecule according to claim 55, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.

59. An isolated nucleic acid molecule according to claim 55, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 20565-21302 of SEQ ID NO:1, nucleotides 25184-25942 of SEQ ID NO:1, nucleotides 29678-30429 of SEQ ID NO:1, nucleotides 35930-36667 of SEQ ID NO:1, nucleotides 42314-43048 of SEQ ID

NO:1, nucleotides 46950-47702 of SEQ ID NO:1, nucleotides 53697-54431 of SEQ ID NO:1, and nucleotides 60362-61099 of SEQ ID NO:1.

60. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a methyltransferase domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6.

61. An isolated nucleic acid molecule according to claim 60, wherein said methyltransferase domain comprises amino acids 2671-3045 of SEQ ID NO:6.

62. An isolated nucleic acid molecule according to claim 60, wherein said nucleotide sequence is substantially similar to nucleotides 51534-52657 of SEQ ID NO:1.

63. An isolated nucleic acid molecule according to claim 60, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of nucleotides 51534-52657 of SEQ ID NO:1.

64. An isolated nucleic acid molecule according to claim 60, wherein said nucleotide sequence is nucleotides 51534-52657 of SEQ ID NO:1.

65. An isolated nucleic acid molecule according to claim 29, wherein said epothilone synthase domain is a thioesterase domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7.

66. An isolated nucleic acid molecule according to claim 65, wherein said thioesterase domain comprises amino acids 2165-2439 of SEQ ID NO:7.

67. An isolated nucleic acid molecule according to claim 65, wherein said nucleotide sequence is substantially similar to nucleotides 61427-62254 of SEQ ID NO:1.

68. An isolated nucleic acid molecule according to claim 65, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of nucleotides 61427-62254 of SEQ ID NO:1.

69. An isolated nucleic acid molecule according to claim 65, wherein said nucleotide sequence is nucleotides 61427-62254 of SEQ ID NO:1.

70. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a non-ribosomal peptide synthetase, wherein said non-ribosomal peptide synthetase comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3.

71. An isolated nucleic acid molecule according to claim 70, wherein said non-ribosomal peptide synthetase comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:3, amino acids 72-81 of SEQ ID NO:3, amino acids 118-125 of SEQ ID NO:3, amino acids 199-212 of SEQ ID NO:3, amino acids 353-363 of SEQ ID NO:3, amino acids 549-565 of SEQ ID NO:3, amino acids 588-603 of SEQ ID NO:3, amino acids 669-684 of SEQ ID NO:3, amino acids 815-821 of SEQ ID NO:3, amino acids 868-892 of SEQ ID NO:3, amino acids 903-912 of SEQ ID NO:3, amino acids 918-940 of SEQ ID NO:3, amino acids 1268-1274 of SEQ ID NO:3, amino acids 1285-1297 of SEQ ID NO:3, amino acids 973-1256 of SEQ ID NO:3, and amino acids 1344-1351 of SEQ ID NO:3.

72. An isolated nucleic acid molecule according to claim 70, wherein said nucleotide sequence is substantially similar to a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID

NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.

73. An isolated nucleic acid molecule according to claim 70, wherein said nucleotide sequence comprises a consecutive 20 base pair nucleotide portion identical in sequence to a consecutive 20 base pair portion of a nucleotide sequence selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.

74. An isolated nucleic acid molecule according to claim 70, wherein said nucleotide sequence is selected from the group consisting of: nucleotides 11872-16104 of SEQ ID NO:1, nucleotides 12085-12114 of SEQ ID NO:1, nucleotides 12223-12246 of SEQ ID NO:1, nucleotides 12466-12507 of SEQ ID NO:1, nucleotides 12928-12960 of SEQ ID NO:1, nucleotides 13516-13566 of SEQ ID NO:1, nucleotides 13633-13680 of SEQ ID NO:1, nucleotides 13876-13923 of SEQ ID NO:1, nucleotides 14313-14334 of SEQ ID NO:1, nucleotides 14473-14547 of SEQ ID NO:1, nucleotides 14578-14607 of SEQ ID NO:1, nucleotides 14623-14692 of SEQ ID NO:1, nucleotides 15673-15693 of SEQ ID NO:1, nucleotides 15724-15762 of SEQ ID NO:1, nucleotides 14788-15639 of SEQ ID NO:1, and nucleotides 15901-15924 of SEQ ID NO:1.

75. A method for heterologous expression of epothilone in a recombinant host, comprising:

- (a) introducing a chimeric gene according to claim 4 into a host; and
- (b) growing the host in conditions that allow biosynthesis of epothilone in the host.

76. A method for producing epothilone, comprising:

- (a) expressing epothilone in a recombinant host by the method of claim 75; and
- (b) extracting epothilone from the recombinant host.

77. An isolated polypeptide comprising an amino acid sequence that consists of an epothilone synthase domain.

78. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a β -ketoacyl-synthase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.

79. An isolated polypeptide according to claim 78, wherein said β -ketoacyl-synthase domain comprises an amino acid sequence selected from the group consisting of: amino acids 11-437 of SEQ ID NO:2, amino acids 7-432 of SEQ ID NO:4, amino acids 39-457 of SEQ ID NO:5, amino acids 1524-1950 of SEQ ID NO:5, amino acids 3024-3449 of SEQ ID NO:5, amino acids 5103-5525 of SEQ ID NO:5, amino acids 35-454 of SEQ ID NO:6, amino acids 1522-1946 of SEQ ID NO: 6, and amino acids 32-450 of SEQ ID NO:7.

80. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is an acyltransferase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

81. An isolated polypeptide according to claim 80, wherein said acyltransferase domain comprises an amino acid sequence selected from the group consisting of: amino

acids 543-864 of SEQ ID NO:2, amino acids 539-859 of SEQ ID NO:4, amino acids 563-884 of SEQ ID NO:5, amino acids 2056-2377 of SEQ ID NO:5, amino acids 3555-3876 of SEQ ID NO:5, amino acids 5631-5951 of SEQ ID NO:5, amino acids 561-881 of SEQ ID NO:6, amino acids 2053-2373 of SEQ ID NO:6, and amino acids 556-877 of SEQ ID NO:7.

82. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is an enoyl reductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

83. An isolated polypeptide according to claim 82, wherein said enoyl reductase domain comprises an amino acid sequence selected from the group consisting of: amino acids 974-1273 of SEQ ID NO:2, amino acids 4433-4719 of SEQ ID NO:5, amino acids 6542-6837 of SEQ ID NO:5, and amino acids 1478-1790 of SEQ ID NO:7.

84. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is an acyl carrier protein domain, wherein said polypeptide comprises an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

85. An isolated polypeptide according to claim 84, wherein said acyl carrier protein domain comprises an amino acid sequence selected from the group consisting of: amino acids 1314-1385 of SEQ ID NO:2, amino acids 1722-1792 of SEQ ID NO:4, amino acids 1434-1506 of SEQ ID NO:5, amino acids 2932-3005 of SEQ ID NO:5, amino acids 5010-5082 of SEQ ID NO:5, amino acids 7140-7211 of SEQ ID NO:5, amino acids 1430-1503 of SEQ ID NO:6, amino acids 3673-3745 of SEQ ID NO:6, and amino acids 2093-2164 of SEQ ID NO:7.

86. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a dehydratase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

87. An isolated polypeptide according to claim 86, wherein said dehydratase domain comprises an amino acid sequence selected from the group consisting of: amino acids 869-1037 of SEQ ID NO:4, amino acids 3886-4048 of SEQ ID NO:5, amino acids 5964-6132 of SEQ ID NO:5, amino acids 2383-2551 of SEQ ID NO:6, and amino acids 887-1051 of SEQ ID NO:7.

88. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a β -ketoreductase domain comprising an amino acid sequence substantially similar to an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

89. An isolated polypeptide according to claim 88, wherein said β -ketoreductase domain comprises an amino acid sequence selected from the group consisting of: amino acids 1439-1684 of SEQ ID NO:4, amino acids 1147-1399 of SEQ ID NO:5, amino acids 2645-2895 of SEQ ID NO:5, amino acids 4729-4974 of SEQ ID NO:5, amino acids 6857-7101 of SEQ ID NO:5, amino acids 1143-1393 of SEQ ID NO:6, amino acids 3392-3636 of SEQ ID NO:6, and amino acids 1810-2055 of SEQ ID NO:7.

90. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a methyltransferase domain comprising an amino acid sequence substantially similar to amino acids 2671-3045 of SEQ ID NO:6.

91. An isolated polypeptide according to claim 90, wherein said methyltransferase domain comprises amino acids 2671-3045 of SEQ ID NO:6.

92. An isolated polypeptide according to claim 77, wherein said epothilone synthase domain is a thioesterase domain comprising an amino acid sequence substantially similar to amino acids 2165-2439 of SEQ ID NO:7.

93. An isolated polypeptide according to claim 77, wherein said thioesterase domain comprises amino acids 2165-2439 of SEQ ID NO:7.

- 1 -

SEQUENCE LISTING

<110> Novartis AG

<120> GENES FOR THE BIOSYNTHESIS OF EPOTHILONES

<130> 4-30582A

<140>

<141>

<160> 30

<170> PatentIn Ver. 2.0

<210> 1

<211> 68750

<212> DNA

<213> Sorangium cellulosum

<400> 1

```

aagcttcgct cgacgcccctc ttgccccgcg ccacctctgc ccgtgtgctc gatgatggcc 60
acggccgggc caccgagcgg catgtgctcg ccgaggcgcg cgggatcgag gacctccgcg 120
ccctccgaga gcacctccgc atccaggaag gggggccgct ctttactgc atgtgcctcg 180
gcgacctgac ggtggagctc ctcgcgcacg accagcccc- cgcgtccatc agcttccacc 240
atgcccgcag cctgaggcac cccgactgga cctcggacgc gatgtcgtc gacggccccg 300
cgctcgctcg gtggctcgcc gcgcgcggcg cgccgggtcc cctccgcgag tacgaagagg 360
agcgcgagcg agcccgaacc gcgcaggagg cgaggcgcc- gtggctcgcg gccgcgccgc 420
cctgtctcgc gcccgatctg ccccgcttcg aggcacgacgc caacgggctg ccgctcggcc 480
cgatgtcgcc tgaagtgcgc gaggccgagc ggccgctccg cgcctcgta- gcgactcctg 540
agctgcgctg tgcgcgcgtg ctgcctcgcc tcgggacggg cgccgggtcc- tggctccggat 600
atcccgccca cgagatgtcg ccagagaatc tgctcctcgg gtttggcctc ccgaccgcga 660
tcgcccgggc ctccgcgccc ggcacatcgg aggcgcgtct cccgggcgca gcgcggctgt 720
tcgctcctcg ggaggtcgta tcgagcaaga agagccagct cggcaacatc cccgaagccc 780
tgtgggagcg gctccggacg atcgtccgcg cgatgggcaa tgcgcgaca- ctctctcgct 840
tcgagcgcgc cgaggcgatc gcggcgaggg tgcgcgcct- gcgcgcacag ccggcgccct 900
tcgcccgggg cgccggcctg gcggtcgctg gggctctctc gagcggcccg ctctcggggc 960
tcgtgaccga cggagacgca ttgtactcgg gcgacggcaa cgacatcg- atgttccaac 1020
ccggccggat ctcccggtc gtgtgctcg ccggaaccga tccctcttc- gagctcgcac 1080
cgccctcag ccagatgtc- ttgctcggc acgccaacgc gggcaccatc tccaaggtcc 1140
tgacggaagg cagccccctc atcgtgatgg caagaaacca ggcgcgaccg atgagcctcg 1200
tccacgctcg cgggttcctg gcgtgggtca accaggccat ggtgcccga- cccgagcggg 1260
gcgcgcctt- cgtcgctcag cgctcgacca tcatggaatt cgagcaccac acgcctcgtt 1320
gtctccacga gcccgccggc agcgcttct- ccctcgcccg cgacgaggag cactctact 1380
ggtgcgagct- ttcggtggc cggtcgagc tatggcgcca cccgcaccac cgccccggcg 1440
ccccgagccg cttcggtgac ctcggcgagc acccattgc- ggcgacctgg taccctcgc 1500
tcacctcaa- tgcgaccac gtgctgtggg ccgacctga- tcgcaggggc atcctcgggg 1560
tcgacaagcg caccggcgta gagcccatcg tctcgcgga- gacgcgccat ccccgccgc 1620
acgtcgtg- cgaggaccgg gacatcttcg cgcttaccgg acagcccgac tcccgcgact 1680
ggcacgtcga gcacatccgc tccggcgcc- ccaccgtcgt ggccgactac cagcgccagc 1740
tatgggaccg ccctgacatg gtgtcaatc- ggccggccct cttcttcacg acgaacgacc 1800
gcactctgac gctcgcccgc agctgacatc gctcgacg- gggccgctca tcgagggcgc 1860
ccggaccgag ctggcgaccc gccgctggcg ggcccgagct catgccgatt cgggtggcgac 1920
gtagacgctg cgccagaaac gctcgagagc ccccgagaac aggaagccgg- cgacttgtgt 1980
catcacgata ccgatcagct cgccggcccg atcatgatc caggacgtcc cgaacccgcc 2040
gtccaccca- tagcgcccg gcacctccga gaccgcgtcc ggcgcggtga ccacggccat 2100
cccataaacc- cagccgtgcg tctcgaagaa gcccgggaaa aacgaggacg ccgccttctg 2160
ggccggcg- aggtgatcgg ccgtcatctc gcgcaccgag gcggcgctca agagcccgcg 2220
gccctcgtgc acaccgcgt- tcatgagcat gcgcgcgaac aggaggtagt cgtccaccgt 2280
cgacacgagc ccggcgcg- ccgaagggaa cgccggcggg ctggcatagg cgctctcgcc 2340
cccgctcgca tccatgcgcg- tcttctcccc cgtctgctcg tcgggtgaag- aaccgcagcc 2400
cgcgaaaccg- gcgagcttgt ccgccccggg- gtgaaagtgc gtgtcccgca tcccgagcgg 2460
cgcgaggatg- cgctcgcgca cgaacgcata gaagccctgg tcggccgcgc gccccacgag 2520
caccctctgc accaggtctc- ccgtgttgta catccactgc gcccccggt- gatgcagtag 2580
cggcagcg- ccgagccg- ggatccactc gtctggcccc- tgcggcgctca tcggcaccgg 2640

```

ctgcgcgcttg acgagccccga gctcgtcgat ggcccgcctgg atcggcgacg atgcgctcgaa 2700
 cgagattccg aagcccatcg tgaacgtcat caggctcgcg accgtgatcg gccgctccgc 2760
 gggcaccgtc tcgtcgatcg gaccatcgat gcgcgccagc accttccggt tcgcgagctc 2820
 cggcaaccat cggtcgacgg gggagtcgag gtcgagcttg ctttctctga cgagcatcat 2880
 caccgcccgtc gcggtgaccg cttctgtcat cgaggcgatc cggaagatcg tgtcccgcgc 2940
 catgggcgcg ctgcccgcga gctcgggtcac gccaccgcgc tccacgtgca cgtcgtcgcc 3000
 gcgcgcgacc agccagaccg ctcccggcat ctgcccgcgc gccacctcgc ccgccatcac 3060
 ctgcgcgcgc ggcgccagcg cgcgcgcccc cgcgtctctgc cctgggtgcc cctcctctc 3120
 ggccccaccc aacgcgcacc ccggcgccgc cacgctgatc aaagctccca taaactcccg 3180
 ccttctcatg accgtcgatg cctctccgag cggggggcgcc tgcccttgcc gagagcactg 3240
 actgcccgcg ccgaaaaaaa tcatcggtgc cccgtcacga tcgcgcgcgg gcgtggctcc 3300
 gcccgccgcg ccgctcgggc gcccgccctt ggacgagcaa agctcgcccg cccgcgctca 3360
 gcacgcccgt tgccatgtcc ggctgcacc cacaccgagg agccaccac cctgatgcac 3420
 ggctcaccg agcggcaggt cctgtctctg ctgctcacc tcgctcat cctcgtgacc 3480
 gcgcgcgcct ccggcgagct cgcgcggcg cgcgcggcg cgcgagtgct cggggagctc 3540
 tccggcgcg tcgtgctggg cccctccgtc gtcggcgcg tcgcgcgcgc gttccatcga 3600
 gccctcttcc aggagccggc ggtcggggtc gtgctctcgg gcatctcctg gataggcgcg 3660
 ctctcctcgc tgcgtgatggc gggcatcgag gtcgacgtgg gcatctcgc caaggaggcg 3720
 cgccccgggg cgtctcggc gctcggcgcg atcgcgcgc cgtcgcgcgc gggcgccgcg 3780
 tctcgcgcgc tcgtgctcga tcggccctt ccgagcgcc tcttctcgc gatcgtgctc 3840
 tcggtgacgg cggtcagcgt gatcgcaag gtgctgatcg agcgcgagtc gatgcgcgcg 3900
 agctatgcgc aggtgacgt ctacggcgcg tcgcgcgcgc tggcggtcgc ctgggtgctc 3960
 gtcgcgatga cgtcgtcgag cgcggcggg gtggtcagcg aggtcgtgc ctcgggtgctc 4020
 ctctcgggca gcggtattct gctgttcat gtgctcgtc ggcgcgcgct caccacctc 4080
 gcgatgcgct ggggtggcga cgcgacgcgc gtctccaagg gacaggtgtc gctcgtctc 4140
 gtcctcacgt tcctggccgc ggcgtgacg cagcggtcgc gcctgtaccc gctgctcgc 4200
 gcgttcgcgc tcggcggtgt gctcaacagc gctcctcgca ccaaccgccc tctcctcgc 4260
 ggctgacga cgctcgtggc ggccctctt gcgcctgtgt tcttctcct cgcgggcatg 4320
 cgctcgacg tgcgcagct gcgcacgcgc gcgcgctggg ggacggtcgc gttgctgctg 4380
 gcgaccgcga cggcgcgcaa ggtcgtcccc gccgcgtcgc gcgcgcggct cggcgggctc 4440
 aggggcagcg aggcggcgct cgtggcggtg ggcctgaaca tgaaggcgcg caccgacctc 4500
 atcgtcgca tcgtcggcgt cagcgtcggg ctctctcca acgaggctta tacgatgtac 4560
 gccgtcgtcg cgttggcac ggtgaccgc tcaccgcgc tctcatctg gtcgagaaa 4620
 agggcgccct cgacgcagga gtagtcggct cgcctcagc gcgaggaggc cgcgaggcgc 4680
 gcgtacatcc ccggggtcga cgggacccg gtcctcgatc tggcgcacgc cctcctcgc 4740
 ttcgccacgg acatcgtgga gagcatcgt gcctccaagg gaaagctcgc cgagacggtc 4800
 gacatcacgg agctctccgt ggagcagcag gcgcgccgcc catcgcgcg cgcgggggag 4860
 gcgagccggg ggctcgcgag gctcggcgcg cgcctccgc tcggcatctg gcggcaaagg 4920
 cgcgagctgc gcggctcgat ccaggcgatc ctgcgcgcct cgcgggatca cgatctgctc 4980
 gtgatccggc cgcgatcgcc ggcgcgcgcg cgcggaatgt cgttcggtcg cctgcaggac 5040
 gcgatcgtcc agcgggccga gtccaacgtg ctgctcgtgg tggcgaccc tccgcgcgcg 5100
 gagcgcgcc cccgcggcg gatcctcgtc ccgatcatcg gcctcagta ctctctcgc 5160
 gcccgccgat tcgcggccca cgtggcgctg gcgtgggagc ccgagctcgt cctgtcagc 5220
 agcgcgcaga ccgatccggg cgcggtcgtc tggcgcgatc gcgagccatc ccgggtgcg 5280
 gcggtggcg ggagcgtcgt cgacgaggcg gtcttccggg ggcgccggct cggcgtgcg 5340
 gtctcgtcgc gcgtgcacgt gggcgcgcac ccgagcgac agataacgc ggagctcgc 5400
 cgcgccccgt acgatctgct cgtgctcgga tgctacgacc atgggcgcgt cggccgctc 5460
 tacctcggca gcacggtcga gtcgggtggt gtccggagcc ggggtgccgt cgcgtgctc 5520
 gtcgcgcatg gagggactcg agagcaggtg aggtgaggct tccaccgcgc tcgcccgtga 5580
 ggaagcgagc gcccggtctt gccgacgat gtcactccc gtcctgttag gcgatcgtc 5640
 tgagcagcgc gttctccgc tgacgcgagt cgagccgggt atgctgcac acgatgggg 5700
 cgtccgattc gatcacgctg gcatagtcg tatcgcgcg gatcggctcg ggttcggtca 5760
 gatcgttgaa ccggacgtgc cgggtgcgcc tcgctggaac ggtcaccgcg taaggcccg 5820
 cggggctcgc gtcgctgaag taaacggtga tggcgacctg cgcgtcccgc tccgacgat 5880
 tcaacaggca ggcggtctca tggtcgtcga ctgcggctc aggtccggtg cctccgctg 5940
 ggatgtagcc ctctgcgatt gcacagcgcg tccgcccgat cggcttgctc atgtgtctc 6000
 cctcctggct cctctttggc agcctccctc tgctgtccag gagcgatggc ctcttcgctc 6060
 gacgcgctcg gggatccatg gctgaggatc ctgcgcgagc gtcctctgcc gaccggcgcg 6120
 ccgagcgccg acgggctttg aaagcgcgcg accggcagc ccggagcgcg gcccgaggg 6180
 gacagtggt ccgcttgaa gcagagaggc gatcgagggt gtgagatgaa acacgtcgac 6240
 acgggcccgc gattcgccgc ccggataggg cacacgctcg gtcttctcgc gagcatggcg 6300
 ctgcgcggct gcggcggtcc gagcgagaaa accgtgcagg gcacgcggct cgcgcccgcg 6360
 gccgatgcgc gcgtcaccgc cgacgtcgac ccgacgcgc cgcgagcggt gctggcggtg 6420
 gacgtcgttc acctctcgcc gcccgagcg ctcgaggccg gcagcgagcg gtcgtcgtc 6480
 tggcagcgtc cgagccccga gtcctcgtgg cgacgggtcg gagtgtcga ctacaatgct 6540

gacagccgaa gaggcaagct ggccgagacg accgtgccgt atgccaactt cgagctgttc 6600
atcacccgagc agaagcagag cagccctcag tcgccatcgt ctgccgcgt catcgggccg 6660
acgtctgtcg ggtgacatcg cgctatcagc agcgctgagc ccgccagcag gccccaggcg 6720
cctgcctcga tggccttccc catcacccct gcgcactcct ccagcgacgg ccgcgacgg 6780
acggccgctg ccaagcaacc gccgtgccgg cgcggtccca cgcgcgcgac aggcgagcgt 6840
cctggcgcgg cctgcgcacg gctggaagga tcggcgaggc atggatagag aatcgaggat 6900
cgcgatcttt gttgccatcg cagccaacgt ggcgatcgcg gcggtcaagt tcacgcgcg 6960
cgccgtgacc ggcagctcgg cgaggcggtt gccgacttcg gcggcgctcc gcgcgtgtcg 7020
ctctacgaca acctcaagag cgccgtcgtc gagcgccacg gcgacgcgat ccggttccac 7080
cccacgctgc tggctctgtc ggccgattac cgcttcgagc cgcgccccgt cgccgtcgcc 7140
cgccgcaacg agaagggccg cgtccagcgc gccatcacgg cgtggacgac atggcgcgga 7200
aacgtcgtcg taaccgccc acaatgtcat gggaaatggc ccttgaatg gccccctgag 7260
ggggctggcc ggggtcgacg atatcgcgcg atctccccgt caattcccga tggtaaaaga 7320
aaaatttgtc atagatcgta agctgtgata gtggtctgtc ttacgttggc tcttcgcac 7380
ctcaggaagc ctgatcgga cgagctaatt cccatccatt tttttgaggc tctgtcaaa 7500
gggattagat cgagtggagc agttcttttg cagtgcgcga agaactggg cctcgaccgg 7560
aggacgatcg acgtccgcga gcgggtcagc cgctgaggat gtgcccgtcg tggcggtcg 7620
ctccagcgag cgcgacggcg aagatccgat tgcgatcgtc ggagcgagtt ccgctctgcc 7680
cggtggcggt atcgatctga gcgggttctg gacgctcttc gagggctcgc gcgacaccgt 7740
cgggcgagtc cccgcgcaac gctgggatgc agcagcggtg tttgatcccg accccgatgc 7800
cccggggaag acgcccgtta cgcgcgcatc tttctgagc gacgtagcct gcttcgacgc 7860
gctggaggtg tgcgggagg cgctggagaa cgccgcgac gctccatcgg cgctcgtcgg 7980
tacggaaaacg ggagtgttca tcgggatcgg cccgtccgaa tatgaggccg cgctgccga 8040
agcgacggcg tccgcagaga tcgacgctca tggcgggctg gggacgatgc ccagcgctcg 8100
agcgggccga atctcgtatg cccctggggt gcgagggccg tgtgtcggg tggatcggc 8160
ctattcgtcc tcgctggtgg ccgttcatct ggctgtcag agcttgcgct ccggggaatg 8220
ctccacggcc ctggctggtg gggatatcgt gatgtgtcg ccgagcacc tcgtgtggct 8280
ctcgaagacc cgggctggtg ccagggacgg tcgctgcaag gcattttcgg ccgagggcga 8340
tgggttcgga cgagcggaag ggtgcgctc cggtgtctc aagcggtca gtggagccg 8400
cgcgacggcg gatcgatat tggcggtgat tcgaggatcc gcgatcaatc acgacggtgc 8460
gagcagcggt ctgaccgtgc cgaacgggag ccccaagaa atcggtgtga aacgggccc 8520
ggcgacgca ggctgcggcg cgtcttcggg gggttatgtc gaggcacac gcacgggac 8580
gaccccatcg aaatccaagc tctgaatcgg gtatacggc tcggggcaga 8640
tgtcgccacg ccgctgctga tcgggtcggg gaagaccaac cttggccatc ctgagtatgc 8700
gtcggggatc actgggctgc tgaaggtcgt cctgtccctc cagcacgggc agattcctgc 8760
gcacctccac gcgcaggcgc tgaacccccg gatctcatgg ggtgatcttc ggctgcctg 8820
cacgctcgcc cggaacacgt ggccggactg gaatacggcg cgacgggccc ggggtgagtc 8880
gttcggcatg agcgggacca acgcgcacgt ggtgctggaa gaggcggccg ccgagcgtg 8940
cacaccgccc gcgcggagc gaccggcaga gctgctggtg ctgtcggcaa ggaccgcgtc 9000
agccctggat gcacaggcgg cgcggtgcg cgaccatctg gagacctacc cttcgagtc 9060
tctgggctga gtggcggtca gttggcgac gacgcgcagc gcgatggagc accggctcgc 9120
gggtggcgcg acgtcgaggg aggggtcgc ggcagccctg gacgctgcgg cgagggaca 9180
gacgtcgccc ggtgcgggtgc gcagtatcgc cgattctca cgcggaagc tcgcttctc 9240
cttcaccgga cagggggcgc agacgctggg catgggcccgt gggctgtacg atgtatggtc 9300
cggttccgc gaggcgttcg acctgtgcgt gaggtgttc aaccaggagc tcgaccggc 9360
gctccgcgag gtgatgtggg ccgaaccggc cagcgtcgac gcccgctgc tcgaccagac 9420
agccttcacc cagccggcgc tgttcacctt cgaatatcg ctcgcgcgc tgtggcggtc 9480
gtgggggtga gagccggagt tggctgcgg ccatagcac ggtgagctgg tggctgcctg 9540
cgtggcgggc gtgttctcgc ttgaggacgc ggtgttctc gtggctgcgc gcgggcgcct 9600
gatgcaaggc ctgccggccg gcggggcgat ggtgtcgatc gaggcggccg aggcgatgt 9660
ggctgctgcg gtggcgccgc acgcagcgtc ggtgtcgatc gcccggtca acgctccga 9720
ccaggtggtc atcgcgggcg ccgggcaacc cgtgcacgc atcgcgcg cgatggccg 9780
gcgcggggcg cgaaccaagg cgctccacgt ctcgcatcg ttcactcac cgctcatggc 9840
cccgatgctg gaggcgttcg ggcgtgtggc cgagtgcgtg agctaccggc ggccgtcgtc 9900
cgtcctggtc agcaatctga gcgggaaggc ttgcacagac gaggtgagct cgccgggcta 9960
tgggtgcgc cacgcgcgag aggtggtgc ctcgcggat gtagtgaagg cgctgcacgc 10020
ggccggtgcg ggcaccttcg tcgaggtcgg tccgaaatcg acgctgctc gcctggtgcc 10080
tgcctgcag ccggacgccc ggccggcgct gctcgcatc tcgcgcgctg ggcgtgacga 10140
ggccgcgacc gtgctcgagg cgctcgggcg gctctgggccc gtcggtggcc tggctcctc 10200
ggccggccct tccccctcag gggggcgggc ggtgcgctg cccaggtacc cttggcagcg 10260
cgagcgctac tggatcgaca cgaaaagccga cgacgcggcg cgtggcgacc gccgtgctc 10320
gggagcgggc cagcagagg tcgagggagg gggcgcggtg cgcgcgggcg accggcgag 10380
cgctcggtc gaccatccgc cgcccgagag cgacgcggc gagaaggctc aggcggcccg 10440

cgaccgtccg	ttccggctcg	agatcgatga	gccaggcgtg	cttgatcacc	tcgtgcttcg	10500
gggtcacggag	cggcgcgccc	ctgggtctggg	cgaggctcgag	atcgccgctcg	acgcggcggg	10560
gctcagcttc	aatgatgtcc	agctcgcgct	gggcatgggtg	cccgcacgacc	tgccgggaaa	10620
gcccacacct	ccgctgctgc	tcggaggcga	gtgcgcggg	cgcatcgctcg	ccgtgggcga	10680
ggggctgaac	ggcctcgtgg	tgggccaacc	ggatcatcgcc	ctttcggcgg	gagcgtttgc	10740
taccacgctc	accacgtcgg	ctgcgtctgg	gctgcctcgg	cctcaggcgc	tctcggcgat	10800
cgaggcggcc	gccatgcccc	tcgcgtacct	gacggcatgg	tacgcgctcg	acagaatagc	10860
ccgccttcag	ccgggggagc	gggtgctgat	ccatgcggcg	accggcgggg	tcggctctgc	10920
cgcggtgcag	tgggcgcgagc	acgtgggagc	cgaggctcat	gcgacggccg	gcacgccccg	10980
gaaacgcgccc	tacctggagt	cgctgggcgt	gcggatgtg	agcgattccc	gctcggaccg	11040
gttcgtcgcc	gacgtgcgcg	cggtggacggg	cggcgaggga	gtagacgtcg	tgctcaactc	11100
gctctcgggc	gagctgatcg	acaagagttt	caatctcctg	cgatcgacg	gccggtttgt	11160
ggagctcggc	aagcgcgact	gttacgcgga	taaccagctc	gggctcgggc	cgttctctcg	11220
caatctctcc	ttctcgtctg	tggtatctcc	gggatgatg	ctcgagcggc	cggcgcgggt	11280
ccgtgcgctc	ttggaggagc	tcctcggcct	gatcgcgga	ggcgtgttca	ccccctcccc	11340
catcgcgacg	ctcccgatcg	cccgctgcgc	cgatgcgttc	cggagcatgg	cgcaggcgca	11400
gcattcttgg	aagctcgtac	tcacgctggg	tgaccgggag	gtccagatcc	gtattccaac	11460
ccacgcaggc	gccggccccg	ccaccgggga	tcgggacctg	ctcgacaggc	tcgctcgacc	11520
tgccgcggcc	gcgcgcgccc	cggcgctgga	ggcgttcctc	cgtagcgagg	tctcgcagg	11580
gctgcgcacg	cccgaatca	aggtcggcgc	ggaggcgtg	ttaccccgcc	tcggcatgga	11640
ctcgctcatg	gccgtggagc	tgccgaatcg	tatcgaggcg	agcctcaagc	tgaagctgtc	11700
gacgacgttc	ctgtccacgt	cccccaatat	cgccttgttg	gccccaaaacc	tggtggatgc	11760
tctcgcacac	gctctctcct	tggaaggcgg	ggcggcggag	aacctacggg	caggcgtgca	11820
aaacgacttc	gtctcatcgg	gcgcagatca	agactgggaa	atcattgccc	tatgacgatc	11880
aatcagcttc	tgaacgagct	cgagcaccag	ggatatcaag	tgccggccga	tggggagcgc	11940
ctccagatag	aggcccccaa	gaaccgccct	aaccggaacc	tgctcgcctc	aatctccgag	12000
cacaaaagca	cgatcctgac	gatgtctcgt	cagagactcc	ccgcagaatc	catcgtgccc	12060
gccccagccg	agcggcacgc	tccgtttcct	ctcacagaca	tccaagaatc	ctactggctg	12120
ggccggacag	gagcgtttac	gggtcccgag	gggatccacg	cctatcgcca	atacgactgt	12180
acggatctcg	acgtgcccag	gctgagccgc	gcctttcgga	aagtcgctgc	gcggcacgac	12240
atgcttcggg	cccacacgct	gcccagacatg	atgcagggtga	tcgagcccaa	agtcgacgcc	12300
gacatcgaga	tcacgtatct	gcgcgggctc	gaccggagca	cacgggaagc	gaggctcgtg	12360
tcgttgcgag	atgcgatgtc	gcaccgcctc	tatgacaccg	agcgcctccc	gctctatcac	12420
gtcgtcgccc	ttcggctgga	cgagcggcaa	atccgtctcg	tgctcagtat	cgatctcatt	12480
aacgttgacc	taggcagcct	gtccatcatc	ttcaaggact	ggctcagctt	ctacgaagat	12540
cccagacctt	ctctccctgt	cctggagctc	tcgtaccgcg	attatgtact	cgcgctggag	12600
tctcgcaaga	agtctgaggg	gcattcaacga	tcgatggatt	actggaagcg	gcgcacgccc	12660
gagctcccac	ctccgccgac	gcttccgatg	aaggccgac	catctaccct	gaaggagatc	12720
cgcttcgggc	acacggagca	atggctgccc	tcggactcct	ggggctcgatt	gaagcggcgt	12780
gtcggggagc	gcgggctgac	cccgcacggc	gtcatcctgg	ctgcattttc	cgaggtagatc	12840
ggggcgttga	gcgcgagccc	ccgggttacg	ctcaacataa	cgctcttcaa	ccggctcccc	12900
gtccatccgc	gcgtgaacga	tatcacgggg	gacttcacgt	cgatggctct	cctggacatc	12960
gacaccactc	gcgacaagag	cttcgaacag	cgcgctaagc	gtattcaaga	gcagctgtgg	13020
gaagcgatgg	atcactgcga	cgtaagcggg	atcgagggtcc	agcgagaggg	cgcccggttc	13080
ctggggatcc	aacgaggcgc	attgtttccc	gtggtgctca	cgagcgcgct	taaccagcaa	13140
gtcgttggtg	tcacctcggt	gcagaggctc	ggaactccgg	tgtaaccacg	cacgcagact	13200
cctcagctgc	tgctggatca	tcagctctac	gagcacgatg	gggacctcgt	cctcgcgtgg	13260
gacatcgtcg	acggagtgtt	cccgcgccgac	cttctggacg	acatgctcga	agcgtacgtc	13320
gtttttctcc	ggcggctcac	tgaggaacca	tggggtgaac	aggtgcgctg	ttcgcttccc	13380
cctgcccagc	tagaagcgcg	ggcgagcgca	aacgcgacca	acgcgctgct	gagcgagcat	13440
acgctgcacg	gcctgttcgc	ggcgcggggtc	gagcagctgc	ccatgcagct	cgccgtgggtg	13500
tcggcgcgca	agacgctcac	gtacgaagag	ctttcgcgcc	gttcgcggcg	acttggcgcg	13560
cggctgcgctg	agcagggggc	acgcccgaac	acattgggtcg	cgggtggtgat	ggagaaaggg	13620
tgggagcagg	ttgtcgcggg	tctcgcgggtg	ctcgagtcag	gcgcggccta	cgtagcagtc	13680
gatgccgacc	taccggcgga	gcgtatccac	tacctcctcg	atcatggtga	ggtaaagctc	13740
gtgctgacgc	agccatgggt	ggatggcaaa	ctgtcatggc	cgccggggat	ccagcggtcg	13800
ctcgtgagcg	aggccggcgt	cgaaggcgac	ggcgaccagc	ctccgatgat	gccccattcg	13860
acaccttcgg	atctcgcgta	tgtaactctc	acctcgggat	ccacagggtt	gcccaagggg	13920
gtgatgatcg	atcatcgggg	tgccgtcaac	acctcctcgt	acatcaaccg	gcgcttcgaa	13980
atagggcccg	gagacagggg	gctggcgctc	tcctcgtgta	gcttcgatct	ctcgggtctat	14040
gatgtgttcg	ggatcctggc	ggcgggcggt	acgatcgtgg	tgccggacgc	gtccaagctg	14100
cgcgatcccg	cgcattgggg	agagttgatc	gaacgagaga	aggtgacggg	gtggaactcg	14160
gtgcggcgcc	tgatgcggat	cattttgagg	gtcgcgccga	ttcgctcgct	14220	
aggtctctgc	ggctttcgct	gctgagcggc	gactggatcc	cgggtgggct	gcctggcgag	14280
ctccaggcca	tcaggcccg	cgtgtcgggtg	atcagcctgg	gcggggccac	cgaagcgtcg	14340

atctgggtcca	tccgggtaccc	cgtgaggaac	gtcgacctat	cgtgggagag	catccccctac	14400
ggccgtccgc	tgcgcaacca	gacgttccac	gtgctcgatg	aggcgctcga	accgcgccccg	14460
gtctgggttc	cgggggcaact	ctacattggc	gggggtcgggc	tggcactggg	ctactggcgc	14520
gatgaagaga	agacgcgcaa	gagcttcctc	gtgcaccccg	agaccgggga	gcgcctctac	14580
aagaccggcg	atctggggccg	ctacctgccc	gatggaaaca	tcgagttcat	ggggcgtag	14640
gacaaccaa	tcaagcttcg	cggataccgc	gttgagctcg	gggaaatcga	ggaaacgctc	14700
aagtacgcac	cgaacgtacg	cgacgcggtg	attgtgcccc	tcgggaacga	cgcggtcgaa	14760
aagctccttc	tagcctatgt	ggctccggag	ggcacacgga	gacgcgctgc	cgagcaggac	14820
gcgagcctca	agaccgagcg	gatcgacgcg	agagcacacg	ccgccgaagc	ggacggtctg	14880
agcgacggcg	agagggtgca	gttcaagctc	gctcgacacg	gactccggag	ggacctggac	14940
ggaaagcccg	tcgtcgatct	gaccgggcag	gatccgcggg	aggcggggct	ggacgtctac	15000
gcgcgtcgcc	gtagcgtccg	aacgttcctt	gaggccccga	ttccgtttgt	tgagtttgg	15060
cgattcctga	gctgcttgag	cagcgtggag	cccgcagcgg	cgacccttcc	caaattccgt	15120
tatccatcgg	cgggcagcac	gtaccgggtg	caaacctacg	cgatgtcaa	atccggccgc	15180
atcgaggcg	tggaacgagg	cttctattat	taccaccgt	tcgagcaccg	tttgctgaag	15240
ctctccgac	acgggatcga	gcgcggagcg	cacgttcggc	aaaacttcga	cgtgttcgat	15300
gaagcggcgt	tcaacctcct	gttcgtgggc	aggatcgacg	ccatcgagtc	gctgtatgga	15360
tcgtcgtcgc	gagaattttg	cctgctggag	gccggatata	tggcgagct	ctgtatggag	15420
caggagccct	cctgcaacat	cgcggtctgt	ccggtggggc	aattcaattt	tgaacaggtt	15480
cggccggttc	tcgacctgcg	acattcggac	gtttacgtgc	acggcatgct	gggcggggcg	15540
gtagacccgc	ggcagttcca	ggctctgtacg	ctcggctcagg	attcctcacc	gaggcgccgc	15600
acgacgcgcg	gcgccccctc	cggccgcgag	cagcacttcg	ccgatatgct	tcgcgacttc	15660
tcgaggacca	aactaccgga	gtacatgggtg	cctacagtct	tcgtggagct	cgatgcgttg	15720
ccgctgacgt	ccaacggcaa	ggctcgatcgt	aaggccctgc	gcgagcggaa	ggataacctg	15780
tcgcccgcgc	attcggggca	cacggcgcca	cgggacgcct	tggaggagat	cctcgtcgcg	15840
gtcgtcacgg	aggtgctcgg	gctggagggtg	gtcgggctcc	agcagagctt	cgtcgatctt	15900
ggtgctgacat	cgattcacat	cgttcgcgatg	aggagcctgt	tcgagaagag	gctggatagg	15960
gagatcgcca	tcaccgagtt	gttccagtac	ccgaacctcg	gctcgtggc	gtccgggttg	16020
cgccgagact	cgagagatct	agatcacgcg	ccgaacatgc	aggaccgagt	ggaggttcgg	16080
gccaaaggga	ggagacgtag	ctaagagcgc	cgaacaaaac	caggccgagc	gggcccgtga	16140
cgcgcaagcc	cgccctgcgtc	accctgggac	tcattctgatc	tgatcgcggg	tacgcgtcgc	16200
gggtgtgccc	gttgagccgt	gttggtcgaa	cgctgaggaa	cggtgagctc	atggaagaa	16260
aagagtcctc	cgctatcgca	gtcatcgcca	gttcggggcg	ttttccgggg	gcgcgggac	16320
tggaggaatt	ctggaggaac	cttcgagacg	gcacggaggc	cgtgcagcgc	ttctccgagc	16380
aggagctcgc	ggcgtccgga	gtcgaccccg	cgctgggtgt	ggacccgagc	tacgtccggg	16440
cgggcagcgt	gctggaagac	gtcgaccggg	tcgacgctgc	tttcttcggc	atcagcccgc	16500
gcgaggcaga	gctcatggat	ccgcagcacc	ggatcttcat	ggaatgcgct	tgggaggcgc	16560
tggagaacgc	cggatacgcg	ccgagggctt	acgagggctc	tatcgccgtg	tacgcggcgc	16620
ccaacatgag	ctcgtacttg	acgtcgaaac	ttccacgagca	cccagcgatg	atgcggtggc	16680
ccggctgggt	tcagacgttg	atcggaacg	acaaggatta	cctcgcgacc	cacgtctcct	16740
acaggctgaa	tctgagaggg	ccgagcatct	ccgttcaaac	tgcttgcctc	acctcgtctg	16800
tggcggttca	cttggcggtg	atgagcctcc	tgagaccgca	gtgcgacatg	gcgctggccg	16860
gcgcggattac	cgctccggatc	ccccatcgag	ccggctatgt	atatgctgag	gggggcatct	16920
tctctcccga	cggccattgc	cgggccttcg	acgccaagcg	gaacggcacg	atcatgggca	16980
acggctcgcg	cggtgtcctc	ctgaagccgc	tggaccgggc	gctctccgat	ggtgatcccg	17040
tccgcgcggg	tatccttggg	tctgccacaa	acaacgacgg	agcagaggaag	atcgggttca	17100
ctgcccagag	tgaggtgggc	caggcgcaag	cgatcatgga	ggcgttggcg	ctggcagggg	17160
tcgaggcccg	gtccatccaa	tacatcgaga	cccacgggac	cggcacgctg	ctcggagacg	17220
ccatcgagac	ggcggcgctg	cggcggtgtg	tcggctcgca	cgcttcggcc	cggagggtctt	17280
gcgcgatcgg	ctccgtgaag	accggcatcg	gacacctcga	atcggcggtc	ggcatcgccg	17340
gtttgatcaa	gacgggtcttg	gcgctggagc	accggcagct	gccgcccagc	ctgaacttcg	17400
agttctctaa	cccatcgatc	gatttcgcga	gcagcccgtt	ctacgtcaat	acctctctta	17460
aggattggaa	taccggctcg	actccgcggc	gggcccggct	cagctcgttc	gggatcggcg	17520
gcaccaacgc	ccatgtcgtg	ctggaggaag	cgcccgcggc	gaagcttcca	gcccgggcgc	17580
cggcgcgctc	tgccgagctc	ttcgtcgtct	cggccaagag	cgacgcggcg	ctggatgccg	17640
cggcggcacg	gctacgagat	catctgcagg	cgcaccaggg	gatttcgttg	ggcgacgtcg	17700
ccttcagcct	ggcgacgacg	cgcagcccca	tggagcaccg	gctcgcgatg	gcggcgccgt	17760
cgcgcgaggc	gttcgcgagc	gggctcgacg	cagcggcgcg	aggccagacc	ccgccgggcg	17820
ccgtgcgtgg	ccgctgctcc	ccaggcaacg	tgccgaaggt	ggctcttcgtc	tttcccggcc	17880
agggtcttca	gtgggtcggc	atgggcccgc	agctcctggc	tgaggaaacc	gtcttccacg	17940
cggcgcttcc	ggcgtgcgac	cggggccatcc	aggccgaagc	tggttgggtg	ctgctcgcg	18000
agctcggcgc	cgacgaaggg	tcctcccagc	tcgagcgcac	cgacgtgggtg	cagccgggtg	18060
gtctcggcct	cggggtggca	tttcggcgcg	tgtggcggtc	gtgggtgtgc	gcgcccagcg	18120
tcgtgatcgg	ccacagcatg	ggcgaggtag	ccgcccgcga	tgctggccggg	gcgctgctgc	18180
tcgaggatgc	gggtggcgatc	atctgcggcg	gcagccggct	gctccggcgc	atcagcggtc	18240

agggcgagat	ggcgggtgacc	gagctgtcgc	tggccgaggc	cgaggcggcg	ctccgaggct	18300
acgaggatcg	ggtgagcgtg	gccgtgagca	acagcccgcg	ctcgacgggtg	ctctcggggcg	18360
agccggcgagc	gatcggcgag	gtgctgtcgt	ccctgaacgc	gaagggggtg	ttctgcccgc	18420
gggtgaaggt	ggatgtcgcc	agccacagcc	cgcaggtcga	cccgtgcgc	gaggacctct	18480
tggcagccct	gggcgggctc	cggccgggtg	cggctgcggg	gccgatgcgc	tcgacgggtga	18540
cgggcgccat	ggtagcgggc	ccggagctcg	gagcgaatta	ctggatgaac	aaacctcaggc	18600
agccagtgcg	cttcgccgag	gtagtcacag	cgcagctcca	aggcggccac	ggtctgttcg	18660
tggagatgag	cccgcatccg	atcctaacga	cttcgggtcga	ggagatgcgg	cgcgcggccc	18720
agcggggcggg	cgcagcgggtg	ggctcgcctgc	ggcgggggca	ggacgagcgc	ccggcgatgc	18780
tggaggcgct	gggcacgctg	tgggcgcagg	gctaccctgt	accctggggg	cggctgtttc	18840
ccgcgggggg	gcggcgggta	ccgctgccga	cctatccctg	gcagcgcgag	cgttactcga	18900
tcgaagcgcc	ggccaagagc	gccgcggggc	atcgcccgcg	cgtgcgtgcg	ggcggctacc	18960
cgtctctcgg	tgaatgcag	accctgtcaa	cccagacgag	cacgcgcctg	tgggagacga	19020
cgttgatct	caagcggtcg	ccgtgggtcg	gcgaccaccg	ggtgcaggga	gcggctcgtgt	19080
ttccggggcg	ggcgtaacctg	gagatggcga	ttctcgtcgg	ggccgaggct	ttggcgagct	19140
gcccttttga	gataactgac	gtggtgctcg	ccgaggcgct	ggccttcgcg	ggcgacgcgg	19200
cgtgtgttgt	ccaggtgggtg	acgacggagc	agccgtcggg	gcggctgcag	ttccagatcg	19260
cgaagccgggc	gcccgggcgt	ggccacgcgt	ccttcggggg	ccacgctcgc	ggcgcgttgc	19320
ttccagtgga	gcgcaccgag	gtcccggtcg	ggcttacgct	ttccgctgtg	gcgcgcgagc	19380
ttcaggccag	catacccgcc	gcggccacct	acgcggagct	gaccgagatg	gggctgcagt	19440
acggccctgc	cttccagggg	attgctgagc	tatggcgggg	tgaaggcgag	gcgctgggac	19500
gggtacgcct	gcccagcgcg	gccggctcgg	cagcggagta	tcggttgcat	cctgcgctgc	19560
tggcggcggtg	cttccagatc	gtcggcagcg	ttctcggccc	cagtggcgag	gcgacgcgct	19620
gggtgcccgt	ggagtgggc	tcgctgcggc	ttctgcagcg	gccttcgggg	gagctgtggg	19680
gccatgcgcg	cgtcgtgaac	catgggcacc	aaacccccga	tcggcagggc	gccgactttt	19740
gggtgggtcga	cagctcgggt	gcagtgggtc	ccgaagtgtg	cgggctcgtg	gcgcagcggc	19800
ttccggggagg	ggtgcgcggg	cgcgaagaag	acgattgggt	cctggagctc	gagtgggaac	19860
ccgcagcggt	cggcacagcc	aaggccaacg	cgggcccggg	gctgctcttc	ggcggcgggc	19920
gtgggctcgg	cgcgcgcttg	cgcgcgatgc	tggaggccgg	cggccatgcc	gtcgtgcagt	19980
cggcagagaa	caacacgagc	gctgcgggcg	tacgcgcgct	cctggcaaa	gcctttgacg	20040
gccagggctcc	gacggcggtg	gtgcacctcg	gcagcctcga	tgggggtggc	gagctcgacc	20100
cagggtcctcg	ggcgcaaggc	gcattggacg	cgccccggag	cgccgacgtc	agtcctcgatg	20160
ccctcgatcc	ggcgtcgtga	cgtggctgcg	acagcgtgct	ctggaccgtg	caggccctgg	20220
ccggcatggg	cttttcgagc	gccccgcgat	tgtggctttt	gacccgcggc	gcacaggccg	20280
tcggcgccgg	cgacgtctcc	gtgacacagg	caccgctgct	ggggctgggc	cgcgtcagtc	20340
ccatggagca	cgcggatctg	cgtgcgctc	gggtcgacct	cgatccagcc	cggcccagg	20400
gggagctcgc	tgcctcgtcg	gccgagctgc	tggccgacga	cgccgaagcg	gaagtgcgct	20460
tgcgcgggtg	cgaagcgtgc	gtcgtcggga	tcgtcccgcc	gcagcccag	acccggcccc	20520
gggggaggat	cgagagctgc	gttccgaccg	acgtcaccat	ccgcgcggac	cgcacctacc	20580
ttgtgaccgg	cggctcgggt	gggctcgggtc	tgagcgtggc	cggatggctg	gccgagcgcg	20640
gcgctcgtca	cctggtgctg	gtgggcccgt	ccggcgccgg	gagcgtggag	caacggggcag	20700
ccgtcgcggc	gctcgaaggc	cgcggcgccg	gcgtcacctg	ggcgaaggcg	gatgtcgccg	20760
atccggcgca	gctcgaagcg	atcctccgcg	aggttaccac	gtcggggatg	ccgctgcggg	20820
gcgtcgtcca	tgcggccggc	atcctggacg	acgggctgct	gatgcagcag	actcccgcgc	20880
ggtttcgtaa	ggtgatggcg	cccaaggctc	agggggcctt	gcacctgcac	gcgttgacgc	20940
gcgaagcgcc	gctttccttc	ttcgtgctgt	acgcttcggg	agtagggctc	ttgggctcgc	21000
cgggcccagg	caactacgcc	cgggccaaca	cgttcctcga	cgtcttggcg	caccaccgga	21060
gggcgcaggg	gctgccagcg	ttgagcgtcg	actggggcct	gttcgcggag	gtgggcatgg	21120
cggccgcgca	ggaagatcgc	ggcgcgccgc	tgggtctccc	cggaatgcgg	agcctcaccc	21180
ccgacgaggg	gctgtccgct	ctggcacggc	tgtcgaag	cggccgcgct	caggtggggg	21240
tgatgccggg	gaacccgcgg	cttggggtgg	agctctaccc	cgcggcgggc	ttctcgcgaa	21300
tgttgcgctg	cctggtgacg	gcgcacgcgc	cgagcgcggg	cgggcccagc	ggggacgggg	21360
acctgctccg	ccgcctcggc	gctgcgcgagc	cgagcgcgcg	gagcgcgctc	ctggagccgc	21420
tcctcccgcc	gcagatctcg	caggtgctgc	gcctccccga	gggcaagatc	gaggtggagc	21480
ccccgctcac	gagcctgggc	atgaactcgc	tgatggggct	cgagctcgcg	aaaccgcatc	21540
aggccatgct	gggcatcacc	gtaccggcaa	cgtgtgtgtg	gacctatccc	acggtggcgg	21600
cgtgagcgg	gcattctggc	cgggaggcat	gcgaagccgc	tcctgtggag	tcaccgcaca	21660
ccaccgcccga	ctctgccctc	gagatcgagg	agatgtcgca	ggacgatctg	acgcagtga	21720
tcgcagcaaa	attcaaggcg	cttacatgac	tactcggcgt	cctacggcac	agcagaatcc	21780
gctgaacaaa	gcggccatca	tcattcagcg	gctggaggag	cggctcgtcg	ggctcgcaca	21840
ggcggaagctg	gaacggaccg	agccgatcgc	catcgtcggg	atcggctgcc	gcttccctcg	21900
cgggtcggac	gctccgggaag	cgttttggga	gctgctcgac	gcggagcgcg	acgcgggtcca	21960
gccgctcgac	atgcgctggg	cgtcgtggg	tgctcgtccc	gtcgaaggcg	tgccgcaact	22020
ggcggggcgtg	ctcaccgagc	cgatagattg	cttcgatgct	gcgttcttcg	gcattctcgcc	22080
tcgggaggcg	cgatcgcctg	acccgcagca	tcgtctgttg	ctggaggctcg	cttgggaggg	22140

gctcaggagac	gccgggtatcc	cgccccgggtc	catcgacggg	agccgcaccg	gtgtgttcgt	22200
cggcgctttc	acggcgggact	acgcgcgcac	ggctcgctcgg	ctgccgcgcg	aggagcgaga	22260
cgcgtagacg	gccaccggca	acatgctcag	catcgccgcc	ggacggctgt	cgtagacgct	22320
gggggtgag	ggaccttgcc	tgaccgtcga	cacggcggtc	tcgtcatcgc	tggtggcgat	22380
tcacctcgcc	tgccgcagcc	tgccgcagag	agagagcgat	ctcgcggttg	cgggagggggt	22440
cagcgcgctc	ctctcccccg	acatgatgga	agccgcggcg	cgcacgcaag	cgctgtcgcc	22500
cgatggctgt	tgccggacct	tcgatgcttc	ggccaacggg	ttcgctccgtg	gcgagggtcg	22560
tgccctgggtc	gtcctcaaac	ggctctccga	cgcgcaacgg	gatggcgacc	gcattctgggc	22620
gctgatccgg	ggctcggcca	tcaaccatga	tggccgggtcg	accgggttga	ccgcgcccaa	22680
cgctgtgggt	caggagacgg	ttctgcgca	ggcgctgcgg	agcgcccacg	tcgaagctgg	22740
ggccgtcgat	tacgtcgaga	cccacggaac	agggacctcg	ctgggctgac	ccatcgaggt	22800
cgaggcggtg	cgggcgacgg	tggggccggc	gcgctccgac	ggcacacgct	gcgtgtggg	22860
cgcggtgaag	accaacatcg	gccatctcga	ggccgcggga	ggcgtagcgg	gcctgatcaa	22920
ggcagcgctt	tcgctgacgc	acgagcgcat	cccagaaaac	ctcaacttcc	gcacgctcaa	22980
ttccgcggtc	cggtctgagg	gcagcgcgct	cgctgtggcg	accgagccgg	tgccgtggcc	23040
gcgcacggac	cgcccccgct	tcgcgggggg	gagctcgttc	gggatgagcg	gaacgaacgc	23100
gcatgtgggt	ctggaagagg	cgccggcggt	ggagctgtgg	cctgccgcgc	cgagcgctc	23160
ggcgggagctt	ttgggtgctgt	cgggcaagag	cgagggggcg	ctcgatgcgc	agggcgcgcg	23220
gctgcgcgag	cacctggaca	tgaccccgga	gtcggggtc	ggggacgtgg	cgctcgagct	23280
gcgcgacgag	cgacgcgca	tgagccaccg	gctcgggtg	gcggtgacgt	cgcgcgaggg	23340
gctgctggcg	gcgctctcgg	ccgtggcgca	ggggcagacg	ccggcggggg	cgcgcgctg	23400
catcgcgagc	tcctcgcgcg	gcaagctggc	gttctctgtt	accggacagg	gcgcgcagac	23460
gcccggggcg	ggccgggggg	tttgcgcggc	gtggccagcg	ttccgggagg	cgctcgagcc	23520
gtcgctggcg	ctgttcgacc	gggagctgga	ccgcccgcgt	cgcgaggtga	tgtggggcgga	23580
ggcgggggagc	gccgagtcgt	tgttgcctga	ccagacggcg	ttcaccacgc	ccgcgctctt	23640
cgcggtggag	tacgcgctga	cggcgctgtg	gcggtcgtgg	ggcgtagagc	cgagctctct	23700
ggctggggcat	agcatcgggg	agctggtggc	ggcggtcggtg	gcgggggtgt	ctctcgctga	23760
agatgggggtg	aggctcgtgg	cgccgcgcgg	gcggtgatg	caggggtctt	cgccggggcg	23820
cgcgatgggtg	tcgctcggag	cgccggaggc	ggaggtggcg	gcggcggttg	cgccgcacgc	23880
ggcgctgggtg	tcgatcgcgg	cggtcaatgg	gccggagcag	gtggtgatcg	cgggcggtga	23940
gcaagcggtg	caggcgatcg	cgccgggggt	cgccgcgcgc	ggcgcgcgca	ccaagcggtc	24000
gcatgtctcg	cacgcgttcc	actcgccgct	gatggaaccg	atgctggagg	agttcggggc	24060
gggtggcgggc	tcgggtgacgt	accggcgggc	aagcgtttcg	ctggtgagca	acctgagcgg	24120
gaaggtgggtc	acggacgagc	tgagcgcgcc	gggggtactg	gtgcggcacg	tgccggaggc	24180
gggtcgcttc	gcggacgggg	tgaaggcgct	gcacgaagcc	ggcgcgggga	gcttcgctga	24240
agtggggccg	aagccgagcg	tgctcgggct	gttgccagcc	tgcttgcggg	agggcgagcc	24300
gacgtcgtctg	gcgtcgttgc	gcgcggggcg	cgaggaggct	gcgggggtgc	tcgagcgctc	24360
ggggcagggtg	tggggccggc	gcggctcggg	cagctggccg	ggcgctcttc	ccacggctgg	24420
gcggcggggtg	ccgctgccga	ccatcccggt	gcagcgcgag	cggtactgga	tcgagcgccg	24480
ggccgaagggt	ctcggagcca	cgcccgccga	tgcgctggcg	cagtggttct	accgggtgga	24540
ctggccccgag	atgcctcgtc	catccgtgga	ttcgcgcgga	gccgggtccg	gcgggtgggt	24600
gggtgtgggc	gaccgggggtg	gagtcgggga	ggcgcccgcg	gcggcgcttt	gctcgcaggg	24660
atgttcgtgc	gccgtgcttc	atgcgcccg	cgaggccctc	gcgggttgcg	agcaggtgac	24720
ccaggccctc	gggtggccgca	acgactggca	gggggtgctg	tacctgtggg	gtctggagcg	24780
cgctcgtggag	gcggggggcat	cgcccgaaaga	ggtcgccaaa	gtcaccatc	ttgcgcgggc	24840
gccggtgctc	gcgctgatcc	aggcgctcgg	cacggggccg	cgctcaccct	ggctctggat	24900
cgtagaccga	ggggcctgca	cggtggggcg	cgagcctgac	gctgccccct	gctcaggcgcc	24960
gctgtgggggt	atggggcggg	tcgcggcgct	agagcatccc	ggctcctggg	gcgggctcgt	25020
ggacctggat	ccggaggaga	gcccgcagga	ggtcgaggcc	ctggtggccg	agctgctttc	25080
gccggagcgc	gaggatcagc	tggcatcccg	ccaggggcg	cgccgcgcag	cgcggttgt	25140
ggccgccccca	ccggagggaa	acgcagcgcc	ggtgtcgctg	ttcgcgagg	ggagttactt	25200
gggtgacgggt	gggctggggc	cccttgccct	cctcgttgcg	cggtggttgg	tggagcgcg	25260
ggcgggggcac	cttgtgctga	tcagccggca	cggattgccc	gaccgcgagg	aatggggccg	25320
agatcagccg	ccagaggtgc	gcgcgcgcat	tgccggcatc	gaggcgctgg	aggcgaggg	25380
cgcgctgggtc	acgctggcg	ggctcgacgt	ggccgatgcc	gaaggcatgg	cgccgctctt	25440
ggcgggcgctc	gagccgcgcg	tgccgggggt	agtgacgccc	gcgggtctgc	tcgacgacgg	25500
gctgctggcc	caccaggacg	ctggtcggct	cgcccggttg	ttgcgcccc	aggtggagg	25560
ggcatgggtg	ctgcacaccc	ttaccgcgga	gcagcgctg	gacctcttcg	tactgttttc	25620
ctggcgctcg	ggcgctcttc	gctcgatcgg	ccagggcagc	tacgcggcag	gcaatgcctt	25680
tttggacgg	ctggcggaac	tcgcgggaac	gcaggggctc	gccgcccctg	gcattcgctg	25740
gggctgtgtg	gcggaggggg	ggatgggctc	gcaggcgag	cgccgggaac	acgaggcatc	25800
gggaattctg	gcgatgccga	cgagtcgggc	cctggcgggc	atggaatggc	tgctcgggtac	25860
gcgcgcgacg	cagcgcggtg	tcattccagat	ggattggggc	catgcgggag	cgccgcggcg	25920
cgacgcgagc	cgaaggccgct	tcggggtatc	gctggtaact	gccacgaaag	aggcctctct	25980
ctcgggcggtg	ccagctgtgg	agcgctggcg	caacgcgctc	gttgtggaga	cccgctcggc	26040

gctctacgag	cttgtgcgcg	gcgtgggtcgc	cggggtgatg	ggctttaccg	accaggggac	26100
gctcgcagtg	cgacgaggct	tcgccgagca	gggcctcgac	tccctgatgg	ccgtggagat	26160
ccgcaaacgg	cttcaggggtg	agctgggtat	gccgctgtcg	gcgacgctag	cgctcgacca	26220
tccgaccgtg	gagcggcttg	tggaatactt	gctgagccag	gcgctggagc	tgcaggaccg	26280
caccgacgtg	cggagcggttc	gggttgcggc	gacagaggac	ccgatcgcca	tcgtgggtgc	26340
cgcttgccgc	ttcccgggcg	gggtcgagga	cctggagtcc	tactggcagc	cggtgaccga	26400
gggctggtg	gtcagcaccg	aggtgcccgc	cgaccggtgg	aatggggcag	acgggcgctg	26460
ccccggctcg	ggagaggcac	agagacagac	ctacgtgccc	aggggtggct	ttctgcgcga	26520
gggtggagag	ttcgatgcgg	cgttcttcca	catctcgcc	cgggaggcga	tgagcctgga	26580
cccgaacag	cggtcgctgc	tggaagtggg	ctgggaggcg	atcgagcgcg	cgggccagga	26640
ccgctcgcg	ctgcgcgaga	gccccacggg	cgtgttcgtg	ggcgcgggcc	ccaacgaata	26700
tgccgagcgg	gtgcaggaac	tcgccgatga	ggcgcggggg	ctctacagcg	gcaccggcaa	26760
catgctcagc	gttgcggcgg	gacggctatc	atttttctctg	ggcctgcacg	ggccgaccct	26820
ggctgtcgat	acggcgctgt	cctcgctcgt	ggtggcgctg	cacctcggtc	gccagagctt	26880
gcgacggggc	gagtgcgacc	aagccctggg	tgccgggggtc	aatatgctgc	tctcgccgaa	26940
gaccttccgc	ctgctctcac	ggatgcacgc	actttcgccc	ggcgggcggt	gcaagacgtt	27000
ctcgcccgac	gcggacggct	acggcggggc	cgagggctgc	gcccgtgggtg	tgctcaagcg	27060
gctcttcgag	cgcgagcgcg	accgcgaccc	catcctggcg	gtgatccggg	gtacggcgat	27120
caatcatgat	ggcccagagca	gcgggctgac	agtgcggcgc	ggccctgccc	aggaggcgct	27180
gttacgccag	gcgctggcgc	acgcaggggg	ggttccggcc	gacgtcgatt	tcgtgggaatg	27240
ccacggggacc	gggacggcgc	tgggcgaccc	gatcgagggtg	cgtgcgctga	gcgacgtgta	27300
cgcgcaagcc	cgccctgcgg	accgaccgct	gatcctggga	gcccgaaggg	ccaacctggg	27360
gcacatggag	cccgcggcgg	gcctggccgg	cttgcctcaag	gcgggtgctcg	cgctggggca	27420
agagcaata	ccagcccagc	cggagctggg	cgagctcaac	ccgctcttgc	cgctgggagcg	27480
gctgcccgtg	gcgggtggccc	gcgcagcggt	gcccgtggccg	cgacgggacc	gcccgcgctt	27540
cgcggggggtg	agctcgcttc	ggatgagcgg	aacgaacgcg	catgtgggtg	tggaagaggc	27600
gcccggcggtg	gagctgtggc	ctgccgcgcc	ggagcgctcg	gcggagcttt	tggtgctgtc	27660
gggcaagagc	gagggggcgc	tcgatgcgca	ggcgcgcgcg	ctgcgcgagc	acctggacat	27720
gcacccggag	ctcgggctcg	gggacgtggc	gttcagcctg	gcgacgacgc	gcagcgcgat	27780
gaaccaccgg	ctcgcgggtg	cgggtgacgtc	gcgcgagggg	ctgctggcgg	cgctttcgcc	27840
cgtggcgagc	gggcagacgc	cgccgggggc	ggcgcgctgc	atcgcgagct	cgctcgcgcg	27900
caagctggcg	ttcctgttca	ccggacaggg	cgcgagagcg	ccgggcatgg	gcccggggct	27960
ttgcgcggcg	tgccagcgtg	tccgggaggg	gttcgaccgg	tgctggcgcg	tgctcgacgg	28020
ggcgggggat	cgcccgcctg	gcgaggtgat	gtgggaggag	ccggggagcg	ccgagctcgt	28080
gttgcctgac	cagacggcgt	tcacccagcc	cgcgctcttc	acgggtggagt	acgcgctgac	28140
ggcgctgtgg	cggctcgtgg	gcgtagagcc	ggagctgggtg	gctgggcata	gcgcccggga	28200
gctggtggcg	gcgtgcgtgg	cgggggtgtt	ctcgctggaa	gatgggggtga	ggctcggtga	28260
gctcgggggg	cggtgatgcg	aggggctctc	ggcgggcgcg	gcgatgggtg	cgctcgggagc	28320
gcccggaggcg	gaggtggcgg	cggcggtggc	gcccgcacgcg	gcgtcggtgt	cgatcgcggc	28380
ggtcaatggg	ccggagcagg	tggtgatcgc	gggcgtggag	caagcggtgc	aggcgatcgc	28440
ggcggggttc	gcggcgcgcg	gcgcgcgcac	caagcggtgc	catgtctcgc	acgcgtccca	28500
ctcgccgctg	atggaaccga	tgctggagga	gttcggcgcg	gtggcgggct	cggtgacgta	28560
ccggcgggcca	agcgtttcgc	tggtgagcaa	cctgagcggg	aaggtgggtcg	cggacgagct	28620
gagcgcgccg	gggtactggg	tgccggcacgt	gcgggaggcg	gtgcgcttcg	cggacggggg	28680
gaaggcgctg	cacgaagccg	gtcggggcac	gttcgtcgaa	gtggggcccg	agccgacgct	28740
gctcggggctg	tgccagccct	gcctgccgga	ggcgagcccg	acgctgctgg	cgctcgttgc	28800
cgccggggcg	gaggaggctg	cgggggtgct	cgaggcgctg	ggcaggctgt	gggcccggcg	28860
cggctcggtc	agctggccgg	gcgtcttccc	cacggctggg	cggcggggtg	cgctgccgac	28920
ctatccgtgg	cagcggcagc	ggtactggcc	cgacatcgag	cctgacagcc	gtcgccacgc	28980
agccgcggat	ccgaccgaag	gctgggttcta	tcgcgtggac	tgcccgagga	tacctcgagc	29040
cctccagaaa	tcagaggagg	cgagccgcgg	gagctggctg	gtattggcgg	ataagggtgg	29100
agtcggcgag	gcggctcgtg	cagcgctgtc	gacacgtgga	cttccatcg	tcgtgctcca	29160
tgccggcgca	gagacatccg	cgaccgcgca	gctgggtgac	gaggctgccc	cggttcgaag	29220
cgattggcag	gtagtgtctt	acctgtgggg	tctggacgc	gtcgctgggtg	cggaggcgctc	29280
gatcgatgag	atcggcgacg	cgaccgcgtc	tgctaccgcg	ccggtgctcg	gcttggtctcg	29340
gtttctgagc	accgtgtctt	gttcgccccg	actctgggtc	gtgacccggg	gggcatgcat	29400
cgttggcgac	gagcctgcga	tcgccccctg	tcaggcgggc	ttatggggca	tgggccgggt	29460
ggcgggcgctc	gagcatcccg	gggcccgggg	cgggctcgcg	gacctggatc	cccagcgag	29520
cccgcgccaa	gccagcccg	tcgacggcga	gatgctcgtc	accgagctat	tgctcgagga	29580
gaccgaggat	cagctcgcc	tcggccatgg	gcgcggcac	gcggcacggc	tggtggccgc	29640
cccgccacag	gggcaagcgg	caccgggtgtc	gctgtctcgc	gaggcgagct	acctgggtgac	29700
gggagggcctc	ggtgggctgg	gcctgatcgt	ggccagctgg	ctgggtggagc	tgggagcgcg	29760
gcacttgggtg	ctgaccagcc	ggcgcggggt	gcccagaccg	caggcggtggt	gcgagcagca	29820
gcccgcctgag	atccgcgcgc	ggatcgagc	ggtcgagggc	ctggaggcgc	gggggtgcacg	29880
ggtgaccgtg	gcagcggtgg	acgtggccga	cgtcgaaccg	atgacagcgc	tggtttcgtc	29940

ggctcgagccc ccgctgagag ggggtgggtgca cgcgctgggc gtcagcgtea tgcgtccact 30000
 ggcggagacg gacgagaccc tgctcgagtc ggtgctccgt cccaaggtgg ccgggagctg 30060
 gctgctgcac cggctgctgc acggccggcc tctcgacctg ttcgtgctgt tctcgctggg 30120
 cgcagcggtg tggggtagcc atagccaggg tgcgtacgcg gcggccaacg ctttccctcga 30180
 cgggctcgcg catcttcggc gttcgcaatc gctgcctgcg ttgagcgctg cgtgggggtct 30240
 ttggggccgag ggaggcatgg cggacgcgga ggtcatgca cgtctgagcg acatcggggg 30300
 tctgccccatg tcgacgtcgg cagcgtttgtc ggcgtccag cgcctggtgg agaccggcg 30360
 ggctcagcgc acggtgaccc ggatggactg ggcgcgcttc gcgccggtgt acaccgctcg 30420
 agggcgctgc aacctgcttt cggcgctggt cgcagggcgc gacatcatcg cgccttcccc 30480
 tccggcgga gcaaccggga actggcggtg cctgtccgtt gcggaagccc gcgtggctct 30540
 gcacgagatc gtccatgggg ccgtcgctcg ggtgctgggc ttcctcgacc cgagcgcgct 30600
 cgatcctggg atggggttca atgagcaggg cctcgactcg ttgatggcgg tggagatccg 30660
 caacctcctt caggctgagc tggacgtgcg gctttcgacg acgctggcct ttgatcatcc 30720
 gacggtacag cggctgggtg agcatctgct cgtcgatgta ctgaagctgg aggatccgag 30780
 gcacacccag catgttcggg cgttggcgct agacgagccc atcgccatcg tgggagcgcg 30840
 ctgcccgttc ccgggcgggg tggaggacct ggagtcctac tggcagctat tggccgaggg 30900
 cgtgggtggtc agcgcggagg tccggccgga ccggtgggat gcggcggact ggtacgaccc 30960
 tgatccggag atcccaggc ggacttacgt gaccaaaggc gccttcctgc gcgatttcca 31020
 gagattggat gcgaccttct tccgcatctc gcctcgagag gcgatgagcc tcgacccgca 31080
 gcagcggttg ctccctggagg taagctggga agcgtcgag agcgcgggta tcgctccgga 31140
 tacgctgcga gatagcccca ccgggggtgt cgtgggtgcg gggcccaatg agtactacac 31200
 gcagcggtcg cgaggcttca ccgacggagc ggcaggggtt tacggcgcca ccgggaacat 31260
 gctcagcggt acggctggac ggtgtcgtt ttctctgggt ctgcacggcc cgacgctggc 31320
 catggatacg gcgtgctcgt catccctggt cgcgctgcac ctgcctgcc agagcctgcg 31380
 actgggagag tgcgatcaag cgtgggttg cggggtcaac gtgctgctcg cgcggagag 31440
 cttcgtctcg ctctcacgga tgcgcgcgct ttcgcccagc gggcggtgca agacgttctc 31500
 ggccgagcgc gacggctacg ccgggggga ggggtgcgcc gtgggtggtg tcaagcggct 31560
 gcgcgatgcg cagcgcgccc gcgactccat cctggcgctg atccggggaa gcgcggtgaa 31620
 ccacgacggc ccgagcagcg ggtgacgct acccaacgga cccgcccagc aagcatctgct 31680
 gcgccaggcg ctctcgcaag caggcgtgtc gcgacccgat cgaggtgagc gcgctgagcg aggtgtatgg 31800
 cgggacaggg tccggggacc gaccgctggt gctgggggccc gccaaaggcca acgtcgcgca 31860
 tccggaggcg gcatctggct tggccagcct gctcaaggcc gtgcttgccg tcgggcacga 31920
 gcagatcccc gccagccgg gcttggggga gctcaacccc cacttgccgt gaaacgctc 31980
 gcccgtggcg gtgccacgta aggcggtgccc gtgggggccc ggcgcacgcc cgcgtcgggc 32040
 cggcgtagcg gcgttcgggt tagcgggaac caactgcat gtcgtgctgg aggagggacc 32100
 ggaaggtggag ccgggcgccc cggcgccggc gcgaccggtg gagctggtcg tgctatcggc 32160
 caagagcgcg gcggcgctgg acgcgcgccc cagccggctc tcggcgccacc tgcctcgccc 32220
 cccggagctg agcctcgccg acgtggcgct cagcctggcg acgacgcgca gcccgatgga 32280
 gcaccggctc gccatcgcgga cgaactcgcg cgaggccctg cgaggcgccg tggacggccc 32340
 ggcgcagcaa aagacgcgc agggcgcggt gcgcggcaag gccgtgtcct cagcggtgta 32400
 gctggcttct cgtttcaccc gacagggcgc gcaaatgccg ggcatgggccc tggggctgta 32460
 cgaaaacgtg cctgctgtcc gggaggcggt cgaccggtg gtggcgctct tcgatcgggga 32520
 gatcgaccag cctctgcgcg aggtgatgtg ggtgcgccc ggcttcgctc aggcggcgcg 32580
 gctcgatcag accgctacg cgacgcccgc tctctttgcg ctggagtagc cgtggctgc 32640
 cctgtggcgt tcgtggggcg tggagccgca cgtactgctc ggtcatagca tcggcgagct 32700
 ggtcgccgccc tgcgtggcgg gcgtgttctc gctcgaagat gcggtgaggt tgggtggccc 32760
 gcgcggggcg ctgatgcagg cgctaccgccc cggcggtgcc atggtagcca tcgcagcgct 32820
 cgaggccgag gtggccgccc ccgtggcgccc ccacgcccgc acggtgtcga tcgcccgggt 32880
 caacggctcct gacgcccgtc tgatcgccgg cgccgaggtg cagggtgctc cctcggcgcc 32940
 gacgttcgcg gcgcgtggga tacgcacgaa gaggtcgcgc gttctccatg cgttccactc 33000
 gccgctcatg gatccgatgc tggaaagact ccagcggtc gctgcgacga tcgctgaccg 33060
 cgcgccagac cgcccgggtg tgtcgaatgt caccggccac gtcgcaggcc ccgagatcgc 33120
 cacgcccag tattgggtcc agcatgtgct aagcgccgtg cgcttcggcg acggggcaaa 33180
 ggcgttgcac gcccggggtg ccgccacgtt cgtcgagggt ggcccgaagc cggctcctgct 33240
 cgggctgttg ccagcgtgcc tcggggaagc ggcgcggtc ctggtgccgt cgctacgcgc 33300
 ggaccgctcg gaatgcgagg tggctcctcgc ggcgctcggg gcttgggtatg cctggggggg 33360
 tgcgttcgac tggaaaggcg tgttccccga tggcgcgcg cgctggctc tcgccatgta 33420
 tccatggcag cgtgagcgcc attggatgga cctcaccgga cgaagcgccg cgcctgcagg 33480
 gatcgaggt cgctggccgc tggctgggtgt cgggctctgc agggctctgc gctgtctgca 33540
 ccaggtgctc tcgatcggac cagcccatga gcccttcttc ggtgatcacc tcgtgtttgg 33600
 caaggtgttg gtgccggcg cctttcatgt cgcggtgac ctacgcatcg ccgcccagcg 33660
 ctggcccag cgggcgatcg agctgacagg cgtggagttc ctgaaggcca tcgcatgga 33720
 gcccgaccag gaggtcgagc tccacggcgt gctcaccgga gaagccggcg gggatggcta 33780
 cctgttcgag ctggcgaccc tggcgcgccc ggagaccgaa cgcgcatgga cgacccacgc 33840

ccgcgggtcgg	gtgcagccga	cagacggcgc	gcccggcgcg	ttgccgcgcc	tcgaggtgct	33900
ggaggaccgc	gcgatccagc	ccctcgactt	cgccggattc	ctcgacaggt	tatcgccggg	33960
gcggatcggc	tgggggtccg	tttggcgatg	gctgcaggac	gggcgcgctc	gcgacgaggc	34020
ctcgcttgcc	acctctgtgc	cgacctatcc	gaacgcccac	gacgtggcgc	ccttgacccc	34080
gatcctgctg	gacaacggct	ttgcgggtgag	cctgctgtca	acccggagcg	agccggaggga	34140
cgacgggacg	cccccgctgc	cgttcgccgt	ggaacgggtg	cggtgggtgg	gggcggccgg	34200
tggaaagggtg	cggtgtggcg	gcgtgcccgc	gtcgcaggca	ttcggtgtct	cgagcttcgt	34260
gctggtcgac	gaaactggcg	aggtgggtcgc	cgaggtggag	ggatttgttt	gccgcccggc	34320
gccgcgagag	gtgttcctgc	ggcaggagtc	gggcgcgctc	actgcagcct	tgtaccgccc	34380
cgactggccc	gaagcgccct	tgcccgatgc	gcctgcggaa	cggtcgagg	agagctgggt	34440
cgtggtggca	gcacctggct	cgagatggc	cgccggcgctc	gcaacacggc	tcaaccgctg	34500
cgtcctcgcc	gaacccaaag	gcctcgaggc	ggccctcgcg	ggggtgtctc	ccgcaggtgt	34560
gatctgcctc	tgggaggctg	gagcccacga	ggaagctccg	gcggcgggcg	agcgtgtggc	34620
gaccgagggc	ctctcggtgg	tgcaggcgct	cagggaccgc	gcggtgcgcc	tgtgtgtggg	34680
gaccatgggc	gcagtggccg	tcgaggccgg	tgagcggggtg	caggtcgcca	cagcgccggg	34740
atggggccctc	ggccggacag	tgatgcaggga	gcgcccggag	ctcagctgca	ctctggtgga	34800
tttggagccg	gagggccgatg	cagcgcgctc	agctgacgtt	ctgttgcggg	agctcggtcg	34860
cgtgcagcac	gagacacagg	tggctttccg	ttccggaaaag	cgccgcgtag	cgccgctggg	34920
caaagcgacg	acccccgaag	ggctcctggg	ccctgacgca	gagtcctatc	gactggaggc	34980
tgggcagaag	ggcacattgg	accagctccg	cctcgcgccg	gcacagcgcc	gggcacctgg	35040
cccgggcgag	gtcgagatca	aggtaacccg	ctcggggctc	aacttccgga	ccgtcctcgc	35100
tgtgctggga	atgtatccgg	gcgacgcggg	gccgatgggc	ggagatttgt	ccggtgtcgc	35160
cacggcggtg	ggccaggggg	tgcgccacgt	cgcggtcgcg	gatgctgtca	tgcagctggg	35220
gacgttgcat	cgattcgtca	cggtcgacgc	gcggctgggtg	gtccggcagc	ctgcagggct	35280
gactcccgcg	caggcagcta	cggtgcgggt	cgctgttcctg	acggcctggc	tcgctctgca	35340
gcacctgggg	aatctgcggc	gcggcgagcg	ggtgctgac	catgctgcgg	ccggcggtgt	35400
gggcatggcc	gcggtgcaaa	tcgcccgatg	gataggggcc	gaggtgttcg	ccacggcgag	35460
cccgctcaag	tgggcagcgg	ttcaggccat	gggcgtgccc	cgacgcaca	tcgccagctc	35520
gcggacgctg	gagtttgctg	agacgttccg	gcaggtcacc	ggcgggccggg	gcgtgagcgt	35580
ggtgctcaac	gcgctggccg	gcgagttcgt	ggacgcgagc	ctgtccctgc	tgtcgacggg	35640
cgggcggttc	ctcgagatgg	ctcagaccga	catacgggat	cgagcccgcg	tcgcgccggc	35700
gcatcccggg	gttcgctatc	gggtattcga	catcctggag	ctcgctccgg	atcgaactcg	35760
agagatcctc	gagcgcggtg	tcgagggcct	tgtcgcgga	catctgcgcg	cattgccggg	35820
gcattcgctc	gcgatcacca	aggccgaggg	agcgtttcgg	ttcatggcgc	aagcgcgga	35880
tcaggggcaag	gtcgtgctgc	tgcggcgccc	ctccgcagcg	cccttggcgc	cgacgggcac	35940
cgtactgctg	accggtgggc	tgggagcgtt	ggggctccac	gtggcccgct	ggctcgccca	36000
gcagggcgctg	ccgcacatgg	tgtctacagg	tcggcggggc	ctggatacgc	cgggcgctgc	36060
caaagccgtc	gcggagatcg	aagcgctcgg	cgctcggggtg	acgatcgcgg	cgctcgatgt	36120
cccgcatcgg	aatgcgctgg	aggctgtgct	ccaggccatt	ccggcgaggt	ggccgttaca	36180
gggcgtgac	catgcagccg	gagcgctcga	tgatgggtgtg	cttgatgagc	agaccaccga	36240
ccgctttctc	cggtgtgctg	caccgaagg	gactggcgcc	tggaaatctgc	atgagctcac	36300
ggcggggcaac	gatctcgctt	tcttcgtgct	gttctcctcc	atgtcggggc	tcttgggctc	36360
ggccggggcag	tccaactatg	cggcgggcga	caccttctct	gacgcgctgg	ccgcgcacgc	36420
gcggggccgaa	ggcctggcgg	cgagagccct	cgctgggggc	ccatggctcg	acggagggcat	36480
ggcagcgggg	ctcagcgcg	cgctgcaggg	gcggctcgct	cggcattggga	tgggagctct	36540
gtcgccggct	cagggcaccc	cgctgctcgg	gcaggcgctg	gctcgccgg	aaacgcagct	36600
cgggggcgatg	tcgctcgacg	tgcgtgcggc	aagccaagct	tcgggagcgg	cagtgccggc	36660
tgtgtggcgc	gcgttgggtg	gcgcggaggc	gcgccatacg	gcggctgggg	cgcagggggc	36720
attggcccg	cgtcttgggg	cgctgcccga	ggcgcgctcg	gccgacgagg	tgcgcaagg	36780
cgtgcaggcc	gagatcgcg	gcgtgctttc	atggagcgcc	gcgagcgccg	tgcccgtcga	36840
tcggccgctg	tcggacttgg	gcctcgactc	gctcacggcg	gtggagctgc	gcaacgtgct	36900
cgggccagcgg	gtgggtgctga	cgctgcccgc	gacgttgcca	ttcgatcacc	cgacggctga	36960
cgcgctcacg	cgctggctgc	tcgataaagg	cctggccggt	gccgagccga	gcgtatcgct	37020
cgcaaatcg	tcgcccaggg	cagagccatt	gccatcatcg	gcatcgctg	gtcggcgctg	37080
ccgtttccca	ggcgcgctgg	ccgatccgga	gtcgttttgg	cggtgctcgc	aagagggcag	37140
cgatgccgtc	gtcgaggtgc	cgcatgagcg	atgggacatc	gacgcgttct	atgatccgga	37200
tcgggatgtg	cgcggaaga	tgacgacacg	cttggggcgc	ttcctgtccg	atatcgaccg	37260
gttcgatccg	gccttcttgc	gcatctcgcc	gcgcaagcg	acgaccatgg	atcccgagca	37320
gcggctgctc	ctggagacga	gctgggaggc	gttcgagcgc	gccgggattt	tgcccgagcg	37380
gctgatgggc	agcgataccg	gcgtgttctg	ggggctcttc	taccaggagt	acgctgcgct	37440
cgccggcgcc	atcgaggcgt	tcgatggcta	tctaggcacc	ggcaccacgg	ccagcgctcg	37500
ctcgggcagg	atctcttatg	tgtctgggct	aaagggggcg	agcctgacgg	tggacaccgc	37560
gtgctcctcg	tcgctggctg	gggtgcaact	ggcctcgccg	gcgctgcggc	ggggcgagtg	37620
ttcggtggcg	ctggccggcg	gcgtggcgct	gatgctcacg	ccggcgacgt	tcgtggaggt	37680
cagccggctg	cgaggcctgg	ctcccgacgg	acggtgcaag	agcttctcgg	ccgcagccga	37740

cggcgtgggg	tggagcgaag	gctgcgccat	gctcctgctc	aaaccgcttc	gcgatgcgca	37800
gcgcgatggg	gatccgatcc	tggcggtgat	ccgcggcacc	gcggtgaacc	aggatggggc	37860
cagcaacggg	ctgacggcgc	ccaacgggtc	gtcgcagcaa	gaggtgatcc	gtcggggccct	37920
ggagcaggcg	gggctggctc	cggcggacgt	cagctacgtc	gagtgccacg	gcaccggcac	37980
gacgttgggc	gaccccatcg	aagtgcaggc	cctggggcgcc	gtgctggcac	agggggcgacc	38040
ctcggaccgg	ccgctcgtga	tccgggtcgt	gaagtccaat	atcggacata	cgcaggctgc	38100
ggcggggcgtg	gccgggtgtca	tcaagggtgg	gctggcgctc	gagcgcgggc	ttatcccag	38160
gagcctgcat	ttcgacgcgc	ccaatccgca	cattccgtgg	tcggagctcg	ccgtgcagg	38220
ggccgcgcaa	cccgtcgaat	ggacgagaaa	cggcgtgccc	cgacgagccg	gggtgagctc	38280
gtttggcgtc	agcgggacca	acgcgcacgt	ggtgctggag	gaggcgccag	cgccggcgtt	38340
cgcccccgcg	gcggcgcggt	cagcggagct	tttcgtgctg	tcggcgaaag	gcgcgcgggc	38400
gctggacgcg	caggcggcgc	ggcttttcgg	gcacgtcgtt	gcgcaccccg	agctcggcct	38460
cgccgacctg	gcgttcagcc	tggcgacgac	ccgcagcccg	atgacgtacc	ggctcgcgg	38520
ggcggcgacc	tcgcgcgagg	cgctgtctgc	cgcgctcgac	acagcggcgc	agggggcagg	38580
gcccgcggca	gcggctcgcg	gccacgcttc	cacaggcagc	gccccaaagg	tggttttcgt	38640
ctttcctggc	cagggtctcc	agtggctggg	catgggcca	aagctcctct	cggaggagcc	38700
cgtcttccgc	gacgcgctct	cggcgtgtga	ccgagcgatt	caggccgaag	ccggctggct	38760
gctgctcgcc	gagctcgcgg	ccgatgagac	cacctcgag	ctcggccgca	tgctcgatgc	38820
gcagccggcg	ctgttcgcga	tcgaggtcgc	gctgtcggcg	ctgtggcggt	cggtgggctg	38880
cgagccggat	gcagtggtag	gccacagcat	gggcgaagt	gcggcccgcg	acgtcggccg	38940
cgcctctgct	ctcgaggatg	ctgtagcgat	catctgccc	cgcagcctgc	tgctgcccgg	39000
gatcagcgcc	caaggcgaga	tggcggtcgt	cgaagctttc	ctggccgagg	cgaggcgagc	39060
gctcctgggc	tacgaagacc	ggctcagcgt	ggcggtagag	aacagcccg	gctcgacgg	39120
gctggcgggc	gagccggcag	cgctcgcaga	ggtgctggcg	atccttgcgg	caaaggggg	39180
gttctgccgt	cgagtcgaag	tggacgtcgc	cagccacagc	ccacagatcg	acccgctgcg	39240
cgacgagcta	ttggcagcat	tggcgagct	cagcccgca	caagcgaccg	tgctcgatgc	39300
ctcgacgggt	acgagcacga	tcattggcg	cccggagctc	gtggcgagct	actggcggga	39360
caacgttcga	cagccgggtg	gcttcgccc	agcggtgcaa	tcgttgatgg	aagacgggtc	39420
tgggctgttc	gtggagatga	gcccgcaccc	gatcctgacg	acatcggtcg	aggagatccg	39480
acggggcgac	aagcgggagg	gagtcgcgg	gggctcgttg	cgccgtggag	aggacgagcg	39540
ctgtctccat	ttggaggcgc	tgggagcgct	ctgggtacac	ggccaggcgg	tgggctggga	39600
gcggctgttc	tcgcggggcg	gcgcgggccc	ccgtcgcgtg	ccgctgccga	cctatccctg	39660
gcagcgcgag	cggtactggg	tcgatgcgcc	gaccggcgcc	gcggcgggcg	gcagccgctt	39720
tgctcactcg	ggcagtcacc	cgctcctggg	tgaatgacag	accctgtcga	ccagaggag	39780
cacgcgcgtg	tgggagacga	cgctggatct	caaacggctg	ccgtggctcg	gcgatcaccg	39840
ggtgcagggg	gcggctcgtg	tcgcggggcg	ggcgtaacct	gagatggcgc	tttcgtcccg	39900
ggccgaggcc	ttgggtgacg	gtccgctcca	ggtcagcgat	gtggtgctcg	ccgaggcgct	39960
ggccttcgcg	gatgatacgc	cggcgggcgt	gcaggtcatg	gcgaccgagg	agcagaccag	40020
ccgcttcgaa	ttccacgttg	cagccggggt	gcccggccac	ggcgggtgctg	cctttcgaag	40080
ccatgcccgc	gggggtgctg	gccagatcga	gcgcgcccag	gtcccggcga	ggctggatct	40140
ggcccgcgct	cgtgcccggc	ttcaggccag	cgcacccgct	gcggctacct	atgcggcgct	40200
ggccgagatg	gggctcagat	acggcccagc	gttccagggg	cttgtcgagc	tttggcgctg	40260
ggaggggcgag	gcgctgggac	gtgtgcccgt	ccccgaggcc	ggcggctccc	cagcccgctg	40320
ccggctccac	cccgcgctct	tggatgcgtg	cttccacgtg	agcagcgcc	tcgctgaccg	40380
cggcgaggcg	acgccatggg	taccctggga	aatcggtcgc	ctcggtgggt	tcagcgggcc	40440
gtcgggggag	ctgtgggtgt	atgcgcggag	tgtgagccac	ggaagccaa	caccgcgacc	40500
gcggagtacc	gacttctggg	tggctgacag	cacgggcgcg	atcgtcgccg	agatctccgg	40560
gctcgtggcg	cagcggctcg	cgggaggtgt	acgcgcggcg	gaagaagacg	actggttcat	40620
ggagccgggt	tgggaaccga	ccgcgggtcc	cggatccgag	gtcatggcgg	gcccgtggct	40680
gctcatcggc	tcggggcgcg	ggctcggcgc	tgcgctccac	tcggcgctga	cggaagctgg	40740
ccatttccgt	gtccacgcga	cagggcgcgg	cacgagcgcc	gcccgggttcg	aggcactctt	40800
gacggcgctc	ttcgacggcc	aggccccgac	gtcgggtggtg	cacctcgcca	gcctcgatga	40860
gcgtggcggt	ctcgacgcgg	atgccccctt	cgacgccgat	gcgcttgagg	agtcgctggt	40920
gcgcggctgc	gacagcgtgc	tctggaccgt	gcaggccgtg	gcccggggcg	gcttccgaga	40980
tcctcccgcg	ttgtggctcg	tgacacgcgg	cgctcaggcc	atcggcgccg	gcgacgtctc	41040
tgtggcgcaa	gcgcccgtcc	tggggctggg	ccgcgttacc	gccttggagc	acgccgagct	41100
gcgctgcgct	cggatcgacc	tcgatccagc	gcggcgcgac	ggagaagtgc	atgagctgct	41160
tgccgagctg	ttggccgacg	acgcgcgagg	ggaagtgcgc	tttcgcgggc	gtgagcgcg	41220
cgtggcccgg	ctcgtccgaa	ggctggcccga	gaccgactgc	cgagagaaaa	tcgagcccg	41280
ggaaggccgg	ccgttccggc	tggagatcga	tgggtccggc	gtgctcgacg	acctgggtgt	41340
ccgagccacg	gagcggcgcc	ctcctggccc	gggcgaggct	gagatcgccg	tcgaggcgcc	41400
ggggctcaac	tttctcgacg	tgatgagggc	catggggatc	tacctggggc	ccggggacgg	41460
tcgggttcgc	ctggggcgccg	agtgcctccg	ccgaattgtc	gcgatggggc	aaggtgtcga	41520
gagccttcgt	atcggccagg	acgtcgtggc	cgtcgcgccc	ttcagtttcg	gcacccacgt	41580
caccatcgac	gcccggatgc	tcgcacctcg	ccccgcggcg	ctgacggcgg	cgcaggcagc	41640

cgcgctgccc	gtcgcattca	tgacggcctg	gtacgggtctc	gtccatctgg	ggaggctccg	41700
ggccggcgag	cgcggtgctca	tccactcggc	gacggggggc	accgggctcg	ctgctgtgca	41760
gacgcggcgc	cacctcggcg	cggagatatt	tgcgaccgct	ggtacaccgg	agaagcgggc	41820
gtggctgcgc	gagcagggga	tcgcgcacgt	gatggactcg	cggctcgctgg	acttcgcccga	41880
gcaagtgcctg	gccgcgacga	agggcgaggg	ggctcgacgtc	gtgttgaaact	cgctgtctcg	41940
cgccgcgac	gacgcgagcc	tttcgaccct	cgtgcgggac	ggccgcttca	tcgagctcgg	42000
caagacggac	atctatgcag	atcgctcgct	ggggctcgct	cacttcagga	agagccctgc	42060
ctacagcgcc	gtcgaatctg	cgggcttggc	cgtgcgtcgg	cccagcgcg	tcgcagcgct	42120
gctggcgagg	gtgggtggacc	tgcctcgacg	gggagcgctg	cagccgcttc	cggtagagat	42180
cttccccctc	tcgcggggcg	cggacgcgtt	ccggaaaatg	gcgcaagcgc	agcatctcgg	42240
gaagctcgctg	ctcgcgctgg	aggaccggga	cgtgcgggac	cgcgttccgg	gcgaatcccg	42300
cgtcgccatc	cgcgcgggag	gcgcctacct	cgtgaccggc	ggtctggggg	ggctcgggtc	42360
gagcgtggct	ggatggctgg	ccgagcaggg	ggctgggcat	ctgggtgctg	tgggcccgtc	42420
cggcgcggtg	agcgcgagc	agcagacggc	tgtcgccgcg	ctcgaggcgc	acggcgcgcg	42480
tgtcacggta	gcgagggcag	acgtcgccga	tcggcgcgag	atggagcgga	tcctcccgca	42540
gggtaccgcg	tcgggggatgc	cgtccgcgg	cgtcgttcat	gcggccggaa	tcctggacga	42600
cgggctgctg	atgcagcaaa	cccccgcgcg	gttccgcggc	gtcatggcgc	ccaaaggtccg	42660
aggggcttgc	cacctgcatg	cgttgacacg	cgaagcgccg	ctctcttctt	tcgtgtgta	42720
cgcttcggga	gcagggtctt	tgggttcgcc	gggccagggc	aactacgctg	cggccaacac	42780
gttcttcgac	gcaactggac	accaccggag	ggcgaggggg	ctgccagcat	tgagcatcga	42840
ctggggcctg	ttcgcggagc	tgggtttggc	cgccggcgag	caaaatcgcg	gcgcacggct	42900
ggtcacccgc	gggacgcgga	gcctcacccc	cgacgaaggc	ctgtgggcgc	tcgagcgctc	42960
gctcgacggc	gatcgacccc	aggccggggt	catgcccgtt	gacgtgcggc	agtggtggga	43020
gttctacccg	gcggcgggcat	cttcgcggag	gttgtcgcg	ctcatgacgg	cacggcgcg	43080
ggcttccggt	cggctcgcgg	gggatcggga	cctgctcgaa	cggctcggca	ccgccgaggc	43140
gggcgcggcg	gcagggatgc	tgcaggaggt	cgtgcgcgcg	caggctctcg	aggtgctgct	43200
ccttcctcgaa	ggcaagctcg	acgtggatgc	gccgctcacg	agcctgggaa	tggactcgtc	43260
gatggggcta	gagctgcgca	accgcatcga	ggcctgctc	ggcatcacca	tgccggcgac	43320
cctgctgtgg	acctacccca	cgggtggcagc	gctgagtgcg	catctggctt	ctcatgtcgt	43380
ctctacgggg	gatggggaa	ccgcgcgccc	ggcgataaca	gggagcgctg	ctccaacgac	43440
ccacgaagtc	gcttcgctcg	acgaagacgg	gttgttcgcg	ttgattgatg	agtcactcgc	43500
gcgcgcggga	aagaggatgat	tgcgtgacag	accgagaagg	ccagctcctg	gagcgcctgc	43560
gtgaggttac	tctggccctt	cgcaagacgc	tgaacgagcg	cgataccctg	gagctcgaga	43620
agaccgagcc	gatcgccatc	gtggggatcg	gctgcccgtt	ccccggcgga	ccggggcactc	43680
cggagggcgt	ctgggagctg	ctcgacgacg	ggcgcgacgc	gatccggccg	ctcgaggagc	43740
gctggggcgt	cgtagggtgtc	gaccacggcg	acgacgtacc	gcgctggggc	gggctgctca	43800
ccgagggcat	cgacggcttc	gacgcgcgct	tcttcggtat	cgcccccccg	gaggcacggg	43860
cgttcgaccc	gcagcatcgc	ctgctgctgg	aggtcgccctg	ggaggggttc	gaagacggcg	43920
gcattccgcg	caggctccctc	gtcgggagcc	gcaccggcgt	gttcgtcggc	gtctgcgcca	43980
cggagtacct	ccacgcccgc	gtcgcgcacc	agccgcgcga	agagcgggac	gcgtacagca	44040
ccaccggcaa	catgctcagc	atcgccgccc	gacggctatc	gtacacgctg	gggctcgagg	44100
gaccttgcct	gaccgtcgat	acggcgctgt	cgtcatcgct	ggtggccatt	cacctcgctt	44160
gccgcagcct	gcgcgctcga	gagagcgatc	tcgcgctggc	gggaggggtc	aacatgcttc	44220
tctcccccg	cacgatgcga	gctctggcgc	gcacccaggc	gctgtcgccc	aatggccggt	44280
gccagacctt	cgacgcgtcg	gccaaacgggt	tcgtccgtgg	ggagggtcgc	ggtctgatcg	44340
tgtcaagcg	attgagcgac	gcgcggcggg	atggggaccg	gatctgggcg	ctgatccgag	44400
gatcgcccat	caatcaggac	ggccggtcga	cgggggtgac	ggcgcccaac	gtgctcgccc	44460
agggggcgct	cttgcgcgag	gcgctcgcca	acgcccggcg	cgaaggcgag	gccatcggtt	44520
acatcgagac	ccacggggcg	gcaacctcgc	tgggcgaccc	catcgagatc	gaagcgctgc	44580
gcgcttgggt	ggggccggcg	cgagccgacg	gagcgcgctg	cgtgctgggc	gcggtgaaga	44640
ccaacctcgg	ccacctggag	ggcgctggcg	gcgtggcggg	cctgatcaag	gcgacgcttc	44700
cgtctacatca	cgagcgcatc	ccgaggaaac	tcaactttcg	tacgctcaat	ccgcggatcc	44760
ggatcgaggg	gaccgcgctc	gcgttggcga	ccgaaccggg	gccttgccg	cggacggggc	44820
ggacgcgctt	cgcgggagtg	agctcgttcg	ggatgagcgg	gaccaacgcg	catgtggtgt	44880
tggaggaggc	gccggcggtg	gagcctgagg	ccgcggccccc	cgaagcgcca	gcggagctgt	44940
tcgtctgtgc	ggcgaagagc	gcggcgcgcg	tggatgcgca	ggcagcccgg	ctgcgggacc	45000
acctggagaa	gcacgtcgag	cttggccctc	gcgatgtggc	gttcagcctg	gcgacgacgc	45060
gcagcgcgat	ggagcaccgg	ctggcggtgc	gcgcgagctc	gcgcgaggcg	ctgcgagggg	45120
cgttttcggc	cgcagcgcat	gggcacacgc	cgccgggagc	cgtgcgtggg	cgggctcctg	45180
gcggcgagcg	gccgaagggt	gtcttcgtgt	ttcccggcca	gggctcgag	tgggtgggca	45240
tgggcccga	gctcatggcc	gaagagccgg	tcttcggggc	ggcgctggag	ggttcgcacc	45300
gggccatcga	ggcggaagcg	ggctggtcgc	gtctcgggga	gctctccgcc	gacgagcgcc	45360
cctcgcagct	cgggcgcac	gacgtggttc	agccgggtgt	cttcgccatg	gaagtgcgcg	45420
tttctgcgct	gtggcggtcg	tggggagtg	agccggaagc	ggtggtgggc	cacagcatcg	45480
gcgaggttgc	ggcgggcgac	gtggccggcg	cgtgtcgtct	cgaaggacgcg	gtggcgatca	45540

tctgccggcg	cagccggctg	ctgcggcgga	tcagcggtea	gggggagatg	gcgctggctg	45600
agctgtcgct	ggaggaggcc	gaggcggcgc	tgcgtggcca	tgagggtcgg	ctgagcgtgg	45660
cggtgagcaa	cagcccgcgc	tcgaccgtgc	tcgcccgcga	gccggcggcg	ctctcgaggg	45720
tgctggcgcc	gctgacggcc	aagggggtgt	tctggcgcca	ggtgaagggt	gacgtcgcca	45780
gccatagccc	gcaggtcgac	ccgctgcgcg	aagagctgat	cgcggcggctg	ggagcgatcc	45840
ggccgcgagc	ggctgcgggtg	ccgatgcgct	cgacggtgac	gggcgggggtg	atcgcggttc	45900
cggagctcgg	tgcgagctac	tgggcggaca	accttcggca	gcgggtgcgc	ttcgctcgcg	45960
cgggcgcaagc	gctgctggag	ggtggccccg	cgctgttcat	cgagatgagc	ccgcacccga	46020
tcctggtgcc	gccccctggac	gagatccaga	cgggcgccga	gcaagggggc	gctgcgggtg	46080
gctcgctcgc	gcgaggggcag	gacgagcgcg	cgacgctgct	ggaggcgctg	gggacgctgt	46140
ggggctccgg	ctatccgggtg	agctgggctc	ggctgttccc	cgcgggcggc	aggcgggttc	46200
cgctgccgac	ctatccctgg	cagcacgagc	ggtgctggat	cgaggctcag	cctgacgccc	46260
gcccgcctcgc	cgcagccgac	cccaccaagg	actggttcta	ccgaacggac	tgggcccgagg	46320
tgccccgcgc	cgccccgaaa	tcggagacag	ctcatgggag	ctggctgctg	ttggccgaca	46380
gggggtgggt	cggtgaggcg	gtcgttgacg	cgctgtcgac	gscgggactt	tcctgcaccg	46440
tgcttcatgc	gtcggctgac	gcctccaccg	tcgccgagca	ggtatccgaa	gctgccagtc	46500
gccgaaacga	ctggcaggga	gtcctctacc	tgtggggcct	cgacgcccgtc	gtcgatgctg	46560
gggcatcgcc	cgacgaagtc	agcgaggcta	cccgcctgct	caccgcaccc	gtccttgggc	46620
tggttcgatt	cctgagcgct	gcgccccatc	ctcctcgctt	ctgggtgggtg	accccgcggg	46680
catgcacggt	gggcggcgag	ccagaggcct	ctctttgcca	agcggcggtg	tgggggcctc	46740
cgcgctcgc	ggcgctggag	caccccgtg	cctgggggtg	cctcgaggac	ctggatccct	46800
agaagagccc	gacggagatc	gagccccctg	tgcccgagct	gctttcgccg	gacgcgagg	46860
atcaactggc	gttccgcagc	ggtcgcaggc	acgcagcacg	ccttgtagcc	gccccgcgg	46920
agggcgacgt	cgcaccgata	tcgctgtccg	cggaggggag	ctacctgggt	acgggcgggc	46980
tggggtggcct	tggctctgctc	gtggctcggt	ggctgggtga	gcggggagct	cgacatctgg	47040
tgctcaccag	ccggcacggg	ctgcagagc	gacaggcgct	gggcggagag	cagccgcccg	47100
aggcccgcgc	gcgcacgcga	gcggctcgagg	ggctggaagc	gcaggggcg	cggggtgacc	47160
tggcagcggt	ggatgtcgcc	gaggccgac	ccatgacggc	gctgctggcc	gccatcgagc	47220
ccccgttgcg	cgggggtgggt	cacggccggc	gcgtcttccc	cgtgcgtcac	ctggcggaga	47280
cggacgaggc	cctgctggag	tcgggtgctc	gtcccaagg	ggccgggagc	tggtgctgct	47340
accggctgct	gcgcgaccgg	cctctcgacc	tgctcgtgct	gttctcgtcg	ggcgcgcgcg	47400
tgtgggggtg	caaaggccaa	ggcgcatacg	ccggggccaa	tgcttccctc	gacgggctcg	47460
cgcaccatcg	ccgcgcgcac	tcgctgccc	cgcttgagcct	cgcctggggc	ttatggggcc	47520
agggaggcat	ggttgatgca	aaggctcatg	cagctctgag	cgacatcggg	gtcctgccc	47580
tgcccacggg	gccggccttg	tcggcgctgg	agcgccctgg	gaacaccagc	gctgtccagc	47640
gttcggtcac	acggatggac	tgggcgcgct	tcgcgcgggt	ctatgcccg	cgaggcgggc	47700
gcaactgtct	ttcggtctctg	gtcgcggagg	acgagcgcg	tgctctccc	ccgggtccga	47760
cggcaaaacc	gatctggcgc	ggcctgtccc	ttcggaagag	ccgctcagcc	ctctcagc	47820
tcgttccgcg	catcgtcgcc	cgggtgctgg	gcttctccga	cccgggcg	ctcgacgtcg	47880
gccgaggctt	cgccgagcag	gggctcgact	ccctgatggc	tctggagatc	cgtaaccgcc	47940
ttcagcgcca	gctggggcaa	cggtgtcg	cgactctggc	cttcgaccac	ccgacgggtg	48000
agcggtggt	ggcgcatctc	ctcacccagc	tgctgaagct	ggaggaccgg	agcgacccc	48060
ggcacatccg	gtcgggtggc	gcggatgacg	acatcgccat	cgctgggtgc	gcctgcccgt	48120
tcccagggtg	ggatgagggc	ctggagacat	actggcgcca	tctggccgag	ggcatgggtg	48180
tcagcaccga	ggtgcccaggc	gaccgggtgg	gcgcggcgga	ctggtacgac	cccgatcccg	48240
aggttccggg	ccggacctat	gtggccaagg	gtgccttccc	ccgcgatgtg	cgcagcttgg	48300
atggcgcggt	cttcgccatt	tccccctcgt	aggcgatgag	cctggacccc	caacagcggc	48360
tggtgctgga	ggtgagctgg	gaggcgatcg	agcgcgctgg	ccaggacccc	atggcgctgc	48420
gcgagagcgc	cacgggcgtg	ttcgtgggca	tgatcgggag	cgagcacg	gagcgggtgc	48480
agggcctcga	cgacgacgcg	gcgttgctgt	acggcaccac	cggcaacctg	ctcagcgctg	48540
ccgctggacg	gctgtcgctc	ttcctgggtc	tgacggccc	gacgatgacg	gtggacaccg	48600
cctgctcgtc	gtcgtgggtg	gcgttgacc	tcgcttgcca	gagcctgcga	ttgggagagt	48660
gcgaccaggc	cctggccggc	gggtccagcg	tgcttttgtc	gccgcgggtc	ttcgtcgcg	48720
cgtcgcgcat	gcgtttgctt	tcgcagatg	ggcggtgcaa	gacgttctcg	ggcgctgacg	48780
acggctttgc	gcgggcccag	ggctgcgcg	tggtgggtg	caagcggtc	cgtgacgcgc	48840
agcgcgaccg	cgaccccatc	ctggcggtgg	tcaggagcac	ggcgatcaac	cacgatggcc	48900
cgagcagcgg	gctcacgggtg	cccagcggtc	ctgcccagca	ggcgttgcta	cgccaggcgc	48960
tgggcgaaagc	gggcgtggcg	ccggccgagg	tcgatattcgt	ggagtggcac	gggacgggga	49020
cagcgctggg	tgacccgatc	gaggtgcagg	cgctgggcgc	ggtgtacggg	cggggcccgc	49080
ccgcggagcg	ggcgctctgg	ctgggctgct	tcaaggccaa	cctcggccac	ctggaggccg	49140
cggcgggctt	ggccggcgctg	ctcaagggtg	tcctggcgct	ggagcacgag	cagattcccg	49200
ctcaaccgga	gctcgcagag	tcaacccgc	acatcccgtg	ggcagagctg	ccagtggccg	49260
ttgtccgcag	ggcggttccc	tcggcgcgcc	gcgcgcgcgc	gcgtcgtgca	ggcgtagcgc	49320
ctttcgccct	gagcggggacc	aacgcgcacg	tggtgttgga	ggaggcgccg	gcggtggagc	49380
ctgtggccgc	ggcccccgag	cgcgcagcgg	agctgttcgt	cctgtcgccg	aagagcgcg	49440

cggcgctgga tgcgcaggca gcccggctgc gggaccacct ggagaagcat gtcgagcttg 49500
 gcctcggcga tgtggcgctc agcctggcga cgacgcgcag cgcgatggag caccggctgg 49560
 cggtggccgc gagctcgcgc gaggcgctgc gaggggcgct ttcggccgca gcgcaggggc 49620
 acacgcgccg gggagccgtg cgtgggcggg cctcgggcgg cagcgcgcgc aaggtggtct 49680
 tcgtgtttcc cggccagggc tcgcagtggt tgggcatggg ccgaaagctc atggccgaag 49740
 agccggctct ccggggggcg ctggagggtt gcgaccgggc catcgaggcg gaagcgggtc 49800
 ggctcgtaag cggggagctc tccgccgacg aggcgcctc gcagctcggg cgcacgcagc 49860
 tggttcagcc ggtgctgttc gccatggaag tagcgcttcc tgcgctgtgg cggctcgtgg 49920
 gaggtagacc ggaagcgggt gtggggccaca gcattgggga ggttcgcgcg gcgcacgtgg 49980
 ccggcgcgct gtcgctcgag gacgcggtgg cgatcatctg ccggcgcgag cggctcgtgc 50040
 tgcgcgaagc cggtcagggg gagatggcgc tggtcgagct gtcgctggag gagggcgagg 50100
 cggcgctgcg tggccatgag ggtcggctga gcgtggcggt gagcaacagc ccgcgctcga 50160
 ccgtgctcgc cggcgaggcg gcggcgctct cggagggtgt gggcgcgctg acggccaagg 50220
 ggggtgtctg gcggcagggt aaggtggagc tcgccagcca tagcccgag gtcgaccgcg 50280
 tgcgcgaaga gctgatcgcg gcgctgggag cgatccggcc gcgagcggct gcggtgccga 50340
 tgcgctcgac ggtgacgggc ggggtgatcg cgggtccgga gctcggtgcg agctactggg 50400
 cggacaacct tcggcagccg gtgcgcttcg ctgcggcggc gcaagcgctg ctggagggtg 50460
 gccccgcgct gttcatcgag atgagcccg acccgatcct ggtgccgccc ctggacgaga 50520
 tccagacggc ggccgagcaa gggggcgctg cgggtgggctc gctgcggcga gggcaggacg 50580
 agcgcgcgac gctgctggag gcgctgggga cgctgtgggc gtccggctat ccggtgagct 50640
 gggctcggct gttcccgcg gcggcgaggc ggggtccgct gccgacctat ccctggcagc 50700
 acgagcggta ctggatcgag gacagcgtgc atgggtcgaa gccctcgctg cggcttcggc 50760
 agcttcgcaa cggcgccacg gaccatccgc tgcctggggc tccattgctc gtctcggcgc 50820
 gacccggagc tcaattgtgg gagcaagcgc tgagcgacga gaggtatccc tacccttcgg 50880
 aacatagggt ccattggcga gccgtgttgc ccagcgcggc gtatgtagag atggcgctcg 50940
 ccgccccgct agatctctat ggcacggcga cgctgggtgt ggagcagctg gcgctcgagc 51000
 cgtgccctcc cgtgccctcc caggatcga gtcgtgagga ggcaggtagg agctgggtgc 51120
 gtcccggtcg ggcctcattc tgtagcggcc agagctcagc ggtgggagcg ttgaaggaa 51180
 ggacacccac gattcaacgg cgatgtccga gcgtcctgtc gtcggaggcg ctctatccgc 51240
 ctccgtggga gattcaacgg gactatggtc cctgcttcca gggcggtggg cagggtgtggc 51300
 tccgacacgg ggaggtgctc ggccgggtac gcttgccagg agacatggca tcccaagt 51360
 gcgcctaccg gattcatccc gccttggtgg atgcatgttt tcagggtgtg acagcgctgc 51420
 tcaccacgac ggaatccatc gagattcgga ggcggctgac ggatctccac gaaccggatc 51480
 tcccgcggtc cagggtcccg gtgaatcaag cgggtgagtg cacctggctg tgggacggcg 51540
 cgctggacgg tggacggcgc cagagcgcgga gcgtgcccg gcacctggtg ctccggcagc 51600
 tccatcgcaa gtgggaggtc atggagcgcc tcgcgcaggc gtacatcatc ggcactctcc 51660
 gcatatggaa cgtcttctgc gctgctggag tacaggaagg tcatcaagcg atggatggaa caccctgtcg 51780
 ggcttcaaat ctctgtctgc gacggagagc attttgtgag ctctcagccg ctgcccggagc 51840
 cgatcggcat ccttgtaggg ggcgggtgct gagggagggc ggagggtgtt cgccgacctc ccagtcctat 51900
 ctgagtggtc caagtttgccc ggggaacggc tcgcgagcgt attgaccggt aagacgctcg 51960
 cgctcgagat cctcttccct ggtggctcgt tcgatatggc ggagcgaatc tatcgagatt 52020
 cggccatcgc ccgttactcg aacggcatcg tgcgcgggtg cgtcgagtcg gcgcgcggg 52080
 tggtagcacc gtcgggaatg ttcagcatct tggagatcgg agcaggggagc ggcgcgacca 52140
 ccgcccgcgt cctcccggtg ttgctgcctg accggacgga gtaccatttc accgatgttt 52200
 ctccgctctt ccttgctcgc gcggagcaaa gatttcgaga ttatccattc ctgaagtatg 52260
 gcattctgga tgtcgaccag gagccagctg gccagggata cgcacatcag aggtttgacg 52320
 tcactcgtcg ggccaatgtc atccatgcga cccgcgatat aagagccacg gcgaagcgctc 52380
 tctgtctggt gctcgcgccc ggaggccttc tgggtgctggc cgaggggaca gggcatccga 52440
 tctgggtcga tatcaccagc ggattgattg aggggtggca gaagtacgaa gatgatcttc 52500
 gtatcgacca tccgctcctg cctgctcgga cctgggtgtg cgtcctgcgc cgggtaggct 52560
 ttgcgggacg cgtgagtcgt ccaggcgacg gatctccggc ggggatcttc ggacagcagc 52620
 tgatcctctc gcgcgcgcgc ggcatagcag gagccgcttg tgacagctcc ggtgagtcgg 52680
 cgaccgaatc gccggccgcg cgtgcagtag ggcaggaaat ggcgatggc tccgctgacg 52740
 tcgtccatcg gatggcgttg gagaggatgt acttccaccg ccggccgggc cggcaggttt 52800
 ggggtccacg tcgattgctg accggtggag gcgcgttcac gaaggcgctc gctggagatc 52860
 tggctcctgt cgaagacacc gggcaggtcg tggcagaggt tcaggggctc gcctcgcgc 52920
 agtcgagggc tctcgtcttc gcccgcgggc acccgcgggc agagtgggtg tacgcttttg 52980
 aatggcagcg caaagaccct ataccagagg ctccggcagc cgcgtctctt tccctccgcg 53040
 gggctctggc cgtgctgatg gaccagggcg ggacaggcgc tgcgctcgta tgcctcgtcg 53100
 aagggcgagg cgaggcgtgc gtgcgcgtca tgcgggtac ggcatacgcc tgcctcgcgc 53160
 cggggctgta tcaagtcgat ccggcgagc cagatggctt tcataccctg ctccgcatg 53220
 cattcggcga ggaccggatt tgcgcgcgg tagtgcatat gtcggagctt gatgcgacg 53280
 cagcagggga gaggcgacga gcggagtcgc ttcaggccga tcaactcctg gggagcctga 53340

gcgcgctttc tctgggtgcag ggcgtggtgc gccggagggtg gcgcaacatg ccgcggcttt 53400
 ggctcttgac ccgcgcctgt catgcgggtg gcgcggaggga cgcagcgcc tcggtggcgc 53460
 aggcgcgggt gtggggcctc ggtcggacgc tcgcgctcga gcatccagag ctgcggtgca 53520
 cgctcgtgga cgtgaacccg gcgcgctctc cagaggacgc agccgcactg gcggtggagc 53580
 tcggggcgag cgacagagag gaccaggctc cattgcgtc ggatggccgc tacgtggcgc 53640
 gcctcgtgcg gagctccttt tccggcaagc ctgctacgga ttgcggcatc cgggcggacg 53700
 gcagctatgt gatcaccgat ggcattggga gagtgggct ctcggtcgcg caatggatgg 53760
 tgatgcaggg ggcccgccat gtggtgctcg tggatcgcg cgcgcttcc gaggcacccc 53820
 gggatgccct ccggtccatg gccgaggctg gcgcggagggt gcagatcgtg gaggcggacg 53880
 ttggtcggcg cgacgatgtc gctcggctcc tctcgaagat cgaaccgtcg atgcgcgcgc 53940
 ttcgggggat cgtgtacgtg gacgggacct tccaggcgga ctctcgatg ctggagctgg 54000
 atgcccgtcg cttcaaggag tggatgtatc ccaagggtct cgagcggtgg aacctgcacg 54060
 cgctgaccag ggatagatcg ctggacttct tcgtcctgta ttcctcgggc acctcgcttc 54120
 tgggcttgcc aggcagggg agccgcgcgc ccggtgacgc cttcttggac gccatcgcg 54180
 atcacccgtg caagggtggc cttacagcga tgagcatcaa ctggggattg ctctccgaag 54240
 catcatcgcc ggcgaccccg aacgacggcg gagcacggct cgaataccgg gggatggaag 54300
 gcctcacgct ggagcagggga gcggcgcgcg tcggggcgctt gctcgacga cccagggcgc 54360
 aggtaggggt gatgcggctg aatctgcgcc agtgggttga gttctatccc aacgcggcgc 54420
 gattggcgct gtgggcggag ctgctgaagg agcgtgaccc cgccgaccga ggcgcgctga 54480
 acgcgtcgaa cctgcgcgag gcgctgcaga gcgccaggcc cgaagatcgt cagttgattc 54540
 tggagaagca cttgagcgag ctggtggggc gggggctgcy ccttccgcgc gagaggatcg 54600
 agcggcacgt gccgttcagc aatctcggca tggactcgt gataggcctg gagctccgca 54660
 accgcacgga ggcgcgcgtc ggcattcacc tgcggcgac cctgctatgg acctacccta 54720
 acgtagcagc tctgagcggg agcttcttag acattctgtt tccgaatgcc ggcgcgaccc 54780
 acgctccggc caccgagcgg gagaagagct tcgagaacga tgccgcagat ctcgaggctc 54840
 tgcggggcat gacggacgag cagaaggacg cgttgcctgc cgaaaagctg gcgcagctcg 54900
 cgcatctcgt tggtagtaaa gggaccgagg gaggatggcg accacgaatg ccgggaagct 54960
 tgagcatgcc cttctgctca tggacaagct tgcgaaaaag aacgcgtctt tggagcaaga 55020
 gcggaccgag ccgatcgcca tcgtaggcat tggctgcccgc ttcctcggcg gagcggaac 55080
 tccggaggca tctggggagc tgcctcagct aggcagagac gcggtccagc cgctcgaccg 55140
 gcgctggggc ctggtcggcg tccatcccag cgaggagggt ccgcgctggg ccggaactgct 55200
 caccgaggcg gtggacggct tcgacgcccgc gttctttggc acctcgccctc gggaggcgcg 55260
 gtcgctcgat cctcagcaac gcctgctgct ggaggtcacc tgggaaggggc tcgaggacgc 55320
 cggcatcgca cccagctccc tcgacggcag ccgcaccggg gtgttccctg gcgcagctcg 55380
 cagcgactac ctcgataccg ttgcgcaaca gcggcgcgag gagcaggacg catacgacat 55440
 caccggcaat acgctcagcg tcgcccggcg acggttctct tatacgctag ggctgcaggg 55500
 accctgctcg accgtcgaca cggcctgctc gtcgtcgctc gtggccatcc accttgctcg 55560
 ccgacgctcg cgcgctcgcg agagcgatct ccgctgggcg catccaggcg ctgtcgcccg atggccactg 55620
 ttcgtccaaag acgatgataa tgctggggcg cgtccgctggg gagggtcgcg gtatggctcg 55680
 ccggacatct gacgcctcgg ccaacggggt cgtccgctggg gagggctgcy gtatggctcg 55740
 gctcaaacgg cttctcgacg cccagcgaca cggcgatcgg atctgggctc tgatccgggg 55800
 ttccggccatg aatcaggatg gccggtcgac aggggttgat gcaccaatg tgctcgctca 55860
 ggaggcgctc ttgcgcgag cgctgcgctc gagcccggg ccacgggtta 55920
 tgctgagacc caccgaacgg ggacctcgct cgcgacccc atcgaggctg aggcgctgcy 55980
 tgccgtgttg gggccggcg gcggccgatg gagccgctgc gtgctggggc cagtgaagac 56040
 aaacctcggc caccggagg gcgctgcagg cgtggcggg ttgatcaagg cggcgctgcy 56100
 tctgcaccac gaactgatcc cgcgaaacct ccatttccac acgctcaatc cgcggatccg 56160
 gatcgagggg accgcgctcg cgctggcgac ggagccgggt ccgtggccgc gggcgggccg 56220
 accgcgcttc gcgggggtga gcgcgttcg cctcagcggc accaacgtcc atgtcgctct 56280
 ggaggaggcg ccggccacgg tgctcgaccc ggcgacgcgc gggcgctcag cggagctttt 56340
 ggtgctgtcg gcgaagagcg ccgcgcgct ggacgcacag gcggcgcgcc tctcagcgca 56400
 catcgccgcy taccggagc agggctctcg agacgtcgcg ttcagcctgg tctcagcgcy 56460
 tagcccgatg gagcacccg gcggggtggc ggcgacctcg cgcgaggcgc tcggaagcgc 56520
 gctggagggt gcggcgacgg ggcagacccc ggcagcgcg gcgcgcggca ggcgcgctc 56580
 ttcgcccggc aagctcgctt tctgttctgc cgggcagggg gcgcaggtg cgggcatggg 56640
 ccgtgggttg tgggagggc ggccggcgct ccgcgagacc ttcgaccggt gcgtcacgct 56700
 cttcgaccgg gagctccatc agccgctctg cgagggtatg tgggcccagc cgggcagcag 56760
 caggctcgctc ttgctggacc agacggcgct caccacggcg gcgctctttg cgctggagta 56820
 cgcgctggcc gcgctcttcc ggtcgtgggg cgtggagccg gagctcgtcg ctggccatag 56880
 cctcggcgag ctgggtggcc cctcggtggc ggggtgtgtc tccctcgagg acgcgctgcy 56940
 cttgggtggc gcgcgcggcc ggttgatgca ggcgctgccc gccggcgggc cgatggctatc 57000
 gatcgccgcy ccggaggccg acgtggctgc cggggtggcg ccgcacgcag cgttgggtgc 57060
 gatcgccgca gtcaatgggc cggagcaggt ggtgatcgcg ggcgcgagaa aatcgtgca 57120
 gcagatcgcy gcggcgctcg cggcgcggg ggcgcgaacc aaaccgctgc atgtctcgca 57180
 cgcgttccac tcgcccgtca tggatccgat gctggaggcg ttcggcgggg tgactgagtc 57240

ggtgacgtac cggcgccctt cgatcgcgct ggtgagcaac ctgagcggga agccctgcac 57300
 cgatgaggtg agcgcgcccg gttactgggt gcgtcacgcg cgagagcgcg tgcgcttcgc 57360
 ggacggagtg aaggcgctgc acggcgcccg tgcgggcctc ttcgtcagag tggggccgaa 57420
 gccgacgctg ctccggcctg tgcgggcctg cctgccggat gccagggccg tgcgtctccc 57480
 agcgtcgcg cccggggcgtg acgaggctgc gagcgcgcta gaggcgctgg gtgggttctg 57540
 ggtcgtcggg ggatcggtea cctggctcggg tctcttccct tcggggcgac ggcgggtacc 57600
 gctgccaacc tatccctggc agcgcgagcg ttactggatc gaagcgccgg tcgactcgtg 57660
 ggcggacggc accggccgtg ctccggcggg gggccacccc cttctgggtg aagctcttct 57720
 cgtgctcgacc catgccggtc tgcgcctgtg ggagacgacg ctggaccgaa agcggtctgc 57780
 gtggctcggc gagcaccggg cgcaggggga ggtcgtgttt cctggcgccg ggtaccgga 57840
 gatggcgctg tcgtcggggg ccgagatctt gggcgatgga ccgatccagg tcacggatgt 57900
 ggtgctcctc gagacgctga ccttcggcggg cgatacggcg gtaccgggtc aggtgggtgac 57960
 gaccgaggtg cgaccgggac ggctgcgggt ccaggtagcg agtcggggagc cgggggaacg 58020
 tcgcgcgccc ttccggatcc acggcccgcg cgtgctgcgc cggatcgggc cgcgtcgagac 58080
 cccggcgagg tcgaacctcg ccgcccgtcg cggcggtt catgcccgcg tgcggcgtgc 58140
 ggctatctat ggtgcgctcg ccgagatggg gcttcaatac ggcccggcgt tgcgggggct 58200
 cgccgagctg tggcggggtg agggcgaggc gctgggcagg gtgagactgc ctgaggccgc 58260
 cggctccgcg acagcctacc agctgcatcc ggtgctgctg gacgctgctg gcgcccgtgg aggtgggtc 58320
 tctgcccgcg ttcccgatc cgcgatgagg gacgcccgtg gcgcccgtgg aggtgggtc 58380
 ggtgcccgtg ttccagcggc cctcggggga gctatggtg catgcccgcg tcgtgagcga 58440
 tggtaacag gcctccagcc ggtggagcgc cgactttgag ttgatggagc gtacgggcgc 58500
 ggtggtcgcc gagatctccc ggctgggtgt ggagcggtt gcgagcggtg tacgccggcg 58560
 cgacgcagac gactgggttc tggagctgga ttgggagccc gcggcgctcg gtggggccaa 58620
 gatcacagcc ggcgggtggc tgcgtcctcg cgagggtggt gggctcgggc gctcgttctg 58680
 ctccggcgctg aaggcccgcg gccatgtcgt cgtccacgcc gcgggggagc acacgagcac 58740
 tgcaggaatg cgcgcgctcc tggccaacgc gttcgacggc caggccccga cggcctggtt 58800
 gcacctcagc agcctcagc gggcgggcca gctcggcccg gggctcgggg cgcagggcgc 58860
 gctcgacgcg ccccgagacc cagatgtcga tgcggatgcc ctgcaatcgg cgtgatgcg 58920
 tggttcgac agcgtgctct cctggtgca agcgtggtt ggcatggacc tccgaaacgc 58980
 gcccgggctg tggctcttga ccccgggggc tcaggcgggc gccgccggcg atgtctcgt 59040
 ggtgcaagcg ccgctgttgg ggtcggggcg caccatcgcc ttggagcacg ccgagctcg 59100
 ctgtatcagc gtcgacctcg atccagccga gcctgaaggg gaagccgatg ctttgcctgg 59160
 cgagctactt gcagatgatg ccgaggagga ggtcgcgctg cgcgggtggc accggctcgt 59220
 tgcgcggctc gtcacccggc tgcggacgc tcagcgccgg gagaaggctg agcccgccgg 59280
 tgacaggccg ttccggctag agatcgatga acccgccgcg ctggaccaac tgggtgctccg 59340
 agccacgggg cgcgcgctc ctggctcggg cgaggtcgag atctcctcgt aagcgccggg 59400
 gctcgactcc atcgacatcc agctggcggt gggcggttct cccaatgatc tgcctggaga 59460
 agaaatcgag ccgttgggtg tcggaagcga gtcgcccggg cgcctcgtcg ctgtggcgca 59520
 gggcgtgaac ggcttctgtg tgggccaagc ggtgatcgcc ctcccgccgg gactatttgc 59580
 taccatgct accacgtcgg ccacgctggt gttgcctcgg cctctggggc tctcggcgac 59640
 cgaggcgggc gcgatgcccc tcgctatctt gacggcctgg tacgcccctg acaaggctcg 59700
 ccacctgca gcggggggag ggtgctgctg ccatcgagg gcccgtggtg tcggtcttct 59760
 cgcggtcgca tgggcgagc gcgtggggcg cgaggtgtat ggcaccgccc acacgcccga 59820
 gaaccgtgac tacctggagt cgttggggcg gcggtacgtg agcgattccc gctcggggcg 59880
 gttcgtcaca gacgtgcatg catggacgga cggcgagggg gtcgacgtcg tgcctgactc 59940
 gctttcgggg gagcgcatcg acaagagcct catggtcctg cgcgcctgtg gtcgcttctg 60000
 gaagctgggc aggcgcgacg actgcccga cagcagcct gggctgcccg cgtcctacg 60060
 gaatttttcc ttctcgagc tggacttgcg ggaatgatg ctcgatcaac cggcgaggat 60120
 ccgtgcgctc ctcgacgagc gtttccgggt ggtcgcagcc ggtgccatca gcccactggg 60180
 gtcgggggtg cgcgttggcg gatccctcac gccaccgccc gtcgagacct tcccgatctc 60240
 tcgcgagccc gaggcattcc ggaggatggc gcaaggacag catctcggga agctcgtgct 60300
 cagcctggac gaccgggagg tgcggatccg cgtcccgccc gaatccagcg tcgccgtccg 60360
 cgcggacggc acctacctt tgcggggcg tctgggtggc ctcggtctcg gcgtggcccg 60420
 atggctggcc gagcgggggc cggggccaact ggtgctgggt ggcgctccc gtgcggcgag 60480
 cgcagagcag cgagccggcg tggcgggcgt ggaggccac ggcgcgcgcg tcacgggtggc 60540
 gaaagcggac gtcgccgatc ggtcaccagat cgagcgggtc ctccgcgagg ttaccgcgtc 60600
 ggggatgctg ctgcccgggt tcgtgcatgc ggcaggtctc gtcgatgacg ggtcgtgat 60660
 gcagcagact cggcgcggt tccgcacggt gatgggacct aaggtccagg ggccttgcga 60720
 cttgcacag ctgacacgc aagcgctct tctctctctc gtgctgtacg cttctgcagc 60780
 tgggcttttc ggctcggcag gccagggcaa ctatgccgca gccaacgcgt cctcgcagc 60840
 cctttcgcat caccgaaggg cgcagggcct gccggcgctg agcatcgact ggggcatgct 60900
 cacggaggtg gggatggccc ttgcgcaaga aaaccgtggc gcgcgccaga tctctcggcg 60960
 gatcgggggc atcaccccc atgaggggtc gtcagctctg gcgcgcttgc tcgaggggtg 61020
 tcgctgagc aggggggtga taccgatcac tccgcggcag tgggtggagt tctacccggc 61080
 aacagcggcc tcacggaggc tgcgcgggt ggtgaccacg cagcgcgcgg tcgctgatcg 61140

gaccgcccggg	gatccgggacc	tgctcgaaca	gcttcgcgtcg	gctgagccga	gcgcgcgggc	61200
ggggctgctg	caggacgtcg	tgcgcgtgca	ggctctcgcat	gtgctgcgtc	tccctgaaga	61260
caagatcgag	gtggatgccc	cgctctcgag	catgggcatg	gactcgctga	tgagcctgga	61320
gctgcgcaac	cgcatcgagg	ctgcgctggg	cgctgcgcgc	cctgcagcct	tggggtggac	61380
gtacccaacg	gtagcagcga	taacgcgctg	gctgctcgac	gacgcccctg	tcgtccggct	61440
tggcggcggg	tcggacacgg	acgaatcgac	ggcgagcgcc	ggttcggttcg	tccacgtctc	61500
ccgctttcgt	cctgtcgtca	agccgcgggc	tcgtctcttc	tgttttcacg	gttctggcgc	61560
ctcgcggcag	ggcttccgtt	cctggctcga	gaagtctgag	tggagcgatc	tggaaatcgt	61620
ggccatgtgg	cacgatcgca	gcctcgcctc	cgaggacgcg	cctggtaaga	agtacgtcca	61680
agaggcggcc	tcgctgattc	agcactatgc	agacgcaccg	tttgcgtag	taggggttcag	61740
cctgggtgtc	cggttcgtca	tggggacagc	cgtagagctc	gccagtcgtt	ccgcgcgacc	61800
ggctccgctg	gccgtcttca	cgttgggcgg	cagcttgatc	tcttcttcag	agatcacccc	61860
ggagatggag	accgatataa	tagccaagct	cttcttccga	aatgccgcgg	gtttcgtgcg	61920
atccacccaa	caagtccagg	ccgatgtctg	cgcagacaag	gtcatcacag	acaccatggt	61980
ggctccggcc	cccggggact	cgaaggagcc	gcccgtgaag	atcgcggtcc	ctatcgtcgc	62040
catcgccggc	tcggacgatg	tgatcgtgcc	tccgagcgac	gttcaggatc	tacaatctcg	62100
caccacggag	cgcttctata	tgcatctcct	tcccggagat	cacgaatttc	tcgtcgatcg	62160
agggcgcgag	atcatgcaca	tcgtcgactc	gcattctcaat	ccgctgctcg	ccgcgaggac	62220
ggcttcgtca	ggccccgcgt	tcgaggcaaa	atgatggcag	cctccctcgg	gcgcgcgaga	62280
tgggtgggag	cagcgtgggc	gctggcggcc	ggcggcaggc	cgcgaggcgc	catgagcctt	62340
cctggacgtt	tgacgtatag	gagattttat	gacacaggag	caagcgaatc	agagtggagac	62400
gaagcctgct	ttcgacttca	agccgttcgc	gcctgggtac	cgggaggacc	cgttccccgc	62460
ctgagagagg	caacccccat	cttctactgg	gatgaaggcc	gctcctgggt	gctcctgggt	62520
cctcacccga	taccacgacg	tgctggcggt	gttccgcgac	gaacgcttcg	cggtcagtcg	62580
agaagagtgg	gaatcgagcg	cgaggtactc	gtcggccatt	cccgcagctc	gcgatatgaa	62640
gaagtacgga	ttgttcgggc	tgccgcggga	ggatcacgct	cgggtccgca	agctcgtcaa	62700
cccgtcgttt	acgtcacgcg	ccatcgacct	gctgcgcgcc	gaaatacagc	gcaccgctga	62760
ccagctgctc	gatgctcgct	ccggacaaga	ggagttcgac	gttggtgcgg	attacgcgga	62820
gggaatcccc	atgcgcgcga	tcagcgctct	gttgaagggt	ccggccgagt	gtgacgagaa	62880
gttccgctcg	ttcggctcgg	cgactgcgcg	cgcgctcggc	gtgggtttgg	tgccccagggt	62940
cgatgaggag	accaagaccc	tggtcgcgtc	cgtaaccgag	gggtctcgcg	tgctccatga	63000
cgtcctcgat	gagcggcgca	ggaacccgct	cgaaaatgac	gtcttgacga	tgctgcttca	63060
ggccgaggcc	gacggcagca	ggctgagcac	gaaggagctg	gtcgcgctcg	tgggtgcgat	63120
tatcgctgct	ggcaccgata	ccacgatcta	ccttatcgcg	ttcgtgtgct	tcaacctgct	63180
gcggtcgcgc	gaggcgctcg	agctgggtgaa	ggccgagccc	gggtcatga	ggaacgcgct	63240
cgatgagggt	ctccgcttcg	acaatatcct	cagaatagga	actgtgcgtt	tcgccaggca	63300
ggacctggag	tactgcgggg	catcgatcaa	gaaaggggag	atggtctttc	tcctgatccc	63360
gagcgcctcg	agagatggga	ctgtattctc	caggccagac	gtgtttgatg	tgcgacggga	63420
cacggggcgc	agcctcgcgt	acggtagagg	cccccatgtc	tgccccgggg	tgctccctgc	63480
tcgcttcgag	gcggagatcg	ccgtgggcac	catcttccgt	aggttccccg	agatgaagct	63540
gaaagaaact	cccgtgtttg	gataccaccc	cgcgttccgg	aacatcgaat	cactcaacct	63600
catcttgaag	ccctccaaag	ctggatagct	cgcgggggta	tcgcttcccc	aacctcattc	63660
cctcatgata	cagctcgcgc	gcgggtgctg	tctgccgcgg	gtgcgattcg	atccagcgga	63720
caagcccatc	gtcagcgcg	gaagatcgaa	tccacggccc	ggagaagagc	ccgtccgggt	63780
gacgtcggaa	gaagtgcggg	gcgcgcacct	gggagcgcaa	agctcgctcg	ttcgcgctca	63840
gcacgcgcgt	cgctcatgtc	ggcctgcac	ccgcgcggag	gagccgccc	ccctgatgca	63900
cggcctcacc	gagcggcagg	ttctgctctc	gctcgtcgcc	ctcgcgctcg	tcctcctgac	63960
cgcgcgcgcc	ttcggcgagc	tcgcgcggcg	gctgcgccag	cccaggtgct	tcggcgagct	64020
cttcggcggc	gtgggtgctg	gcccgtccgt	cgctggcgcg	ctcgtctcct	ggttccatcg	64080
agtcctcttc	caggatccgg	cggctggggg	cgtgctcttc	ggcatctcct	ggataggcgc	64140
gctcgtccct	ctgctcatgg	cgggtatcga	ggctcgatgtg	agcatcctgc	gcaaggaggc	64200
gcgccccggg	gcgctctcgg	cgctcggcgc	gatcgcgcgc	ccgctcgcga	cgccggggcc	64260
gctggtgcag	cgcatgcagg	gcgcgttcac	gtgggatctc	gacgtctcgc	cgcgacgctc	64320
tgcgcaagcc	tgagcctcgg	cgcttgctcg	tacacctcgc	cgggtgctcg	tccgcccgcg	64380
gacatccggc	gcgccggcg	ggcccagctc	gagccggact	cgccggatga	cgaggccgac	64440
gaggccgacg	aggcgctccg	cccgttccgc	gacgcgatcg	ccgcgtactc	ggaggccggt	64500
cgggtgggcgg	aggcggcgca	gcggcccgcg	ctggagagcc	tcgtgcggct	cgcgatctgt	64560
cggctgggca	aggcgtctga	caaggtcccc	ttcgcgcaca	cgacggccgg	cgtctcccag	64620
atcgccggca	gactccagaa	cgatcgggct	tgggttcgatg	tcgcgcggcg	gtacgcgagc	64680
ttccgcgcgg	cgacggagca	cgcgctccgc	gacgcggcgt	cggccatgga	ggcgctcgcg	64740
gcccggccgt	accgcggatc	gagccgcgtg	ttcgctgccc	taggggagtt	tcgggggggag	64800
cggcgcgccc	ttcacccccg	ggaccgtgta	cccgcgtccc	accagcagat	cctgaccgcg	64860
ctgcgcggag	ccgagcggcg	gctcatcgcg	ctctacactg	cggtcggccc	tgaggagtcg	64920
gcctctctcg	ggcgagcgcg	agcggcgggc	tgccgggtgg	tccctcttcg	caaccatgac	64980
cggagccgcg	ctcgggtccgc	gcagcggcta	gcgcgcgtcg	cggcagagat	cgctggagcg	65040

acaggcgacg acccgcccga ggggtgtcgaa cggattgccc cagccctcat tgcggatccc 65100
 ctccagacac tcgttcagct gcttggcgct gatgccgccc gggcactcgc cgaaggtcag 65160
 ctctgtcgcg cactcggatc ggatcttgtt cgagcacgcg tccttgctcg aatactccc 65220
 gtcttgtccg atgttgttgc accgcgcctc gcggtcgcac cgcgcgcga cgatgctatc 65280
 gacggcgctg ccgactggca ccggcgctc gccctgcgcg ccacccgggg tttgcgcctc 65340
 cccgcctgac cgcttttcgc cgccgcacgc cgcgagcagg ctcatctccg acaccgagat 65400
 caggccccacg accagcttcc cagcaatctt ttgcatggct tccccctcct cagcacacgt 65460
 cacatcagag actctccgct cggtcgtcgc gttcgcacagc cggcgacggc cagcagcaga 65520
 accgtccccg accagaacag ccgcatgccc gtttctcgca acatgccccg acatccttgc 65580
 gactacgggt cctccgctcg tgccgagatc ggctgtcctg tgcgacggca atatcctgcg 65640
 atcggccggg caggaggtac cgacacgggc gccggggggg aggtgccgccc acgggtcga 65700
 aatgtgctgc ggcagggccc tccatgcccc cagccgggaa cgcggcgccc ggccagcctc 65760
 ggggtgacgc cgcaaacggg agatgtctcc ggagaggcgc cgggcacagc cgagcgcgt 65820
 caccaccgtg cgcactcgtg agctccagct cctcggcata gaagagaccg tcaactccc 65880
 tccgtgtagg cgatcgtgct gatcagcgcg ttctccgctc gacgcgagtc gagccgggta 65940
 tgctgcacga caatgggaac gtccgattcg atcacgctgg catagtccgt atcgcgcggg 66000
 atcgggtcgg gttcgggtcag atcgttgaa cggacgtgccc ggggtgcgct cgctgggagc 66060
 gtccaccggg acggcccggc ggggtcgcgg tcgctgaagt agacgggtgat ggcgacctgc 66120
 gcgtccccgt ccgacgcatt caacaggcag gccgtctcat ggctcgtcat ctgcggctcg 66180
 ggtcctgttc tccggcctgg gatgtagccc tctgcgattg ccacgcgctc ccgccgatc 66240
 ggtctctcca tatgtctctc ctgtcggtc ctctttggct gccctcctc gctgtccagg 66300
 agcgacggcc tcttctcccg acgcgctcgg ggatccatgg ctgaggatcc tcgccgagcg 66360
 ctcttgcgg accggcgcg cgagcgccga cgggctttga aagcacgcga ccggacacgt 66420
 gatgccggcg cgacgagggc gcccgcgctc tgatcccgat cgtgacatcg cgacgtccgc 66480
 cggcgccctc gcaggccggc ctgagcgttg cgcggtcag gtctcctcgc cgtcacggcc 66540
 acccgccgat tcacatccca ccgcggcacg acgcttgctc aaaccgcggc gagacggcgg 66600
 ggcggctgtg gtaccggcca gcccggacgc gagggccgag agggacagtg ggtccgccc 66660
 gaagcagtgga ggcgatcgag gtggcagatg aaacacgttg acacggggcg acgagtcggc 66720
 cgccggatag ggttcacgct cggctctctc gcgagcatgg cgctcgccgg ctgtggcgcg 66780
 ccgagcgaga aaatcgtgca gggcacgcgg ctccgcgccg gcgccgatg gcacgtcgcc 66840
 gccgacgtcg accccgacgc cgcgaccacg cggctggcgg tggacgtcgt tcacctctcg 66900
 ccgcccagag gcacagggc cggcagcgag cgggttcgtc tctggcagcg tccgagctcc 66960
 gagtccccgt ggcaacgggt cggagtgtc gactacaacg ctgccagcg aagaggcaag 67020
 ctggccgaga cgaccgtgcc gcatgccaac ttcgagctgc tcatcacct cgagaagcag 67080
 agcagccctc agtctccatc ttctgccgccc gtcatcgggc cgacgtccgt cgggtaacat 67140
 cgcgctatca gcagcgtga gcccgcgacg agggcccgaga gccctgcctc gatcgcttc 67200
 tccatcatat catccctgcg tactctctca gcgacggcgg cgtcgaagca accgcgctgc 67260
 cgggctggct ctacgtgcgc gacaggagag cgtcctggcg cggcctgcgc atcgctggaa 67320
 ggatcggcgg agcatggaga aagaatcgag gatcgcgatc tacggcgcca tcgcagcaa 67380
 cgtggcgatc gcggcggtca agttcatcgc cgcgcgctg accggcagct cggcgatgtc 67440
 ctccgagggc gtgcaactcc tcgtcgatac tgacacggg ggccacggca aggagctcta 67500
 gcaccggagc gcacgcccgc ccgacgcca gcatccgttc ggccacggca aggagctcta 67560
 tttctggacg ctgatcgtcg ccatcatgat ctctgcgcg ggccggcgcg tctcgatcta 67620
 cgaagggatc ttgcacctct tgcaccccg ccagatcgag gatccgacgt ggaactacgt 67680
 cgtcctcggc gcagcgcccg tcttcgagg gacgtcgctc atcatctcga tccacgagtt 67740
 caagaagaag gacggacagg gctacctcgc ggcgatgccc tccagcaagg acccgacgac 67800
 gttcacgatc gtcctggagg actccgcggc gctcgccggg ctcaccatcg ccttccctcg 67860
 cgtctggctc gggcaccgccc tgggaaaccc ctacctcgac ggcgcggcgt cgatcggcat 67920
 cggcctcgtg ctccgcccgg tcgcggtctt cctcgccagc cagagccgtg ggctcctcgt 67980
 gggggagagc ggcggacagg agctcctcgc cgcgatccgc gcgctcgcca gcgcagatcc 68040
 tggcgtgtcg gcggtggggc ggcctctgac gatgcacttc ggtccgcacg aagtcctggt 68100
 cgtgctgcgc atcgagttcg acgcccgcct cagggcgctc ggggtcgcgg aggcgatcga 68160
 gcgcatcgag acccgatcac ggagcgagcg acccgacgtg aagcacatct acgtcgaggc 68220
 caggctcgtc caccagcgcg cgaggcgctg acgcgcgctg gagagaccgc gcgcggcctc 68280
 cgccatctc cgccggcgccc gggctcaggt ggccctcgca gcaggcgcg cctggcgggc 68340
 aaaccgtgca gacgtcgtcc ttcgacgcga ggtacgctgg ttgcaagtgc tcacgcccga 68400
 tcgagaggtc cggcagcgcc ggagccccgg cgggcccggc gcacgaaggc gcggcgagcg 68460
 caggcttcga gggggcgagc gtcagaggga agccagggc gcatggggcg atgctcggcg 68520
 ggcgagatga cggctggcgt cgcgccctcc ccggcgccgg cgcgcttcgc gccgcgctcc 68580
 agcgcggctc ctccgcgcat ctccgcccgc gccggctcat cgcctccgtg tccctcgccg 68640
 gcggcgccag catggcggtc gttcgtctgt tccagctcgg gatcatcgag cgcctgccc 68700
 atctccgct tccagggttc gattcggcca aggtgacgag ctccgatata 68750

<210> 2

<211> 1421

- 19 -

<212> PRT

<213> Sorangium cellulosum

<400> 2

Val Ala Asp Arg Pro Ile Glu Arg Ala Ala Glu Asp Pro Ile Ala Ile
 1 5 10 15
 Val Gly Ala Ser Cys Arg Leu Pro Gly Gly Val Ile Asp Leu Ser Gly
 20 25 30
 Phe Trp Thr Leu Leu Glu Gly Ser Arg Asp Thr Val Gly Arg Val Pro
 35 40 45
 Ala Glu Arg Trp Asp Ala Ala Ala Trp Phe Asp Pro Asp Pro Asp Ala
 50 55 60
 Pro Gly Lys Thr Pro Val Thr Arg Ala Ser Phe Leu Ser Asp Val Ala
 65 70 75 80
 Cys Phe Asp Ala Ser Phe Phe Gly Ile Ser Pro Arg Glu Ala Leu Arg
 85 90 95
 Met Asp Pro Ala His Arg Leu Leu Leu Glu Val Cys Trp Glu Ala Leu
 100 105 110
 Glu Asn Ala Ala Ile Ala Pro Ser Ala Leu Val Gly Thr Glu Thr Gly
 115 120 125
 Val Phe Ile Gly Ile Gly Pro Ser Glu Tyr Glu Ala Ala Leu Pro Gln
 130 135 140
 Ala Thr Ala Ser Ala Glu Ile Asp Ala His Gly Gly Leu Gly Thr Met
 145 150 155 160
 Pro Ser Val Gly Ala Gly Arg Ile Ser Tyr Ala Leu Gly Leu Arg Gly
 165 170 175
 Pro Cys Val Ala Val Asp Thr Ala Tyr Ser Ser Ser Leu Val Ala Val
 180 185 190
 His Leu Ala Cys Gln Ser Leu Arg Ser Gly Glu Cys Ser Thr Ala Leu
 195 200 205
 Ala Gly Gly Val Ser Leu Met Leu Ser Pro Ser Thr Leu Val Trp Leu
 210 215 220
 Ser Lys Thr Arg Ala Leu Ala Arg Asp Gly Arg Cys Lys Ala Phe Ser
 225 230 235 240
 Ala Glu Ala Asp Gly Phe Gly Arg Gly Glu Gly Cys Ala Val Val Val
 245 250 255
 Leu Lys Arg Leu Ser Gly Ala Arg Ala Asp Gly Asp Arg Ile Leu Ala
 260 265 270
 Val Ile Arg Gly Ser Ala Ile Asn His Asp Gly Ala Ser Ser Gly Leu
 275 280 285
 Thr Val Pro Asn Gly Ser Ser Gln Glu Ile Val Leu Lys Arg Ala Leu
 290 295 300
 Ala Asp Ala Gly Cys Ala Ala Ser Ser Val Gly Tyr Val Glu Ala His
 305 310 315 320
 Gly Thr Gly Thr Thr Leu Gly Asp Pro Ile Glu Ile Gln Ala Leu Asn

- 20 -

325										330					335				
Ala	Val	Tyr	Gly	Leu	Gly	Arg	Asp	Val	Ala	Thr	Pro	Leu	Leu	Ile	Gly				
			340						345				350						
Ser	Val	Lys	Thr	Asn	Leu	Gly	His	Pro	Glu	Tyr	Ala	Ser	Gly	Ile	Thr				
		355					360					365							
Gly	Leu	Leu	Lys	Val	Val	Leu	Ser	Leu	Gln	His	Gly	Gln	Ile	Pro	Ala				
	370					375					380								
His	Leu	His	Ala	Gln	Ala	Leu	Asn	Pro	Arg	Ile	Ser	Trp	Gly	Asp	Leu				
385					390					395					400				
Arg	Leu	Thr	Val	Thr	Arg	Ala	Arg	Thr	Pro	Trp	Pro	Asp	Trp	Asn	Thr				
				405					410					415					
Pro	Arg	Arg	Ala	Gly	Val	Ser	Ser	Phe	Gly	Met	Ser	Gly	Thr	Asn	Ala				
			420					425					430						
His	Val	Val	Leu	Glu	Glu	Ala	Pro	Ala	Ala	Thr	Cys	Thr	Pro	Pro	Ala				
	435						440					445							
Pro	Glu	Arg	Pro	Ala	Glu	Leu	Leu	Val	Leu	Ser	Ala	Arg	Thr	Ala	Ser				
	450					455					460								
Ala	Leu	Asp	Ala	Gln	Ala	Ala	Arg	Leu	Arg	Asp	His	Leu	Glu	Thr	Tyr				
465					470					475					480				
Pro	Ser	Gln	Cys	Leu	Gly	Asp	Val	Ala	Phe	Ser	Leu	Ala	Thr	Thr	Arg				
			485						490					495					
Ser	Ala	Met	Glu	His	Arg	Leu	Ala	Val	Ala	Ala	Thr	Ser	Arg	Glu	Gly				
		500						505					510						
Leu	Arg	Ala	Ala	Leu	Asp	Ala	Ala	Gln	Gly	Gln	Thr	Ser	Pro	Gly					
		515					520				525								
Ala	Val	Arg	Ser	Ile	Ala	Asp	Ser	Ser	Arg	Gly	Lys	Leu	Ala	Phe	Leu				
	530					535					540								
Phe	Thr	Gly	Gln	Gly	Ala	Gln	Thr	Leu	Gly	Met	Gly	Arg	Gly	Leu	Tyr				
545					550					555					560				
Asp	Val	Trp	Ser	Ala	Phe	Arg	Glu	Ala	Phe	Asp	Leu	Cys	Val	Arg	Leu				
			565						570					575					
Phe	Asn	Gln	Glu	Leu	Asp	Arg	Pro	Leu	Arg	Glu	Val	Met	Trp	Ala	Glu				
		580						585					590						
Pro	Ala	Ser	Val	Asp	Ala	Ala	Leu	Leu	Asp	Gln	Thr	Ala	Phe	Thr	Gln				
		595					600					605							
Pro	Ala	Leu	Phe	Thr	Phe	Glu	Tyr	Ala	Leu	Ala	Ala	Leu	Trp	Arg	Ser				
	610					615					620								
Trp	Gly	Val	Glu	Pro	Glu	Leu	Val	Ala	Gly	His	Ser	Ile	Gly	Glu	Leu				
625					630					635					640				
Val	Ala	Ala	Cys	Val	Ala	Gly	Val	Phe	Ser	Leu	Glu	Asp	Ala	Val	Phe				
			645						650					655					
Leu	Val	Ala	Ala	Arg	Gly	Arg	Leu	Met	Gln	Ala	Leu	Pro	Ala	Gly	Gly				
			660					665					670						

- 21 -

Ala Met Val Ser Ile Glu Ala Pro Glu Ala Asp Val Ala Ala Ala Val
 675 680 685
 Ala Pro His Ala Ala Ser Val Ser Ile Ala Ala Val Asn Ala Pro Asp
 690 695 700
 Gln Val Val Ile Ala Gly Ala Gly Gln Pro Val His Ala Ile Ala Ala
 705 710 715 720
 Ala Met Ala Ala Arg Gly Ala Arg Thr Lys Ala Leu His Val Ser His
 725 730 735
 Ala Phe His Ser Pro Leu Met Ala Pro Met Leu Glu Ala Phe Gly Arg
 740 745 750
 Val Ala Glu Ser Val Ser Tyr Arg Arg Pro Ser Ile Val Leu Val Ser
 755 760 765
 Asn Leu Ser Gly Lys Ala Cys Thr Asp Glu Val Ser Ser Pro Gly Tyr
 770 775 780
 Trp Val Arg His Ala Arg Glu Val Val Arg Phe Ala Asp Gly Val Lys
 785 790 795 800
 Ala Leu His Ala Ala Gly Ala Gly Thr Phe Val Glu Val Gly Pro Lys
 805 810 815
 Ser Thr Leu Leu Gly Leu Val Pro Ala Cys Met Pro Asp Ala Arg Pro
 820 825 830
 Ala Leu Leu Ala Ser Ser Arg Ala Gly Arg Asp Glu Pro Ala Thr Val
 835 840 845
 Leu Glu Ala Leu Gly Gly Leu Trp Ala Val Gly Gly Leu Val Ser Trp
 850 855 860
 Ala Gly Leu Phe Pro Ser Gly Gly Arg Arg Val Pro Leu Pro Thr Tyr
 865 870 875 880
 Pro Trp Gln Arg Glu Arg Tyr Trp Ile Asp Thr Lys Ala Asp Asp Ala
 885 890 895
 Ala Arg Gly Asp Arg Arg Ala Pro Gly Ala Gly His Asp Glu Val Glu
 900 905 910
 Glu Gly Gly Ala Val Arg Gly Gly Asp Arg Arg Ser Ala Arg Leu Asp
 915 920 925
 His Pro Pro Pro Glu Ser Gly Arg Arg Glu Lys Val Glu Ala Ala Gly
 930 935 940
 Asp Arg Pro Phe Arg Leu Glu Ile Asp Glu Pro Gly Val Leu Asp His
 945 950 955 960
 Leu Val Leu Arg Val Thr Glu Arg Arg Ala Pro Gly Leu Gly Glu Val
 965 970 975
 Glu Ile Ala Val Asp Ala Ala Gly Leu Ser Phe Asn Asp Val Gln Leu
 980 985 990
 Ala Leu Gly Met Val Pro Asp Asp Leu Pro Gly Lys Pro Asn Pro Pro
 995 1000 1005
 Leu Leu Leu Gly Gly Glu Cys Ala Gly Arg Ile Val Ala Val Gly Glu
 1010 1015 1020

- 22 -

Gly Val Asn Gly Leu Val Val Gly Gln Pro Val Ile Ala Leu Ser Ala
 1025 1030 1035 1040
 Gly Ala Phe Ala Thr His Val Thr Thr Ser Ala Ala Leu Val Leu Pro
 1045 1050 1055
 Arg Pro Gln Ala Leu Ser Ala Ile Glu Ala Ala Ala Met Pro Val Ala
 1060 1065 1070
 Tyr Leu Thr Ala Trp Tyr Ala Leu Asp Arg Ile Ala Arg Leu Gln Pro
 1075 1080 1085
 Gly Glu Arg Val Leu Ile His Ala Ala Thr Gly Gly Val Gly Leu Ala
 1090 1095 1100
 Ala Val Gln Trp Ala Gln His Val Gly Ala Glu Val His Ala Thr Ala
 1105 1110 1115 1120
 Gly Thr Pro Glu Lys Arg Ala Tyr Leu Glu Ser Leu Gly Val Arg Tyr
 1125 1130 1135
 Val Ser Asp Ser Arg Ser Asp Arg Phe Val Ala Asp Val Arg Ala Trp
 1140 1145 1150
 Thr Gly Gly Glu Gly Val Asp Val Val Leu Asn Ser Leu Ser Gly Glu
 1155 1160 1165
 Leu Ile Asp Lys Ser Phe Asn Leu Leu Arg Ser His Gly Arg Phe Val
 1170 1175 1180
 Glu Leu Gly Lys Arg Asp Cys Tyr Ala Asp Asn Gln Leu Gly Leu Arg
 1185 1190 1195 1200
 Pro Phe Leu Arg Asn Leu Ser Phe Ser Leu Val Asp Leu Arg Gly Met
 1205 1210 1215
 Met Leu Glu Arg Pro Ala Arg Val Arg Ala Leu Leu Glu Glu Leu Leu
 1220 1225 1230
 Gly Leu Ile Ala Ala Gly Val Phe Thr Pro Pro Pro Ile Ala Thr Leu
 1235 1240 1245
 Pro Ile Ala Arg Val Ala Asp Ala Phe Arg Ser Met Ala Gln Ala Gln
 1250 1255 1260
 His Leu Gly Lys Leu Val Leu Thr Leu Gly Asp Pro Glu Val Gln Ile
 1265 1270 1275 1280
 Arg Ile Pro Thr His Ala Gly Ala Gly Pro Ser Thr Gly Asp Arg Asp
 1285 1290 1295
 Leu Leu Asp Arg Leu Ala Ser Ala Ala Pro Ala Ala Arg Ala Ala Ala
 1300 1305 1310
 Leu Glu Ala Phe Leu Arg Thr Gln Val Ser Gln Val Leu Arg Thr Pro
 1315 1320 1325
 Glu Ile Lys Val Gly Ala Glu Ala Leu Phe Thr Arg Leu Gly Met Asp
 1330 1335 1340
 Ser Leu Met Ala Val Glu Leu Arg Asn Arg Ile Glu Ala Ser Leu Lys
 1345 1350 1355 1360
 Leu Lys Leu Ser Thr Thr Phe Leu Ser Thr Ser Pro Asn Ile Ala Leu

- 23 -

1365 1370 1375
 Leu Ala Gln Asn Leu Leu Asp Ala Leu Ala Thr Ala Leu Ser Leu Glu
 1380 1385 1390
 Arg Val Ala Ala Glu Asn Leu Arg Ala Gly Val Gln Asn Asp Phe Val
 1395 1400 1405
 Ser Ser Gly Ala Asp Gln Asp Trp Glu Ile Ile Ala Leu
 1410 1415 1420

 <210> 3
 <211> 1410
 <212> PRT
 <213> Sorangium cellulosum

 <400> 3
 Met Thr Ile Asn Gln Leu Leu Asn Glu Leu Glu His Gln Gly Ile Lys
 1 5 10 15
 Leu Ala Ala Asp Gly Glu Arg Leu Gln Ile Gln Ala Pro Lys Asn Ala
 20 25 30
 Leu Asn Pro Asn Leu Leu Ala Arg Ile Ser Glu His Lys Ser Thr Ile
 35 40 45
 Leu Thr Met Leu Arg Gln Arg Leu Pro Ala Glu Ser Ile Val Pro Ala
 50 55 60
 Pro Ala Glu Arg His Ala Pro Phe Pro Leu Thr Asp Ile Gln Glu Ser
 65 70 75 80
 Tyr Trp Leu Gly Arg Thr Gly Ala Phe Thr Val Pro Ser Gly Ile His
 85 90 95
 Ala Tyr Arg Glu Tyr Asp Cys Thr Asp Leu Asp Val Pro Arg Leu Ser
 100 105 110
 Arg Ala Phe Arg Lys Val Val Ala Arg His Asp Met Leu Arg Ala His
 115 120 125
 Thr Leu Pro Asp Met Met Gln Val Ile Glu Pro Lys Val Asp Ala Asp
 130 135 140
 Ile Glu Ile Ile Asp Leu Arg Gly Leu Asp Arg Ser Thr Arg Glu Ala
 145 150 155 160
 Arg Leu Val Ser Leu Arg Asp Ala Met Ser His Arg Ile Tyr Asp Thr
 165 170 175
 Glu Arg Pro Pro Leu Tyr His Val Val Ala Val Arg Leu Asp Glu Arg
 180 185 190
 Gln Thr Arg Leu Val Leu Ser Ile Asp Leu Ile Asn Val Asp Leu Gly
 195 200 205
 Ser Leu Ser Ile Ile Phe Lys Asp Trp Leu Ser Phe Tyr Glu Asp Pro
 210 215 220
 Glu Thr Ser Leu Pro Val Leu Glu Leu Ser Tyr Arg Asp Tyr Val Leu
 225 230 235 240
 Ala Leu Glu Ser Arg Lys Lys Ser Glu Ala His Gln Arg Ser Met Asp
 245 250 255

- 24 -

Tyr Trp Lys Arg Arg Ile Ala Glu Leu Pro Pro Pro Pro Thr Leu Pro
 260 265 270
 Met Lys Ala Asp Pro Ser Thr Leu Lys Glu Ile Arg Phe Arg His Thr
 275 280 285
 Glu Gln Trp Leu Pro Ser Asp Ser Trp Gly Arg Leu Lys Arg Arg Val
 290 295 300
 Gly Glu Arg Gly Leu Thr Pro Thr Gly Val Ile Leu Ala Ala Phe Ser
 305 310 315 320
 Glu Val Ile Gly Arg Trp Ser Ala Ser Pro Arg Phe Thr Leu Asn Ile
 325 330 335
 Thr Leu Phe Asn Arg Leu Pro Val His Pro Arg Val Asn Asp Ile Thr
 340 345 350
 Gly Asp Phe Thr Ser Met Val Leu Leu Asp Ile Asp Thr Thr Arg Asp
 355 360 365
 Lys Ser Phe Glu Gln Arg Ala Lys Arg Ile Gln Glu Gln Leu Trp Glu
 370 375 380
 Ala Met Asp His Cys Asp Val Ser Gly Ile Glu Val Gln Arg Glu Ala
 385 390 395 400
 Ala Arg Val Leu Gly Ile Gln Arg Gly Ala Leu Phe Pro Val Val Leu
 405 410 415
 Thr Ser Ala Leu Asn Gln Gln Val Val Gly Val Thr Ser Leu Gln Arg
 420 425 430
 Leu Gly Thr Pro Val Tyr Thr Ser Thr Gln Thr Pro Gln Leu Leu Leu
 435 440 445
 Asp His Gln Leu Tyr Glu His Asp Gly Asp Leu Val Leu Ala Trp Asp
 450 455 460
 Ile Val Asp Gly Val Phe Pro Pro Asp Leu Leu Asp Asp Met Leu Glu
 465 470 475 480
 Ala Tyr Val Val Phe Leu Arg Arg Leu Thr Glu Glu Pro Trp Gly Glu
 485 490 495
 Gln Val Arg Cys Ser Leu Pro Pro Ala Gln Leu Glu Ala Arg Ala Ser
 500 505 510
 Ala Asn Ala Thr Asn Ala Leu Leu Ser Glu His Thr Leu His Gly Leu
 515 520 525
 Phe Ala Ala Arg Val Glu Gln Leu Pro Met Gln Leu Ala Val Val Ser
 530 535 540
 Ala Arg Lys Thr Leu Thr Tyr Glu Glu Leu Ser Arg Arg Ser Arg Arg
 545 550 555 560
 Leu Gly Ala Arg Leu Arg Glu Gln Gly Ala Arg Pro Asn Thr Leu Val
 565 570 575
 Ala Val Val Met Glu Lys Gly Trp Glu Gln Val Val Ala Val Leu Ala
 580 585 590
 Val Leu Glu Ser Gly Ala Ala Tyr Val Pro Ile Asp Ala Asp Leu Pro

- 25 -

595					600					605					
Ala	Glu	Arg	Ile	His	Tyr	Leu	Leu	Asp	His	Gly	Glu	Val	Lys	Leu	Val
610						615					620				
Leu	Thr	Gln	Pro	Trp	Leu	Asp	Gly	Lys	Leu	Ser	Trp	Pro	Pro	Gly	Ile
625					630					635					640
Gln	Arg	Leu	Leu	Val	Ser	Glu	Ala	Gly	Val	Glu	Gly	Asp	Gly	Asp	Gln
				645					650					655	
Pro	Pro	Met	Met	Pro	Ile	Gln	Thr	Pro	Ser	Asp	Leu	Ala	Tyr	Val	Ile
				660				665					670		
Tyr	Thr	Ser	Gly	Ser	Thr	Gly	Leu	Pro	Lys	Gly	Val	Met	Ile	Asp	His
		675					680					685			
Arg	Gly	Ala	Val	Asn	Thr	Ile	Leu	Asp	Ile	Asn	Glu	Arg	Phe	Glu	Ile
		690					695				700				
Gly	Pro	Gly	Asp	Arg	Val	Leu	Ala	Leu	Ser	Ser	Leu	Ser	Phe	Asp	Leu
705					710					715					720
Ser	Val	Tyr	Asp	Val	Phe	Gly	Ile	Leu	Ala	Ala	Gly	Gly	Thr	Ile	Val
				725					730					735	
Val	Pro	Asp	Ala	Ser	Lys	Leu	Arg	Asp	Pro	Ala	His	Trp	Ala	Glu	Leu
				740					745					750	
Ile	Glu	Arg	Glu	Lys	Val	Thr	Val	Trp	Asn	Ser	Val	Pro	Ala	Leu	Met
		755					760					765			
Arg	Met	Leu	Val	Glu	His	Phe	Glu	Gly	Arg	Pro	Asp	Ser	Leu	Ala	Arg
		770				775					780				
Ser	Leu	Arg	Leu	Ser	Leu	Leu	Ser	Gly	Asp	Trp	Ile	Pro	Val	Gly	Leu
785					790					795					800
Pro	Gly	Glu	Leu	Gln	Ala	Ile	Arg	Pro	Gly	Val	Ser	Val	Ile	Ser	Leu
				805					810					815	
Gly	Gly	Ala	Thr	Glu	Ala	Ser	Ile	Trp	Ser	Ile	Gly	Tyr	Pro	Val	Arg
				820					825					830	
Asn	Val	Asp	Leu	Ser	Trp	Ala	Ser	Ile	Pro	Tyr	Gly	Arg	Pro	Leu	Arg
		835					840					845			
Asn	Gln	Thr	Phe	His	Val	Leu	Asp	Glu	Ala	Leu	Glu	Pro	Arg	Pro	Val
		850				855					860				
Trp	Val	Pro	Gly	Gln	Leu	Tyr	Ile	Gly	Gly	Val	Gly	Leu	Ala	Leu	Gly
865					870					875					880
Tyr	Trp	Arg	Asp	Glu	Glu	Lys	Thr	Arg	Lys	Ser	Phe	Leu	Val	His	Pro
				885					890					895	
Glu	Thr	Gly	Glu	Arg	Leu	Tyr	Lys	Thr	Gly	Asp	Leu	Gly	Arg	Tyr	Leu
				900				905						910	
Pro	Asp	Gly	Asn	Ile	Glu	Phe	Met	Gly	Arg	Glu	Asp	Asn	Gln	Ile	Lys
		915					920					925			
Leu	Arg	Gly	Tyr	Arg	Val	Glu	Leu	Gly	Glu	Ile	Glu	Glu	Thr	Leu	Lys
		930					935					940			

- 26 -

Ser His Pro Asn Val Arg Asp Ala Val Ile Val Pro Val Gly Asn Asp
 945 950 955 960
 Ala Ala Asn Lys Leu Leu Leu Ala Tyr Val Val Pro Glu Gly Thr Arg
 965 970 975
 Arg Arg Ala Ala Glu Gln Asp Ala Ser Leu Lys Thr Glu Arg Ile Asp
 980 985 990
 Ala Arg Ala His Ala Ala Glu Ala Asp Gly Leu Ser Asp Gly Glu Arg
 995 1000 1005
 Val Gln Phe Lys Leu Ala Arg His Gly Leu Arg Arg Asp Leu Asp Gly
 1010 1015 1020
 Lys Pro Val Val Asp Leu Thr Gly Gln Asp Pro Arg Glu Ala Gly Leu
 1025 1030 1035 1040
 Asp Val Tyr Ala Arg Arg Arg Ser Val Arg Thr Phe Leu Glu Ala Pro
 1045 1050 1055
 Ile Pro Phe Val Glu Phe Gly Arg Phe Leu Ser Cys Leu Ser Ser Val
 1060 1065 1070
 Glu Pro Asp Gly Ala Thr Leu Pro Lys Phe Arg Tyr Pro Ser Ala Gly
 1075 1080 1085
 Ser Thr Tyr Pro Val Gln Thr Tyr Ala Tyr Val Lys Ser Gly Arg Ile
 1090 1095 1100
 Glu Gly Val Asp Glu Gly Phe Tyr Tyr Tyr His Pro Phe Glu His Arg
 1105 1110 1115 1120
 Leu Leu Lys Leu Ser Asp His Gly Ile Glu Arg Gly Ala His Val Arg
 1125 1130 1135
 Gln Asn Phe Asp Val Phe Asp Glu Ala Ala Phe Asn Leu Leu Phe Val
 1140 1145 1150
 Gly Arg Ile Asp Ala Ile Glu Ser Leu Tyr Gly Ser Ser Ser Arg Glu
 1155 1160 1165
 Phe Cys Leu Leu Glu Ala Gly Tyr Met Ala Gln Leu Leu Met Glu Gln
 1170 1175 1180
 Ala Pro Ser Cys Asn Ile Gly Val Cys Pro Val Gly Gln Phe Asn Phe
 1185 1190 1195 1200
 Glu Gln Val Arg Pro Val Leu Asp Leu Arg His Ser Asp Val Tyr Val
 1205 1210 1215
 His Gly Met Leu Gly Gly Arg Val Asp Pro Arg Gln Phe Gln Val Cys
 1220 1225 1230
 Thr Leu Gly Gln Asp Ser Ser Pro Arg Arg Ala Thr Thr Arg Gly Ala
 1235 1240 1245
 Pro Pro Gly Arg Glu Gln His Phe Ala Asp Met Leu Arg Asp Phe Leu
 1250 1255 1260
 Arg Thr Lys Leu Pro Glu Tyr Met Val Pro Thr Val Phe Val Glu Leu
 1265 1270 1275 1280
 Asp Ala Leu Pro Leu Thr Ser Asn Gly Lys Val Asp Arg Lys Ala Leu
 1285 1290 1295

- 27 -

Arg Glu Arg Lys Asp Thr Ser Ser Pro Arg His Ser Gly His Thr Ala
 1300 1305 1310
 Pro Arg Asp Ala Leu Glu Glu Ile Leu Val Ala Val Val Arg Glu Val
 1315 1320 1325
 Leu Gly Leu Glu Val Val Gly Leu Gln Gln Ser Phe Val Asp Leu Gly
 1330 1335 1340
 Ala Thr Ser Ile His Ile Val Arg Met Arg Ser Leu Leu Gln Lys Arg
 1345 1350 1355 1360
 Leu Asp Arg Glu Ile Ala Ile Thr Glu Leu Phe Gln Tyr Pro Asn Leu
 1365 1370 1375
 Gly Ser Leu Ala Ser Gly Leu Arg Arg Asp Ser Arg Asp Leu Asp Gln
 1380 1385 1390
 Arg Pro Asn Met Gln Asp Arg Val Glu Val Arg Arg Lys Gly Arg Arg
 1395 1400 1405
 Arg Ser
 1410

<210> 4
 <211> 1832
 <212> PRT
 <213> Sorangium cellulosum

<400> 4
 Met Glu Glu Gln Glu Ser Ser Ala Ile Ala Val Ile Gly Met Ser Gly
 1 5 10 15
 Arg Phe Pro Gly Ala Arg Asp Leu Asp Glu Phe Trp Arg Asn Leu Arg
 20 25 30
 Asp Gly Thr Glu Ala Val Gln Arg Phe Ser Glu Gln Glu Leu Ala Ala
 35 40 45
 Ser Gly Val Asp Pro Ala Leu Val Leu Asp Pro Ser Tyr Val Arg Ala
 50 55 60
 Gly Ser Val Leu Glu Asp Val Asp Arg Phe Asp Ala Ala Phe Phe Gly
 65 70 75 80
 Ile Ser Pro Arg Glu Ala Glu Leu Met Asp Pro Gln His Arg Ile Phe
 85 90 95
 Met Glu Cys Ala Trp Glu Ala Leu Glu Asn Ala Gly Tyr Asp Pro Thr
 100 105 110
 Ala Tyr Glu Gly Ser Ile Gly Val Tyr Ala Gly Ala Asn Met Ser Ser
 115 120 125
 Tyr Leu Thr Ser Asn Leu His Glu His Pro Ala Met Met Arg Trp Pro
 130 135 140
 Gly Trp Phe Gln Thr Leu Ile Gly Asn Asp Lys Asp Tyr Leu Ala Thr
 145 150 155 160
 His Val Ser Tyr Arg Leu Asn Leu Arg Gly Pro Ser Ile Ser Val Gln
 165 170 175

- 28 -

Thr Ala Cys Ser Thr Ser Leu Val Ala Val His Leu Ala Cys Met Ser
 180 185 190
 Leu Leu Asp Arg Glu Cys Asp Met Ala Leu Ala Gly Gly Ile Thr Val
 195 200 205
 Arg Ile Pro His Arg Ala Gly Tyr Val Tyr Ala Glu Gly Gly Ile Phe
 210 215 220
 Ser Pro Asp Gly His Cys Arg Ala Phe Asp Ala Lys Ala Asn Gly Thr
 225 230 235 240
 Ile Met Gly Asn Gly Cys Gly Val Val Leu Leu Lys Pro Leu Asp Arg
 245 250 255
 Ala Leu Ser Asp Gly Asp Pro Val Arg Ala Val Ile Leu Gly Ser Ala
 260 265 270
 Thr Asn Asn Asp Gly Ala Arg Lys Ile Gly Phe Thr Ala Pro Ser Glu
 275 280 285
 Val Gly Gln Ala Gln Ala Ile Met Glu Ala Leu Ala Leu Ala Gly Val
 290 295 300
 Glu Ala Arg Ser Ile Gln Tyr Ile Glu Thr His Gly Thr Gly Thr Leu
 305 310 315 320
 Leu Gly Asp Ala Ile Glu Thr Ala Ala Leu Arg Arg Val Phe Gly Arg
 325 330 335
 Asp Ala Ser Ala Arg Arg Ser Cys Ala Ile Gly Ser Val Lys Thr Gly
 340 345 350
 Ile Gly His Leu Glu Ser Ala Ala Gly Ile Ala Gly Leu Ile Lys Thr
 355 360 365
 Val Leu Ala Leu Glu His Arg Gln Leu Pro Pro Ser Leu Asn Phe Glu
 370 375 380
 Ser Pro Asn Pro Ser Ile Asp Phe Ala Ser Ser Pro Phe Tyr Val Asn
 385 390 395 400
 Thr Ser Leu Lys Asp Trp Asn Thr Gly Ser Thr Pro Arg Arg Ala Gly
 405 410 415
 Val Ser Ser Phe Gly Ile Gly Gly Thr Asn Ala His Val Val Leu Glu
 420 425 430
 Glu Ala Pro Ala Ala Lys Leu Pro Ala Ala Ala Pro Ala Arg Ser Ala
 435 440 445
 Glu Leu Phe Val Val Ser Ala Lys Ser Ala Ala Ala Leu Asp Ala Ala
 450 455 460
 Ala Ala Arg Leu Arg Asp His Leu Gln Ala His Gln Gly Ile Ser Leu
 465 470 475 480
 Gly Asp Val Ala Phe Ser Leu Ala Thr Thr Arg Ser Pro Met Glu His
 485 490 495
 Arg Leu Ala Met Ala Ala Pro Ser Arg Glu Ala Leu Arg Glu Gly Leu
 500 505 510
 Asp Ala Ala Ala Arg Gly Gln Thr Pro Pro Gly Ala Val Arg Gly Arg
 515 520 525

- 29 -

Cys Ser Pro Gly Asn Val Pro Lys Val Val Phe Val Phe Pro Gly Gln
 530 535 540
 Gly Ser Gln Trp Val Gly Met Gly Arg Gln Leu Leu Ala Glu Glu Pro
 545 550 555 560
 Val Phe His Ala Ala Leu Ser Ala Cys Asp Arg Ala Ile Gln Ala Glu
 565 570 575
 Ala Gly Trp Ser Leu Leu Ala Glu Leu Ala Ala Asp Glu Gly Ser Ser
 580 585 590
 Gln Leu Glu Arg Ile Asp Val Val Gln Pro Val Leu Phe Ala Leu Ala
 595 600 605
 Val Ala Phe Ala Ala Leu Trp Arg Ser Trp Gly Val Ala Pro Asp Val
 610 615 620
 Val Ile Gly His Ser Met Gly Glu Val Ala Ala Ala His Val Ala Gly
 625 630 635 640
 Ala Leu Ser Leu Glu Asp Ala Val Ala Ile Ile Cys Arg Arg Ser Arg
 645 650 655
 Leu Leu Arg Arg Ile Ser Gly Gln Gly Glu Met Ala Val Thr Glu Leu
 660 665 670
 Ser Leu Ala Glu Ala Glu Ala Ala Leu Arg Gly Tyr Glu Asp Arg Val
 675 680 685
 Ser Val Ala Val Ser Asn Ser Pro Arg Ser Thr Val Leu Ser Gly Glu
 690 695 700
 Pro Ala Ala Ile Gly Glu Val Leu Ser Ser Leu Asn Ala Lys Gly Val
 705 710 715 720
 Phe Cys Arg Arg Val Lys Val Asp Val Ala Ser His Ser Pro Gln Val
 725 730 735
 Asp Pro Leu Arg Glu Asp Leu Leu Ala Ala Leu Gly Gly Leu Arg Pro
 740 745 750
 Gly Ala Ala Ala Val Pro Met Arg Ser Thr Val Thr Gly Ala Met Val
 755 760 765
 Ala Gly Pro Glu Leu Gly Ala Asn Tyr Trp Met Asn Asn Leu Arg Gln
 770 775 780
 Pro Val Arg Phe Ala Glu Val Val Gln Ala Gln Leu Gln Gly Gly His
 785 790 795 800
 Gly Leu Phe Val Glu Met Ser Pro His Pro Ile Leu Thr Thr Ser Val
 805 810 815
 Glu Glu Met Arg Arg Ala Ala Gln Arg Ala Gly Ala Ala Val Gly Ser
 820 825 830
 Leu Arg Arg Gly Gln Asp Glu Arg Pro Ala Met Leu Glu Ala Leu Gly
 835 840 845
 Thr Leu Trp Ala Gln Gly Tyr Pro Val Pro Trp Gly Arg Leu Phe Pro
 850 855 860
 Ala Gly Gly Arg Arg Val Pro Leu Pro Thr Tyr Pro Trp Gln Arg Glu

- 30 -

865		870		875		880
Arg Tyr Trp Ile Glu Ala Pro Ala Lys Ser Ala Ala Gly Asp Arg Arg						
		885		890		895
Gly Val Arg Ala Gly Gly His Pro Leu Leu Gly Glu Met Gln Thr Leu						
		900		905		910
Ser Thr Gln Thr Ser Thr Arg Leu Trp Glu Thr Thr Leu Asp Leu Lys						
		915		920		925
Arg Leu Pro Trp Leu Gly Asp His Arg Val Gln Gly Ala Val Val Phe						
		930		935		940
Pro Gly Ala Ala Tyr Leu Glu Met Ala Ile Ser Ser Gly Ala Glu Ala						
		945		950		955
Leu Gly Asp Gly Pro Leu Gln Ile Thr Asp Val Val Leu Ala Glu Ala						
		965		970		975
Leu Ala Phe Ala Gly Asp Ala Ala Val Leu Val Gln Val Val Thr Thr						
		980		985		990
Glu Gln Pro Ser Gly Arg Leu Gln Phe Gln Ile Ala Ser Arg Ala Pro						
		995		1000		1005
Gly Ala Gly His Ala Ser Phe Arg Val His Ala Arg Gly Ala Leu Leu						
		1010		1015		1020
Arg Val Glu Arg Thr Glu Val Pro Ala Gly Leu Thr Leu Ser Ala Val						
		1025		1030		1035
Arg Ala Arg Leu Gln Ala Ser Ile Pro Ala Ala Ala Thr Tyr Ala Glu						
		1045		1050		1055
Leu Thr Glu Met Gly Leu Gln Tyr Gly Pro Ala Phe Gln Gly Ile Ala						
		1060		1065		1070
Glu Leu Trp Arg Gly Glu Gly Glu Ala Leu Gly Arg Val Arg Leu Pro						
		1075		1080		1085
Asp Ala Ala Gly Ser Ala Ala Glu Tyr Arg Leu His Pro Ala Leu Leu						
		1090		1095		1100
Asp Ala Cys Phe Gln Ile Val Gly Ser Leu Phe Ala Arg Ser Gly Glu						
		1105		1110		1115
Ala Thr Pro Trp Val Pro Val Glu Leu Gly Ser Leu Arg Leu Leu Gln						
		1125		1130		1135
Arg Pro Ser Gly Glu Leu Trp Cys His Ala Arg Val Val Asn His Gly						
		1140		1145		1150
His Gln Thr Pro Asp Arg Gln Gly Ala Asp Phe Trp Val Val Asp Ser						
		1155		1160		1165
Ser Gly Ala Val Val Ala Glu Val Cys Gly Leu Val Ala Gln Arg Leu						
		1170		1175		1180
Pro Gly Gly Val Arg Arg Arg Glu Glu Asp Asp Trp Phe Leu Glu Leu						
		1185		1190		1195
Glu Trp Glu Pro Ala Ala Val Gly Thr Ala Lys Val Asn Ala Gly Arg						
		1205		1210		1215

- 31 -

Trp Leu Leu Leu Gly Gly Gly Gly Gly Leu Gly Ala Ala Leu Arg Ala
 1220 1225 1230
 Met Leu Glu Ala Gly Gly His Ala Val Val His Ala Ala Glu Asn Asn
 1235 1240 1245
 Thr Ser Ala Ala Gly Val Arg Ala Leu Leu Ala Lys Ala Phe Asp Gly
 1250 1255 1260
 Gln Ala Pro Thr Ala Val Val His Leu Gly Ser Leu Asp Gly Gly Gly
 1265 1270 1275 1280
 Glu Leu Asp Pro Gly Leu Gly Ala Gln Gly Ala Leu Asp Ala Pro Arg
 1285 1290 1295
 Ser Ala Asp Val Ser Pro Asp Ala Leu Asp Pro Ala Leu Val Arg Gly
 1300 1305 1310
 Cys Asp Ser Val Leu Trp Thr Val Gln Ala Leu Ala Gly Met Gly Phe
 1315 1320 1325
 Arg Asp Ala Pro Arg Leu Trp Leu Leu Thr Arg Gly Ala Gln Ala Val
 1330 1335 1340
 Gly Ala Gly Asp Val Ser Val Thr Gln Ala Pro Leu Leu Gly Leu Gly
 1345 1350 1355 1360
 Arg Val Ile Ala Met Glu His Ala Asp Leu Arg Cys Ala Arg Val Asp
 1365 1370 1375
 Leu Asp Pro Ala Arg Pro Glu Gly Glu Leu Ala Ala Leu Leu Ala Glu
 1380 1385 1390
 Leu Leu Ala Asp Asp Ala Glu Ala Glu Val Ala Leu Arg Gly Gly Glu
 1395 1400 1405
 Arg Cys Val Ala Arg Ile Val Arg Arg Gln Pro Glu Thr Arg Pro Arg
 1410 1415 1420
 Gly Arg Ile Glu Ser Cys Val Pro Thr Asp Val Thr Ile Arg Ala Asp
 1425 1430 1435 1440
 Ser Thr Tyr Leu Val Thr Gly Gly Leu Gly Gly Leu Gly Leu Ser Val
 1445 1450 1455
 Ala Gly Trp Leu Ala Glu Arg Gly Ala Gly His Leu Val Leu Val Gly
 1460 1465 1470
 Arg Ser Gly Ala Ala Ser Val Glu Gln Arg Ala Ala Val Ala Ala Leu
 1475 1480 1485
 Glu Ala Arg Gly Ala Arg Val Thr Val Ala Lys Ala Asp Val Ala Asp
 1490 1495 1500
 Arg Ala Gln Leu Glu Arg Ile Leu Arg Glu Val Thr Thr Ser Gly Met
 1505 1510 1515 1520
 Pro Leu Arg Gly Val Val His Ala Ala Gly Ile Leu Asp Asp Gly Leu
 1525 1530 1535
 Leu Met Gln Gln Thr Pro Ala Arg Phe Arg Lys Val Met Ala Pro Lys
 1540 1545 1550
 Val Gln Gly Ala Leu His Leu His Ala Leu Thr Arg Glu Ala Pro Leu
 1555 1560 1565

- 32 -

Ser Phe Phe Val Leu Tyr Ala Ser Gly Val Gly Leu Leu Gly Ser Pro
 1570 1575 1580
 Gly Gln Gly Asn Tyr Ala Ala Ala Asn Thr Phe Leu Asp Ala Leu Ala
 1585 1590 1595 1600
 His His Arg Arg Ala Gln Gly Leu Pro Ala Leu Ser Val Asp Trp Gly
 1605 1610 1615
 Leu Phe Ala Glu Val Gly Met Ala Ala Ala Gln Glu Asp Arg Gly Ala
 1620 1625 1630
 Arg Leu Val Ser Arg Gly Met Arg Ser Leu Thr Pro Asp Glu Gly Leu
 1635 1640 1645
 Ser Ala Leu Ala Arg Leu Leu Glu Ser Gly Arg Ala Gln Val Gly Val
 1650 1655 1660
 Met Pro Val Asn Pro Arg Leu Trp Val Glu Leu Tyr Pro Ala Ala Ala
 1665 1670 1675 1680
 Ser Ser Arg Met Leu Ser Arg Leu Val Thr Ala His Arg Ala Ser Ala
 1685 1690 1695
 Gly Gly Pro Ala Gly Asp Gly Asp Leu Leu Arg Arg Leu Ala Ala Ala
 1700 1705 1710
 Glu Pro Ser Ala Arg Ser Ala Leu Leu Glu Pro Leu Leu Arg Ala Gln
 1715 1720 1725
 Ile Ser Gln Val Leu Arg Leu Pro Glu Gly Lys Ile Glu Val Asp Ala
 1730 1735 1740
 Pro Leu Thr Ser Leu Gly Met Asn Ser Leu Met Gly Leu Glu Leu Arg
 1745 1750 1755 1760
 Asn Arg Ile Glu Ala Met Leu Gly Ile Thr Val Pro Ala Thr Leu Leu
 1765 1770 1775
 Trp Thr Tyr Pro Thr Val Ala Ala Leu Ser Gly His Leu Ala Arg Glu
 1780 1785 1790
 Ala Cys Glu Ala Ala Pro Val Glu Ser Pro His Thr Thr Ala Asp Ser
 1795 1800 1805
 Ala Val Glu Ile Glu Glu Met Ser Gln Asp Asp Leu Thr Gln Leu Ile
 1810 1815 1820
 Ala Ala Lys Phe Lys Ala Leu Thr
 1825 1830
 <210> 5
 <211> 7257
 <212> PRT
 <213> Sorangium cellulosum
 <400> 5
 Met Thr Thr Arg Gly Pro Thr Ala Gln Gln Asn Pro Leu Lys Gln Ala
 1 5 10 15
 Ala Ile Ile Ile Gln Arg Leu Glu Glu Arg Leu Ala Gly Leu Ala Gln
 20 25 30

- 33 -

Ala Glu Leu Glu Arg Thr Glu Pro Ile Ala Ile Val Gly Ile Gly Cys
 35 40 45
 Arg Phe Pro Gly Gly Ala Asp Ala Pro Glu Ala Phe Trp Glu Leu Leu
 50 55 60
 Asp Ala Glu Arg Asp Ala Val Gln Pro Leu Asp Met Arg Trp Ala Leu
 65 70 75 80
 Val Gly Val Ala Pro Val Glu Ala Val Pro His Trp Ala Gly Leu Leu
 85 90 95
 Thr Glu Pro Ile Asp Cys Phe Asp Ala Ala Phe Phe Gly Ile Ser Pro
 100 105 110
 Arg Glu Ala Arg Ser Leu Asp Pro Gln His Arg Leu Leu Glu Val
 115 120 125
 Ala Trp Glu Gly Leu Glu Asp Ala Gly Ile Pro Pro Arg Ser Ile Asp
 130 135 140
 Gly Ser Arg Thr Gly Val Phe Val Gly Ala Phe Thr Ala Asp Tyr Ala
 145 150 155 160
 Arg Thr Val Ala Arg Leu Pro Arg Glu Glu Arg Asp Ala Tyr Ser Ala
 165 170 175
 Thr Gly Asn Met Leu Ser Ile Ala Ala Gly Arg Leu Ser Tyr Thr Leu
 180 185 190
 Gly Leu Gln Gly Pro Cys Leu Thr Val Asp Thr Ala Cys Ser Ser Ser
 195 200 205
 Leu Val Ala Ile His Leu Ala Cys Arg Ser Leu Arg Ala Gly Glu Ser
 210 215 220
 Asp Leu Ala Leu Ala Gly Gly Val Ser Ala Leu Leu Ser Pro Asp Met
 225 230 235 240
 Met Glu Ala Ala Ala Arg Thr Gln Ala Leu Ser Pro Asp Gly Arg Cys
 245 250 255
 Arg Thr Phe Asp Ala Ser Ala Asn Gly Phe Val Arg Gly Glu Gly Cys
 260 265 270
 Gly Leu Val Val Leu Lys Arg Leu Ser Asp Ala Gln Arg Asp Gly Asp
 275 280 285
 Arg Ile Trp Ala Leu Ile Arg Gly Ser Ala Ile Asn His Asp Gly Arg
 290 295 300
 Ser Thr Gly Leu Thr Ala Pro Asn Val Leu Ala Gln Glu Thr Val Leu
 305 310 315 320
 Arg Glu Ala Leu Arg Ser Ala His Val Glu Ala Gly Ala Val Asp Tyr
 325 330 335
 Val Glu Thr His Gly Thr Gly Thr Ser Leu Gly Asp Pro Ile Glu Val
 340 345 350
 Glu Ala Leu Arg Ala Thr Val Gly Pro Ala Arg Ser Asp Gly Thr Arg
 355 360 365
 Cys Val Leu Gly Ala Val Lys Thr Asn Ile Gly His Leu Glu Ala Ala
 370 375 380

- 34 -

Ala Gly Val Ala Gly Leu Ile Lys Ala Ala Leu Ser Leu Thr His Glu
 385 390 395 400
 Arg Ile Pro Arg Asn Leu Asn Phe Arg Thr Leu Asn Pro Arg Ile Arg
 405 410 415
 Leu Glu Gly Ser Ala Leu Ala Leu Ala Thr Glu Pro Val Pro Trp Pro
 420 425 430
 Arg Thr Asp Arg Pro Arg Phe Ala Gly Val Ser Ser Phe Gly Met Ser
 435 440 445
 Gly Thr Asn Ala His Val Val Leu Glu Glu Ala Pro Ala Val Glu Leu
 450 455 460
 Trp Pro Ala Ala Pro Glu Arg Ser Ala Glu Leu Leu Val Leu Ser Gly
 465 470 475 480
 Lys Ser Glu Gly Ala Leu Asp Ala Gln Ala Ala Arg Leu Arg Glu His
 485 490 495
 Leu Asp Met His Pro Glu Leu Gly Leu Gly Asp Val Ala Phe Ser Leu
 500 505 510
 Ala Thr Thr Arg Ser Ala Met Ser His Arg Leu Ala Val Ala Val Thr
 515 520 525
 Ser Arg Glu Gly Leu Leu Ala Ala Leu Ser Ala Val Ala Gln Gly Gln
 530 535 540
 Thr Pro Ala Gly Ala Ala Arg Cys Ile Ala Ser Ser Ser Arg Gly Lys
 545 550 555 560
 Leu Ala Phe Leu Phe Thr Gly Gln Gly Ala Gln Thr Pro Gly Met Gly
 565 570 575
 Arg Gly Leu Cys Ala Ala Trp Pro Ala Phe Arg Glu Ala Phe Asp Arg
 580 585 590
 Cys Val Ala Leu Phe Asp Arg Glu Leu Asp Arg Pro Leu Arg Glu Val
 595 600 605
 Met Trp Ala Glu Ala Gly Ser Ala Glu Ser Leu Leu Leu Asp Gln Thr
 610 615 620
 Ala Phe Thr Gln Pro Ala Leu Phe Ala Val Glu Tyr Ala Leu Thr Ala
 625 630 635 640
 Leu Trp Arg Ser Trp Gly Val Glu Pro Glu Leu Leu Val Gly His Ser
 645 650 655
 Ile Gly Glu Leu Val Ala Ala Cys Val Ala Gly Val Phe Ser Leu Glu
 660 665 670
 Asp Gly Val Arg Leu Val Ala Ala Arg Gly Arg Leu Met Gln Gly Leu
 675 680 685
 Ser Ala Gly Gly Ala Met Val Ser Leu Gly Ala Pro Glu Ala Glu Val
 690 695 700
 Ala Ala Ala Val Ala Pro His Ala Ala Ser Val Ser Ile Ala Ala Val
 705 710 715 720
 Asn Gly Pro Glu Gln Val Val Ile Ala Gly Val Glu Gln Ala Val Gln

Ala	Ile	Ala	Ala	Gly	Phe	Ala	Ala	Arg	Gly	Ala	Arg	Thr	Lys	Arg	Leu
			740					745					750		
His	Val	Ser	His	Ala	Phe	His	Ser	Pro	Leu	Met	Glu	Pro	Met	Leu	Glu
		755					760					765			
Glu	Phe	Gly	Arg	Val	Ala	Ala	Ser	Val	Thr	Tyr	Arg	Arg	Pro	Ser	Val
		770				775					780				
Ser	Leu	Val	Ser	Asn	Leu	Ser	Gly	Lys	Val	Val	Thr	Asp	Glu	Leu	Ser
					790					795					800
Ala	Pro	Gly	Tyr	Trp	Val	Arg	His	Val	Arg	Glu	Ala	Val	Arg	Phe	Ala
				805					810					815	
Asp	Gly	Val	Lys	Ala	Leu	His	Glu	Ala	Gly	Ala	Gly	Thr	Phe	Val	Glu
			820					825					830		
Val	Gly	Pro	Lys	Pro	Thr	Leu	Leu	Gly	Leu	Leu	Pro	Ala	Cys	Leu	Pro
		835					840					845			
Glu	Ala	Glu	Pro	Thr	Leu	Leu	Ala	Ser	Leu	Arg	Ala	Gly	Arg	Glu	Glu
		850				855					860				
Ala	Ala	Gly	Val	Leu	Glu	Ala	Leu	Gly	Arg	Leu	Trp	Ala	Ala	Gly	Gly
					870					875					880
Ser	Val	Ser	Trp	Pro	Gly	Val	Phe	Pro	Thr	Ala	Gly	Arg	Arg	Val	Pro
				885					890					895	
Leu	Pro	Thr	Tyr	Pro	Trp	Gln	Arg	Gln	Arg	Tyr	Trp	Ile	Glu	Ala	Pro
			900					905					910		
Ala	Glu	Gly	Leu	Gly	Ala	Thr	Ala	Ala	Asp	Ala	Leu	Ala	Gln	Trp	Phe
		915					920					925			
Tyr	Arg	Val	Asp	Trp	Pro	Glu	Met	Pro	Arg	Ser	Ser	Val	Asp	Ser	Arg
	930					935					940				
Arg	Ala	Arg	Ser	Gly	Gly	Trp	Leu	Val	Leu	Ala	Asp	Arg	Gly	Gly	Val
	945				950					955					960
Gly	Glu	Ala	Ala	Ala	Ala	Ala	Leu	Ser	Ser	Gln	Gly	Cys	Ser	Cys	Ala
				965					970					975	
Val	Leu	His	Ala	Pro	Ala	Glu	Ala	Ser	Ala	Val	Ala	Glu	Gln	Val	Thr
			980					985					990		
Gln	Ala	Leu	Gly	Gly	Arg	Asn	Asp	Trp	Gln	Gly	Val	Leu	Tyr	Leu	Trp
		995				1000					1005				
Gly	Leu	Asp	Ala	Val	Val	Glu	Ala	Gly	Ala	Ser	Ala	Glu	Glu	Val	Ala
	1010					1015					1020				
Lys	Val	Thr	His	Leu	Ala	Ala	Ala	Pro	Val	Leu	Ala	Leu	Ile	Gln	Ala
	1025				1030					1035					1040
Leu	Gly	Thr	Gly	Pro	Arg	Ser	Pro	Arg	Leu	Trp	Ile	Val	Thr	Arg	Gly
				1045					1050					1055	
Ala	Cys	Thr	Val	Gly	Gly	Glu	Pro	Asp	Ala	Ala	Pro	Cys	Gln	Ala	Ala
			1060					1065					1070		

- 36 -

Leu Trp Gly Met Gly Arg Val Ala Ala Leu Glu His Pro Gly Ser Trp
 1075 1080 1085
 Gly Gly Leu Val Asp Leu Asp Pro Glu Glu Ser Pro Thr Glu Val Glu
 1090 1095 1100
 Ala Leu Val Ala Glu Leu Leu Ser Pro Asp Ala Glu Asp Gln Leu Ala
 1105 1110 1115 1120
 Phe Arg Gln Gly Arg Arg Arg Ala Ala Arg Leu Val Ala Ala Pro Pro
 1125 1130 1135
 Glu Gly Asn Ala Ala Pro Val Ser Leu Ser Ala Glu Gly Ser Tyr Leu
 1140 1145 1150
 Val Thr Gly Gly Leu Gly Ala Leu Gly Leu Leu Val Ala Arg Trp Leu
 1155 1160 1165
 Val Glu Arg Gly Ala Gly His Leu Val Leu Ile Ser Arg His Gly Leu
 1170 1175 1180
 Pro Asp Arg Glu Glu Trp Gly Arg Asp Gln Pro Pro Glu Val Arg Ala
 1185 1190 1195 1200
 Arg Ile Ala Ala Ile Glu Ala Leu Glu Ala Gln Gly Ala Arg Val Thr
 1205 1210 1215
 Val Ala Ala Val Asp Val Ala Asp Ala Glu Gly Met Ala Ala Leu Leu
 1220 1225 1230
 Ala Ala Val Glu Pro Pro Leu Arg Gly Val Val His Ala Ala Gly Leu
 1235 1240 1245
 Leu Asp Asp Gly Leu Leu Ala His Gln Asp Ala Gly Arg Leu Ala Arg
 1250 1255 1260
 Val Leu Arg Pro Lys Val Glu Gly Ala Trp Val Leu His Thr Leu Thr
 1265 1270 1275 1280
 Arg Glu Gln Pro Leu Asp Leu Phe Val Leu Phe Ser Ser Ala Ser Gly
 1285 1290 1295
 Val Phe Gly Ser Ile Gly Gln Gly Ser Tyr Ala Ala Gly Asn Ala Phe
 1300 1305 1310
 Leu Asp Ala Leu Ala Asp Leu Arg Arg Thr Gln Gly Leu Ala Ala Leu
 1315 1320 1325
 Ser Ile Ala Trp Gly Leu Trp Ala Glu Gly Gly Met Gly Ser Gln Ala
 1330 1335 1340
 Gln Arg Arg Glu His Glu Ala Ser Gly Ile Trp Ala Met Pro Thr Ser
 1345 1350 1355 1360
 Arg Ala Leu Ala Ala Met Glu Trp Leu Leu Gly Thr Arg Ala Thr Gln
 1365 1370 1375
 Arg Val Val Ile Gln Met Asp Trp Ala His Ala Gly Ala Ala Pro Arg
 1380 1385 1390
 Asp Ala Ser Arg Gly Arg Phe Trp Asp Arg Leu Val Thr Ala Thr Lys
 1395 1400 1405
 Glu Ala Ser Ser Ser Ala Val Pro Ala Val Glu Arg Trp Arg Asn Ala
 1410 1415 1420

- 37 -

Ser Val Val Glu Thr Arg Ser Ala Leu Tyr Glu Leu Val Arg Gly Val
 1425 1430 1435 1440
 Val Ala Gly Val Met Gly Phe Thr Asp Gln Gly Thr Leu Asp Val Arg
 1445 1450 1455
 Arg Gly Phe Ala Glu Gln Gly Leu Asp Ser Leu Met Ala Val Glu Ile
 1460 1465 1470
 Arg Lys Arg Leu Gln Gly Glu Leu Gly Met Pro Leu Ser Ala Thr Leu
 1475 1480 1485
 Ala Phe Asp His Pro Thr Val Glu Arg Leu Val Glu Tyr Leu Leu Ser
 1490 1495 1500
 Gln Ala Leu Glu Leu Gln Asp Arg Thr Asp Val Arg Ser Val Arg Leu
 1505 1510 1515 1520
 Pro Ala Thr Glu Asp Pro Ile Ala Ile Val Gly Ala Ala Cys Arg Phe
 1525 1530 1535
 Pro Gly Gly Val Glu Asp Leu Glu Ser Tyr Trp Gln Leu Leu Thr Glu
 1540 1545 1550
 Gly Val Val Val Ser Thr Glu Val Pro Ala Asp Arg Trp Asn Gly Ala
 1555 1560 1565
 Asp Gly Arg Val Pro Gly Ser Gly Glu Ala Gln Arg Gln Thr Tyr Val
 1570 1575 1580
 Pro Arg Gly Gly Phe Leu Arg Glu Val Glu Thr Phe Asp Ala Ala Phe
 1585 1590 1595 1600
 Phe His Ile Ser Pro Arg Glu Ala Met Ser Leu Asp Pro Gln Gln Arg
 1605 1610 1615
 Leu Leu Leu Glu Val Ser Trp Glu Ala Ile Glu Arg Ala Gly Gln Asp
 1620 1625 1630
 Pro Ser Ala Leu Arg Glu Ser Pro Thr Gly Val Phe Val Gly Ala Gly
 1635 1640 1645
 Pro Asn Glu Tyr Ala Glu Arg Val Gln Glu Leu Ala Asp Glu Ala Ala
 1650 1655 1660
 Gly Leu Tyr Ser Gly Thr Gly Asn Met Leu Ser Val Ala Ala Gly Arg
 1665 1670 1675 1680
 Leu Ser Phe Phe Leu Gly Leu His Gly Pro Thr Leu Ala Val Asp Thr
 1685 1690 1695
 Ala Cys Ser Ser Ser Leu Val Ala Leu His Leu Gly Cys Gln Ser Leu
 1700 1705 1710
 Arg Arg Gly Glu Cys Asp Gln Ala Leu Val Gly Gly Val Asn Met Leu
 1715 1720 1725
 Leu Ser Pro Lys Thr Phe Ala Leu Leu Ser Arg Met His Ala Leu Ser
 1730 1735 1740
 Pro Gly Gly Arg Cys Lys Thr Phe Ser Ala Asp Ala Asp Gly Tyr Ala
 1745 1750 1755 1760
 Arg Ala Glu Gly Cys Ala Val Val Val Leu Lys Arg Leu Ser Asp Ala

- 38 -

1765	1770	1775
Gln Arg Asp Arg Asp Pro Ile Leu Ala Val Ile Arg Gly Thr Ala Ile 1780 1785 1790		
Asn His Asp Gly Pro Ser Ser Gly Leu Thr Val Pro Ser Gly Pro Ala 1795 1800 1805		
Gln Glu Ala Leu Leu Arg Gln Ala Leu Ala His Ala Gly Val Val Pro 1810 1815 1820		
Ala Asp Val Asp Phe Val Glu Cys His Gly Thr Gly Thr Ala Leu Gly 1825 1830 1835 1840		
Asp Pro Ile Glu Val Arg Ala Leu Ser Asp Val Tyr Gly Gln Ala Arg 1845 1850 1855		
Pro Ala Asp Arg Pro Leu Ile Leu Gly Ala Ala Lys Ala Asn Leu Gly 1860 1865 1870		
His Met Glu Pro Ala Ala Gly Leu Ala Gly Leu Leu Lys Ala Val Leu 1875 1880 1885		
Ala Leu Gly Gln Glu Gln Ile Pro Ala Gln Pro Glu Leu Gly Glu Leu 1890 1895 1900		
Asn Pro Leu Leu Pro Trp Glu Ala Leu Pro Val Ala Val Ala Arg Ala 1905 1910 1915 1920		
Ala Val Pro Trp Pro Arg Thr Asp Arg Pro Arg Phe Ala Gly Val Ser 1925 1930 1935		
Ser Phe Gly Met Ser Gly Thr Asn Ala His Val Val Leu Glu Glu Ala 1940 1945 1950		
Pro Ala Val Glu Leu Trp Pro Ala Ala Pro Glu Arg Ser Ala Glu Leu 1955 1960 1965		
Leu Val Leu Ser Gly Lys Ser Glu Gly Ala Leu Asp Ala Gln Ala Ala 1970 1975 1980		
Arg Leu Arg Glu His Leu Asp Met His Pro Glu Leu Gly Leu Gly Asp 1985 1990 1995 2000		
Val Ala Phe Ser Leu Ala Thr Thr Arg Ser Ala Met Asn His Arg Leu 2005 2010 2015		
Ala Val Ala Val Thr Ser Arg Glu Gly Leu Leu Ala Ala Leu Ser Ala 2020 2025 2030		
Val Ala Gln Gly Gln Thr Pro Pro Gly Ala Ala Arg Cys Ile Ala Ser 2035 2040 2045		
Ser Ser Arg Gly Lys Leu Ala Phe Leu Phe Thr Gly Gln Gly Ala Gln 2050 2055 2060		
Thr Pro Gly Met Gly Arg Gly Leu Cys Ala Ala Trp Pro Ala Phe Arg 2065 2070 2075 2080		
Glu Ala Phe Asp Arg Cys Val Ala Leu Phe Asp Arg Glu Leu Asp Arg 2085 2090 2095		
Pro Leu Arg Glu Val Met Trp Ala Glu Pro Gly Ser Ala Glu Ser Leu 2100 2105 2110		

- 39 -

Leu Leu Asp Gln Thr Ala Phe Thr Gln Pro Ala Leu Phe Thr Val Glu
 2115 2120 2125
 Tyr Ala Leu Thr Ala Leu Trp Arg Ser Trp Gly Val Glu Pro Glu Leu
 2130 2135 2140
 Val Ala Gly His Ser Ala Gly Glu Leu Val Ala Ala Cys Val Ala Gly
 2145 2150 2155 2160
 Val Phe Ser Leu Glu Asp Gly Val Arg Leu Val Ala Ala Arg Gly Arg
 2165 2170 2175
 Leu Met Gln Gly Leu Ser Ala Gly Gly Ala Met Val Ser Leu Gly Ala
 2180 2185 2190
 Pro Glu Ala Glu Val Ala Ala Ala Val Ala Pro His Ala Ala Ser Val
 2195 2200 2205
 Ser Ile Ala Ala Val Asn Gly Pro Glu Gln Val Val Ile Ala Gly Val
 2210 2215 2220
 Glu Gln Ala Val Gln Ala Ile Ala Ala Gly Phe Ala Ala Arg Gly Ala
 2225 2230 2235 2240
 Arg Thr Lys Arg Leu His Val Ser His Ala Ser His Ser Pro Leu Met
 2245 2250 2255
 Glu Pro Met Leu Glu Glu Phe Gly Arg Val Ala Ala Ser Val Thr Tyr
 2260 2265 2270
 Arg Arg Pro Ser Val Ser Leu Val Ser Asn Leu Ser Gly Lys Val Val
 2275 2280 2285
 Ala Asp Glu Leu Ser Ala Pro Gly Tyr Trp Val Arg His Val Arg Glu
 2290 2295 2300
 Ala Val Arg Phe Ala Asp Gly Val Lys Ala Leu His Glu Ala Gly Ala
 2305 2310 2315 2320
 Gly Thr Phe Val Glu Val Gly Pro Lys Pro Thr Leu Leu Gly Leu Leu
 2325 2330 2335
 Pro Ala Cys Leu Pro Glu Ala Glu Pro Thr Leu Leu Ala Ser Leu Arg
 2340 2345 2350
 Ala Gly Arg Glu Glu Ala Ala Gly Val Leu Glu Ala Leu Gly Arg Leu
 2355 2360 2365
 Trp Ala Ala Gly Gly Ser Val Ser Trp Pro Gly Val Phe Pro Thr Ala
 2370 2375 2380
 Gly Arg Arg Val Pro Leu Pro Thr Tyr Pro Trp Gln Arg Gln Arg Tyr
 2385 2390 2395 2400
 Trp Pro Asp Ile Glu Pro Asp Ser Arg Arg His Ala Ala Ala Asp Pro
 2405 2410 2415
 Thr Gln Gly Trp Phe Tyr Arg Val Asp Trp Pro Glu Ile Pro Arg Ser
 2420 2425 2430
 Leu Gln Lys Ser Glu Glu Ala Ser Arg Gly Ser Trp Leu Val Leu Ala
 2435 2440 2445
 Asp Lys Gly Gly Val Gly Glu Ala Val Ala Ala Ala Leu Ser Thr Arg
 2450 2455 2460

- 40 -

Gly Leu Pro Cys Val Val Leu His Ala Pro Ala Glu Thr Ser Ala Thr
 2465 2470 2475 2480
 Ala Glu Leu Val Thr Glu Ala Ala Gly Gly Arg Ser Asp Trp Gln Val
 2485 2490 2495
 Val Leu Tyr Leu Trp Gly Leu Asp Ala Val Val Gly Ala Glu Ala Ser
 2500 2505 2510
 Ile Asp Glu Ile Gly Asp Ala Thr Arg Arg Ala Thr Ala Pro Val Leu
 2515 2520 2525
 Gly Leu Ala Arg Phe Leu Ser Thr Val Ser Cys Ser Pro Arg Leu Trp
 2530 2535 2540
 Val Val Thr Arg Gly Ala Cys Ile Val Gly Asp Glu Pro Ala Ile Ala
 2545 2550 2555 2560
 Pro Cys Gln Ala Ala Leu Trp Gly Met Gly Arg Val Ala Ala Leu Glu
 2565 2570 2575
 His Pro Gly Ala Trp Gly Gly Leu Val Asp Leu Asp Pro Arg Ala Ser
 2580 2585 2590
 Pro Pro Gln Ala Ser Pro Ile Asp Gly Glu Met Leu Val Thr Glu Leu
 2595 2600 2605
 Leu Ser Gln Glu Thr Glu Asp Gln Leu Ala Phe Arg His Gly Arg Arg
 2610 2615 2620
 His Ala Ala Arg Leu Val Ala Ala Pro Pro Gln Gly Gln Ala Ala Pro
 2625 2630 2635 2640
 Val Ser Leu Ser Ala Glu Ala Ser Tyr Leu Val Thr Gly Gly Leu Gly
 2645 2650 2655
 Gly Leu Gly Leu Ile Val Ala Gln Trp Leu Val Glu Leu Gly Ala Arg
 2660 2665 2670
 His Leu Val Leu Thr Ser Arg Arg Gly Leu Pro Asp Arg Gln Ala Trp
 2675 2680 2685
 Cys Glu Gln Gln Pro Pro Glu Ile Arg Ala Arg Ile Ala Ala Val Glu
 2690 2695 2700
 Ala Leu Glu Ala Arg Gly Ala Arg Val Thr Val Ala Ala Val Asp Val
 2705 2710 2715 2720
 Ala Asp Val Glu Pro Met Thr Ala Leu Val Ser Ser Val Glu Pro Pro
 2725 2730 2735
 Leu Arg Gly Val Val His Ala Ala Gly Val Ser Val Met Arg Pro Leu
 2740 2745 2750
 Ala Glu Thr Asp Glu Thr Leu Leu Glu Ser Val Leu Arg Pro Lys Val
 2755 2760 2765
 Ala Gly Ser Trp Leu Leu His Arg Leu Leu His Gly Arg Pro Leu Asp
 2770 2775 2780
 Leu Phe Val Leu Phe Ser Ser Gly Ala Ala Val Trp Gly Ser His Ser
 2785 2790 2795 2800
 Gln Gly Ala Tyr Ala Ala Ala Asn Ala Phe Leu Asp Gly Leu Ala His

- 41 -

2805	2810	2815
Leu Arg Arg Ser Gln Ser Leu Pro Ala Leu Ser Val Ala Trp Gly Leu 2820 2825 2830		
Trp Ala Glu Gly Gly Met Ala Asp Ala Glu Ala His Ala Arg Leu Ser 2835 2840 2845		
Asp Ile Gly Val Leu Pro Met Ser Thr Ser Ala Ala Leu Ser Ala Leu 2850 2855 2860		
Gln Arg Leu Val Glu Thr Gly Ala Ala Gln Arg Thr Val Thr Arg Met 2865 2870 2875 2880		
Asp Trp Ala Arg Phe Ala Pro Val Tyr Thr Ala Arg Gly Arg Arg Asn 2885 2890 2895		
Leu Leu Ser Ala Leu Val Ala Gly Arg Asp Ile Ile Ala Pro Ser Pro 2900 2905 2910		
Pro Ala Ala Ala Thr Arg Asn Trp Arg Gly Leu Ser Val Ala Glu Ala 2915 2920 2925		
Arg Val Ala Leu His Glu Ile Val His Gly Ala Val Ala Arg Val Leu 2930 2935 2940		
Gly Phe Leu Asp Pro Ser Ala Leu Asp Pro Gly Met Gly Phe Asn Glu 2945 2950 2955 2960		
Gln Gly Leu Asp Ser Leu Met Ala Val Glu Ile Arg Asn Leu Leu Gln 2965 2970 2975		
Ala Glu Leu Asp Val Arg Leu Ser Thr Thr Leu Ala Phe Asp His Pro 2980 2985 2990		
Thr Val Gln Arg Leu Val Glu His Leu Leu Val Asp Val Leu Lys Leu 2995 3000 3005		
Glu Asp Arg Ser Asp Thr Gln His Val Arg Ser Leu Ala Ser Asp Glu 3010 3015 3020		
Pro Ile Ala Ile Val Gly Ala Ala Cys Arg Phe Pro Gly Gly Val Glu 3025 3030 3035 3040		
Asp Leu Glu Ser Tyr Trp Gln Leu Leu Ala Glu Gly Val Val Val Ser 3045 3050 3055		
Ala Glu Val Pro Ala Asp Arg Trp Asp Ala Ala Asp Trp Tyr Asp Pro 3060 3065 3070		
Asp Pro Glu Ile Pro Gly Arg Thr Tyr Val Thr Lys Gly Ala Phe Leu 3075 3080 3085		
Arg Asp Leu Gln Arg Leu Asp Ala Thr Phe Phe Arg Ile Ser Pro Arg 3090 3095 3100		
Glu Ala Met Ser Leu Asp Pro Gln Gln Arg Leu Leu Leu Glu Val Ser 3105 3110 3115 3120		
Trp Glu Ala Leu Glu Ser Ala Gly Ile Ala Pro Asp Thr Leu Arg Asp 3125 3130 3135		
Ser Pro Thr Gly Val Phe Val Gly Ala Gly Pro Asn Glu Tyr Tyr Thr 3140 3145 3150		

- 42 -

Gln Arg Leu Arg Gly Phe Thr Asp Gly Ala Ala Gly Leu Tyr Gly Gly
 3155 3160 3165
 Thr Gly Asn Met Leu Ser Val Thr Ala Gly Arg Leu Ser Phe Phe Leu
 3170 3175 3180
 Gly Leu His Gly Pro Thr Leu Ala Met Asp Thr Ala Cys Ser Ser Ser
 3185 3190 3195 3200
 Leu Val Ala Leu His Leu Ala Cys Gln Ser Leu Arg Leu Gly Glu Cys
 3205 3210 3215
 Asp Gln Ala Leu Val Gly Gly Val Asn Val Leu Leu Ala Pro Glu Thr
 3220 3225 3230
 Phe Val Leu Leu Ser Arg Met Arg Ala Leu Ser Pro Asp Gly Arg Cys
 3235 3240 3245
 Lys Thr Phe Ser Ala Asp Ala Asp Gly Tyr Ala Arg Gly Glu Gly Cys
 3250 3255 3260
 Ala Val Val Val Leu Lys Arg Leu Arg Asp Ala Gln Arg Ala Gly Asp
 3265 3270 3275 3280
 Ser Ile Leu Ala Leu Ile Arg Gly Ser Ala Val Asn His Asp Gly Pro
 3285 3290 3295
 Ser Ser Gly Leu Thr Val Pro Asn Gly Pro Ala Gln Gln Ala Leu Leu
 3300 3305 3310
 Arg Gln Ala Leu Ser Gln Ala Gly Val Ser Pro Val Asp Val Asp Phe
 3315 3320 3325
 Val Glu Cys His Gly Thr Gly Thr Ala Leu Gly Asp Pro Ile Glu Val
 3330 3335 3340
 Gln Ala Leu Ser Glu Val Tyr Gly Pro Gly Arg Ser Gly Asp Arg Pro
 3345 3350 3355 3360
 Leu Val Leu Gly Ala Ala Lys Ala Asn Val Ala His Leu Glu Ala Ala
 3365 3370 3375
 Ser Gly Leu Ala Ser Leu Leu Lys Ala Val Leu Ala Leu Arg His Glu
 3380 3385 3390
 Gln Ile Pro Ala Gln Pro Glu Leu Gly Glu Leu Asn Pro His Leu Pro
 3395 3400 3405
 Trp Asn Thr Leu Pro Val Ala Val Pro Arg Lys Ala Val Pro Trp Gly
 3410 3415 3420
 Arg Gly Ala Arg Pro Arg Arg Ala Gly Val Ser Ala Phe Gly Leu Ser
 3425 3430 3435 3440
 Gly Thr Asn Val His Val Val Leu Glu Glu Ala Pro Glu Val Glu Pro
 3445 3450 3455
 Ala Pro Ala Ala Pro Ala Arg Pro Val Glu Leu Val Val Leu Ser Ala
 3460 3465 3470
 Lys Ser Ala Ala Ala Leu Asp Ala Ala Ala Arg Leu Ser Ala His
 3475 3480 3485
 Leu Ser Ala His Pro Glu Leu Ser Leu Gly Asp Val Ala Phe Ser Leu
 3490 3495 3500

- 43 -

Ala Thr Thr Arg Ser Pro Met Glu His Arg Leu Ala Ile Ala Thr Thr
 3505 3510 3515 3520
 Ser Arg Glu Ala Leu Arg Gly Ala Leu Asp Ala Ala Ala Gln Gln Lys
 3525 3530 3535
 Thr Pro Gln Gly Ala Val Arg Gly Lys Ala Val Ser Ser Arg Gly Lys
 3540 3545 3550
 Leu Ala Phe Leu Phe Thr Gly Gln Gly Ala Gln Met Pro Gly Met Gly
 3555 3560 3565
 Arg Gly Leu Tyr Glu Thr Trp Pro Ala Phe Arg Glu Ala Phe Asp Arg
 3570 3575 3580
 Cys Val Ala Leu Phe Asp Arg Glu Ile Asp Gln Pro Leu Arg Glu Val
 3585 3590 3595 3600
 Met Trp Ala Ala Pro Gly Leu Ala Gln Ala Ala Arg Leu Asp Gln Thr
 3605 3610 3615
 Ala Tyr Ala Gln Pro Ala Leu Phe Ala Leu Glu Tyr Ala Leu Ala Ala
 3620 3625 3630
 Leu Trp Arg Ser Trp Gly Val Glu Pro His Val Leu Leu Gly His Ser
 3635 3640 3645
 Ile Gly Glu Leu Val Ala Ala Cys Val Ala Gly Val Phe Ser Leu Glu
 3650 3655 3660
 Asp Ala Val Arg Leu Val Ala Ala Arg Gly Arg Leu Met Gln Ala Leu
 3665 3670 3675 3680
 Pro Ala Gly Gly Ala Met Val Ala Ile Ala Ala Ser Glu Ala Glu Val
 3685 3690 3695
 Ala Ala Ser Val Ala Pro His Ala Ala Thr Val Ser Ile Ala Ala Val
 3700 3705 3710
 Asn Gly Pro Asp Ala Val Val Ile Ala Gly Ala Glu Val Gln Val Leu
 3715 3720 3725
 Ala Leu Gly Ala Thr Phe Ala Ala Arg Gly Ile Arg Thr Lys Arg Leu
 3730 3735 3740
 Ala Val Ser His Ala Phe His Ser Pro Leu Met Asp Pro Met Leu Glu
 3745 3750 3755 3760
 Asp Phe Gln Arg Val Ala Ala Thr Ile Ala Tyr Arg Ala Pro Asp Arg
 3765 3770 3775
 Pro Val Val Ser Asn Val Thr Gly His Val Ala Gly Pro Glu Ile Ala
 3780 3785 3790
 Thr Pro Glu Tyr Trp Val Arg His Val Arg Ser Ala Val Arg Phe Gly
 3795 3800 3805
 Asp Gly Ala Lys Ala Leu His Ala Ala Gly Ala Ala Thr Phe Val Glu
 3810 3815 3820
 Val Gly Pro Lys Pro Val Leu Leu Gly Leu Leu Pro Ala Cys Leu Gly
 3825 3830 3835 3840
 Glu Ala Asp Ala Val Leu Val Pro Ser Leu Arg Ala Asp Arg Ser Glu

- 44 -

3845	3850	3855
Cys Glu Val Val Leu Ala Ala Leu Gly Ala Trp Tyr Ala Trp Gly Gly		
3860	3865	3870
Ala Leu Asp Trp Lys Gly Val Phe Pro Asp Gly Ala Arg Arg Val Ala		
3875	3880	3885
Leu Pro Met Tyr Pro Trp Gln Arg Glu Arg His Trp Met Asp Leu Thr		
3890	3895	3900
Pro Arg Ser Ala Ala Pro Ala Gly Ile Ala Gly Arg Trp Pro Leu Ala		
3905	3910	3915
Gly Val Gly Leu Cys Met Pro Gly Ala Val Leu His His Val Leu Ser		
3925	3930	3935
Ile Gly Pro Arg His Gln Pro Phe Leu Gly Asp His Leu Val Phe Gly		
3940	3945	3950
Lys Val Val Val Pro Gly Ala Phe His Val Ala Val Ile Leu Ser Ile		
3955	3960	3965
Ala Ala Glu Arg Trp Pro Glu Arg Ala Ile Glu Leu Thr Gly Val Glu		
3970	3975	3980
Phe Leu Lys Ala Ile Ala Met Glu Pro Asp Gln Glu Val Glu Leu His		
3985	3990	4000
Ala Val Leu Thr Pro Glu Ala Ala Gly Asp Gly Tyr Leu Phe Glu Leu		
4005	4010	4015
Ala Thr Leu Ala Ala Pro Glu Thr Glu Arg Arg Trp Thr Thr His Ala		
4020	4025	4030
Arg Gly Arg Val Gln Pro Thr Asp Gly Ala Pro Gly Ala Leu Pro Arg		
4035	4040	4045
Leu Glu Val Leu Glu Asp Arg Ala Ile Gln Pro Leu Asp Phe Ala Gly		
4050	4055	4060
Phe Leu Asp Arg Leu Ser Ala Val Arg Ile Gly Trp Gly Pro Leu Trp		
4065	4070	4075
Arg Trp Leu Gln Asp Gly Arg Val Gly Asp Glu Ala Ser Leu Ala Thr		
4085	4090	4095
Leu Val Pro Thr Tyr Pro Asn Ala His Asp Val Ala Pro Leu His Pro		
4100	4105	4110
Ile Leu Leu Asp Asn Gly Phe Ala Val Ser Leu Leu Ser Thr Arg Ser		
4115	4120	4125
Glu Pro Glu Asp Asp Gly Thr Pro Pro Leu Pro Phe Ala Val Glu Arg		
4130	4135	4140
Val Arg Trp Trp Arg Ala Pro Val Gly Arg Val Arg Cys Gly Gly Val		
4145	4150	4155
Pro Arg Ser Gln Ala Phe Gly Val Ser Ser Phe Val Leu Val Asp Glu		
4165	4170	4175
Thr Gly Glu Val Val Ala Glu Val Glu Gly Phe Val Cys Arg Arg Ala		
4180	4185	4190

- 45 -

Pro Arg Glu Val Phe Leu Arg Gln Glu Ser Gly Ala Ser Thr Ala Ala
 4195 4200 4205
 Leu Tyr Arg Leu Asp Trp Pro Glu Ala Pro Leu Pro Asp Ala Pro Ala
 4210 4215 4220
 Glu Arg Ile Glu Glu Ser Trp Val Val Val Ala Ala Pro Gly Ser Glu
 4225 4230 4235 4240
 Met Ala Ala Ala Leu Ala Thr Arg Leu Asn Arg Cys Val Leu Ala Glu
 4245 4250 4255
 Pro Lys Gly Leu Glu Ala Ala Leu Ala Gly Val Ser Pro Ala Gly Val
 4260 4265 4270
 Ile Cys Leu Trp Glu Ala Gly Ala His Glu Glu Ala Pro Ala Ala Ala
 4275 4280 4285
 Gln Arg Val Ala Thr Glu Gly Leu Ser Val Val Gln Ala Leu Arg Asp
 4290 4295 4300
 Arg Ala Val Arg Leu Trp Trp Val Thr Met Gly Ala Val Ala Val Glu
 4305 4310 4315 4320
 Ala Gly Glu Arg Val Gln Val Ala Thr Ala Pro Val Trp Gly Leu Gly
 4325 4330 4335
 Arg Thr Val Met Gln Glu Arg Pro Glu Leu Ser Cys Thr Leu Val Asp
 4340 4345 4350
 Leu Glu Pro Glu Ala Asp Ala Ala Arg Ser Ala Asp Val Leu Leu Arg
 4355 4360 4365
 Glu Leu Gly Arg Ala Asp Asp Glu Thr Gln Val Ala Phe Arg Ser Gly
 4370 4375 4380
 Lys Arg Arg Val Ala Arg Leu Val Lys Ala Thr Thr Pro Glu Gly Leu
 4385 4390 4395 4400
 Leu Val Pro Asp Ala Glu Ser Tyr Arg Leu Glu Ala Gly Gln Lys Gly
 4405 4410 4415
 Thr Leu Asp Gln Leu Arg Leu Ala Pro Ala Gln Arg Arg Ala Pro Gly
 4420 4425 4430
 Pro Gly Glu Val Glu Ile Lys Val Thr Ala Ser Gly Leu Asn Phe Arg
 4435 4440 4445
 Thr Val Leu Ala Val Leu Gly Met Tyr Pro Gly Asp Ala Gly Pro Met
 4450 4455 4460
 Gly Gly Asp Cys Ala Gly Val Ala Thr Ala Val Gly Gln Gly Val Arg
 4465 4470 4475 4480
 His Val Ala Val Gly Asp Ala Val Met Thr Leu Gly Thr Leu His Arg
 4485 4490 4495
 Phe Val Thr Val Asp Ala Arg Leu Val Val Arg Gln Pro Ala Gly Leu
 4500 4505 4510
 Thr Pro Ala Gln Ala Ala Thr Val Pro Val Ala Phe Leu Thr Ala Trp
 4515 4520 4525
 Leu Ala Leu His Asp Leu Gly Asn Leu Arg Arg Gly Glu Arg Val Leu
 4530 4535 4540

- 46 -

Ile His Ala Ala Ala Gly Gly Val Gly Met Ala Ala Val Gln Ile Ala
 4545 4550 4555 4560
 Arg Trp Ile Gly Ala Glu Val Phe Ala Thr Ala Ser Pro Ser Lys Trp
 4565 4570 4575
 Ala Ala Val Gln Ala Met Gly Val Pro Arg Thr His Ile Ala Ser Ser
 4580 4585 4590
 Arg Thr Leu Glu Phe Ala Glu Thr Phe Arg Gln Val Thr Gly Gly Arg
 4595 4600 4605
 Gly Val Asp Val Val Leu Asn Ala Leu Ala Gly Glu Phe Val Asp Ala
 4610 4615 4620
 Ser Leu Ser Leu Leu Ser Thr Gly Gly Arg Phe Leu Glu Met Gly Lys
 4625 4630 4635 4640
 Thr Asp Ile Arg Asp Arg Ala Ala Val Ala Ala Ala His Pro Gly Val
 4645 4650 4655
 Arg Tyr Arg Val Phe Asp Ile Leu Glu Leu Ala Pro Asp Arg Thr Arg
 4660 4665 4670
 Glu Ile Leu Glu Arg Val Val Glu Gly Phe Ala Ala Gly His Leu Arg
 4675 4680 4685
 Ala Leu Pro Val His Ala Phe Ala Ile Thr Lys Ala Glu Ala Ala Phe
 4690 4695 4700
 Arg Phe Met Ala Gln Ala Arg His Gln Gly Lys Val Val Leu Leu Pro
 4705 4710 4715 4720
 Ala Pro Ser Ala Ala Pro Leu Ala Pro Thr Gly Thr Val Leu Leu Thr
 4725 4730 4735
 Gly Gly Leu Gly Ala Leu Gly Leu His Val Ala Arg Trp Leu Ala Gln
 4740 4745 4750
 Gln Gly Val Pro His Met Val Leu Thr Gly Arg Arg Gly Leu Asp Thr
 4755 4760 4765
 Pro Gly Ala Ala Lys Ala Val Ala Glu Ile Glu Ala Leu Gly Ala Arg
 4770 4775 4780
 Val Thr Ile Ala Ala Ser Asp Val Ala Asp Arg Asn Ala Leu Glu Ala
 4785 4790 4795 4800
 Val Leu Gln Ala Ile Pro Ala Glu Trp Pro Leu Gln Gly Val Ile His
 4805 4810 4815
 Ala Ala Gly Ala Leu Asp Asp Gly Val Leu Asp Glu Gln Thr Thr Asp
 4820 4825 4830
 Arg Phe Ser Arg Val Leu Ala Pro Lys Val Thr Gly Ala Trp Asn Leu
 4835 4840 4845
 His Glu Leu Thr Ala Gly Asn Asp Leu Ala Phe Phe Val Leu Phe Ser
 4850 4855 4860
 Ser Met Ser Gly Leu Leu Gly Ser Ala Gly Gln Ser Asn Tyr Ala Ala
 4865 4870 4875 4880
 Ala Asn Thr Phe Leu Asp Ala Leu Ala Ala His Arg Arg Ala Glu Gly

- 47 -

4885	4890	4895
Leu Ala Ala Gln Ser Leu Ala Trp Gly Pro Trp Ser Asp Gly Gly Met 4900 4905 4910		
Ala Ala Gly Leu Ser Ala Ala Leu Gln Ala Arg Leu Ala Arg His Gly 4915 4920 4925		
Met Gly Ala Leu Ser Pro Ala Gln Gly Thr Ala Leu Leu Gly Gln Ala 4930 4935 4940		
Leu Ala Arg Pro Glu Thr Gln Leu Gly Ala Met Ser Leu Asp Val Arg 4945 4950 4955 4960		
Ala Ala Ser Gln Ala Ser Gly Ala Ala Val Pro Pro Val Trp Arg Ala 4965 4970 4975		
Leu Val Arg Ala Glu Ala Arg His Thr Ala Ala Gly Ala Gln Gly Ala 4980 4985 4990		
Leu Ala Ala Arg Leu Gly Ala Leu Pro Glu Ala Arg Arg Ala Asp Glu 4995 5000 5005		
Val Arg Lys Val Val Gln Ala Glu Ile Ala Arg Val Leu Ser Trp Ser 5010 5015 5020		
Ala Ala Ser Ala Val Pro Val Asp Arg Pro Leu Ser Asp Leu Gly Leu 5025 5030 5035 5040		
Asp Ser Leu Thr Ala Val Glu Leu Arg Asn Val Leu Gly Gln Arg Val 5045 5050 5055		
Gly Ala Thr Leu Pro Ala Thr Leu Ala Phe Asp His Pro Thr Val Asp 5060 5065 5070		
Ala Leu Thr Arg Trp Leu Leu Asp Lys Val Leu Ala Val Ala Glu Pro 5075 5080 5085		
Ser Val Ser Ser Ala Lys Ser Ser Pro Gln Val Ala Leu Asp Glu Pro 5090 5095 5100		
Ile Ala Ile Ile Gly Ile Gly Cys Arg Phe Pro Gly Gly Val Ala Asp 5105 5110 5115 5120		
Pro Glu Ser Phe Trp Arg Leu Leu Glu Glu Gly Ser Asp Ala Val Val 5125 5130 5135		
Glu Val Pro His Glu Arg Trp Asp Ile Asp Ala Phe Tyr Asp Pro Asp 5140 5145 5150		
Pro Asp Val Arg Gly Lys Met Thr Thr Arg Phe Gly Gly Phe Leu Ser 5155 5160 5165		
Asp Ile Asp Arg Phe Asp Pro Ala Phe Phe Gly Ile Ser Pro Arg Glu 5170 5175 5180		
Ala Thr Thr Met Asp Pro Gln Gln Arg Leu Leu Leu Glu Thr Ser Trp 5185 5190 5195 5200		
Glu Ala Phe Glu Arg Ala Gly Ile Leu Pro Glu Arg Leu Met Gly Ser 5205 5210 5215		
Asp Thr Gly Val Phe Val Gly Leu Phe Tyr Gln Glu Tyr Ala Ala Leu 5220 5225 5230		

- 48 -

Ala Gly Gly Ile Glu Ala Phe Asp Gly Tyr Leu Gly Thr Gly Thr Thr
 5235 5240 5245
 Ala Ser Val Ala Ser Gly Arg Ile Ser Tyr Val Leu Gly Leu Lys Gly
 5250 5255 5260
 Pro Ser Leu Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Val
 5265 5270 5275 5280
 His Leu Ala Cys Gln Ala Leu Arg Arg Gly Glu Cys Ser Val Ala Leu
 5285 5290 5295
 Ala Gly Gly Val Ala Leu Met Leu Thr Pro Ala Thr Phe Val Glu Phe
 5300 5305 5310
 Ser Arg Leu Arg Gly Leu Ala Pro Asp Gly Arg Cys Lys Ser Phe Ser
 5315 5320 5325
 Ala Ala Ala Asp Gly Val Gly Trp Ser Glu Gly Cys Ala Met Leu Leu
 5330 5335 5340
 Leu Lys Pro Leu Arg Asp Ala Gln Arg Asp Gly Asp Pro Ile Leu Ala
 5345 5350 5355 5360
 Val Ile Arg Gly Thr Ala Val Asn Gln Asp Gly Arg Ser Asn Gly Leu
 5365 5370 5375
 Thr Ala Pro Asn Gly Ser Ser Gln Gln Glu Val Ile Arg Arg Ala Leu
 5380 5385 5390
 Glu Gln Ala Gly Leu Ala Pro Ala Asp Val Ser Tyr Val Glu Cys His
 5395 5400 5405
 Gly Thr Gly Thr Thr Leu Gly Asp Pro Ile Glu Val Gln Ala Leu Gly
 5410 5415 5420
 Ala Val Leu Ala Gln Gly Arg Pro Ser Asp Arg Pro Leu Val Ile Gly
 5425 5430 5435 5440
 Ser Val Lys Ser Asn Ile Gly His Thr Gln Ala Ala Ala Gly Val Ala
 5445 5450 5455
 Gly Val Ile Lys Val Ala Leu Ala Leu Glu Arg Gly Leu Ile Pro Arg
 5460 5465 5470
 Ser Leu His Phe Asp Ala Pro Asn Pro His Ile Pro Trp Ser Glu Leu
 5475 5480 5485
 Ala Val Gln Val Ala Ala Lys Pro Val Glu Trp Thr Arg Asn Gly Val
 5490 5495 5500
 Pro Arg Arg Ala Gly Val Ser Ser Phe Gly Val Ser Gly Thr Asn Ala
 5505 5510 5515 5520
 His Val Val Leu Glu Glu Ala Pro Ala Ala Ala Phe Ala Pro Ala Ala
 5525 5530 5535
 Ala Arg Ser Ala Glu Leu Phe Val Leu Ser Ala Lys Ser Ala Ala Ala
 5540 5545 5550
 Leu Asp Ala Gln Ala Ala Arg Leu Ser Ala His Val Val Ala His Pro
 5555 5560 5565
 Glu Leu Gly Leu Gly Asp Leu Ala Phe Ser Leu Ala Thr Thr Arg Ser
 5570 5575 5580

- 49 -

Pro Met Thr Tyr Arg Leu Ala Val Ala Ala Thr Ser Arg Glu Ala Leu
 5585 5590 5595 5600
 Ser Ala Ala Leu Asp Thr Ala Ala Gln Gly Gln Ala Pro Pro Ala Ala
 5605 5610 5615
 Ala Arg Gly His Ala Ser Thr Gly Ser Ala Pro Lys Val Val Phe Val
 5620 5625 5630
 Phe Pro Gly Gln Gly Ser Gln Trp Leu Gly Met Gly Gln Lys Leu Leu
 5635 5640 5645
 Ser Glu Glu Pro Val Phe Arg Asp Ala Leu Ser Ala Cys Asp Arg Ala
 5650 5655 5660
 Ile Gln Ala Glu Ala Gly Trp Ser Leu Leu Ala Glu Leu Ala Ala Asp
 5665 5670 5675 5680
 Glu Thr Thr Ser Gln Leu Gly Arg Ile Asp Val Val Gln Pro Ala Leu
 5685 5690 5695
 Phe Ala Ile Glu Val Ala Leu Ser Ala Leu Trp Arg Ser Trp Gly Val
 5700 5705 5710
 Glu Pro Asp Ala Val Val Gly His Ser Met Gly Glu Val Ala Ala Ala
 5715 5720 5725
 His Val Ala Gly Ala Leu Ser Leu Glu Asp Ala Val Ala Ile Ile Cys
 5730 5735 5740
 Arg Arg Ser Leu Leu Leu Arg Arg Ile Ser Gly Gln Gly Glu Met Ala
 5745 5750 5755 5760
 Val Val Glu Leu Ser Leu Ala Glu Ala Glu Ala Ala Leu Leu Gly Tyr
 5765 5770 5775
 Glu Asp Arg Leu Ser Val Ala Val Ser Asn Ser Pro Arg Ser Thr Val
 5780 5785 5790
 Leu Ala Gly Glu Pro Ala Ala Leu Ala Glu Val Leu Ala Ile Leu Ala
 5795 5800 5805
 Ala Lys Gly Val Phe Cys Arg Arg Val Lys Val Asp Val Ala Ser His
 5810 5815 5820
 Ser Pro Gln Ile Asp Pro Leu Arg Asp Glu Leu Leu Ala Ala Leu Gly
 5825 5830 5835 5840
 Glu Leu Glu Pro Arg Gln Ala Thr Val Ser Met Arg Ser Thr Val Thr
 5845 5850 5855
 Ser Thr Ile Met Ala Gly Pro Glu Leu Val Ala Ser Tyr Trp Ala Asp
 5860 5865 5870
 Asn Val Arg Gln Pro Val Arg Phe Ala Glu Ala Val Gln Ser Leu Met
 5875 5880 5885
 Glu Asp Gly His Gly Leu Phe Val Glu Met Ser Pro His Pro Ile Leu
 5890 5895 5900
 Thr Thr Ser Val Glu Glu Ile Arg Arg Ala Thr Lys Arg Glu Gly Val
 5905 5910 5915 5920
 Ala Val Gly Ser Leu Arg Arg Gly Gln Asp Glu Arg Leu Ser Met Leu

- 50 -

5925	5930	5935
Glu Ala Leu Gly Ala Leu Trp Val His Gly Gln Ala Val Gly Trp Glu 5940 5945 5950		
Arg Leu Phe Ser Ala Gly Gly Ala Gly Leu Arg Arg Val Pro Leu Pro 5955 5960 5965		
Thr Tyr Pro Trp Gln Arg Glu Arg Tyr Trp Val Asp Ala Pro Thr Gly 5970 5975 5980		
Gly Ala Ala Gly Gly Ser Arg Phe Ala His Ala Gly Ser His Pro Leu 5985 5990 5995 6000		
Leu Gly Glu Met Gln Thr Leu Ser Thr Gln Arg Ser Thr Arg Val Trp 6005 6010 6015		
Glu Thr Thr Leu Asp Leu Lys Arg Leu Pro Trp Leu Gly Asp His Arg 6020 6025 6030		
Val Gln Gly Ala Val Val Phe Pro Gly Ala Ala Tyr Leu Glu Met Ala 6035 6040 6045		
Leu Ser Ser Gly Ala Glu Ala Leu Gly Asp Gly Pro Leu Gln Val Ser 6050 6055 6060		
Asp Val Val Leu Ala Glu Ala Leu Ala Phe Ala Asp Asp Thr Pro Ala 6065 6070 6075 6080		
Ala Val Gln Val Met Ala Thr Glu Glu Arg Pro Gly Arg Leu Gln Phe 6085 6090 6095		
His Val Ala Ser Arg Val Pro Gly His Gly Gly Ala Ala Phe Arg Ser 6100 6105 6110		
His Ala Arg Gly Val Leu Arg Gln Ile Glu Arg Ala Glu Val Pro Ala 6115 6120 6125		
Arg Leu Asp Leu Ala Ala Leu Arg Ala Arg Leu Gln Ala Ser Ala Pro 6130 6135 6140		
Ala Ala Ala Thr Tyr Ala Ala Leu Ala Glu Met Gly Leu Glu Tyr Gly 6145 6150 6155 6160		
Pro Ala Phe Gln Gly Leu Val Glu Leu Trp Arg Gly Glu Gly Glu Ala 6165 6170 6175		
Leu Gly Arg Val Arg Leu Pro Glu Ala Ala Gly Ser Pro Ala Ala Cys 6180 6185 6190		
Arg Leu His Pro Ala Leu Leu Asp Ala Cys Phe His Val Ser Ser Ala 6195 6200 6205		
Phe Ala Asp Arg Gly Glu Ala Thr Pro Trp Val Pro Val Glu Ile Gly 6210 6215 6220		
Ser Leu Arg Trp Phe Gln Arg Pro Ser Gly Glu Leu Trp Cys His Ala 6225 6230 6235 6240		
Arg Ser Val Ser His Gly Lys Pro Thr Pro Asp Arg Arg Ser Thr Asp 6245 6250 6255		
Phe Trp Val Val Asp Ser Thr Gly Ala Ile Val Ala Glu Ile Ser Gly 6260 6265 6270		

- 51 -

Leu Val Ala Gln Arg Leu Ala Gly Gly Val Arg Arg Arg Glu Glu Asp
 6275 6280 6285
 Asp Trp Phe Met Glu Pro Ala Trp Glu Pro Thr Ala Val Pro Gly Ser
 6290 6295 6300
 Glu Val Met Ala Gly Arg Trp Leu Leu Ile Gly Ser Gly Gly Gly Leu
 6305 6310 6315 6320
 Gly Ala Ala Leu His Ser Ala Leu Thr Glu Ala Gly His Ser Val Val
 6325 6330 6335
 His Ala Thr Gly Arg Gly Thr Ser Ala Ala Gly Leu Gln Ala Leu Leu
 6340 6345 6350
 Thr Ala Ser Phe Asp Gly Gln Ala Pro Thr Ser Val Val His Leu Gly
 6355 6360 6365
 Ser Leu Asp Glu Arg Gly Val Leu Asp Ala Asp Ala Pro Phe Asp Ala
 6370 6375 6380
 Asp Ala Leu Glu Glu Ser Leu Val Arg Gly Cys Asp Ser Val Leu Trp
 6385 6390 6395 6400
 Thr Val Gln Ala Val Ala Gly Ala Gly Phe Arg Asp Pro Pro Arg Leu
 6405 6410 6415
 Trp Leu Val Thr Arg Gly Ala Gln Ala Ile Gly Ala Gly Asp Val Ser
 6420 6425 6430
 Val Ala Gln Ala Pro Leu Leu Gly Leu Gly Arg Val Ile Ala Leu Glu
 6435 6440 6445
 His Ala Glu Leu Arg Cys Ala Arg Ile Asp Leu Asp Pro Ala Arg Arg
 6450 6455 6460
 Asp Gly Glu Val Asp Glu Leu Leu Ala Glu Leu Leu Ala Asp Asp Ala
 6465 6470 6475 6480
 Glu Glu Glu Val Ala Phe Arg Gly Gly Glu Arg Arg Val Ala Arg Leu
 6485 6490 6495
 Val Arg Arg Leu Pro Glu Thr Asp Cys Arg Glu Lys Ile Glu Pro Ala
 6500 6505 6510
 Glu Gly Arg Pro Phe Arg Leu Glu Ile Asp Gly Ser Gly Val Leu Asp
 6515 6520 6525
 Asp Leu Val Leu Arg Ala Thr Glu Arg Arg Pro Pro Gly Pro Gly Glu
 6530 6535 6540
 Val Glu Ile Ala Val Glu Ala Ala Gly Leu Asn Phe Leu Asp Val Met
 6545 6550 6555 6560
 Arg Ala Met Gly Ile Tyr Pro Gly Pro Gly Asp Gly Pro Val Ala Leu
 6565 6570 6575
 Gly Ala Glu Cys Ser Gly Arg Ile Val Ala Met Gly Glu Gly Val Glu
 6580 6585 6590
 Ser Leu Arg Ile Gly Gln Asp Val Val Ala Val Ala Pro Phe Ser Phe
 6595 6600 6605
 Gly Thr His Val Thr Ile Asp Ala Arg Met Leu Ala Pro Arg Pro Ala
 6610 6615 6620

- 52 -

Ala Leu Thr Ala Ala Gln Ala Ala Ala Leu Pro Val Ala Phe Met Thr
 6625 6630 6635 6640
 Ala Trp Tyr Gly Leu Val His Leu Gly Arg Leu Arg Ala Gly Glu Arg
 6645 6650 6655
 Val Leu Ile His Ser Ala Thr Gly Gly Thr Gly Leu Ala Ala Val Gln
 6660 6665 6670
 Ile Ala Arg His Leu Gly Ala Glu Ile Phe Ala Thr Ala Gly Thr Pro
 6675 6680 6685
 Glu Lys Arg Ala Trp Leu Arg Glu Gln Gly Ile Ala His Val Met Asp
 6690 6695 6700
 Ser Arg Ser Leu Asp Phe Ala Glu Gln Val Leu Ala Ala Thr Lys Gly
 6705 6710 6715 6720
 Glu Gly Val Asp Val Val Leu Asn Ser Leu Ser Gly Ala Ala Ile Asp
 6725 6730 6735
 Ala Ser Leu Ser Thr Leu Val Pro Asp Gly Arg Phe Ile Glu Leu Gly
 6740 6745 6750
 Lys Thr Asp Ile Tyr Ala Asp Arg Ser Leu Gly Leu Ala His Phe Arg
 6755 6760 6765
 Lys Ser Leu Ser Tyr Ser Ala Val Asp Leu Ala Gly Leu Ala Val Arg
 6770 6775 6780
 Arg Pro Glu Arg Val Ala Ala Leu Leu Ala Glu Val Val Asp Leu Leu
 6785 6790 6795 6800
 Ala Arg Gly Ala Leu Gln Pro Leu Pro Val Glu Ile Phe Pro Leu Ser
 6805 6810 6815
 Arg Ala Ala Asp Ala Phe Arg Lys Met Ala Gln Ala Gln His Leu Gly
 6820 6825 6830
 Lys Leu Val Leu Ala Leu Glu Asp Pro Asp Val Arg Ile Arg Val Pro
 6835 6840 6845
 Gly Glu Ser Gly Val Ala Ile Arg Ala Asp Gly Ala Tyr Leu Val Thr
 6850 6855 6860
 Gly Gly Leu Gly Gly Leu Gly Leu Ser Val Ala Gly Trp Leu Ala Glu
 6865 6870 6875 6880
 Gln Gly Ala Gly His Leu Val Leu Val Gly Arg Ser Gly Ala Val Ser
 6885 6890 6895
 Ala Glu Gln Gln Thr Ala Val Ala Ala Leu Glu Ala His Gly Ala Arg
 6900 6905 6910
 Val Thr Val Ala Arg Ala Asp Val Ala Asp Arg Ala Gln Met Glu Arg
 6915 6920 6925
 Ile Leu Arg Glu Val Thr Ala Ser Gly Met Pro Leu Arg Gly Val Val
 6930 6935 6940
 His Ala Ala Gly Ile Leu Asp Asp Gly Leu Leu Met Gln Gln Thr Pro
 6945 6950 6955 6960
 Ala Arg Phe Arg Ala Val Met Ala Pro Lys Val Arg Gly Ala Leu His

- 53 -

6965	6970	6975
Leu His Ala Leu Thr Arg Glu Ala Pro Leu Ser Phe Phe Val Leu Tyr 6980 6985 6990		
Ala Ser Gly Ala Gly Leu Leu Gly Ser Pro Gly Gln Gly Asn Tyr Ala 6995 7000 7005		
Ala Ala Asn Thr Phe Leu Asp Ala Leu Ala His His Arg Arg Ala Gln 7010 7015 7020		
Gly Leu Pro Ala Leu Ser Ile Asp Trp Gly Leu Phe Ala Asp Val Gly 7025 7030 7035 7040		
Leu Ala Ala Gly Gln Gln Asn Arg Gly Ala Arg Leu Val Thr Arg Gly 7045 7050 7055		
Thr Arg Ser Leu Thr Pro Asp Glu Gly Leu Trp Ala Leu Glu Arg Leu 7060 7065 7070		
Leu Asp Gly Asp Arg Thr Gln Ala Gly Val Met Pro Phe Asp Val Arg 7075 7080 7085		
Gln Trp Val Glu Phe Tyr Pro Ala Ala Ala Ser Ser Arg Arg Leu Ser 7090 7095 7100		
Arg Leu Met Thr Ala Arg Arg Val Ala Ser Gly Arg Leu Ala Gly Asp 7105 7110 7115 7120		
Arg Asp Leu Leu Glu Arg Leu Ala Thr Ala Glu Ala Gly Ala Arg Ala 7125 7130 7135		
Gly Met Leu Gln Glu Val Val Arg Ala Gln Val Ser Gln Val Leu Arg 7140 7145 7150		
Leu Ser Glu Gly Lys Leu Asp Val Asp Ala Pro Leu Thr Ser Leu Gly 7155 7160 7165		
Met Asp Ser Leu Met Gly Leu Glu Leu Arg Asn Arg Ile Glu Ala Val 7170 7175 7180		
Leu Gly Ile Thr Met Pro Ala Thr Leu Leu Trp Thr Tyr Pro Thr Val 7185 7190 7195 7200		
Ala Ala Leu Ser Ala His Leu Ala Ser His Val Val Ser Thr Gly Asp 7205 7210 7215		
Gly Glu Ser Ala Arg Pro Pro Asp Thr Gly Ser Val Ala Pro Thr Thr 7220 7225 7230		
His Glu Val Ala Ser Leu Asp Glu Asp Gly Leu Phe Ala Leu Ile Asp 7235 7240 7245		
Glu Ser Leu Ala Arg Ala Gly Lys Arg 7250 7255		

<210> 6
 <211> 3798
 <212> PRT
 <213> Sorangium cellulosum

<400> 6
 Val Thr Asp Arg Glu Gly Gln Leu Leu Glu Arg Leu Arg Glu Val Thr
 1 5 10 15

- 54 -

Leu Ala Leu Arg Lys Thr Leu Asn Glu Arg Asp Thr Leu Glu Leu Glu
 20 25 30
 Lys Thr Glu Pro Ile Ala Ile Val Gly Ile Gly Cys Arg Phe Pro Gly
 35 40 45
 Gly Ala Gly Thr Pro Glu Ala Phe Trp Glu Leu Leu Asp Asp Gly Arg
 50 55 60
 Asp Ala Ile Arg Pro Leu Glu Glu Arg Trp Ala Leu Val Gly Val Asp
 65 70 75 80
 Pro Gly Asp Asp Val Pro Arg Trp Ala Gly Leu Leu Thr Glu Ala Ile
 85 90 95
 Asp Gly Phe Asp Ala Ala Phe Phe Gly Ile Ala Pro Arg Glu Ala Arg
 100 105 110
 Ser Leu Asp Pro Gln His Arg Leu Leu Leu Glu Val Ala Trp Glu Gly
 115 120 125
 Phe Glu Asp Ala Gly Ile Pro Pro Arg Ser Leu Val Gly Ser Arg Thr
 130 135 140
 Gly Val Phe Val Gly Val Cys Ala Thr Glu Tyr Leu His Ala Ala Val
 145 150 155 160
 Ala His Gln Pro Arg Glu Glu Arg Asp Ala Tyr Ser Thr Thr Gly Asn
 165 170 175
 Met Leu Ser Ile Ala Ala Gly Arg Leu Ser Tyr Thr Leu Gly Leu Gln
 180 185 190
 Gly Pro Cys Leu Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala
 195 200 205
 Ile His Leu Ala Cys Arg Ser Leu Arg Ala Arg Glu Ser Asp Leu Ala
 210 215 220
 Leu Ala Gly Gly Val Asn Met Leu Leu Ser Pro Asp Thr Met Arg Ala
 225 230 235 240
 Leu Ala Arg Thr Gln Ala Leu Ser Pro Asn Gly Arg Cys Gln Thr Phe
 245 250 255
 Asp Ala Ser Ala Asn Gly Phe Val Arg Gly Glu Gly Cys Gly Leu Ile
 260 265 270
 Val Leu Lys Arg Leu Ser Asp Ala Arg Arg Asp Gly Asp Arg Ile Trp
 275 280 285
 Ala Leu Ile Arg Gly Ser Ala Ile Asn Gln Asp Gly Arg Ser Thr Gly
 290 295 300
 Leu Thr Ala Pro Asn Val Leu Ala Gln Gly Ala Leu Leu Arg Glu Ala
 305 310 315 320
 Leu Arg Asn Ala Gly Val Glu Ala Glu Ala Ile Gly Tyr Ile Glu Thr
 325 330 335
 His Gly Ala Ala Thr Ser Leu Gly Asp Pro Ile Glu Ile Glu Ala Leu
 340 345 350
 Arg Ala Val Val Gly Pro Ala Arg Ala Asp Gly Ala Arg Cys Val Leu

- 55 -

355	360	365
Gly Ala Val Lys Thr Asn Leu Gly His Leu Glu Gly Ala Ala Gly Val 370 375 380		
Ala Gly Leu Ile Lys Ala Thr Leu Ser Leu His His Glu Arg Ile Pro 385 390 395 400		
Arg Asn Leu Asn Phe Arg Thr Leu Asn Pro Arg Ile Arg Ile Glu Gly 405 410 415		
Thr Ala Leu Ala Leu Ala Thr Glu Pro Val Pro Trp Pro Arg Thr Gly 420 425 430		
Arg Thr Arg Phe Ala Gly Val Ser Ser Phe Gly Met Ser Gly Thr Asn 435 440 445		
Ala His Val Val Leu Glu Glu Ala Pro Ala Val Glu Pro Glu Ala Ala 450 455 460		
Ala Pro Glu Arg Ala Ala Glu Leu Phe Val Leu Ser Ala Lys Ser Ala 465 470 475 480		
Ala Ala Leu Asp Ala Gln Ala Ala Arg Leu Arg Asp His Leu Glu Lys 485 490 495		
His Val Glu Leu Gly Leu Gly Asp Val Ala Phe Ser Leu Ala Thr Thr 500 505 510		
Arg Ser Ala Met Glu His Arg Leu Ala Val Ala Ala Ser Ser Arg Glu 515 520 525		
Ala Leu Arg Gly Ala Leu Ser Ala Ala Ala Gln Gly His Thr Pro Pro 530 535 540		
Gly Ala Val Arg Gly Arg Ala Ser Gly Gly Ser Ala Pro Lys Val Val 545 550 555 560		
Phe Val Phe Pro Gly Gln Gly Ser Gln Trp Val Gly Met Gly Arg Lys 565 570 575		
Leu Met Ala Glu Glu Pro Val Phe Arg Ala Ala Leu Glu Gly Cys Asp 580 585 590		
Arg Ala Ile Glu Ala Glu Ala Gly Trp Ser Leu Leu Gly Glu Leu Ser 595 600 605		
Ala Asp Glu Ala Ala Ser Gln Leu Gly Arg Ile Asp Val Val Gln Pro 610 615 620		
Val Leu Phe Ala Met Glu Val Ala Leu Ser Ala Leu Trp Arg Ser Trp 625 630 635 640		
Gly Val Glu Pro Glu Ala Val Val Gly His Ser Met Gly Glu Val Ala 645 650 655		
Ala Ala His Val Ala Gly Ala Leu Ser Leu Glu Asp Ala Val Ala Ile 660 665 670		
Ile Cys Arg Arg Ser Arg Leu Leu Arg Arg Ile Ser Gly Gln Gly Glu 675 680 685		
Met Ala Leu Val Glu Leu Ser Leu Glu Glu Ala Glu Ala Ala Leu Arg 690 695 700		

- 56 -

Gly His Glu Gly Arg Leu Ser Val Ala Val Ser Asn Ser Pro Arg Ser
 705 710 715 720
 Thr Val Leu Ala Gly Glu Pro Ala Ala Leu Ser Glu Val Leu Ala Ala
 725 730 735
 Leu Thr Ala Lys Gly Val Phe Trp Arg Gln Val Lys Val Asp Val Ala
 740 745 750
 Ser His Ser Pro Gln Val Asp Pro Leu Arg Glu Glu Leu Ile Ala Ala
 755 760 765
 Leu Gly Ala Ile Arg Pro Arg Ala Ala Ala Val Pro Met Arg Ser Thr
 770 775 780
 Val Thr Gly Gly Val Ile Ala Gly Pro Glu Leu Gly Ala Ser Tyr Trp
 785 790 795 800
 Ala Asp Asn Leu Arg Gln Pro Val Arg Phe Ala Ala Ala Ala Gln Ala
 805 810 815
 Leu Leu Glu Gly Gly Pro Ala Leu Phe Ile Glu Met Ser Pro His Pro
 820 825 830
 Ile Leu Val Pro Pro Leu Asp Glu Ile Gln Thr Ala Ala Glu Gln Gly
 835 840 845
 Gly Ala Ala Val Gly Ser Leu Arg Arg Gly Gln Asp Glu Arg Ala Thr
 850 855 860
 Leu Leu Glu Ala Leu Gly Thr Leu Trp Ala Ser Gly Tyr Pro Val Ser
 865 870 875 880
 Trp Ala Arg Leu Phe Pro Ala Gly Gly Arg Arg Val Pro Leu Pro Thr
 885 890 895
 Tyr Pro Trp Gln His Glu Arg Cys Trp Ile Glu Val Glu Pro Asp Ala
 900 905 910
 Arg Arg Leu Ala Ala Ala Asp Pro Thr Lys Asp Trp Phe Tyr Arg Thr
 915 920 925
 Asp Trp Pro Glu Val Pro Arg Ala Ala Pro Lys Ser Glu Thr Ala His
 930 935 940
 Gly Ser Trp Leu Leu Leu Ala Asp Arg Gly Gly Val Gly Glu Ala Val
 945 950 955 960
 Ala Ala Ala Leu Ser Thr Arg Gly Leu Ser Cys Thr Val Leu His Ala
 965 970 975
 Ser Ala Asp Ala Ser Thr Val Ala Glu Gln Val Ser Glu Ala Ala Ser
 980 985 990
 Arg Arg Asn Asp Trp Gln Gly Val Leu Tyr Leu Trp Gly Leu Asp Ala
 995 1000 1005
 Val Val Asp Ala Gly Ala Ser Ala Asp Glu Val Ser Glu Ala Thr Arg
 1010 1015 1020
 Arg Ala Thr Ala Pro Val Leu Gly Leu Val Arg Phe Leu Ser Ala Ala
 1025 1030 1035 1040
 Pro His Pro Pro Arg Phe Trp Val Val Thr Arg Gly Ala Cys Thr Val
 1045 1050 1055

- 57 -

Gly Gly Glu Pro Glu Ala Ser Leu Cys Gln Ala Ala Leu Trp Gly Leu
 1060 1065 1070
 Ala Arg Val Ala Ala Leu Glu His Pro Ala Ala Trp Gly Gly Leu Val
 1075 1080 1085
 Asp Leu Asp Pro Gln Lys Ser Pro Thr Glu Ile Glu Pro Leu Val Ala
 1090 1095 1100
 Glu Leu Leu Ser Pro Asp Ala Glu Asp Gln Leu Ala Phe Arg Ser Gly
 1105 1110 1115 1120
 Arg Arg His Ala Ala Arg Leu Val Ala Ala Pro Pro Glu Gly Asp Val
 1125 1130 1135
 Ala Pro Ile Ser Leu Ser Ala Glu Gly Ser Tyr Leu Val Thr Gly Gly
 1140 1145 1150
 Leu Gly Gly Leu Gly Leu Leu Val Ala Arg Trp Leu Val Glu Arg Gly
 1155 1160 1165
 Ala Arg His Leu Val Leu Thr Ser Arg His Gly Leu Pro Glu Arg Gln
 1170 1175 1180
 Ala Ser Gly Gly Glu Gln Pro Pro Glu Ala Arg Ala Arg Ile Ala Ala
 1185 1190 1195 1200
 Val Glu Gly Leu Glu Ala Gln Gly Ala Arg Val Thr Val Ala Ala Val
 1205 1210 1215
 Asp Val Ala Glu Ala Asp Pro Met Thr Ala Leu Leu Ala Ala Ile Glu
 1220 1225 1230
 Pro Pro Leu Arg Gly Val Val His Ala Ala Gly Val Phe Pro Val Arg
 1235 1240 1245
 His Leu Ala Glu Thr Asp Glu Ala Leu Leu Glu Ser Val Leu Arg Pro
 1250 1255 1260
 Lys Val Ala Gly Ser Trp Leu Leu His Arg Leu Leu Arg Asp Arg Pro
 1265 1270 1275 1280
 Leu Asp Leu Phe Val Leu Phe Ser Ser Gly Ala Ala Val Trp Gly Gly
 1285 1290 1295
 Lys Gly Gln Gly Ala Tyr Ala Ala Ala Asn Ala Phe Leu Asp Gly Leu
 1300 1305 1310
 Ala His His Arg Arg Ala His Ser Leu Pro Ala Leu Ser Leu Ala Trp
 1315 1320 1325
 Gly Leu Trp Ala Glu Gly Gly Met Val Asp Ala Lys Ala His Ala Arg
 1330 1335 1340
 Leu Ser Asp Ile Gly Val Leu Pro Met Ala Thr Gly Pro Ala Leu Ser
 1345 1350 1355 1360
 Ala Leu Glu Arg Leu Val Asn Thr Ser Ala Val Gln Arg Ser Val Thr
 1365 1370 1375
 Arg Met Asp Trp Ala Arg Phe Ala Pro Val Tyr Ala Ala Arg Gly Arg
 1380 1385 1390
 Arg Asn Leu Leu Ser Ala Leu Val Ala Glu Asp Glu Arg Ala Ala Ser

- 58 -

1395	1400	1405
Pro Pro Val Pro Thr Ala Asn Arg Ile Trp Arg Gly Leu Ser Val Ala 1410 1415 1420		
Glu Ser Arg Ser Ala Leu Tyr Glu Leu Val Arg Gly Ile Val Ala Arg 1425 1430 1435 1440		
Val Leu Gly Phe Ser Asp Pro Gly Ala Leu Asp Val Gly Arg Gly Phe 1445 1450 1455		
Ala Glu Gln Gly Leu Asp Ser Leu Met Ala Leu Glu Ile Arg Asn Arg 1460 1465 1470		
Leu Gln Arg Glu Leu Gly Glu Arg Leu Ser Ala Thr Leu Ala Phe Asp 1475 1480 1485		
His Pro Thr Val Glu Arg Leu Val Ala His Leu Leu Thr Asp Val Leu 1490 1495 1500		
Lys Leu Glu Asp Arg Ser Asp Thr Arg His Ile Arg Ser Val Ala Ala 1505 1510 1515 1520		
Asp Asp Asp Ile Ala Ile Val Gly Ala Ala Cys Arg Phe Pro Gly Gly 1525 1530 1535		
Asp Glu Gly Leu Glu Thr Tyr Trp Arg His Leu Ala Glu Gly Met Val 1540 1545 1550		
Val Ser Thr Glu Val Pro Ala Asp Arg Trp Arg Ala Ala Asp Trp Tyr 1555 1560 1565		
Asp Pro Asp Pro Glu Val Pro Gly Arg Thr Tyr Val Ala Lys Gly Ala 1570 1575 1580		
Phe Leu Arg Asp Val Arg Ser Leu Asp Ala Ala Phe Phe Ala Ile Ser 1585 1590 1595 1600		
Pro Arg Glu Ala Met Ser Leu Asp Pro Gln Gln Arg Leu Leu Leu Glu 1605 1610 1615		
Val Ser Trp Glu Ala Ile Glu Arg Ala Gly Gln Asp Pro Met Ala Leu 1620 1625 1630		
Arg Glu Ser Ala Thr Gly Val Phe Val Gly Met Ile Gly Ser Glu His 1635 1640 1645		
Ala Glu Arg Val Gln Gly Leu Asp Asp Asp Ala Ala Leu Leu Tyr Gly 1650 1655 1660		
Thr Thr Gly Asn Leu Leu Ser Val Ala Ala Gly Arg Leu Ser Phe Phe 1665 1670 1675 1680		
Leu Gly Leu His Gly Pro Thr Met Thr Val Asp Thr Ala Cys Ser Ser 1685 1690 1695		
Ser Leu Val Ala Leu His Leu Ala Cys Gln Ser Leu Arg Leu Gly Glu 1700 1705 1710		
Cys Asp Gln Ala Leu Ala Gly Gly Ser Ser Val Leu Leu Ser Pro Arg 1715 1720 1725		
Ser Phe Val Ala Ala Ser Arg Met Arg Leu Leu Ser Pro Asp Gly Arg 1730 1735 1740		

- 59 -

Cys Lys Thr Phe Ser Ala Ala Ala Asp Gly Phe Ala Arg Ala Glu Gly
 1745 1750 1755 1760
 Cys Ala Val Val Val Leu Lys Arg Leu Arg Asp Ala Gln Arg Asp Arg
 1765 1770 1775
 Asp Pro Ile Leu Ala Val Val Arg Ser Thr Ala Ile Asn His Asp Gly
 1780 1785 1790
 Pro Ser Ser Gly Leu Thr Val Pro Ser Gly Pro Ala Gln Gln Ala Leu
 1795 1800 1805
 Leu Arg Gln Ala Leu Ala Gln Ala Gly Val Ala Pro Ala Glu Val Asp
 1810 1815 1820
 Phe Val Glu Cys His Gly Thr Gly Thr Ala Leu Gly Asp Pro Ile Glu
 1825 1830 1835 1840
 Val Gln Ala Leu Gly Ala Val Tyr Gly Arg Gly Arg Pro Ala Glu Arg
 1845 1850 1855
 Pro Leu Trp Leu Gly Ala Val Lys Ala Asn Leu Gly His Leu Glu Ala
 1860 1865 1870
 Ala Ala Gly Leu Ala Gly Val Leu Lys Val Leu Leu Ala Leu Glu His
 1875 1880 1885
 Glu Gln Ile Pro Ala Gln Pro Glu Leu Asp Glu Leu Asn Pro His Ile
 1890 1895 1900
 Pro Trp Ala Glu Leu Pro Val Ala Val Val Arg Arg Ala Val Pro Trp
 1905 1910 1915 1920
 Pro Arg Gly Ala Arg Pro Arg Arg Ala Gly Val Ser Ala Phe Gly Leu
 1925 1930 1935
 Ser Gly Thr Asn Ala His Val Val Leu Glu Glu Ala Pro Ala Val Glu
 1940 1945 1950
 Pro Val Ala Ala Ala Pro Glu Arg Ala Ala Glu Leu Phe Val Leu Ser
 1955 1960 1965
 Ala Lys Ser Ala Ala Ala Leu Asp Ala Gln Ala Ala Arg Leu Arg Asp
 1970 1975 1980
 His Leu Glu Lys His Val Glu Leu Gly Leu Gly Asp Val Ala Phe Ser
 1985 1990 1995 2000
 Leu Ala Thr Thr Arg Ser Ala Met Glu His Arg Leu Ala Val Ala Ala
 2005 2010 2015
 Ser Ser Arg Glu Ala Leu Arg Gly Ala Leu Ser Ala Ala Ala Gln Gly
 2020 2025 2030
 His Thr Pro Pro Gly Ala Val Arg Gly Arg Ala Ser Gly Gly Ser Ala
 2035 2040 2045
 Pro Lys Val Val Phe Val Phe Pro Gly Gln Gly Ser Gln Trp Val Gly
 2050 2055 2060
 Met Gly Arg Lys Leu Met Ala Glu Glu Pro Val Phe Arg Ala Ala Leu
 2065 2070 2075 2080
 Glu Gly Cys Asp Arg Ala Ile Glu Ala Glu Ala Gly Trp Ser Leu Leu
 2085 2090 2095

- 60 -

Gly Glu Leu Ser Ala Asp Glu Ala Ala Ser Gln Leu Gly Arg Ile Asp
 2100 2105 2110
 Val Val Gln Pro Val Leu Phe Ala Met Glu Val Ala Leu Ser Ala Leu
 2115 2120 2125
 Trp Arg Ser Trp Gly Val Glu Pro Glu Ala Val Val Gly His Ser Met
 2130 2135 2140
 Gly Glu Val Ala Ala Ala His Val Ala Gly Ala Leu Ser Leu Glu Asp
 2145 2150 2155 2160
 Ala Val Ala Ile Ile Cys Arg Arg Ser Arg Leu Leu Arg Arg Ile Ser
 2165 2170 2175
 Gly Gln Gly Glu Met Ala Leu Val Glu Leu Ser Leu Glu Glu Ala Glu
 2180 2185 2190
 Ala Ala Leu Arg Gly His Glu Gly Arg Leu Ser Val Ala Val Ser Asn
 2195 2200 2205
 Ser Pro Arg Ser Thr Val Leu Ala Gly Glu Pro Ala Ala Leu Ser Glu
 2210 2215 2220
 Val Leu Ala Ala Leu Thr Ala Lys Gly Val Phe Trp Arg Gln Val Lys
 2225 2230 2235 2240
 Val Asp Val Ala Ser His Ser Pro Gln Val Asp Pro Leu Arg Glu Glu
 2245 2250 2255
 Leu Ile Ala Ala Leu Gly Ala Ile Arg Pro Arg Ala Ala Ala Val Pro
 2260 2265 2270
 Met Arg Ser Thr Val Thr Gly Gly Val Ile Ala Gly Pro Glu Leu Gly
 2275 2280 2285
 Ala Ser Tyr Trp Ala Asp Asn Leu Arg Gln Pro Val Arg Phe Ala Ala
 2290 2295 2300
 Ala Ala Gln Ala Leu Leu Glu Gly Gly Pro Ala Leu Phe Ile Glu Met
 2305 2310 2315 2320
 Ser Pro His Pro Ile Leu Val Pro Pro Leu Asp Glu Ile Gln Thr Ala
 2325 2330 2335
 Ala Glu Gln Gly Gly Ala Ala Val Gly Ser Leu Arg Arg Gly Gln Asp
 2340 2345 2350
 Glu Arg Ala Thr Leu Leu Glu Ala Leu Gly Thr Leu Trp Ala Ser Gly
 2355 2360 2365
 Tyr Pro Val Ser Trp Ala Arg Leu Phe Pro Ala Gly Gly Arg Arg Val
 2370 2375 2380
 Pro Leu Pro Thr Tyr Pro Trp Gln His Glu Arg Tyr Trp Ile Glu Asp
 2385 2390 2395 2400
 Ser Val His Gly Ser Lys Pro Ser Leu Arg Leu Arg Gln Leu Arg Asn
 2405 2410 2415
 Gly Ala Thr Asp His Pro Leu Leu Gly Ala Pro Leu Leu Val Ser Ala
 2420 2425 2430
 Arg Pro Gly Ala His Leu Trp Glu Gln Ala Leu Ser Asp Glu Arg Leu

- 61 -

2435	2440	2445
Ser Tyr Leu Ser Glu His Arg Val His Gly Glu Ala Val Leu Pro Ser		
2450	2455	2460
Ala Ala Tyr Val Glu Met Ala Leu Ala Ala Gly Val Asp Leu Tyr Gly		
2465	2470	2475 2480
Thr Ala Thr Leu Val Leu Glu Gln Leu Ala Leu Glu Arg Ala Leu Ala		
	2485	2490 2495
Val Pro Ser Glu Gly Gly Arg Ile Val Gln Val Ala Leu Ser Glu Glu		
	2500	2505 2510
Gly Pro Gly Arg Ala Ser Phe Gln Val Ser Ser Arg Glu Glu Ala Gly		
	2515	2520 2525
Arg Ser Trp Val Arg His Ala Thr Gly His Val Cys Ser Gly Gln Ser		
	2530	2535 2540
Ser Ala Val Gly Ala Leu Lys Glu Ala Pro Trp Glu Ile Gln Arg Arg		
2545	2550	2555 2560
Cys Pro Ser Val Leu Ser Ser Glu Ala Leu Tyr Pro Leu Leu Asn Glu		
	2565	2570 2575
His Ala Leu Asp Tyr Gly Pro Cys Phe Gln Gly Val Glu Gln Val Trp		
	2580	2585 2590
Leu Gly Thr Gly Glu Val Leu Gly Arg Val Arg Leu Pro Gly Asp Met		
	2595	2600 2605
Ala Ser Ser Ser Gly Ala Tyr Arg Ile His Pro Ala Leu Leu Asp Ala		
	2610	2615 2620
Cys Phe Gln Val Leu Thr Ala Leu Leu Thr Thr Pro Glu Ser Ile Glu		
2625	2630	2635 2640
Ile Arg Arg Arg Leu Thr Asp Leu His Glu Pro Asp Leu Pro Arg Ser		
	2645	2650 2655
Arg Ala Pro Val Asn Gln Ala Val Ser Asp Thr Trp Leu Trp Asp Ala		
	2660	2665 2670
Ala Leu Asp Gly Gly Arg Arg Gln Ser Ala Ser Val Pro Val Asp Leu		
	2675	2680 2685
Val Leu Gly Ser Phe His Ala Lys Trp Glu Val Met Glu Arg Leu Ala		
	2690	2695 2700
Gln Ala Tyr Ile Ile Gly Thr Leu Arg Ile Trp Asn Val Phe Cys Ala		
2705	2710	2715 2720
Ala Gly Glu Arg His Thr Ile Asp Glu Leu Leu Val Arg Leu Gln Ile		
	2725	2730 2735
Ser Val Val Tyr Arg Lys Val Ile Lys Arg Trp Met Glu His Leu Val		
	2740	2745 2750
Ala Ile Gly Ile Leu Val Gly Asp Gly Glu His Phe Val Ser Ser Gln		
	2755	2760 2765
Pro Leu Pro Glu Pro Asp Leu Ala Ala Val Leu Glu Glu Ala Gly Arg		
	2770	2775 2780

- 62 -

Val Phe Ala Asp Leu Pro Val Leu Phe Glu Trp Cys Lys Phe Ala Gly
 2785 2790 2795 2800
 Glu Arg Leu Ala Asp Val Leu Thr Gly Lys Thr Leu Ala Leu Glu Ile
 2805 2810 2815
 Leu Phe Pro Gly Gly Ser Phe Asp Met Ala Glu Arg Ile Tyr Arg Asp
 2820 2825 2830
 Ser Pro Ile Ala Arg Tyr Ser Asn Gly Ile Val Arg Gly Val Val Glu
 2835 2840 2845
 Ser Ala Ala Arg Val Val Ala Pro Ser Gly Met Phe Ser Ile Leu Glu
 2850 2855 2860
 Ile Gly Ala Gly Thr Gly Ala Thr Thr Ala Ala Val Leu Pro Val Leu
 2865 2870 2875 2880
 Leu Pro Asp Arg Thr Glu Tyr His Phe Thr Asp Val Ser Pro Leu Phe
 2885 2890 2895
 Leu Ala Arg Ala Glu Gln Arg Phe Arg Asp Tyr Pro Phe Leu Lys Tyr
 2900 2905 2910
 Gly Ile Leu Asp Val Asp Gln Glu Pro Ala Gly Gln Gly Tyr Ala His
 2915 2920 2925
 Gln Arg Phe Asp Val Ile Val Ala Ala Asn Val Ile His Ala Thr Arg
 2930 2935 2940
 Asp Ile Arg Ala Thr Ala Lys Arg Leu Leu Ser Leu Leu Ala Pro Gly
 2945 2950 2955 2960
 Gly Leu Leu Val Leu Val Glu Gly Thr Gly His Pro Ile Trp Phe Asp
 2965 2970 2975
 Ile Thr Thr Gly Leu Ile Glu Gly Trp Gln Lys Tyr Glu Asp Asp Leu
 2980 2985 2990
 Arg Ile Asp His Pro Leu Leu Pro Ala Arg Thr Trp Cys Asp Val Leu
 2995 3000 3005
 Arg Arg Val Gly Phe Ala Asp Ala Val Ser Leu Pro Gly Asp Gly Ser
 3010 3015 3020
 Pro Ala Gly Ile Leu Gly Gln His Val Ile Leu Ser Arg Ala Pro Gly
 3025 3030 3035 3040
 Ile Ala Gly Ala Ala Cys Asp Ser Ser Gly Glu Ser Ala Thr Glu Ser
 3045 3050 3055
 Pro Ala Ala Arg Ala Val Arg Gln Glu Trp Ala Asp Gly Ser Ala Asp
 3060 3065 3070
 Val Val His Arg Met Ala Leu Glu Arg Met Tyr Phe His Arg Arg Pro
 3075 3080 3085
 Gly Arg Gln Val Trp Val His Gly Arg Leu Arg Thr Gly Gly Gly Ala
 3090 3095 3100
 Phe Thr Lys Ala Leu Ala Gly Asp Leu Leu Leu Phe Glu Asp Thr Gly
 3105 3110 3115 3120
 Gln Val Val Ala Glu Val Gln Gly Leu Arg Leu Pro Gln Leu Glu Ala
 3125 3130 3135

- 63 -

Ser Ala Phe Ala Pro Arg Asp Pro Arg Glu Glu Trp Leu Tyr Ala Leu
 3140 3145 3150
 Glu Trp Gln Arg Lys Asp Pro Ile Pro Glu Ala Pro Ala Ala Ser
 3155 3160 3165
 Ser Ser Ser Ala Gly Ala Trp Leu Val Leu Met Asp Gln Gly Gly Thr
 3170 3175 3180
 Gly Ala Ala Leu Val Ser Leu Leu Glu Gly Arg Gly Glu Ala Cys Val
 3185 3190 3195 3200
 Arg Val Ile Ala Gly Thr Ala Tyr Ala Cys Leu Ala Pro Gly Leu Tyr
 3205 3210 3215
 Gln Val Asp Pro Ala Gln Pro Asp Gly Phe His Thr Leu Leu Arg Asp
 3220 3225 3230
 Ala Phe Gly Glu Asp Arg Ile Cys Arg Ala Val Val His Met Trp Ser
 3235 3240 3245
 Leu Asp Ala Thr Ala Ala Gly Glu Arg Ala Thr Ala Glu Ser Leu Gln
 3250 3255 3260
 Ala Asp Gln Leu Leu Gly Ser Leu Ser Ala Leu Ser Leu Val Gln Ala
 3265 3270 3275 3280
 Leu Val Arg Arg Arg Trp Arg Asn Met Pro Arg Leu Trp Leu Leu Thr
 3285 3290 3295
 Arg Ala Val His Ala Val Gly Ala Glu Asp Ala Ala Ala Ser Val Ala
 3300 3305 3310
 Gln Ala Pro Val Trp Gly Leu Gly Arg Thr Leu Ala Leu Glu His Pro
 3315 3320 3325
 Glu Leu Arg Cys Thr Leu Val Asp Val Asn Pro Ala Pro Ser Pro Glu
 3330 3335 3340
 Asp Ala Ala Ala Leu Ala Val Glu Leu Gly Ala Ser Asp Arg Glu Asp
 3345 3350 3355 3360
 Gln Val Ala Leu Arg Ser Asp Gly Arg Tyr Val Ala Arg Leu Val Arg
 3365 3370 3375
 Ser Ser Phe Ser Gly Lys Pro Ala Thr Asp Cys Gly Ile Arg Ala Asp
 3380 3385 3390
 Gly Ser Tyr Val Ile Thr Asp Gly Met Gly Arg Val Gly Leu Ser Val
 3395 3400 3405
 Ala Gln Trp Met Val Met Gln Gly Ala Arg His Val Val Leu Val Asp
 3410 3415 3420
 Arg Gly Gly Ala Ser Glu Ala Ser Arg Asp Ala Leu Arg Ser Met Ala
 3425 3430 3435 3440
 Glu Ala Gly Ala Glu Val Gln Ile Val Glu Ala Asp Val Ala Arg Arg
 3445 3450 3455
 Asp Asp Val Ala Arg Leu Leu Ser Lys Ile Glu Pro Ser Met Pro Pro
 3460 3465 3470
 Leu Arg Gly Ile Val Tyr Val Asp Gly Thr Phe Gln Gly Asp Ser Ser

- 64 -

3475 3480 3485
 Met Leu Glu Leu Asp Ala Arg Arg Phe Lys Glu Trp Met Tyr Pro Lys
 3490 3495 3500
 Val Leu Gly Ala Trp Asn Leu His Ala Leu Thr Arg Asp Arg Ser Leu
 3505 3510 3515 3520
 Asp Phe Phe Val Leu Tyr Ser Ser Gly Thr Ser Leu Leu Gly Leu Pro
 3525 3530 3535
 Gly Gln Gly Ser Arg Ala Ala Gly Asp Ala Phe Leu Asp Ala Ile Ala
 3540 3545 3550
 His His Arg Cys Lys Val Gly Leu Thr Ala Met Ser Ile Asn Trp Gly
 3555 3560 3565
 Leu Leu Ser Glu Ala Ser Ser Pro Ala Thr Pro Asn Asp Gly Gly Ala
 3570 3575 3580
 Arg Leu Glu Tyr Arg Gly Met Glu Gly Leu Thr Leu Glu Gln Gly Ala
 3585 3590 3595 3600
 Ala Ala Leu Gly Arg Leu Leu Ala Arg Pro Arg Ala Gln Val Gly Val
 3605 3610 3615
 Met Arg Leu Asn Leu Arg Gln Trp Leu Glu Phe Tyr Pro Asn Ala Ala
 3620 3625 3630
 Arg Leu Ala Leu Trp Ala Glu Leu Leu Lys Glu Arg Asp Arg Ala Asp
 3635 3640 3645
 Arg Gly Ala Ser Asn Ala Ser Asn Leu Arg Glu Ala Leu Gln Ser Ala
 3650 3655 3660
 Arg Pro Glu Asp Arg Gln Leu Ile Leu Glu Lys His Leu Ser Glu Leu
 3665 3670 3675 3680
 Leu Gly Arg Gly Leu Arg Leu Pro Pro Glu Arg Ile Glu Arg His Val
 3685 3690 3695
 Pro Phe Ser Asn Leu Gly Met Asp Ser Leu Ile Gly Leu Glu Leu Arg
 3700 3705 3710
 Asn Arg Ile Glu Ala Ala Leu Gly Ile Thr Val Pro Ala Thr Leu Leu
 3715 3720 3725
 Trp Thr Tyr Pro Asn Val Ala Ala Leu Ser Gly Ser Leu Leu Asp Ile
 3730 3735 3740
 Leu Phe Pro Asn Ala Gly Ala Thr His Ala Pro Ala Thr Glu Arg Glu
 3745 3750 3755 3760
 Lys Ser Phe Glu Asn Asp Ala Ala Asp Leu Glu Ala Leu Arg Gly Met
 3765 3770 3775
 Thr Asp Glu Gln Lys Asp Ala Leu Leu Ala Glu Lys Leu Ala Gln Leu
 3780 3785 3790
 Ala Gln Ile Val Gly Glu
 3795

<210> 7

<211> 2439

- 65 -

<212> PRT

<213> Sorangium cellulosum

<400> 7

```

Met Ala Thr Thr Asn Ala Gly Lys Leu Glu His Ala Leu Leu Leu Met
 1          5          10          15

Asp Lys Leu Ala Lys Lys Asn Ala Ser Leu Glu Gln Glu Arg Thr Glu
          20          25          30

Pro Ile Ala Ile Val Gly Ile Gly Cys Arg Phe Pro Gly Gly Ala Asp
 35          40          45

Thr Pro Glu Ala Phe Trp Glu Leu Leu Asp Ser Gly Arg Asp Ala Val
 50          55          60

Gln Pro Leu Asp Arg Arg Trp Ala Leu Val Gly Val His Pro Ser Glu
 65          70          75          80

Glu Val Pro Arg Trp Ala Gly Leu Leu Thr Glu Ala Val Asp Gly Phe
          85          90          95

Asp Ala Ala Phe Phe Gly Thr Ser Pro Arg Glu Ala Arg Ser Leu Asp
          100          105          110

Pro Gln Gln Arg Leu Leu Leu Glu Val Thr Trp Glu Gly Leu Glu Asp
          115          120          125

Ala Gly Ile Ala Pro Gln Ser Leu Asp Gly Ser Arg Thr Gly Val Phe
 130          135          140

Leu Gly Ala Cys Ser Ser Asp Tyr Ser His Thr Val Ala Gln Gln Arg
 145          150          155          160

Arg Glu Glu Gln Asp Ala Tyr Asp Ile Thr Gly Asn Thr Leu Ser Val
          165          170          175

Ala Ala Gly Arg Leu Ser Tyr Thr Leu Gly Leu Gln Gly Pro Cys Leu
          180          185          190

Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Val Ala Ile His Leu Ala
 195          200          205

Cys Arg Ser Leu Arg Ala Arg Glu Ser Asp Leu Ala Leu Ala Gly Gly
 210          215          220

Val Asn Met Leu Leu Ser Ser Lys Thr Met Ile Met Leu Gly Arg Ile
 225          230          235          240

Gln Ala Leu Ser Pro Asp Gly His Cys Arg Thr Phe Asp Ala Ser Ala
          245          250          255

Asn Gly Phe Val Arg Gly Glu Gly Cys Gly Met Val Val Leu Lys Arg
          260          265          270

Leu Ser Asp Ala Gln Arg His Gly Asp Arg Ile Trp Ala Leu Ile Arg
          275          280          285

Gly Ser Ala Met Asn Gln Asp Gly Arg Ser Thr Gly Leu Met Ala Pro
 290          295          300

Asn Val Leu Ala Gln Glu Ala Leu Leu Arg Glu Ala Leu Gln Ser Ala
 305          310          315          320

Arg Val Asp Ala Gly Ala Ile Gly Tyr Val Glu Thr His Gly Thr Gly

```

- 66 -

325										330					335				
Thr	Ser	Leu	Gly	Asp	Pro	Ile	Glu	Val	Glu	Ala	Leu	Arg	Ala	Val	Leu				
			340						345					350					
Gly	Pro	Ala	Arg	Ala	Asp	Gly	Ser	Arg	Cys	Val	Leu	Gly	Ala	Val	Lys				
		355					360					365							
Thr	Asn	Leu	Gly	His	Leu	Glu	Gly	Ala	Ala	Gly	Val	Ala	Gly	Leu	Ile				
	370					375					380								
Lys	Ala	Ala	Leu	Ala	Leu	His	His	Glu	Leu	Ile	Pro	Arg	Asn	Leu	His				
	385				390					395				400					
Phe	His	Thr	Leu	Asn	Pro	Arg	Ile	Arg	Ile	Glu	Gly	Thr	Ala	Leu	Ala				
				405					410					415					
Leu	Ala	Thr	Glu	Pro	Val	Pro	Trp	Pro	Arg	Ala	Gly	Arg	Pro	Arg	Phe				
			420					425					430						
Ala	Gly	Val	Ser	Ala	Phe	Gly	Leu	Ser	Gly	Thr	Asn	Val	His	Val	Val				
		435					440					445							
Leu	Glu	Glu	Ala	Pro	Ala	Thr	Val	Leu	Ala	Pro	Ala	Thr	Pro	Gly	Arg				
	450					455					460								
Ser	Ala	Glu	Leu	Leu	Val	Leu	Ser	Ala	Lys	Ser	Ala	Ala	Ala	Leu	Asp				
	465				470				475					480					
Ala	Gln	Ala	Ala	Arg	Leu	Ser	Ala	His	Ile	Ala	Ala	Tyr	Pro	Glu	Gln				
				485					490					495					
Gly	Leu	Gly	Asp	Val	Ala	Phe	Ser	Leu	Val	Ser	Thr	Arg	Ser	Pro	Met				
			500					505					510						
Glu	His	Arg	Leu	Ala	Val	Ala	Ala	Thr	Ser	Arg	Glu	Ala	Leu	Arg	Ser				
		515					520					525							
Ala	Leu	Glu	Val	Ala	Ala	Gln	Gly	Gln	Thr	Pro	Ala	Gly	Ala	Ala	Arg				
	530					535					540								
Gly	Arg	Ala	Ala	Ser	Ser	Pro	Gly	Lys	Leu	Ala	Phe	Leu	Phe	Ala	Gly				
	545				550					555					560				
Gln	Gly	Ala	Gln	Val	Pro	Gly	Met	Gly	Arg	Gly	Leu	Trp	Glu	Ala	Trp				
			565						570				575						
Pro	Ala	Phe	Arg	Glu	Thr	Phe	Asp	Arg	Cys	Val	Thr	Leu	Phe	Asp	Arg				
			580				585						590						
Glu	Leu	His	Gln	Pro	Leu	Cys	Glu	Val	Met	Trp	Ala	Glu	Pro	Gly	Ser				
		595					600					605							
Ser	Arg	Ser	Ser	Leu	Leu	Asp	Gln	Thr	Ala	Phe	Thr	Gln	Pro	Ala	Leu				
	610					615					620								
Phe	Ala	Leu	Glu	Tyr	Ala	Leu	Ala	Ala	Leu	Phe	Arg	Ser	Trp	Gly	Val				
	625				630					635				640					
Glu	Pro	Glu	Leu	Val	Ala	Gly	His	Ser	Leu	Gly	Glu	Leu	Val	Ala	Ala				
			645						650					655					
Cys	Val	Ala	Gly	Val	Phe	Ser	Leu	Glu	Asp	Ala	Val	Arg	Leu	Val	Val				
			660					665					670						

- 67 -

Ala Arg Gly Arg Leu Met Gln Ala Leu Pro Ala Gly Gly Ala Met Val
 675 680 685
 Ser Ile Ala Ala Pro Glu Ala Asp Val Ala Ala Ala Val Ala Pro His
 690 695 700
 Ala Ala Leu Val Ser Ile Ala Ala Val Asn Gly Pro Glu Gln Val Val
 705 710 715 720
 Ile Ala Gly Ala Glu Lys Phe Val Gln Gln Ile Ala Ala Ala Phe Ala
 725 730 735
 Ala Arg Gly Ala Arg Thr Lys Pro Leu His Val Ser His Ala Phe His
 740 745 750
 Ser Pro Leu Met Asp Pro Met Leu Glu Ala Phe Arg Arg Val Thr Glu
 755 760 765
 Ser Val Thr Tyr Arg Arg Pro Ser Ile Ala Leu Val Ser Asn Leu Ser
 770 775 780
 Gly Lys Pro Cys Thr Asp Glu Val Ser Ala Pro Gly Tyr Trp Val Arg
 785 790 795 800
 His Ala Arg Glu Ala Val Arg Phe Ala Asp Gly Val Lys Ala Leu His
 805 810 815
 Ala Ala Gly Ala Gly Leu Phe Val Glu Val Gly Pro Lys Pro Thr Leu
 820 825 830
 Leu Gly Leu Val Pro Ala Cys Leu Pro Asp Ala Arg Pro Val Leu Leu
 835 840 845
 Pro Ala Ser Arg Ala Gly Arg Asp Glu Ala Ala Ser Ala Leu Glu Ala
 850 855 860
 Leu Gly Gly Phe Trp Val Val Gly Gly Ser Val Thr Trp Ser Gly Val
 865 870 875 880
 Phe Pro Ser Gly Gly Arg Arg Val Pro Leu Pro Thr Tyr Pro Trp Gln
 885 890 895
 Arg Glu Arg Tyr Trp Ile Glu Ala Pro Val Asp Arg Glu Ala Asp Gly
 900 905 910
 Thr Gly Arg Ala Arg Ala Gly Gly His Pro Leu Leu Gly Glu Val Phe
 915 920 925
 Ser Val Ser Thr His Ala Gly Leu Arg Leu Trp Glu Thr Thr Leu Asp
 930 935 940
 Arg Lys Arg Leu Pro Trp Leu Gly Glu His Arg Ala Gln Gly Glu Val
 945 950 955 960
 Val Phe Pro Gly Ala Gly Tyr Leu Glu Met Ala Leu Ser Ser Gly Ala
 965 970 975
 Glu Ile Leu Gly Asp Gly Pro Ile Gln Val Thr Asp Val Val Leu Ile
 980 985 990
 Glu Thr Leu Thr Phe Ala Gly Asp Thr Ala Val Pro Val Gln Val Val
 995 1000 1005
 Thr Thr Glu Glu Arg Pro Gly Arg Leu Arg Phe Gln Val Ala Ser Arg
 1010 1015 1020

- 68 -

Glu Pro Gly Glu Arg Arg Ala Pro Phe Arg Ile His Ala Arg Gly Val
 1025 1030 1035 1040
 Leu Arg Arg Ile Gly Arg Val Glu Thr Pro Ala Arg Ser Asn Leu Ala
 1045 1050 1055
 Ala Leu Arg Ala Arg Leu His Ala Ala Val Pro Ala Ala Ala Ile Tyr
 1060 1065 1070
 Gly Ala Leu Ala Glu Met Gly Leu Gln Tyr Gly Pro Ala Leu Arg Gly
 1075 1080 1085
 Leu Ala Glu Leu Trp Arg Gly Glu Gly Glu Ala Leu Gly Arg Val Arg
 1090 1095 1100
 Leu Pro Glu Ala Ala Gly Ser Ala Thr Ala Tyr Gln Leu His Pro Val
 1105 1110 1115 1120
 Leu Leu Asp Ala Cys Val Gln Met Ile Val Gly Ala Phe Ala Asp Arg
 1125 1130 1135
 Asp Glu Ala Thr Pro Trp Ala Pro Val Glu Val Gly Ser Val Arg Leu
 1140 1145 1150
 Phe Gln Arg Ser Pro Gly Glu Leu Trp Cys His Ala Arg Val Val Ser
 1155 1160 1165
 Asp Gly Gln Gln Ala Ser Ser Arg Trp Ser Ala Asp Phe Glu Leu Met
 1170 1175 1180
 Asp Gly Thr Gly Ala Val Val Ala Glu Ile Ser Arg Leu Val Val Glu
 1185 1190 1195 1200
 Arg Leu Ala Ser Gly Val Arg Arg Arg Asp Ala Asp Asp Trp Phe Leu
 1205 1210 1215
 Glu Leu Asp Trp Glu Pro Ala Ala Leu Gly Gly Pro Lys Ile Thr Ala
 1220 1225 1230
 Gly Arg Trp Leu Leu Leu Gly Glu Gly Gly Gly Leu Gly Arg Ser Leu
 1235 1240 1245
 Cys Ser Ala Leu Lys Ala Ala Gly His Val Val Val His Ala Ala Gly
 1250 1255 1260
 Asp Asp Thr Ser Thr Ala Gly Met Arg Ala Leu Leu Ala Asn Ala Phe
 1265 1270 1275 1280
 Asp Gly Gln Ala Pro Thr Ala Val Val His Leu Ser Ser Leu Asp Gly
 1285 1290 1295
 Gly Gly-Gln Leu Gly Pro Gly Leu Gly Ala Gln Gly Ala Leu Asp Ala
 1300 1305 1310
 Pro Arg Ser Pro Asp Val Asp Ala Asp Ala Leu Glu Ser Ala Leu Met
 1315 1320 1325
 Arg Gly Cys Asp Ser Val Leu Ser Leu Val Gln Ala Leu Val Gly Met
 1330 1335 1340
 Asp Leu Arg Asn Ala Pro Arg Leu Trp Leu Leu Thr Arg Gly Ala Gln
 1345 1350 1355 1360
 Ala Ala Ala Ala Gly Asp Val Ser Val Val Gln Ala Pro Leu Leu Gly

- 69 -

1365	1370	1375
Leu Gly Arg Thr Ile Ala Leu Glu His Ala Glu Leu Arg Cys Ile Ser 1380 1385 1390		
Val Asp Leu Asp Pro Ala Glu Pro Glu Gly Glu Ala Asp Ala Leu Leu 1395 1400 1405		
Ala Glu Leu Leu Ala Asp Asp Ala Glu Glu Glu Val Ala Leu Arg Gly 1410 1415 1420		
Gly Asp Arg Leu Val Ala Arg Leu Val His Arg Leu Pro Asp Ala Gln 1425 1430 1435 1440		
Arg Arg Glu Lys Val Glu Pro Ala Gly Asp Arg Pro Phe Arg Leu Glu 1445 1450 1455		
Ile Asp Glu Pro Gly Ala Leu Asp Gln Leu Val Leu Arg Ala Thr Gly 1460 1465 1470		
Arg Arg Ala Pro Gly Pro Gly Glu Val Glu Ile Ser Val Glu Ala Ala 1475 1480 1485		
Gly Leu Asp Ser Ile Asp Ile Gln Leu Ala Leu Gly Val Ala Pro Asn 1490 1495 1500		
Asp Leu Pro Gly Glu Glu Ile Glu Pro Leu Val Leu Gly Ser Glu Cys 1505 1510 1515 1520		
Ala Gly Arg Ile Val Ala Val Gly Glu Gly Val Asn Gly Leu Val Val 1525 1530 1535		
Gly Gln Pro Val Ile Ala Leu Ala Ala Gly Val Phe Ala Thr His Val 1540 1545 1550		
Thr Thr Ser Ala Thr Leu Val Leu Pro Arg Pro Leu Gly Leu Ser Ala 1555 1560 1565		
Thr Glu Ala Ala Ala Met Pro Leu Ala Tyr Leu Thr Ala Trp Tyr Ala 1570 1575 1580		
Leu Asp Lys Val Ala His Leu Gln Ala Gly Glu Arg Val Leu Ile His 1585 1590 1595 1600		
Ala Glu Ala Gly Gly Val Gly Leu Cys Ala Val Arg Trp Ala Gln Arg 1605 1610 1615		
Val Gly Ala Glu Val Tyr Ala Thr Ala Asp Thr Pro Glu Asn Arg Ala 1620 1625 1630		
Tyr Leu Glu Ser Leu Gly Val Arg Tyr Val Ser Asp Ser Arg Ser Gly 1635 1640 1645		
Arg Phe Val Thr Asp Val His Ala Trp Thr Asp Gly Glu Gly Val Asp 1650 1655 1660		
Val Val Leu Asp Ser Leu Ser Gly Glu Arg Ile Asp Lys Ser Leu Met 1665 1670 1675 1680		
Val Leu Arg Ala Cys Gly Arg Leu Val Lys Leu Gly Arg Arg Asp Asp 1685 1690 1695		
Cys Ala Asp Thr Gln Pro Gly Leu Pro Pro Leu Leu Arg Asn Phe Ser 1700 1705 1710		

- 70 -

Phe Ser Gln Val Asp Leu Arg Gly Met Met Leu Asp Gln Pro Ala Arg
 1715 1720 1725
 Ile Arg Ala Leu Leu Asp Glu Leu Phe Gly Leu Val Ala Ala Gly Ala
 1730 1735 1740
 Ile Ser Pro Leu Gly Ser Gly Leu Arg Val Gly Gly Ser Leu Thr Pro
 1745 1750 1755 1760
 Pro Pro Val Glu Thr Phe Pro Ile Ser Arg Ala Ala Glu Ala Phe Arg
 1765 1770 1775
 Arg Met Ala Gln Gly Gln His Leu Gly Lys Leu Val Leu Thr Leu Asp
 1780 1785 1790
 Asp Pro Glu Val Arg Ile Arg Ala Pro Ala Glu Ser Ser Val Ala Val
 1795 1800 1805
 Arg Ala Asp Gly Thr Tyr Leu Val Thr Gly Gly Leu Gly Gly Leu Gly
 1810 1815 1820
 Leu Arg Val Ala Gly Trp Leu Ala Glu Arg Gly Ala Gly Gln Leu Val
 1825 1830 1835 1840
 Leu Val Gly Arg Ser Gly Ala Ala Ser Ala Glu Gln Arg Ala Ala Val
 1845 1850 1855
 Ala Ala Leu Glu Ala His Gly Ala Arg Val Thr Val Ala Lys Ala Asp
 1860 1865 1870
 Val Ala Asp Arg Ser Gln Ile Glu Arg Val Leu Arg Glu Val Thr Ala
 1875 1880 1885
 Ser Gly Met Pro Leu Arg Gly Val Val His Ala Ala Gly Leu Val Asp
 1890 1895 1900
 Asp Gly Leu Leu Met Gln Gln Thr Pro Ala Arg Phe Arg Thr Val Met
 1905 1910 1915 1920
 Gly Pro Lys Val Gln Gly Ala Leu His Leu His Thr Leu Thr Arg Glu
 1925 1930 1935
 Ala Pro Leu Ser Phe Phe Val Leu Tyr Ala Ser Ala Ala Gly Leu Phe
 1940 1945 1950
 Gly Ser Pro Gly Gln Gly Asn Tyr Ala Ala Ala Asn Ala Phe Leu Asp
 1955 1960 1965
 Ala Leu Ser His His Arg Arg Ala Gln Gly Leu Pro Ala Leu Ser Ile
 1970 1975 1980
 Asp Trp Gly Met Phe Thr Glu Val Gly Met Ala Val Ala Gln Glu Asn
 1985 1990 1995 2000
 Arg Gly Ala Arg Gln Ile Ser Arg Gly Met Arg Gly Ile Thr Pro Asp
 2005 2010 2015
 Glu Gly Leu Ser Ala Leu Ala Arg Leu Leu Glu Gly Asp Arg Val Gln
 2020 2025 2030
 Thr Gly Val Ile Pro Ile Thr Pro Arg Gln Trp Val Glu Phe Tyr Pro
 2035 2040 2045
 Ala Thr Ala Ala Ser Arg Arg Leu Ser Arg Leu Val Thr Thr Gln Arg
 2050 2055 2060

- 71 -

Ala Val Ala Asp Arg Thr Ala Gly Asp Arg Asp Leu Leu Glu Gln Leu
 2065 2070 2075 2080
 Ala Ser Ala Glu Pro Ser Ala Arg Ala Gly Leu Leu Gln Asp Val Val
 2085 2090 2095
 Arg Val Gln Val Ser His Val Leu Arg Leu Pro Glu Asp Lys Ile Glu
 2100 2105 2110
 Val Asp Ala Pro Leu Ser Ser Met Gly Met Asp Ser Leu Met Ser Leu
 2115 2120 2125
 Glu Leu Arg Asn Arg Ile Glu Ala Ala Leu Gly Val Ala Ala Pro Ala
 2130 2135 2140
 Ala Leu Gly Trp Thr Tyr Pro Thr Val Ala Ala Ile Thr Arg Trp Leu
 2145 2150 2155 2160
 Leu Asp Asp Ala Leu Val Val Arg Leu Gly Gly Gly Ser Asp Thr Asp
 2165 2170 2175
 Glu Ser Thr Ala Ser Ala Gly Ser Phe Val His Val Leu Arg Phe Arg
 2180 2185 2190
 Pro Val Val Lys Pro Arg Ala Arg Leu Phe Cys Phe His Gly Ser Gly
 2195 2200 2205
 Gly Ser Pro Glu Gly Phe Arg Ser Trp Ser Glu Lys Ser Glu Trp Ser
 2210 2215 2220
 Asp Leu Glu Ile Val Ala Met Trp His Asp Arg Ser Leu Ala Ser Glu
 2225 2230 2235 2240
 Asp Ala Pro Gly Lys Lys Tyr Val Gln Glu Ala Ala Ser Leu Ile Gln
 2245 2250 2255
 His Tyr Ala Asp Ala Pro Phe Ala Leu Val Gly Phe Ser Leu Gly Val
 2260 2265 2270
 Arg Phe Val Met Gly Thr Ala Val Glu Leu Ala Ser Arg Ser Gly Ala
 2275 2280 2285
 Pro Ala Pro Leu Ala Val Phe Thr Leu Gly Gly Ser Leu Ile Ser Ser
 2290 2295 2300
 Ser Glu Ile Thr Pro Glu Met Glu Thr Asp Ile Ile Ala Lys Leu Phe
 2305 2310 2315 2320
 Phe Arg Asn Ala Ala Gly Phe Val Arg Ser Thr Gln Gln Val Gln Ala
 2325 2330 2335
 Asp Ala Arg Ala Asp Lys Val Ile Thr Asp Thr Met Val Ala Pro Ala
 2340 2345 2350
 Pro Gly Asp Ser Lys Glu Pro Pro Val Lys Ile Ala Val Pro Ile Val
 2355 2360 2365
 Ala Ile Ala Gly Ser Asp Asp Val Ile Val Pro Pro Ser Asp Val Gln
 2370 2375 2380
 Asp Leu Gln Ser Arg Thr Thr Glu Arg Phe Tyr Met His Leu Leu Pro
 2385 2390 2395 2400
 Gly Asp His Glu Phe Leu Val Asp Arg Gly Arg Glu Ile Met His Ile

<400>	8																		
Met	Thr	Gln	Glu	Gln	Ala	Asn	Gln	Ser	Glu	Thr	Lys	Pro	Ala	Phe	Asp				
1				5					10					15					
Phe	Lys	Pro	Phe	Ala	Pro	Gly	Tyr	Ala	Glu	Asp	Pro	Phe	Pro	Ala	Ile				
			20					25					30						
Glu	Arg	Leu	Arg	Glu	Ala	Thr	Pro	Ile	Phe	Tyr	Trp	Asp	Glu	Gly	Arg				
		35					40					45							
Ser	Trp	Val	Leu	Thr	Arg	Tyr	His	Asp	Val	Ser	Ala	Val	Phe	Arg	Asp				
		50				55					60								
Glu	Arg	Phe	Ala	Val	Ser	Arg	Glu	Glu	Trp	Glu	Ser	Ser	Ala	Glu	Tyr				
65					70					75					80				
Ser	Ser	Ala	Ile	Pro	Glu	Leu	Ser	Asp	Met	Lys	Lys	Tyr	Gly	Leu	Phe				
				85					90					95					
Gly	Leu	Pro	Pro	Glu	Asp	His	Ala	Arg	Val	Arg	Lys	Leu	Val	Asn	Pro				
			100					105					110						
Ser	Phe	Thr	Ser	Arg	Ala	Ile	Asp	Leu	Leu	Arg	Ala	Glu	Ile	Gln	Arg				
		115					120					125							
Thr	Val	Asp	Gln	Leu	Leu	Asp	Ala	Arg	Ser	Gly	Gln	Glu	Glu	Phe	Asp				
		130				135					140								
Val	Val	Arg	Asp	Tyr	Ala	Glu	Gly	Ile	Pro	Met	Arg	Ala	Ile	Ser	Ala				
145					150					155					160				
Leu	Leu	Lys	Val	Pro	Ala	Glu	Cys	Asp	Glu	Lys	Phe	Arg	Arg	Phe	Gly				
				165					170					175					
Ser	Ala	Thr	Ala	Arg	Ala	Leu	Gly	Val	Gly	Leu	Val	Pro	Gln	Val	Asp				
			180					185					190						
Glu	Glu	Thr	Lys	Thr	Leu	Val	Ala	Ser	Val	Thr	Glu	Gly	Leu	Ala	Leu				
		195					200					205							
Leu	His	Asp	Val	Leu	Asp	Glu	Arg	Arg	Arg	Asn	Pro	Leu	Glu	Asn	Asp				
		210				215					220								
Val	Leu	Thr	Met	Leu	Leu	Gln	Ala	Glu	Ala	Asp	Gly	Ser	Arg	Leu	Ser				
225					230					235					240				
Thr	Lys	Glu	Leu	Val	Ala	Leu	Val	Gly	Ala	Ile	Ile	Ala	Ala	Gly	Thr				
				245					250					255					
Asp	Thr	Thr	Ile	Tyr	Leu	Ile	Ala	Phe	Ala	Val	Leu	Asn	Leu	Leu	Arg				
			260					265					270						

- 73 -

Ser Pro Glu Ala Leu Glu Leu Val Lys Ala Glu Pro Gly Leu Met Arg
 275 280 285
 Asn Ala Leu Asp Glu Val Leu Arg Phe Asp Asn Ile Leu Arg Ile Gly
 290 295 300
 Thr Val Arg Phe Ala Arg Gln Asp Leu Glu Tyr Cys Gly Ala Ser Ile
 305 310 315 320
 Lys Lys Gly Glu Met Val Phe Leu Leu Ile Pro Ser Ala Leu Arg Asp
 325 330 335
 Gly Thr Val Phe Ser Arg Pro Asp Val Phe Asp Val Arg Arg Asp Thr
 340 345 350
 Gly Ala Ser Leu Ala Tyr Gly Arg Gly Pro His Val Cys Pro Gly Val
 355 360 365
 Ser Leu Ala Arg Leu Glu Ala Glu Ile Ala Val Gly Thr Ile Phe Arg
 370 375 380
 Arg Phe Pro Glu Met Lys Leu Lys Glu Thr Pro Val Phe Gly Tyr His
 385 390 395 400
 Pro Ala Phe Arg Asn Ile Glu Ser Leu Asn Val Ile Leu Lys Pro Ser
 405 410 415
 Lys Ala Gly

<210> 9
 <211> 607
 <212> PRT
 <213> Sorangium cellulosum

<400> 9
 Ala Ser Leu Asp Ala Leu Phe Ala Arg Ala Thr Ser Ala Arg Val Leu
 1 5 10 15
 Asp Asp Gly His Gly Arg Ala Thr Glu Arg His Val Leu Ala Glu Ala
 20 25 30
 Arg Gly Ile Glu Asp Leu Arg Ala Leu Arg Glu His Leu Arg Ile Gln
 35 40 45
 Glu Gly Gly Pro Ser Phe His Cys Met Cys Leu Gly Asp Leu Thr Val
 50 55 60
 Glu Leu Leu Ala His Asp Gln Pro Leu Ala Ser Ile Ser Phe His His
 65 70 75 80
 Ala Arg-Ser Leu Arg His Pro Asp Trp Thr Ser Asp Ala Met Leu Val
 85 90 95
 Asp Gly Pro Ala Leu Val Arg Trp Leu Ala Ala Arg Gly Ala Pro Gly
 100 105 110
 Pro Leu Arg Glu Tyr Glu Glu Glu Arg Glu Arg Ala Arg Thr Ala Gln
 115 120 125
 Glu Ala Arg Arg Leu Trp Leu Ala Ala Ala Pro Pro Cys Phe Ala Pro
 130 135 140

- 74 -

Asp Leu Pro Arg Phe Glu Asp Asp Ala Asn Gly Leu Pro Leu Gly Pro
 145 150 155 160
 Met Ser Pro Glu Val Ala Glu Ala Glu Arg Arg Leu Arg Ala Ser Tyr
 165 170 175
 Ala Thr Pro Glu Leu Ala Cys Ala Ala Leu Leu Ala Trp Leu Gly Thr
 180 185 190
 Gly Ala Gly Pro Trp Ser Gly Tyr Pro Ala Tyr Glu Met Leu Pro Glu
 195 200 205
 Asn Leu Leu Leu Gly Phe Gly Leu Pro Thr Ala Ile Ala Ala Ala Ser
 210 215 220
 Ala Pro Gly Thr Ser Glu Ala Ala Leu Arg Gly Ala Ala Arg Leu Phe
 225 230 235 240
 Ala Ser Trp Glu Val Val Ser Ser Lys Lys Ser Gln Leu Gly Asn Ile
 245 250 255
 Pro Glu Ala Leu Trp Glu Arg Leu Arg Thr Ile Val Arg Ala Met Gly
 260 265 270
 Asn Ala Asp Asn Leu Ser Arg Phe Glu Arg Ala Glu Ala Ile Ala Ala
 275 280 285
 Glu Val Arg Arg Leu Arg Ala Gln Pro Ala Pro Phe Ala Ala Gly Ala
 290 295 300
 Gly Leu Ala Val Ala Gly Val Ser Ser Ser Gly Arg Leu Ser Gly Leu
 305 310 315 320
 Val Thr Asp Gly Asp Ala Leu Tyr Ser Gly Asp Gly Asn Asp Ile Val
 325 330 335
 Met Phe Gln Pro Gly Arg Ile Ser Pro Val Val Leu Leu Ala Gly Thr
 340 345 350
 Asp Pro Phe Phe Glu Leu Ala Pro Pro Leu Ser Gln Met Leu Phe Val
 355 360 365
 Ala His Ala Asn Ala Gly Thr Ile Ser Lys Val Leu Thr Glu Gly Ser
 370 375 380
 Pro Leu Ile Val Met Ala Arg Asn Gln Ala Arg Pro Met Ser Leu Val
 385 390 395 400
 His Ala Arg Gly Phe Met Ala Trp Val Asn Gln Ala Met Val Pro Asp
 405 410 415
 Pro Glu Arg Gly Ala Pro Phe Val Val Gln Arg Ser Thr Ile Met Glu
 420 425 430
 Phe Glu His Pro Thr Pro Arg Cys Leu His Glu Pro Ala Gly Ser Ala
 435 440 445
 Phe Ser Leu Ala Cys Asp Glu Glu His Leu Tyr Trp Cys Glu Leu Ser
 450 455 460
 Ala Gly Arg Leu Glu Leu Trp Arg His Pro His His Arg Pro Gly Ala
 465 470 475 480
 Pro Ser Arg Phe Ala Tyr Leu Gly Glu His Pro Ile Ala Ala Thr Trp
 485 490 495

- 75 -

Tyr Pro Ser Leu Thr Leu Asn Ala Thr His Val Leu Trp Ala Asp Pro
 500 505 510
 Asp Arg Arg Ala Ile Leu Gly Val Asp Lys Arg Thr Gly Val Glu Pro
 515 520 525
 Ile Val Leu Ala Glu Thr Arg His Pro Pro Ala His Val Val Ser Glu
 530 535 540
 Asp Arg Asp Ile Phe Ala Leu Thr Gly Gln Pro Asp Ser Arg Asp Trp
 545 550 555 560
 His Val Glu His Ile Arg Ser Gly Ala Ser Thr Val Val Ala Asp Tyr
 565 570 575
 Gln Arg Gln Leu Trp Asp Arg Pro Asp Met Val Leu Asn Arg Arg Gly
 580 585 590
 Leu Phe Phe Thr Thr Asn Asp Arg Ile Leu Thr Leu Ala Arg Ser
 595 600 605

<210> 10
 <211> 423
 <212> PRT
 <213> Sorangium cellulosum

<400> 10
 Met Gly Ala Leu Ile Ser Val Ala Ala Pro Gly Cys Ala Leu Gly Gly
 1 5 10 15
 Ala Glu Glu Glu Gly Gln Pro Gly Gln Asp Ala Gly Ala Gly Ala Leu
 20 25 30
 Ala Pro Ala Arg Glu Val Met Ala Ala Glu Val Ala Ala Gly Gln Met
 35 40 45
 Pro Gly Ala Val Trp Leu Val Ala Arg Gly Asp Asp Val His Val Asp
 50 55 60
 Ala Val Gly Val Thr Glu Leu Gly Gly Ser Ala Pro Met Arg Arg Asp
 65 70 75 80
 Thr Ile Phe Arg Ile Ala Ser Met Thr Lys Ala Val Thr Ala Thr Ala
 85 90 95
 Val Met Met Leu Val Glu Glu Gly Lys Leu Asp Leu Asp Ser Pro Val
 100 105 110
 Asp Arg Trp Leu Pro Glu Leu Ala Asn Arg Lys Val Leu Ala Arg Ile
 115 120 125
 Asp Gly Pro Ile Asp Glu Thr Val Pro Ala Glu Arg Pro Ile Thr Val
 130 135 140
 Arg Asp Leu Met Thr Phe Thr Met Gly Phe Gly Ile Ser Phe Asp Ala
 145 150 155 160
 Ser Ser Pro Ile Gln Arg Ala Ile Asp Glu Leu Gly Leu Val Asn Ala
 165 170 175
 Gln Pro Val Pro Met Thr Pro His Gly Pro Asp Glu Trp Ile Arg Arg
 180 185 190

- 76 -

Leu Gly Thr Leu Pro Leu Met His Gln Pro Gly Ala Gln Trp Met Tyr
 195 200 205
 Asn Thr Gly Ser Leu Val Gln Gly Val Leu Val Gly Arg Ala Ala Asp
 210 215 220
 Gln Gly Phe Asp Ala Phe Val Arg Glu Arg Ile Leu Ala Pro Leu Gly
 225 230 235 240
 Met Arg Asp Thr Asp Phe His Val Pro Ala Asp Lys Leu Ala Arg Phe
 245 250 255
 Ala Gly Cys Gly Tyr Phe Thr Asp Glu Gln Thr Gly Glu Lys Thr Arg
 260 265 270
 Met Asp Arg Asp Gly Ala Glu Ser Ala Tyr Ala Ser Pro Pro Ala Phe
 275 280 285
 Pro Ser Gly Ala Ala Gly Leu Val Ser Thr Val Asp Asp Tyr Leu Leu
 290 295 300
 Phe Ala Arg Met Leu Met Asn Gly Gly Val His Glu Gly Arg Arg Leu
 305 310 315 320
 Leu Ser Ala Ala Ser Val Arg Glu Met Thr Ala Asp His Leu Thr Pro
 325 330 335
 Ala Gln Lys Ala Ala Ser Ser Phe Phe Pro Gly Phe Phe Glu Thr His
 340 345 350
 Gly Trp Gly Tyr Gly Met Ala Val Val Thr Ala Pro Asp Ala Val Ser
 355 360 365
 Glu Val Pro Gly Arg Tyr Gly Trp Asp Gly Gly Phe Gly Thr Ser Trp
 370 375 380
 Ile Asn Asp Pro Gly Arg Glu Leu Ile Gly Ile Val Met Thr Gln Ser
 385 390 395 400
 Ala Gly Phe Leu Phe Ser Gly Ala Leu Glu Arg Phe Trp Arg Ser Val
 405 410 415
 Tyr Val Ala Thr Glu Ser Ala
 420

<210> 11
 <211> 713
 <212> PRT
 <213> Sorangium cellulosum

<400> 11
 Met His Gly Leu Thr Glu Arg Gln Val Leu Leu Ser Leu Val Thr Leu
 1 5 10 15
 Ala Leu Ile Leu Val Thr Ala Arg Ala Ser Gly Glu Leu Ala Arg Arg
 20 25 30
 Leu Arg Gln Pro Glu Val Leu Gly Glu Leu Phe Gly Gly Val Val Leu
 35 40 45
 Gly Pro Ser Val Val Gly Ala Leu Ala Pro Gly Phe His Arg Ala Leu
 50 55 60
 Phe Gln Glu Pro Ala Val Gly Val Val Leu Ser Gly Ile Ser Trp Ile

- 77 -

65		70		75		80
Gly Ala Leu Leu Leu Leu Leu Met Ala Gly Ile Glu Val Asp Val Gly						
		85		90		95
Ile Leu Arg Lys Glu Ala Arg Pro Gly Ala Leu Ser Ala Leu Gly Ala						
		100		105		110
Ile Ala Pro Pro Leu Ala Ala Gly Ala Ala Phe Ser Ala Leu Val Leu						
		115		120		125
Asp Arg Pro Leu Pro Ser Gly Leu Phe Leu Gly Ile Val Leu Ser Val						
		130		135		140
Thr Ala Val Ser Val Ile Ala Lys Val Leu Ile Glu Arg Glu Ser Met						
		145		150		155
Arg Arg Ser Tyr Ala Gln Val Thr Leu Ala Ala Gly Val Val Ser Glu						
		165		170		175
Val Ala Ala Trp Val Leu Val Ala Met Thr Ser Ser Ser Tyr Gly Ala						
		180		185		190
Ser Pro Ala Leu Ala Val Ala Arg Ser Ala Leu Leu Ala Ser Gly Phe						
		195		200		205
Leu Leu Phe Met Val Leu Val Gly Arg Arg Leu Thr His Leu Ala Met						
		210		215		220
Arg Trp Val Ala Asp Ala Thr Arg Val Ser Lys Gly Gln Val Ser Leu						
		225		230		235
Val Leu Val Leu Thr Phe Leu Ala Ala Ala Leu Thr Gln Arg Leu Gly						
		245		250		255
Leu His Pro Leu Leu Gly Ala Phe Ala Leu Gly Val Leu Leu Asn Ser						
		260		265		270
Ala Pro Arg Thr Asn Arg Pro Leu Leu Asp Gly Val Gln Thr Leu Val						
		275		280		285
Ala Gly Leu Phe Ala Pro Val Phe Phe Val Leu Ala Gly Met Arg Val						
		290		295		300
Asp Val Ser Gln Leu Arg Thr Pro Ala Ala Trp Gly Thr Val Ala Leu						
		305		310		315
Leu Leu Ala Thr Ala Thr Ala Ala Lys Val Val Pro Ala Ala Leu Gly						
		325		330		335
Ala Arg Leu Gly Gly Leu Arg Gly Ser Glu Ala Ala Leu Val Ala Val						
		340		345		350
Gly Leu Asn Met Lys Gly Gly Thr Asp Leu Ile Val Ala Ile Val Gly						
		355		360		365
Val Glu Leu Gly Leu Leu Ser Asn Glu Ala Tyr Thr Met Tyr Ala Val						
		370		375		380
Val Ala Leu Val Thr Val Thr Ala Ser Pro Ala Leu Leu Ile Trp Leu						
		385		390		395
Glu Lys Arg Ala Pro Pro Thr Gln Glu Glu Ser Ala Arg Leu Glu Arg						
		405		410		415

- 78 -

Glu Glu Ala Ala Arg Arg Ala Tyr Ile Pro Gly Val Glu Arg Ile Leu
 420 425 430
 Val Pro Ile Val Ala His Ala Leu Pro Gly Phe Ala Thr Asp Ile Val
 435 440 445
 Glu Ser Ile Val Ala Ser Lys Arg Lys Leu Gly Glu Thr Val Asp Ile
 450 455 460
 Thr Glu Leu Ser Val Glu Gln Gln Ala Pro Gly Pro Ser Arg Ala Ala
 465 470 475 480
 Gly Glu Ala Ser Arg Gly Leu Ala Arg Leu Gly Ala Arg Leu Arg Val
 485 490 495
 Gly Ile Trp Arg Gln Arg Arg Glu Leu Arg Gly Ser Ile Gln Ala Ile
 500 505 510
 Leu Arg Ala Ser Arg Asp His Asp Leu Leu Val Ile Gly Ala Arg Ser
 515 520 525
 Pro Ala Arg Ala Arg Gly Met Ser Phe Gly Arg Leu Gln Asp Ala Ile
 530 535 540
 Val Gln Arg Ala Glu Ser Asn Val Leu Val Val Val Gly Asp Pro Pro
 545 550 555 560
 Ala Ala Glu Arg Ala Ser Ala Arg Arg Ile Leu Val Pro Ile Ile Gly
 565 570 575
 Leu Glu Tyr Ser Phe Ala Ala Ala Asp Leu Ala Ala His Val Ala Leu
 580 585 590
 Ala Trp Asp Ala Glu Leu Val Leu Leu Ser Ser Ala Gln Thr Asp Pro
 595 600 605
 Gly Ala Val Val Trp Arg Asp Arg Glu Pro Ser Arg Val Arg Ala Val
 610 615 620
 Ala Arg Ser Val Val Asp Glu Ala Val Phe Arg Gly Arg Arg Leu Gly
 625 630 635 640
 Val Arg Val Ser Ser Arg Val His Val Gly Ala His Pro Ser Asp Glu
 645 650 655
 Ile Thr Arg Glu Leu Ala Arg Ala Pro Tyr Asp Leu Leu Val Leu Gly
 660 665 670
 Cys Tyr Asp His Gly Pro Leu Gly Arg Leu Tyr Leu Gly Ser Thr Val
 675 680 685
 Glu Ser Val Val Val Arg Ser Arg Val Pro Val Ala Leu Leu Val Ala
 690 695 700
 His Gly Gly Thr Arg Glu Gln Val Arg
 705 710

<210> 12
 <211> 126
 <212> PRT
 <213> Sorangium cellulosum

<400> 12
 Met Asp Lys Pro Ile Gly Arg Thr Arg Cys Ala Ile Ala Glu Gly Tyr

- 79 -

1	5	10	15
Ile Pro Gly Gly Ser Asn Gly Pro Glu Pro Gln Met Thr Ser His Glu	20	25	30
Thr Ala Cys Leu Leu Asn Ala Ser Asp Arg Asp Ala Gln Val Ala Ile	35	40	45
Thr Val Tyr Phe Ser Asp Arg Asp Pro Ala Gly Pro Tyr Arg Val Thr	50	55	60
Val Pro Ala Arg Arg Thr Arg His Val Arg Phe Asn Asp Leu Thr Glu	65	70	75
Pro Glu Pro Ile Pro Arg Asp Thr Asp Tyr Ala Ser Val Ile Glu Ser	85	90	95
Asp Ala Pro Ile Val Val Gln His Thr Arg Leu Asp Ser Arg Gln Ala	100	105	110
Glu Asn Ala Leu Leu Ser Thr Ile Ala Tyr Thr Asp Arg Glu	115	120	125

<210> 13
 <211> 149
 <212> PRT
 <213> Sorangium cellulosum

<400> 13
Met Lys His Val Asp Thr Gly Arg Arg Phe Gly Arg Arg Ile Gly His
1 5 10 15
Thr Leu Gly Leu Leu Ala Ser Met Ala Leu Ala Gly Cys Gly Gly Pro
20 25 30
Ser Glu Lys Thr Val Gln Gly Thr Arg Leu Ala Pro Gly Ala Asp Ala
35 40 45
Arg Val Thr Ala Asp Val Asp Pro Asp Ala Ala Thr Thr Arg Leu Ala
50 55 60
Val Asp Val Val His Leu Ser Pro Pro Glu Arg Leu Glu Ala Gly Ser
65 70 75 80
Glu Arg Phe Val Val Trp Gln Arg Pro Ser Pro Glu Ser Pro Trp Arg
85 90 95
Arg Val Gly Val Leu Asp Tyr Asn Ala Asp Ser Arg Arg Gly Lys Leu
100 105 110
Ala Glu Thr Thr Val Pro Tyr Ala Asn Phe Glu Leu Leu Ile Thr Ala
115 120 125
Glu Lys Gln Ser Ser Pro Gln Ser Pro Ser Ser Ala Ala Val Ile Gly
130 135 140
Pro Thr Ser Val Gly
145

<210> 14
 <211> 184
 <212> PRT
 <213> Sorangium cellulosum

- 80 -

<400> 14

Val Thr Ser Glu Glu Val Pro Gly Ala Ala Leu Gly Ala Gln Ser Ser
 1 5 10 15
 Leu Val Arg Ala Gln His Ala Ala Arg His Val Arg Pro Cys Thr Arg
 20 25 30
 Ala Glu Glu Pro Pro Ala Leu Met His Gly Leu Thr Glu Arg Gln Val
 35 40 45
 Leu Leu Ser Leu Val Ala Leu Ala Leu Val Leu Leu Thr Ala Arg Ala
 50 55 60
 Phe Gly Glu Leu Ala Arg Arg Leu Arg Gln Pro Glu Val Leu Gly Glu
 65 70 75 80
 Leu Phe Gly Gly Val Val Leu Gly Pro Ser Val Val Gly Ala Leu Ala
 85 90 95
 Pro Gly Phe His Arg Val Leu Phe Gln Asp Pro Ala Val Gly Val Val
 100 105 110
 Leu Ser Gly Ile Ser Trp Ile Gly Ala Leu Val Leu Leu Leu Met Ala
 115 120 125
 Gly Ile Glu Val Asp Val Ser Ile Leu Arg Lys Glu Ala Arg Pro Gly
 130 135 140
 Ala Leu Ser Ala Leu Gly Ala Ile Ala Pro Pro Leu Arg Thr Pro Gly
 145 150 155 160
 Pro Leu Val Gln Arg Met Gln Gly Ala Phe Thr Trp Asp Leu Asp Val
 165 170 175
 Ser Pro Arg Arg Ser Ala Gln Ala
 180

<210> 15

<211> 145

<212> PRT

<213> Sorangium cellulosum

<400> 15

Val Asn Ala Pro Cys Met Arg Cys Thr Ser Gly Pro Gly Val Arg Ser
 1 5 10 15
 Gly Gly Ala Ile Ala Pro Ser Ala Glu Ser Ala Pro Gly Arg Ala Ser
 20 25 30
 Leu Arg Arg Met Leu Thr Ser Thr Ser Ile Pro Ala Met Ser Ser Arg
 35 40 45
 Thr Ser Ala Pro Ile Gln Glu Met Pro Glu Ser Thr Thr Pro Thr Ala
 50 55 60
 Gly Ser Trp Lys Arg Thr Arg Trp Asn Pro Gly Ala Ser Ala Pro Thr
 65 70 75 80
 Thr Asp Gly Pro Ser Thr Thr Pro Pro Lys Ser Ser Pro Ser Thr Ser
 85 90 95
 Gly Trp Arg Ser Arg Arg Ala Ser Ser Pro Lys Ala Arg Ala Val Arg
 100 105 110

- 81 -

Arg Thr Ser Ala Arg Ala Thr Ser Glu Ser Arg Thr Cys Arg Ser Val
 115 120 125
 Arg Pro Cys Ile Arg Ala Gly Gly Ser Ser Ala Arg Val Gln Gly Arg
 130 135 140
 Thr
 145

<210> 16
 <211> 185
 <212> PRT
 <213> Sorangium cellulosum

<400> 16
 Val Leu Ala Pro Pro Ala Asp Ile Arg Pro Pro Ala Ala Ala Gln Leu
 1 5 10 15
 Glu Pro Asp Ser Pro Asp Asp Glu Ala Asp Glu Ala Asp Glu Ala Leu
 20 25 30
 Arg Pro Phe Arg Asp Ala Ile Ala Ala Tyr Ser Glu Ala Val Arg Trp
 35 40 45
 Ala Glu Ala Ala Gln Arg Pro Arg Leu Glu Ser Leu Val Arg Leu Ala
 50 55 60
 Ile Val Arg Leu Gly Lys Ala Leu Asp Lys Val Pro Phe Ala His Thr
 65 70 75 80
 Thr Ala Gly Val Ser Gln Ile Ala Gly Arg Leu Gln Asn Asp Ala Val
 85 90 95
 Trp Phe Asp Val Ala Ala Arg Tyr Ala Ser Phe Arg Ala Ala Thr Glu
 100 105 110
 His Ala Leu Arg Asp Ala Ala Ser Ala Met Glu Ala Leu Ala Ala Gly
 115 120 125
 Pro Tyr Arg Gly Ser Ser Arg Val Ser Ala Ala Val Gly Glu Phe Arg
 130 135 140
 Gly Glu Ala Ala Arg Leu His Pro Ala Asp Arg Val Pro Ala Ser Asp
 145 150 155 160
 Gln Gln Ile Leu Thr Ala Leu Arg Ala Ala Glu Arg Ala Leu Ile Ala
 165 170 175
 Leu Tyr Thr Ala Phe Ala Arg Glu Glu
 180 185

<210> 17
 <211> 146
 <212> PRT
 <213> Sorangium cellulosum

<400> 17
 Met Ala Asp Ala Ala Ser Arg Ser Ala Cys Ser Val Ala Ala Arg Lys
 1 5 10 15
 Leu Ala Tyr Arg Ala Ala Thr Ser Asn Gln Thr Ala Ser Phe Trp Ser
 20 25 30

- 82 -

Leu Pro Ala Ile Trp Glu Thr Pro Ala Val Val Cys Ala Lys Gly Thr
 35 40 45
 Leu Ser Ser Ala Leu Pro Ser Arg Thr Ile Ala Ser Arg Thr Arg Leu
 50 55 60
 Ser Ser Arg Gly Arg Cys Ala Ala Ser Ala His Arg Thr Ala Ser Glu
 65 70 75 80
 Tyr Ala Ala Ile Ala Ser Arg Asn Gly Arg Ser Ala Ser Ser Ala Ser
 85 90 95
 Ser Ala Ser Ser Ser Gly Glu Ser Gly Ser Ser Trp Ala Ala Ala Gly
 100 105 110
 Gly Arg Met Ser Ala Gly Gly Ala Ser Thr Gly Glu Val Tyr Glu Gln
 115 120 125
 Ala Pro Arg Leu Arg Leu Ala Gln Ser Val Ala Ala Arg Arg Arg Asp
 130 135 140
 Pro Thr
 145

<210> 18
 <211> 288
 <212> PRT
 <213> Sorangium cellulosum

<400> 18
 Val Thr Val Ser Ser Met Pro Arg Ser Trp Ser Ser Arg Val Arg Thr
 1 5 10 15
 Val Val Thr Ala Leu Gly Cys Ala Arg Arg Leu Ser Gly Ser Ile Ser
 20 25 30
 Arg Leu Arg Arg His Pro Glu Ala Gly Arg Ala Pro Arg Ser Arg Leu
 35 40 45
 Arg Ala Trp Arg Arg Leu Pro Gln His Ile Ser Ser Pro Trp Arg His
 50 55 60
 Leu Pro Pro Gly Ala Arg Val Gly Thr Ser Cys Pro Ala Asp Arg Arg
 65 70 75 80
 Ile Leu Pro Ser His Arg Thr Ala Asp Leu Gly Thr Ser Gly Gly Thr
 85 90 95
 Leu Val Ala Arg Met Ser Gly His Val Ala Arg Asn Pro His Ala Ala
 100 105 110
 Val Leu Val Gly Asp Gly Ser Ala Arg Gly Arg Arg Arg Leu Ser Asn
 115 120 125
 Arg Arg Ala Glu Arg Arg Val Ser Asp Val Thr Cys Arg Glu Gly Gly
 130 135 140
 Glu Ala Met Gln Lys Ile Ala Gly Lys Leu Val Val Gly Leu Ile Ser
 145 150 155 160
 Val Ser Gly Met Ser Leu Leu Ala Ala Cys Gly Gly Glu Lys Arg Ser
 165 170 175

- 83 -

Gly Gly Glu Ala Gln Thr Pro Gly Gly Ala Gln Gly Glu Ala Pro Val
 180 185 190
 Pro Val Gly Ser Ala Val Asp Ser Ile Val Ala Ala Arg Cys Asp Arg
 195 200 205
 Glu Ala Arg Cys Asn Asn Ile Gly Gln Asp Arg Glu Tyr Ser Ser Lys
 210 215 220
 Asp Ala Cys Ser Asn Lys Ile Arg Ser Glu Trp Arg Asp Glu Leu Thr
 225 230 235 240
 Phe Gly Glu Cys Pro Gly Gly Ile Asp Ala Lys Gln Leu Asn Glu Cys
 245 250 255
 Leu Glu Gly Ile Arg Asn Glu Gly Cys Gly Asn Pro Phe Asp Thr Leu
 260 265 270
 Gly Arg Val Val Ala Cys Arg Ser Ser Asp Leu Cys Arg Asp Ala Arg
 275 280 285

<210> 19
 <211> 288
 <212> PRT
 <213> Sorangium cellulosum

<400> 19
 Val Thr Val Ser Ser Met Pro Arg Ser Trp Ser Ser Arg Val Arg Thr
 1 5 10 15
 Val Val Thr Ala Leu Gly Cys Ala Arg Arg Leu Ser Gly Ser Ile Ser
 20 25 30
 Arg Leu Arg Arg His Pro Glu Ala Gly Arg Ala Pro Arg Ser Arg Leu
 35 40 45
 Arg Ala Trp Arg Arg Leu Pro Gln His Ile Ser Ser Pro Trp Arg His
 50 55 60
 Leu Pro Pro Gly Ala Arg Val Gly Thr Ser Cys Pro Ala Asp Arg Arg
 65 70 75 80
 Ile Leu Pro Ser His Arg Thr Ala Asp Leu Gly Thr Ser Gly Gly Thr
 85 90 95
 Leu Val Ala Arg Met Ser Gly His Val Ala Arg Asn Pro His Ala Ala
 100 105 110
 Val Leu Val Gly Asp Gly Ser Ala Arg Gly Arg Arg Arg Leu Ser Asn
 115 120 125
 Arg Arg Ala Glu Arg Arg Val Ser Asp Val Thr Cys Arg Glu Gly Gly
 130 135 140
 Glu Ala Met Gln Lys Ile Ala Gly Lys Leu Val Val Gly Leu Ile Ser
 145 150 155 160
 Val Ser Gly Met Ser Leu Leu Ala Ala Cys Gly Gly Glu Lys Arg Ser
 165 170 175
 Gly Gly Glu Ala Gln Thr Pro Gly Gly Ala Gln Gly Glu Ala Pro Val

- 84 -

	180		185		190
Pro Val Gly Ser Ala Val Asp Ser Ile Val Ala Ala Arg Cys Asp Arg	195	200	205		
Glu Ala Arg Cys Asn Asn Ile Gly Gln Asp Arg Glu Tyr Ser Ser Lys	210	215	220		
Asp Ala Cys Ser Asn Lys Ile Arg Ser Glu Trp Arg Asp Glu Leu Thr	225	230	235	240	
Phe Gly Glu Cys Pro Gly Gly Ile Asp Ala Lys Gln Leu Asn Glu Cys	245	250	255		
Leu Glu Gly Ile Arg Asn Glu Gly Cys Gly Asn Pro Phe Asp Thr Leu	260	265	270		
Gly Arg Val Val Ala Cys Arg Ser Ser Asp Leu Cys Arg Asp Ala Arg	275	280	285		

<210> 20
 <211> 155
 <212> PRT
 <213> Sorangium cellulosum

<400> 20
Met Asp Pro Arg Ala Arg Arg Glu Lys Arg Pro Ser Leu Leu Asp Ser
1 5 10 15
Arg Gly Arg Gln Pro Lys Arg Ser Gln Gln Gly Gly His Met Glu Lys
20 25 30
Pro Ile Gly Arg Thr Arg Trp Ala Ile Ala Glu Gly Tyr Ile Pro Gly
35 40 45
Arg Ser Asn Gly Pro Glu Pro Gln Met Thr Ser His Glu Thr Ala Cys
50 55 60
Leu Leu Asn Ala Ser Asp Arg Asp Ala Gln Val Ala Ile Thr Val Tyr
65 70 75 80
Phe Ser Asp Arg Asp Pro Ala Gly Pro Tyr Arg Val Thr Val Pro Ala
85 90 95
Arg Arg Thr Arg His Val Arg Phe Asn Asp Leu Thr Glu Pro Glu Pro
100 105 110
Ile Pro Arg Asp Thr Asp Tyr Ala Ser Val Ile Glu Ser Asp Val Pro
115 120 125
Ile Val Val Gln His Thr Arg Leu Asp Ser Arg Gln Ala Glu Asn Ala
130 135 140
Leu Ile Ser Thr Ile Ala Tyr Thr Asp Arg Glu
145 150 155

<210> 21
 <211> 156
 <212> PRT
 <213> Sorangium cellulosum

- 85 -

<400> 21

Val Arg Arg Ser Arg Trp Gln Met Lys His Val Asp Thr Gly Arg Arg
 1 5 10 15
 Val Gly Arg Arg Ile Gly Leu Thr Leu Gly Leu Leu Ala Ser Met Ala
 20 25 30
 Leu Ala Gly Cys Gly Gly Pro Ser Glu Lys Ile Val Gln Gly Thr Arg
 35 40 45
 Leu Ala Pro Gly Ala Asp Ala His Val Ala Ala Asp Val Asp Pro Asp
 50 55 60
 Ala Ala Thr Thr Arg Leu Ala Val Asp Val Val His Leu Ser Pro Pro
 65 70 75 80
 Glu Arg Ile Glu Ala Gly Ser Glu Arg Phe Val Val Trp Gln Arg Pro
 85 90 95
 Ser Ser Glu Ser Pro Trp Gln Arg Val Gly Val Leu Asp Tyr Asn Ala
 100 105 110
 Ala Ser Arg Arg Gly Lys Leu Ala Glu Thr Thr Val Pro His Ala Asn
 115 120 125
 Phe Glu Leu Leu Ile Thr Val Glu Lys Gln Ser Ser Pro Gln Ser Pro
 130 135 140
 Ser Ser Ala Ala Val Ile Gly Pro Thr Ser Val Gly
 145 150 155

<210> 22

<211> 305

<212> PRT

<213> Sorangium cellulosum

<400> 22

Met Glu Lys Glu Ser Arg Ile Ala Ile Tyr Gly Ala Ile Ala Ala Asn
 1 5 10 15
 Val Ala Ile Ala Ala Val Lys Phe Ile Ala Ala Ala Val Thr Gly Ser
 20 25 30
 Ser Ala Met Leu Ser Glu Gly Val His Ser Leu Val Asp Thr Ala Asp
 35 40 45
 Gly Leu Leu Leu Leu Leu Gly Lys His Arg Ser Ala Arg Pro Pro Asp
 50 55 60
 Ala Glu His Pro Phe Gly His Gly Lys Glu Leu Tyr Phe Trp Thr Leu
 65 70 75 80
 Ile Val Ala Ile Met Ile Phe Ala Ala Gly Gly Gly Val Ser Ile Tyr
 85 90 95
 Glu Gly Ile Leu His Leu Leu His Pro Arg Gln Ile Glu Asp Pro Thr
 100 105 110
 Trp Asn Tyr Val Val Leu Gly Ala Ala Ala Val Phe Glu Gly Thr Ser
 115 120 125
 Leu Ile Ile Ser Ile His Glu Phe Lys Lys Lys Asp Gly Gln Gly Tyr
 130 135 140

- 86 -

Leu Ala Ala Met Arg Ser Ser Lys Asp Pro Thr Thr Phe Thr Ile Val
 145 150 155 160
 Leu Glu Asp Ser Ala Ala Leu Ala Gly Leu Thr Ile Ala Phe Leu Gly
 165 170 175
 Val Trp Leu Gly His Arg Leu Gly Asn Pro Tyr Leu Asp Gly Ala Ala
 180 185 190
 Ser Ile Gly Ile Gly Leu Val Leu Ala Ala Val Ala Val Phe Leu Ala
 195 200 205
 Ser Gln Ser Arg Gly Leu Leu Val Gly Glu Ser Ala Asp Arg Glu Leu
 210 215 220
 Leu Ala Ala Ile Arg Ala Leu Ala Ser Ala Asp Pro Gly Val Ser Ala
 225 230 235 240
 Val Gly Arg Pro Leu Thr Met His Phe Gly Pro His Glu Val Leu Val
 245 250 255
 Val Leu Arg Ile Glu Phe Asp Ala Ala Leu Thr Ala Ser Gly Val Ala
 260 265 270
 Glu Ala Ile Glu Arg Ile Glu Thr Arg Ile Arg Ser Glu Arg Pro Asp
 275 280 285
 Val Lys His Ile Tyr Val Glu Ala Arg Ser Leu His Gln Arg Ala Arg
 290 295 300
 Ala
 305

<210> 23
 <211> 135
 <212> PRT
 <213> Sorangium cellulosum

<400> 23
 Val Gln Thr Ser Ser Phe Asp Ala Arg Tyr Ala Gly Cys Lys Ser Ser
 1 5 10 15
 Arg Arg Ile Ala Arg Ser Gly Ser Ala Gly Ala Arg Ala Gly Arg Ala
 20 25 30
 His Glu Gly Ala Ala Ser Ala Gly Phe Glu Gly Gly Asp Val Met Arg
 35 40 45
 Lys Ala Arg Ala His Gly Ala Met Leu Gly Gly Arg Asp Asp Gly Trp
 50 55 60
 Arg Arg-Gly Leu Pro Gly Ala Gly Ala Leu Arg Ala Ala Leu Gln Arg
 65 70 75 80
 Gly Arg Ser Arg Asp Leu Ala Arg Arg Arg Leu Ile Ala Ser Val Ser
 85 90 95
 Leu Ala Gly Gly Ala Ser Met Ala Val Val Ser Leu Phe Gln Leu Gly
 100 105 110
 Ile Ile Glu Arg Leu Pro Asp Pro Pro Leu Pro Gly Phe Asp Ser Ala
 115 120 125

- 87 -

Lys Val Thr Ser Ser Asp Ile
130 135

<210> 24
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: universal
reverse primer

<400> 24
ggaaacagct atgaccatg 19

<210> 25
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: universal
forward primer

<400> 25
gtaaaacgac ggccagt 17

<210> 26
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer
NH24 end "B"

<400> 26
gtgactggcg cctggaatct gcatgagc 28

<210> 27
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer NH2
end "A"

<400> 27
agcgggagct tgctagacat tctgtttc 28

<210> 28
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer NH2
end "B"

<400> 28
gacgcgcctc gggcagcgcc ccaa 24

<210> 29

- 88 -

<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer
pEPO15-NH6 end "B"

<400> 29
caccgaagcg tcgatctggt ccatc

25

<210> 30
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer
pEPO15H2.7 end "A"

<400> 30
cggtcagatc gacgacgggc tttcc

25



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12N 15/52, C07D 493/00, C07K 14/535	A3	(11) International Publication Number: WO 99/66028 (43) International Publication Date: 23 December 1999 (23.12.1999)
--	-----------	---

(21) International Application Number: PCT/EP99/04171

(22) International Filing Date: 16 June 1999 (16.06.1999)

(30) Priority Data:

09/099,504 18 June 1998 (18.06.1998) US
60/101,631 24 September 1998 (24.09.1998) US
60/118,906 05 February 1999 (05.02.1999) US

(60) Parent Application or Grant

NOVARTIS AG [/]; (). NOVARTIS-ERFINDUNGEN
VERWALTUNGSGESELLSCHAFT MBH [/]; (). SCHUPP,
Thomas [/]; (). LIGON, James, Madison [/]; (). MOLNAR,
Istvan [/]; (). ZIRKLE, Ross [/]; (). GÖRLACH, Jörn [/];
(). CYR, Devon [/]; (). SCHUPP, Thomas [/]; (). LIGON,
James, Madison [/]; (). MOLNAR, Istvan [/]; (). ZIRKLE,
Ross [/]; (). GÖRLACH, Jörn [/]; (). CYR, Devon [/];
(). BECKER, Konrad ; ().

Published

(54) Title: GENES FOR THE BIOSYNTHESIS OF EPOTHILONES

(54) Titre: GENES POUR LA BIOSYNTHESE D'EPOTHILONESES

(57) Abstract

Nucleic acid molecules are isolated from *Sorangium cellulosum* that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.

(57) Abrégé

L'invention porte: sur des molécules d'acide nucléique isolées à partir de *Sorangium cellulosum* et codant pour des polypeptides nécessaires à la biosynthèse de l'épothilone; sur des procédés de production d'épothilone dans des hôtes de recombinaison transformés au moyen des gènes de l'invention. On peut ainsi produire l'épothilone en quantités suffisantes pour permettre sa purification et son utilisation dans des préparations pharmaceutiques telles que celles utilisées pour le traitement du cancer.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/52, C07K 14/535, C07D 493/00		A3	(11) International Publication Number: WO 99/66028
			(43) International Publication Date: 23 December 1999 (23.12.99)
(21) International Application Number: PCT/EP99/04171		[US/US]; 413 Vuncannon Drive, Fuquay-Varina, NC 27526 (US).	
(22) International Filing Date: 16 June 1999 (16.06.99)		(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).	
(30) Priority Data: 09/099,504 18 June 1998 (18.06.98) US 60/101,631 24 September 1998 (24.09.98) US 60/118,906 5 February 1999 (05.02.99) US		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except AT/US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).			
(72) Inventors; and (75) Inventors/Applicants (for US only): SCHUPP, Thomas [CH/CH]; Fröschmattweg 5, CH-4313 Möhlin (CH). LIGON, James, Madison [US/US]; 3616 South Pointe Drive, Apex, NC 27502 (US). MOLNAR, Istvan [HU/US]; 4004 Branchwood Drive, Durham, NC 27705 (US). ZIRKLE, Ross [US/US]; 6532 Wynbrook Way, Raleigh, NC 27612 (US). GÖRLACH, Jörn [DE/US]; 3907 King Charles Road, Durham, NC 27707 (US). CYR, Devon			
(88) Date of publication of the international search report: 29 June 2000 (29.06.00)			
(54) Title: GENES FOR THE BIOSYNTHESIS OF EPOTHILONES			
(57) Abstract Nucleic acid molecules are isolated from <i>Sorangium cellulosum</i> that encode polypeptides necessary for the biosynthesis of epothilone. Disclosed are methods for the production of epothilone in recombinant hosts transformed with the genes of the invention. In this manner, epothilone can be produced in quantities large enough to enable their purification and use in pharmaceutical formulations such as those for the treatment of cancer.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP 99/04171

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/52 C07K14/535 C07D493/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C07K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 22461 A (BIOTECHNOLOG FORSCHUNG GMBH ; GERTH KLAUS (DE); HOFLE GERHARD (DE)) 28 May 1998 (1998-05-28) the whole document	1-10
Y	SCHUPP T. ET AL.: "A Sorangium cellulosum (myxobacterium) gene cluster for the biosynthesis of the macrolide antibiotic soraphen A: cloning, characterization and homology to polyketide synthase genes from actinomycetes" J. BACTERIOL., vol. 177, no. 13, 1995, pages 3673-3679, XP000893003 the whole document	1-10

-/-

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

Date of the actual completion of the international search

17 April 2000

Date of mailing of the international search report

03/05/2000

Name and mailing address of the ISA

European Patent Office, P.O. 5516 Patentean 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3018

Authorized officer

Panzica, G

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/04171

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	MOLNAR I. ET AL.: "The biosynthetic gene cluster for the microtubule-stabilizing agents epothilones A and B from <i>Sorangium cellulosum</i> So ce90" CHEM. BIOL., vol. 7, 2000, pages 97-109, XP000904734 the whole document	1-93
T	TANG LI, ET AL.: "Cloning and heterologous expression of the epothilone gene cluster." SCIENCE, vol. 287, 28 January 2000 (2000-01-28), pages 640-642, XP002135841 the whole document	1-93

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 99/04171

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9822461 A	28-05-1998	AU 5483798 A	10-06-1998
		CN 1237970 A	08-12-1999
		CZ 9901750 A	15-09-1999
		EP 0941227 A	15-09-1999
		NO 992338 A	14-05-1999
		PL 333435 A	06-12-1999